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Periocular malignancy represents an increasing burden and currently requires disfiguring 
surgery in an attempt to cure patients. Basal cell carcinoma (BCC) is the commonest 
cancer worldwide and morphoeic BCC (mBCC) is an aggressive subtype. Sebaceous 
gland carcinoma (SGC) is a rare, but life-threatening condition that often requires 
blinding surgery to prevent mortality, especially in the pagetoid subtype.  
 
MBCC has a high risk of local recurrence compared to the more indolent nodular subtype 
reflected by a different set of driver genes including FLNB and HECTD4. Surrounding 
mBCC stroma is abnormal, containing mutations in EPHA3 and GLI3. Four common 
dysregulated pathways detected using both whole exome and RNA sequencing for mBCC 
were; ‘hedgehog (Hh) signalling pathway’, ‘BCC’, ‘Natural killer cell mediated 
cytotoxicity’ and ‘Fc Epsilon RI signalling pathway’. Hh mutational profile for nodular 
BCC was not reflected in the RNA and protein expression. In contrast, Hh overexpression 
is seen in the tumour and stroma of morphoeic tissue with the latter potentially being 
partly responsible for its aggressive nature and risk of recurrence that may warrant 
removal to prevent recurrence.  
 
SGC has a low overall mutational burden, no UV signature and defective mismatch repair 
signature. Driver genes included TP53, RB1 and the dynein family is a novel driver 
possibly involved in chromatid segregation as marked chromosomal instability was 
demonstrated on copy number analysis. Correlation of whole exome and RNA 
sequencing data demonstrated upregulated ‘cell cycle’, ‘ubiquitin mediated proteolysis’ 
and ‘wnt signalling’.  
 
Subtype analysis of pagetoid and nodular SGC revealed the histone gene cluster family 
as important to both. Oncomir hsa-miR-21 was overexpressed in both and loss of hsa-
miR-199a occurs in pagetoid. Increased protein expression of HIST1H2BD was seen in 
both subtypes as was Hh expression. These novel SGC findings support a chromosomally 
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1.1 A brief history of cancer 
 
Cancer poses the greatest burden on humanity as the leading cause of global death with 
figures rising annually not only because of population growth, but also due to our 
increasing longevity. In 2012, there was an estimated 14 million new cases with 8.2 
million deaths from cancer.(Torre et al., 2015) Documentation of cancer has occurred 
throughout history and recordings have been made during Egyptian, Greek and Syrian 
times to name but a few (Figure 1.1). The word cancer comes from the Middle English 
word Canker that denotes a tumour by describing it as a crab or ulcer. It is derived from 
Latin, which in turn, comes from the Greek word karkinos, meaning a tumour surrounded 
by veins resembling a crab legs.  
 
Observations recorded by notable physicians hinted to the progressive, temporal nature 
of cancer by highlighting the different phases of initiation, promotion, and recurrence. 
Claudius Galen (AD 138-201), a Roman doctor who was taught by a Hippocratist, 
described liver cancer as a hard, malignant tumour with or without ulceration. The 
Byzantine physician Paul of Aegina in the early 7th century noted that the uterus and 
breast were the most frequent site for cancer to form. He goes on to state that surgical 
excision of uterine cancer is futile due to the high recurrence rate and that breast cancer 
should be excised without the use of cautery. Although there is no good reason to the 
refusal of cautery today, excessive tissue destruction can lead to a nidus for infection and 
may be where the advice stems from. It is certainly used today as electrocautery or 
surgical diathermy, whereby a high-frequency alternating current causes temperatures of 
up to 1000°C that results in vaporisation of water within the cell, providing the surgeon 
with a cutting tool and haemostasis. Moreover, it probably kills any stray cancer cells in 







Figure 1.1 Timeline on the historic recordings of cancer. 
 
 
Visceral cancers were being successfully removed with the improvement in aseptic 
surgical technique: with the use of gloves, gowns, sterilised instruments and the control 
of bleeding. A French surgeon Jacques Lisfranc de St Martin resected nine rectal cancers 
in 1833. Removal of tumours from more audacious parts of the body were attempted with 
the successful removal of a meningioma in 1888 by the first American brain surgeon, 
William Williams Keen, Jr. At a similar time, surgeons started to publish the follow up 
of their patients who had surgical excision of breast tumours.  
 
Cellular descriptions of cancer cells started to become more commonplace at the start of 
the 20th century with German pathologist David von Hansemann describing the concept 
of anaplasia in 1902. He observed that tumour cells become more embryonic in 
appearance and nature with rapid division being the hallmark of anaplasia (Figure 1.2). 
American pathologist James Ewing collated these descriptions in a book entitled 
neoplastic diseases.(Ewing, 1919) Furthermore, the German physiologist and Nobel 
laureate (1931), Otto Warburg, demonstrated the peculiar fermentative type of 
metabolism seen in the cancer cell. The Warburg effect is the phenomenon whereby 
cancer cells undergo anaerobic metabolism despite having high levels of oxygen - aerobic 
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glycolysis.(Warburg, 1924) Subsequently, the enzyme pyruvate kinase muscle (PKM) 
has been identified as the unregulated culprit in many cancer cells.(Christofk et al., 2008) 
 
Also at the turn of the century, the effects of radiation on neoplastic tissue were 
investigated. Thor Stenbeck, Swedish röntgenotherapist (early term for a radiologist), 
used in 1899, fractionated X-rays to treat basal cell carcinoma. Radium (emitting gamma 
rays) were used at the same time following the discovery by Polish (naturalised French) 
physicist and Nobel laureate Marie Curie who ironically, died from her life saving 
treatment: excessive radiation exposure induced aplastic anaemia.  
 
Katsusaburo Yamagiwa, a Japanese pathologist demonstrated that repeated application 
of coal tar produced skin cancer and so confirmed the presence of environmental risk 
factors known as carcinogens.(Yamagiwa, 1916) This linked specific chemicals to the 
aetiology of certain cancers, along with the importance of temporal and dose dependent 
exposure. Johannes Fibiger, Nobel laureate and Danish pathologist, suggested that cancer 
models could be developed as shown by the induction of presumed gastric carcinoma in 
rats fed by cockroaches laced with a nematode called spiroptera (ganglyonema 
neoplasticum). It was later proven that the changes seen in the rat were merely gastric 
hyperplasia, however, the concept of developing cancer models was a breakthrough in 
itself and worthy enough to be awarded the Nobel Prize.  In 1932, French pathologist, 
Antoine Lacassagne, discovered the role of oestrogens in the aetiology of male mice 
breast cancer by injecting them with folliculin, an observation that greatly stimulated 
interest in endocrine carcinogenesis. Furthermore, he was the forerunner in the successful 
treatment of prostate carcinoma with oestrogens (it is still used today in refractory 








Figure 1.2 Sebaceous gland carcinoma of the eyelid. Rapidly dividing sebaceous gland carcinoma cells 
that resemble embryonic tissue, an observation made by German pathologist David von Hansemann in 
1902 as the hallmark of anaplasia (cancer). 
 
Concerns about cancer led to the formation of many societies, institutes and periodicals 
devoted to the subject in the early 20th century. Research into cancer exploded and its 
understanding at a molecular level improved: Coman showed in 1944 that the 
invasiveness of cancer cells was down to the fact that malignant cells do not stick well to 
each other compared to their benign counterparts or normal tissue, allowing them to 
invade locally.(Coman, 1944) Observations made by Murray and Little in 1933 found an 
extra-chromosomal milk factor caused mammary tumours in mice. This later turned out 
to be mouse mammary tumour virus, sparking a desperate search for a similar pathogen 
in humans, but this remains elusive (and a virus may not be the initiator in 
humans).(Jackson and Little, 1933) We are now aware that a virus can integrate into and 
modify the hosts DNA, and that cancer is a genetic disorder (see section 1.5). The same 
group noticed the incidence of mammary cancer in hybrid mice was determined by the 
degree of cancer susceptibility of the mother highlighting the effect of inherited factors 
on cancer development. Many inherited cancers have subsequently been identified such 
as retinoblastoma, however, even if we don’t directly inherit a cancer forming gene, our 
genetic makeup will influence the risk of developing a particular type of cancer, making 
certain individuals more susceptible when exposed to an identical environment factor. 
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Modifying these genetic risk factors before the cancer develops could involve having 
augmented viruses inserted into our genome that corrects or removes the defective gene.  
Gene therapy attempts to remove these defects and up until recently relied on 
reprogramming viruses to insert the correct gene amongst other strategies.(Freytag et al., 
2007) In fact, there is a whole journal aptly named Cancer Gene Therapy dedicated to 
this task. Breakthrough technology using clustered regularly interspaced short 
palindromic repeats (CRISPR)-associated enzyme Cas9 (derived from bacteria) to amend 
(insert and remove) DNA sequences with great accuracy, could be used for this process 
in the future.(Sternberg et al., 2014) 
 
1.1.1 Basic language of cancer today 
 
Tissues normally divide when new cells are required, however, loss of their normal 
constraints for reproduction lead to an expanding clone of abnormal cells: cancer. If this 
remains localised, it is described as benign, whereas invasion or colonization of territories 
that are normally reserved for other cells, is described as malignant. Some cancers follow 
a stepwise transition from benign, premalignant to malignant, however, this is certainly 
not a universal phenomenon. There may be a stepwise transition at a molecular level 
whereby the cell gains more mutations and diverges away from normality, but a simple 
linear transition is sadly far from reality. Malignancy is a spectrum, with some being slow 
to grow or invade, giving time for their detection and treatment versus aggressive, locally 
invasive tumour that metastasis early. What determines the cancers ability to locally 
invade, spread and plunder the body’s cellular machinery to its own advantage is the 
subject of this research and this dearth of data in eyelid cancer requires attention. 
 
1.1.2 Non-melanoma skin cancer –the world’s most common cancer 
 
Non-melanoma skin cancers (NMSC) are the most common human cancers and their 
incidence continues to rise.(Madan et al., 2010, Kwasniak and Garcia-Zuazaga, 2011) 
The vast majority of eyelid NMSC are basal cell carcinomas (BCC) with 5% attributed 
to sebaceous gland carcinoma (SGC).(Shields et al., 2005) Morphoeic BCC (mBCC) is a 
particularly aggressive subtype, which invades local tissue, such as the eye socket and 
adjacent structures including the nose, in an uncompromising manner. SGC is a 
masquerader of benign conditions; it is often picked up late and results in death in up to 
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22% of patients.(Boniuk and Zimmerman, 1968, Doxanas and Green, 1984, Rao et al., 
1982) Both can lead to significant eye morbidity from the disease itself along with the 
tissue destructive surgical treatment. In addition, some cases require total removal of the 
eye and its supporting structures (exenteration) leading to blindness. BCC numbers are 
increasing by 10% worldwide per annum and will soon be more prevalent than all other 
cancers combined.(Madan et al., 2010) A growing older population and amplified UV 
light exposure may in part explain this increase, but they are unlikely to be the only 
factors. MBCC and SGC require more invasive treatment modalities and little is known 
on the development of these cancers. This lack of knowledge combined with their 
increasing prevalence demands detailed research into the behaviour of these eyelid 
tumours. 
 
1.2 Periocular cancer 
 
Figure 1.3 Periocular malignancies: (A) Trichoepithelioma at the medial canthus. This mimics nodular 
BCC, but is a benign neoplasm of the hair follicle. (B) Melanoma in-situ. A well circumscribed lesion that 
could easily be labelled as a naevus, however, was actually a melanoma in-situ. (C) Lentigo maligna of 
the upper and lower eyelid. This is a melanoma in-situ that can undergo invasive change to melanoma 
proper. (D) Invasive Melanoma of the upper eyelid. A discrete mass within the upper eyelid and not 
obviously on the skin surface, which could be misdiagnosed as a chalazion, however, the dark pigmentation 
gives a clue to its true nature (E) Actinic keratosis with a keratin horn of the lower eyelid. A 
premalignant condition that can transform into squamous cell carcinoma. It can also present as a flat scaly 
lesion. (F) Squamous cell carcinoma of the lower eyelid. A plaque type of SCC represents around 2-5% 
of eyelid malignancies, but has a greater propensity to spread compared to BCC. 
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1.2.1 Local anatomy and associated tumours 
 
The periocular region (defined as the area within the orbital margin surrounding the 
globe) encompasses many different tissue types and comprised of orbital content 
(extraocular muscles, fat, optic nerve, cranial nerves and blood vessels), conjunctiva, 
eyelids (skin, tarsal plate and orbicularis oculi muscle), lacrimal system (tear production 
and drainage system) and the surrounding bone. An aberration can occur in any of these 
tissues and so a wide variety of tumour is seen in a very small space (Figure 1.3). 
Moreover, a tumour can arise from the globe (extraocular extension) and mimic a 
periorbital lesion. Each tissue or compartment has its own commonest primary cancer 
and are listed in Table 1.1. This makes diagnosis more challenging and stresses the 
importance of obtaining a histological sample in order to characterise the tumour type; 
even on a microscopic level it can be a balance of probability with the clinical details 
being a decisive factor (such as speed of onset, age, associated symptoms to name a few). 
Choroidal melanoma is a cancer where a histological biopsy is avoided as the diagnosis 
can often be made on clinical grounds alone; a biopsy has to traverse the globe structures 
and has the potential to be either sight damaging or seed (spread) the cancer. Lacrimal 
gland (pleomorphic) adenoma is another tumour where a biopsy is avoided. Not because 
there are delicate structures to traverse with the biopsy needle, rather that piercing of the 
tumour capsule causes seeding and an unacceptable recurrence rate. Fortunately, classical 
features of lacrimal fossa expansion, indentation of the globe, well-circumscribed lesion 
with calcification present in 30%, allows for a radiological diagnosis and subsequent 
treatment with surgical removal of the intact tumour with a surrounding pseudo-capsule 
to prevent seeding. Although all tumours are encompassed in the term periocular, eyelid 














Possible tissue of origin 
Malignant  Premalignant Benign Comment 
Eyelid     Commonest 
Hair follicle Basal cell carcinoma   Commonest 





    Squamous cell 
papilloma 
 
Hair follicle Keratocanthoma     
Dendritic cells (neural 
crest) 
melanoma Lentigo maligna   
Epidermal stem cells Merkel cell carcinoma    
Human herpes simplex 
virus 8 infected endothelial 
cells 
Kaposi’s sarcoma    
 Primary eccrine 
porocarcinoma 
   
 Apocine carcinoma    
 Sebaceous gland 
carcinoma 
   





Orbit     
Optic nerve Glioma    
Blood vessels Angioma    
Connective tissue Rhabdomyosarcoma   Commonest 
malignant orbital 
lesion in children 
Smooth muscle Leiomyoma    
Lymph lymphoma    









Bone Osteosarcoma  Osteoma  
Globe       
Retinal Retinoblastoma   Commonest 
ocular tumour in 
children 
 Astrocytoma    
Uveal 
Melanocyte (neural crest 
cells) 
Uveal melanoma (iris, 
ciliary body, 
choroidal) 
   
 
Table 1.1 Periocular tumours grouped by compartment. Each compartment has its own commonest 
primary cancer.  
 
 
1.2.2 Periocular skin and conjunctiva 
 
The eyelids are essential for maintaining corneal health, which in turn, affords clear 
vision. Their role is to maintain the wetting of the cornea with lacrimal secretions using 
a wiper effect, contribute to tear production and drainage, protect the globe from injury 
(blink reflex) and modulate the light entering the eye including obstructing it completely 
during sleep. The eyelid is often split into anterior and posterior lamellae for descriptive 
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purposes (Figure 1.4). This stems from the fact that during development, folds cover the 
cornea in two phases (during the seventh week and seventh month of embryogenesis) 
separated by a mesodermal layer that differentiates into the tarsus and orbital septum. 
Surgically, the two layers can be split at the site of the grey line and serves as an important 
dissection plane where minimal scarring occurs. The anterior lamella comprises of skin, 
subcutaneous tissue, and muscle fibres of the orbicularis oculi. The posterior lamella 
comprises orbital septum/tarsal plate, smooth muscle and palpebral conjunctiva. 
 
The skin of the eyelid is unique in that it is the thinnest in the body as it contains no fat 
and undergoes the most movement (you blink 16 times a minute). It is fairly elastic and 
forms many folds, most notably the superior palpebral furrow of the upper eyelid. The 
skin is stratified squamous containing numerous melanocytes, with less sebaceous glands, 
sweat glands, hair follicles and dermal papillae compared to normal skin with the 
exception of the eyelid margin where they are numerous. Below, the subcutaneous tissue 
contains abundant elastic tissue. The hairs at the margin are coarser forming eyelashes, 
the connective tissue is denser and more collagenous, and the dermal papillae are higher. 
The eyelashes are arranged in two or three rows with 150 in the upper eyelid and 75 in 
the lower. They are replaced every 4 to 6 months, but can grow back within 2 if cut. A 
modified sebaceous gland of Zeiss opens into each hair follicle and between them are the 
eccrine sweat glands, sebaceous glands and apocrine sweat glands of Moll. The grey line 
at the eyelid margin depicts the junction between the skin and the non-keratinised 
conjunctival epithelium, just in front of the orifices of the meibomian glands which reside 
in the tarsal plate. The meibomian is a large holocrine (sebaceous) gland, secreting a 
phospholipid that prevents the evaporation of the aqueous portion of the tear film and 
increases surface tension. The skin lymphatics drain to the anterior cervical chain 
inferomedially, submandibular glands inferiorly and the parotid gland laterally. Tumours 
that invade the lymphatics such as sebaceous gland carcinoma (SGC) typically spread to 









Figure 1.4 Periocular region. (A) Photograph of the periocular region that is contained with the orbital 
margin denoted by the blue dotted line. (B) A cross section of the eyelid demonstrating the internal 
structures and the site of the grey line that separates it into anterior and posterior lamellae. UL, upper eyelid; 
LL, lower eyelid; GL, grey line; C, caruncle; MC, medial canthus.  
 
The conjunctiva is 2-5 layered stratified squamous (non-keratinised) at the eyelid margin, 
thins out to 2 layers with a cuboidal structure over the tarsal plate of the posterior lamella 
(palpebral conjunctiva) and changes into stratified columnar over the globe (bulbar 
conjunctiva), only to return to a squamous structure at the corneal limbus. Scattered 
within the epithelium are mucin secreting goblet cells and microvilli secreting 
glycoproteins. The epithelium sits on a stromal nest (substantia propria) containing a 
superficial lymphoid and deep fibrous layer. The former is essential for immune 
surveillance and contains mast cells, lymphocytes, plasma cells and neutrophils. In 
addition, there are accessory lacrimal glands of Krause and Wolfing. The fibrous layer 
contains the neurovascular complexes and lymph vessels; it almost thins to non-existence 
over the tarsal plate where the conjunctiva is very adherent to the tarsal plate. At the inner 
part of the eye a semilunar fold (plica semilunaris) of bulbar conjunctiva is formed 
surrounding a bulge known as the caruncle which contains large sweat gland and lanugo 
hair.  The plica semilunaris probably represents a rudimentary nictitating membrane seen 
in animals. The plica stroma can contain cartilaginous tissue and the caruncle stroma can 
contain striated muscle fibres. 
 
Periocular carcinomas, especially BCCs, have a predilection for the eyelid margin with 
their excision being potentially hazardous for future eyeball protection. Excision of the 
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lesion if fairly straight forward as long as you avoid damaging the globe. More difficult 
is the reconstruction of the eyelid post excision: it is essential to try and regain some of 
the aforementioned eyelid properties and the type of reconstruction depends on the 
amount of skin lost during removal. In addition, both the anterior and posterior lamellae 
need to be replaced ideally. Loss of less than a third can be repaired with direct closure, 
between a third to a half using a modified Beard-Cutler or Hughes flap for the lower and 
upper eyelid respectively. Removal of over half of the eyelid warrants rotational 
myocutaneous flaps remembering to replace the posterior lamella with a mucous 
membrane graft or equivalent. 
 
1.3 Basal cell carcinoma 
 
BCCs are the commonest cancers in the world with an incidence of 100 in 100,000 in the 
UK and highest in Australia at 884 in 100,000.(Staples et al., 2006, Madan et al., 2010) 
This suggests that there is a strong environmental risk factor, namely UV light exposure 
(both solar irradiance and sun beds). The head is a common location for BCC supporting 
the UV theory, however, up to a third of BCC occur in areas with minimal or no UV light 
exposure.(Firnhaber, 2012) Our increased longevity makes age a factor for developing 
BCCs, although the incidence is increasing in the young too.(Kwasniak and Garcia-
Zuazaga, 2011) Other environmental risk factors include arsenic, coal tar, ionizing 
radiation demonstrated by increased incidence in Nagasaki, and 
immunosuppression.(Guo et al., 2001, Kishikawa et al., 2005, Berg and Otley, 2002) 
Genetic factors are highlighted by the susceptibility to BCC according to skin type. 
Fitzpatrick type 1 (light skin, eyes and hair colour) has the highest risk of UV-induced 
skin lesions including BCC.(Ravnbak, 2010) Specific genetic changes have been eluded 
too from studying basal cell naevus syndrome (BCNS aka Gorlin syndrome) and are 
discussed in section 1.5.   
 
1.3.1 Macroscopic features 
 
High risk macroscopic factors include mid facial location (H-zone, see Fig 1.6) large size, 
longstanding and recurrence. Local destruction is where the complications occur, making 
the periocular region particularly vulnerable (Figure 1.5). The term ‘rodent ulcer’ was 
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given to BCC, as left untreated, the rodent ulcer will slowly ‘eat’ the skin coverings 
exposing the underlying flesh and bone.  
 
 
Figure 1.5 Macroscopic appearance of basal cell carcinoma. (A) Morphoeic BCC of the lower eyelid 
with loss of normal structures and ulceration of the skin. (B) Post-Moh’s excision of morphoeic lesion 
demonstrating loss of the lower and the lateral canthus in its entirety along with a portion of the upper 
eyelid. (C) Nodular BCC of the lower eyelid with notching of the eyelid margin, ulceration and distortion 
of normal structures plus loss of eyelashes. (D) Post-Moh’s excision of the nodular lesion demonstrating 







Figure 1.6 High risk H-zone. The H-zone consists of the periocular, nasal alar, nasolabial fold and 
auricular regions with confers a higher risk of BCC recurrence. A large basal cell carcinoma is seen on the 
right lower eyelid whose histology revealed a morphoeic subtype and also confers a high risk of recurrence.  
 
 
1.3.2 Microscopic features 
 
There are several different classifications for BCC, however, a clinically relevant 
description relating to patient risk is laid out in the RCpath Dataset.(Slater, 2014) Growth 
pattern and differentiation are the two microscopic factors that relate to risk. Growth 
pattern is divided into low and high risk subtypes. The former subtypes are superficial, 
nodular and fibroepithelial. The nature of BCCs are classically associated with these 
subtypes as they are indolent in nature. Superficial BCC consists of a focal collection of 
germ cells in close contact with the epidermis or a hair follicle, does not extend beyond 
the papillary dermis, is less than 1mm thick and often coupled with a stromal reaction. It 
is not clear if superficial BCC represents a form of in-situ disease, but this may explain 
its localised nature making it readily amenable to topical immunomodulatory treatment. 
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Nodular BCC (nodBCC) are round lesions greater than 0.15 mm in diameter 
(differentiating them from micronodular; a high-risk subtype). They can be cystic, 
pseudoglandular or rippled in appearance (Figure 1.6).  Fibroepithelial are small 
pedunculated lesions and can be regarded as a benign trichblastoma, but the WHO 
consider it a BCC. 
 
High risk subtypes include morphoeic (as known as infiltrating or sclerosing) and 
micronodular. MBCC contain irregular, spiky strands of cells often accompanied by 
stromal fibrosis (Figure 1.7). Micronodular are small round lesions less than 0.15 mm, 
often with less than 25 cells per island. As mentioned, the individual growth patterns are 
fairly academic and it has been proposed that the high-risk samples should be grouped 
under one umbrella term: infiltrative.  
 
 
Figure 1.7 Microscopic appearance of basal cell carcinoma. (A) Morphoeic BCC with irregular, spiky 
strands of tumour cells. (B) Nodular BCC with a well circumscribed collection of cells with palisading of 
the outer cells. 
 
 
Microscopic heterogeneity exists, with samples often a mixture of the above subtypes.  
Any sample that contains both high and low risk (Table 1.3) subtypes must be defined as 




There are a vast number of different histological differentiation patterns including 
pigmented, clear cell, eccrine, follicular and sebaceous to name a few. These represent no 
increased risk, however, squamous (basosquamous) differentiation with moderate or 
severe atypia is associated with metastasis and local recurrence.(Le Boit PE, 2008) 
  
Staging of the cancer is done using the tumour, node and metastasis (TNM) categorisation 
of malignant tumours (Table 1.2).(Sobin LH, 2009) Perineural and lymphovascular 
invasion are high risk factors with the former a determinant of tumour staging T4. The 
latter has less robust evidence to be a T4 determinant and the risk of metastasis or 
recurrence is less than perineural invasion, but is usually a feature if basosquamous BCC; 
in this context, it does determine an increased risk of metastasis. Lymphovascular 
invasion without squamous differentiated is noted in the pathology report, although 
currently its relevance is unknown. 
 
Tumour Node Metastasis 
Symbol Description Symbol Description Symbol Description 
Tx Tumour not assessable Nx Regional lymph node not 
assessable 
M0 No distant 
metastasis 
Tis Carcinoma in-situ N0 No lymph node involvement M1 Distant 
metastasis 
T0 No primary tumour N1 Single, ipsilateral lymph node 
≤30 mm size 
 
T1 ≤ 20 mm N2a Single, ipsilateral lymph 
node, >30 mm to ≤60 mm 
T2 ≥ 20 mm N2b Multiple, ipsilateral lymph 
nodes ≤60 mm 
T3 Local invasion of bone 
(orbit, temporal or maxilla) 
N2c Bilateral or contralateral 
lymph nodes ≤60 mm 
T4 Local invasion of skeleton 
(axial or appendicular) or 
skull base or perineural 
invasion 
N3 Lymph node ≥ 60mm 









Low risk clinical features 
>24yr history 
No immunosuppression 
No genetic predisposition 
Below the clavicle 




Not on an important structure 
Not highly visible with an either a poor cosmetic risk or difficult closure 
Table 1.3 Low risk BCC features. BCC that meet these clinical features could be managed in the 




There are a vast number of treatment modalities for BCC which reflects the tumour 
heterogeneity (i.e. the different nature of the subtypes mentioned earlier) and the lack of 
an ideal treatment for this condition. Surgery has been the mainstay of treatment and still 
is when it comes to the removal of high risk subtypes (Table 1.4). In such cases, Mohs 
micrographic surgery is employed to ensure that all of the cancer is cleared in one sitting. 
It involves real time histology, i.e. assessment of the tumour under the microscope during 
the surgical removal. It is labour intensive, requires a large team of staff to rapidly process 
the tissue and can last up to 8 hours, making it stressful for patients. And this excludes 
reconstruction which tends to be done the following day. Nevertheless, Mohs 
micrographic surgery is the gold standard for high-risk cases. Standard surgical excision 
normally involves removal with a 3mm margin of tissue, although this varies between 3-
15mm.(Telfer et al., 2008) 
 
Status Description 
Growth pattern Infiltrative  
Differentiation Basosquamous 
Level of invasion Deeper than subcutaneous fat 
Perineural invasion Present 
Lymphovascular invasion in basosquamous  Present 
TNM staging pT2, T3, T4 
Margins Involved or <1 mm clearance 
Table 1.4 High risk BCC features. Summary of high risk microscopic features. Adapted from the Royal 




1.3.4 Spread and Prognosis 
 
The risk of metastasis is generally low (0.2%) if you include both low and high risk BCCs 
together. Due to small numbers of high risk BCCs, it is difficult to have a reliable 
outcome, but they have been quoted as having 2% risk of metastasis if looked at 
independently.(Snow et al., 1994) Five year recurrence rates depends on treatment 
modality (Table 1.5). 
 
Treatment RTR % 5yDFR % Reference 
Surgical excision low risk 3mm 15  (Breuninger and Dietz, 1991) 
Surgical excision low risk 4-5mm 5  (Kimyai-Asadi et al., 2005) 
Surgical excision high risk 3mm 34  (Breuninger and Dietz, 1991) 
Surgical excision high risk 5mm 18  (Breuninger and Dietz, 1991) 
Surgical excision high risk 15mm 5  (Breuninger and Dietz, 1991) 
Mohs mSx for primary BCC  98.6-100 (Malhotra et al., 2004) 
Mohs mSx for recurrent BCC  92.2-96 (Leibovitch et al., 2005) 
Curettage and electrodissection 33  (Suhge d'Aubermont and Bennett, 1984) 
Radiotherapy for primary BCC  91.3 (Rowe et al., 1989a) 
Radiotherapy for recurrent BCC  90.2 (Rowe et al., 1989b) 
PDT for superficial and nodular BCC 25  (Wang et al., 2001)  
Cryotherapy periocular low risk cases  8 (Buschmann, 2002) 
5% Imiquimod in superficial BCC 18  (Geisse et al., 2004) 
SMO inhibitor (Vismodegib) for *BCC  50-66  (Gill et al., 2013, Sekulic et al., 2015) 
 
Table 1.5 BCC treatments. List of various modalities used to treat BCC highlighting the percentage of 
patients with residual tumour using that technique and risk of recurrence by showing the percentage of 
patients who are disease free after 5 years of treatment. RTR %, percentage residual tumour rate; 5yDFR 
%, percentage of 5-year disease free rate; mSx, micrographic surgery; *BCC not amenable to other 
treatment modalities 
 
1.4 Sebaceous gland carcinoma 
 
Sebaceous gland carcinoma (aka sebaceous cell carcinoma, cutaneous sebaceous 
carcinoma, sebaceous adenocarcinoma) is a rare aggressive cancer that has a predilection 
for the periorbital region, perhaps due to the multitude of glands surrounding the eyeball, 
but can come from extraocular sites, albeit mainly within the head region.(Deprez and 
Uffer, 2009) The incidence in the UK is estimated at 1 in 1000,000. Geographical 
variation is significant with the incidence around 0.65 per 100,000 in Canada versus 
China where it represents almost a third of the malignant eyelid workload and second to 
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BCC in frequency.(Kuzel et al., 2012, Xu et al., 2008) In a Japan, the rate of SGC equalled 
that of BCC in one study.(Obata et al., 2005) Risk factors include radiation exposure such 
external beam radiotherapy which used to be the mainstay of treatment for retinoblastoma 
(Kivela et al., 2001). Immunosuppression with HIV or the presence of HPV may also be 
a risk factor. 
 
1.4.1 Macroscopic features 
 
There are two broad macroscopic presentations, namely nodular (local) or pagetoid 
(spreading). Misdiagnosis is common, often labelled as a benign chronic meibomian cyst 
(chalazion) in its nodular form or conjunctivitis in its conjunctival pagetoid type (Figure 
1.8). Thus, it is described as a masquerader lesion with delays to diagnosis often greater 
than a year. If it involves the eyelid margin, madarosis (loss of eyelashes), atrophy, 
thickening or notching of the margin is seen. Pagetoid expansion of the skin or 
conjunctiva (conjunctival intraepithelial invasion) carries a higher risk of removing the 
whole of the orbital content (exenteration). (Chao et al., 2001) In contrast to BCC, SGC 
more commonly effect the upper eyelid and the majority are unicentric.(Rao et al., 1982, 
Ni, 1982) When cut, the nodular form can be yellow-white or ivory in colour reflecting 
the fatty content that is associated with SGC.  
 
 
Figure 1.8 Macroscopic features of SGC. (A) Nodular (local) SGC presenting as an eyelid lump. (B) 
Pagetoid (spreading) SGC presenting as a red eye and misdiagnosed as conjunctivitis for 18 months.  
 
1.4.2 Microscopic features 
 
The presumed cell of origin is the holocrine sebaceous gland that is distributed throughout 
the skin except the palms of the hand and soles of the feet. They are found within the 
tarsal plate as meibomian glands, the caruncle, at the mucocutaneous junction and when 
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associated with the eyelashes, are termed glands of Zeiss. Nevertheless, there is marked 
morphological variability in terms of cytology and architecture amongst SGC tumours. 
Compounded by the fact that it is rare, there is no universal classification and diagnosis 
can be difficult if the ‘classical features’ are not present.  
 
‘Classical features’ include positive staining for intracytoplasmic fat in frothy acinar-like 
arranged cells (Figure 1.9). This make the diagnosis fairly straightforward in well 
differentiated tumours. Perilipin 2 (PLIN2) stained positively in the majority of a small 
case series of 9: the group found that a panel of stains (PLIN2; cyclin-dependent kinase 
Inhibitor 2A, CDKN2A; mucin 1 cell surface associated, MUC1; androgen receptor 
(AR), keratin 7, type II, KRT7; marker of proliferation Ki67, MKI67) were useful in 
differentiating SGC from BCC or squamous cell carcinoma (SCC).(Ali-Ridha, 2014) 
SGC stained four antibodies: MUC1, PLIN2, CDKN2A and AR; BCC exhibited positive 
staining for KRT7; SCC stained for MUC1 only. A similar small case series supported 
the use of PLIN2 for SGC diagnosis and the presence strong AR staining in pagetoid 
spreading type, although the latter was noted in varying intensities in both BCC and SCC. 
(Becker, 2014) 
 
Staging involves the TNM system and similar to Table 1.3. Microscopic features can be 
divided into growth pattern and differentiation, but in contrast to BCC, it they have a 
different meaning (Figure 1.9). In SGC, growth pattern relates to the lineage of 
differentiation, which essentially means sebaceous cell (rather than eccrine, apocrine or 
follicular gland). This is because SGC can be difficult to diagnose without the ‘classical 
features’ mentioned above especially if it is poorly differentiated. Differentiation is split 
into well, moderately or poorly differentiated; increasing de-differentiation correlates 
with a higher risk of metastasis and recurrence. The presence of poorly differentiated 
carcinoma is a high-risk feature irrespective of the amount seen. Thickness of greater than 
2 mm upgrades the staging from T1 to T2 and confers a higher risk.(Edge SB, 2010) 
Lymphovascular invasion and perineural invasion are noted with increased chance of 
local recurrence and metastasis. Other risk factors include vascular and lymphatic 
invasion, orbital invasion, involvement of upper and lower eyelids, poor differentiation, 
multicentric origin, diameter greater than 10 mm, infiltrative growth pattern and pagetoid 





Figure 1.9 Microscopic appearance of SGC. (A) Pagetoid SGC demonstrating the various skip lesions 
on the conjunctiva of both upper and lower eyelids in this exenterated specimen. (B) SGC highlighting 




Unlike BCC, more intensive staging of the tumour is required to see if it has extensive 
local spread or metastasis. The principles of treatment are to save life, save vision, save 
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normal tissue (best cosmetic outcome) whilst saving dignity as the surgery is mutilating. 
Assessment of the regional lymph nodes using ultrasound, computerised tomography 
(CT) scanning of the orbit, magnetic resonance imaging (MRI) of the head and thorax 
and positron emission tomography (PET) scanning are some of the radiological options 
for staging the disease. If it is localised to the eyelid, then a wide local excision may be 
all that is required to clear the disease. With extensive disease, removal of the whole globe 
and orbital content, exenteration, may be required. If the eyelid skin is not involved (i.e. 
just the conjunctiva and globe) then a skin sparing exenteration is more cosmetically 
acceptable and probably just as safe.(Shields et al., 2001) Furthermore, this may be 
combined with sampling of the regional lymph nodes such as a sentinel node biopsy. 
Local alternative treatment to surgery is radiotherapy although there is controversy to 
how radiosensitive SGC is.(Harvey and Anderson, 1982, Hendley et al., 1979, Nunery et 
al., 1983, Matsumoto et al., 1995, Pardo et al., 1989) Newer techniques of radiation 
delivery such as target splitting non-coplanar RapidArc may be more effective.(Boeva et 
al., 2014) Distant metastasis requires chemotherapy, although it is not clear which 
regimen or length of time is best. Cisplatin and doxorubicin have been successful in one 
patient with lung metastasis.(Koyama et al., 1994) Neoadjuvant chemotherapy with 5-
fluorouracil and carboplatin has also been used with success and prevented lymph node 
dissection. (Murthy et al., 2005, Lisman et al., 1989) 
 
1.4.4 Prognosis and spread 
 
Despite aggressive treatment there is a high recurrence rate and metastasis often occurs 
via the lymphatics to the cervical lymph nodes.(Buitrago and Joseph, 2008) Mortality 
rates were once very high at 29%, but there is a significant range depending on which 
treatment modality is employed and in a can be good as 6% in a centre of 










1.5 Genetic basis for cancer 
 
Cancer is a genetic disease. The discovery of the DNA blueprint for life in 1953 led to 
many theories that mutations transform normal DNA into cancer supporting DNA. These 
mutations can be induced by either environmental factors (UV light, radiation), local 
endogenous factors (reactive oxygen or nitrogen species), be inherited in the germline or 
a combination of all three. The publication of the human genome project in 2001 is one 
of the greatest milestones in understanding the human blueprint and allows us to classify 
these mutations involved in carcinogenesis.(Lander et al., 2001, Venter et al., 2001) It is 
true that in some cases the initiating factor is not a dysregulated gene. For example, 
hepatitis C initiates hepatocellular cancer, Epstein Barr virus initiates Burkett lymphoma, 
asbestos initiates mesothelioma. These external, environmental triggers (carcinogens) do 
effect the genetic makeup and ultimately the progression of the tumour is genetic in 
nature. 
 
Mutations occur spontaneously at 10-8 mutations per base per cell division; with an 
estimate of 1016 cell divisions of our body over a lifetime, then each base within the 
genome has roughly undergone 108 mutations.(Drake et al., 1998) Clearly, we don’t all 
develop cancer (although 1 in 3 will) thanks to the check and controls that either repair 
or remove aberrant DNA. With increasing time, mutations accumulate within the cell and 
the chance of a pathological mutation escaping the normal repair mechanisms increases, 
which is why age is such a strong risk factor in so many tumours. Interestingly, germline 
mutation rates differ from somatic cells with the former actually being lower than the 
latter by almost a half at 10-12.(Orr, 1995) 
 
Not all mutations are pathogenic, the vast majority are synonymous single base change 
whereby the replacement base makes no alteration in the translated protein (Table 1.6).  
Mutations within the DNA encompass a spectrum, ranging from a single base to huge 
chromosomal alterations. There can be confusion with terminology and there are many 
ways to describe a mutation. Therefore, basic genetic and mutation terminology is 
summarised in Tables 1.6 and 1.7. For example, a point mutation means something has 
happened to a single base, but it doesn’t tell you about functional outcome. Synonymous 
and non-synonymous change informs that there is no change in protein, change in protein 
respectively, however, what is the functional outcome of the non-synonymous change. 
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The most ideal layout would be a description of the mutation’s physical change followed 
by a functional report. The latter does however require more investigation with either 
experimentation or the use of predictive algorithms; hence the functional significance of 
the mutation is not always provided. Conventional views on spontaneous mutagenesis 
suggests it is a random event with natural selection shaping the evolution of change, 
though more recently it has been found that the mutational rate varies considerably 
depending on genome location and is influenced by local genetic and epigenetic 




Allele (allelomorph) Alternative form of the same gene located at the same chromosomal position or genetic 
locus. Being diploid, we have 2 alleles at each genetic locus, normally inherited from 
each parent 
Genotype  Actual sequence of the gene 
Phenotype Physical characteristic of a human or organism 
Genetic heterogeneity Similar or identical phenotypes produced by different genotypes 
Pleiotropy A single gene that causes multiple phenotypes 
Polymorphism Variation in the general population that occurs more or equal to 1% 
Transition Replacement of a purine by another purine or pyrimidine by another pyrimidine 
Transversion  Replacement of a purine by a pyrimidine (or vice versa) 
Germline mutation Mutation within the germ cell (sperm/oocyte) making them heritable 
Somatic mutation Acquired mutation occurring in a cell (often referring to the cancer cell) after the first 
division of the embryo. It cannot be passed onto to its progeny 
Driver mutation A mutation actively involved in tumour growth or progression. Deciphering the early 
driver mutation is the dream of the cancer researcher 
Passenger mutation A mutation that plays no active role in tumour development. Nevertheless, passenger 
mutation can become driver mutations during the evolution of the tumour (and vice 
versa). 
Conserved Same amino acid is coded or tolerable change in amino acid sequence 
Null No active product produced 
Gain of function Hyperactive or new function of a gene or protein product 
Loss of function Reduced or no function of a gene or protein product 
Table 1.6 Basic genetic vocabulary. 
 
 
Genes involved in cancer can be broadly described by their functional phenotype into 
three categories namely the oncogene, its nemesis, the tumour suppressor gene (TSG) and 
the stability gene. An oncogene is an inappropriately expressed gene that leads to 
carcinogenesis. A proto-oncogene is the gene in its prior, controlled normal state. Well 
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known oncogene products include growth receptors (for example epidermal growth 
factors, EGF), intracellular signalling molecules (for example tyrosine kinase), cell cycle 
regulators (for example cyclins) and survival factors (for example apoptosis regulator 
Bcl-2, BCL2). Their products can be any type of cellular protein. A collection of 
mutations in growth promoting genes (oncogenes) is thought to happen early in cancer. 
A good example is avian myelocytoviral oncogene (MYC) proto-oncogene that encodes 
a DNA-binding factor, located on 8q24.21, that can activate transcription.(Dang et al., 
1999) Finding these early oncogenes (the early driver mutations) specific to the cancer 
variety will assist in early intervention with a view to cure. Timing is everything, as the 
more the tumour proliferates, the more mutations it collects causing it to ‘branch’ away 
from the tissue of origin (germline DNA) so much so that modification of the early ‘trunk’ 
mutations may no longer have a significant impact on the course of disease. Tumours 
contain millions of cells and the studying the origin and evolution of these cells is termed 
cancer phylogenetics. 
 
TSGs provide the appropriate stop mechanism to normally proliferating cells. Their 
normal function is to control the cell cycle and apoptosis. In contrast to oncogene 
activation, it is ‘loss’ of the tumour suppressor gene that allows uncontrolled growth. 
Presence of these ‘suppressor products’ was demonstrated in an elegant experiment where 
malignant cells that were fused with normal cells started to lose their tumorigenic 
behaviour.(Harris et al., 1969) Over time, loss of certain part of the chromosome in the 
normal cell allowed the return of their tumorigenic behaviour.  
 
The paradigm tumour suppressor gene is the retinoblastoma 1 (RB1) gene found on 
chromosome (Chr) 13q14.1-q14.2 and causes the hereditary childhood cancer, 
retinoblastoma (RB). The RB1 protein binds to the E2F family of transcription factors 
and represses the transcription of genes needed for the S phase of the cell cycle, thus is a 
repressor of the cell cycle. (Nevins, 2001) Furthermore, RB is a paradigm for the 
Knudson’s two hit hypothesis whereby loss of both RB1 genes are required for the tumour 
to develop.(Cavenee et al., 1983) RB can be broadly split into germline (autosomal 
dominant) and sporadic RB cases, although only 10% of children have a positive family 
history: the majority of germline cases are new mutations. Overall 40% of cases carry a 
germline mutation of the RB1 gene with the rest been sporadic. Sporadic mutations only 
occur in one primitive retinal cell (retinoblast) making them unilateral in nature (only 
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affecting one eye) and have no risk of passing it onto their offspring. A germline, 
heterozygous mutation is present in all cells of the body and so the chance of each eye 
containing thousands of retinal cells getting a second hit is high and so tend to present 
with multifocal or bilateral (affecting both eyes) tumours. Nevertheless, unilateral cases 
do not exclude the presence of a germline mutation and 15% of unilateral cases are 
germline in nature, thus genetic screening is done on all patients to determine risk of 
inheritance and prognosis. All germline tumour patients are at risk of secondary tumours 
especially osteosarcoma, and soft tissue sarcoma in up to 19% of cases.(Derkinderen et 
al., 1987) External beam radiation used to be a mainstay treatment for RB, but fortunately 
alternative therapies are available, subsequently reducing the risk of future tumours. The 
risk to offspring of germline carrier RB1 mutations of developing RB is 45% as the 
mutation is non-penetrant in 10% of carriers.  
 
Other common tumour suppressor genes have been discovered in a similar fashion to RB, 
as a result of their specific involvement in familial cancer syndromes: BRCA1/2 in 
breast/ovarian cancer and P53 in Li Fraumeni familial cancer syndrome. P53 is also 
inactivated by somatic mutations and is often found in many types of cancer. TP53, via 
p53 expression, controls DNA synthesis, apoptosis, angiogenesis and senescence in 
normal cells. Loss of p53 expression allows the aforementioned processes to go 
unimpeded and ultimately promote tumour development. 
 
Aberrant stability genes (caretaker genes) don’t promote growth directly, instead they 
lead to either genomic instability or a chromosomal rearrangement that allows an increase 
in mutation rate and uncontrolled replication. Examples of genes involved in stability 
include nucleotide or base excision repair, mismatch repair, telomere metabolism and non 
homologous end joining genes. Moreover, replication timing in somatic cells influence 
the rate of mutagenesis and may contribute to the development or progression of cancer. 
Genome instability can lead to a higher or lower than normal number of chromosomes or 
aneuploidy. Another phenomenon that causes genetic change is chromothripsis. This is 
where the genome undergoes a single catastrophic event whereby one or several 
chromosomes shatter into hundreds of fragments and the DNA repair machinery 
recombines these fragments in an erroneous fashion. Massive gene amplifications or 
deletions can occur to multiple oncogenes or TSGs in a single event. The exact definition 
of chromothripsis is not in agreement, but as a minimum includes 10 copy number 
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variations (CNV) or loss of heterozygosity (LOH) transitions on a single chromosome 
arm. CNV in cancer is termed copy number aberration (CNA) and plays an important role 
in altering genetic function. Detection of this is traditionally done using karyotyping 
where multiple copies or loss of a chromosome is detected using photographs of dividing 
cells arrested in metaphase and stained with Giemsa. Evolution of the technique resulted 
in multicolour fluorescent in-situ hybridisation or spectral karyotyping where each 
chromosome is given its own colour which makes it easier to pick up chromosomal 
rearrangements especially if they are balanced. Comparative genomic hybridisation 
allows the patient normal DNA (say blood) and the tumour DNA to compete with binding 
to normal chromosomes, each with a different colour, say red/green respectively. 
Unaltered regions are demonstrated with equal binding (thus colour) for that region. If 
the region is amplified in the tumour, more green colour would be seen. Newer 
bioinformatic programs have allowed the mining of whole exome sequencing (WES) to 
detect CNA and LOH. This allows the appropriate interrogation of WES data: a variant 
detected  may only be on one allele of the chromosome, but if the opposing allele is lost 
or there are multiple copies of that allele then it will have more of an effect. We used 
three two techniques to interrogate our WES including ASCAT, DNA copy and Varscan 
2 (see Chapter 2). 
 
Descriptive terminology Variant or mutation Alternative terminology 
Synonymous single 
nucleotide variant (snv) 
Single base change with same 
protein 
Synonymous substitution 
Non-synonymous snv Single base change with 
different protein/no protein 
Non-synonymous substitution  
Nonsense if stop codon 
Null mutation if no product 
Mis-sense mutation if one amino acid replaced by 
another  
Point mutation 









Deletion Deletion of any number of 
bases 
 
Insertion Insertion of any number of 
bases 
 
Frameshift Insertion/deletion that alters the 
triplet reading frame 
 
Amplification Increased number of copies of 
gene coding sequence 
 
Copy number variation  Increase in DNA sequence 
(usually large) 
DNA copy number (more copies of a gene within the 
DNA) 
Loss of heterozygosity Loss of one copy of an allele  
Mosacisim  Cells within the same 
individual contain different 
genotypes 
Somatic mosacisim: non-gamete cells contain different 
genotypes 
Germline mosacisim: gamete cells contan different 
genotypes 
Table 1.7 Basic terminologies for describing DNA mutations change in code. 
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Finding the relevant early driver mutations is the desire of cancer geneticists and it may 
then be possible to modify the genes in the future to halt or stem the disease. These critical 
early mutations are significant enough to provide a growth advantage, induce enough 
instability in a relatively normal cell that have defence mechanisms and thus there are 
probably only a few ways it which the mutation can induce uncontrolled proliferation at 
the initiation stage. Other genes are activated at later stages as the cancer diverges from 
normal, although they could have been present at an early stage (termed passenger 
mutations), but had no biological value to the proliferating tumour at that time. These 
passenger mutations, for reasons just mentioned, should not be totally disregarded. 
Identification of critical mutations is often done by comparing the DNA of the tumour 
with the patients germline DNA, say from a blood sample (assuming that it is not a 
haematopoietic cancer; you could use saliva in such cases). Any mutations identified only 
in the tumour DNA are deemed relevant, however, they still need to be grouped into 
harmful or harmless changes. These genetic mechanisms of tumour progression fits well 
with the clonal expansion theory whereby mutant tumour cells have a growth advantage, 
expand and become the dominant cell population.   
  
Changes do not just occur at the somatic or germline genome level, but also happen at an 
epigenetic level too. Epigenetics is about the way the DNA is packaged into chromatin. 
This involves methylation of DNA, histone modification, nucleosome positioning and 
spatial arrangement of the chromatin.  This spatial arrangement allows unpackaging of 
the DNA at certain areas so that only a specific set of genes in the genome are expressed. 
The more specialized the cell, the more epigenetic controls are required. These epigenetic 
controls are passed on to daughter cells and are heritable to allow the developing embryo 
to form, however, whether alterations in these controls can be passed on from parent to 
child is unclear.  Cancer gains reprogrammed epigenetic controls that confer an 
advantage. DNA methylation only occurs (in humans) at cytosine bases located 5’ to a 
guanosine in a CpG dinucleotide, a so called CpG island.(Bird, 2002) These islands are 
both hypo- and hypermethylated in cancer. As almost half of all genes have a CpG island 
associated with their promotor, the tumour takes advantage of this. Promotor methylation 
can silent certain genes and silencing of TSGs occurs in tumours. Interestingly, some 
genes are only silence by methylation, others only by genomic mutation and others still 
by both mechanisms. For example, MutS Homolog 2 (MSH2) is never silenced 
epigenetically whereas MutL Homolog 1 (MLH1) is often epigenetically silenced.(Jones 
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and Baylin, 2002, Baylin and Jones, 2011) In contrast, hypomethylation may induce 
chromosomal instability. A newer concept in epigenetics are topographically associated 
domains (TADs) whereby the human genome is organised into regions of megabases with 
distinct boundaries.(Lupianez et al., 2015) Enhancers and promotors act within a TAD 
and the boundaries act as a shield to those genes outside of this region. Re-arrangements 
of these boundaries can cause enhances to act upon genes outside of their original TAD. 
Loss of these boundaries occur with so called ‘balanced’ CNV or non-coding DNA CNV 
and go on to explain why these changes are tumourigenic.  
 
The ability of tumours to maintain a proliferative state is thought to be related to some 
cancer cells having the ability of self renewal and behaving like a pluripotent stem cell.  
The cancer stem cell theory goes on to say that only a few cancer cells have this ability 
and are there from the very beginning, thus are the initiators of tumorigenesis, but also 
maintains cell division as the tumour progresses. The theory is more robust for 
haematologically malignancies where first evidence came the transplantation of acute 
myeloid leukaemia in mice using a few cells only.(Lapidot et al., 1994) This built on 
evidence of tumour transplantation demonstrated as early as 1937.(Southam and 
Brunschwig, 1961, Hewitt, 1958) Solid tumours have also demonstrated the existence of 
cancer stem cells with it first identified in breast cancer.(Al-Hajj et al., 2003)  
Uncontrolled self renewal is an attractive proposal, however, how they arise in the first 
place and what mechanisms allow their pluripotency are just starting to be unravelled. 
The stem cell theory and clonal expansion theory do not have to be mutually exclusive 
and it is more likely that both mechanisms are acting within cancer. 
   
MicoRNA (miRNA) are short non-coding RNA 22 nucelotide sequences that function as 
post-transcriptional regulation of gene expression in both the physiological and 
pathological state. MiRNA are described with the prefix as the organism, hsa- being homo 
sapiens. Naming of the gene uses a small r, for example hsa-mir-100, whereas the mature 
22 nucleotide sequence has a large R, namely hsa-miR-100. Sequences can be derived 
from both the 3’ and 5’ hairpin precursor with increasing evidence to suggest that both 
are biologically active. They are described with the suffix -3p or -5p. Identical miRNA 
sequences can arise from different genomic loci and a numerical suffix -1, -2 is added to 
distinguish between them. Very similar sequences which are only differ by a few bases 
have a small alphabetic letter suffix to the main numerical identifier, for example hsa-
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100a and hsa-100b. The public repository miRBase is useful resource to  correctly 
describe and discover their genomic location.(Kozomara and Griffiths-Jones, 2014) 
MiRNA and epigenetic factors are regulators of gene expression. MiRNA undergo 
epigenetic modification under that same constraints as protein coding genes, however, 
miRNA can directly target epigenetic machinery such as DNA methyltransferases or 
histone deacetylases. This epigenetic-miRNA regulatory circuit can be disturbed in 
tumours and adds another layer of complexity when trying to dissect carcinogenesis.(Sato 
et al., 2011) MiRNA binds to messenger RNA and depending on their degree of base pair 
homology (Watsonian match), the mRNA undergoes cleavage or translational repression. 
This causes silencing of mRNA expression, however, it can also increase the expression 
of mRNA. Moreover, they have been shown to target DNA directly. Genomic regions 
associated with cancer that undergo LOH, amplification and deletion also contain miRNA 
plus the alteration of the miRNome has been shown in several cancers.(Calin 2004Proc , 
calin 2006Nat rev) In a similar fashion to gene, oncogenic miRNA are labelled oncomiR 
and others, such as hsa-miR-199a,  have been found to be tumour suppressive.(Cho, 2007, 
Cheng et al., 2012) 
 
1.6 Basal cell carcinoma genetics 
 
The genetics of BCC has been alluded to by the analysis of basal cell naevus syndrome 
(BCNS, aka Gorlin syndrome). This is a condition where patients develop multiple BCCs, 
medulloblastoma and craniofacial defects. It is an autosomal dominant, heterozygous 
germline deletion of the gene Patched 1 receptor (PTCH1) located on Chr9q.22.32 (Table 
1.8).(Lorenz and Fuhrmann, 1978) The location of the gene was initially identified using 
linkage analysis and narrowed down to Ch9q22.3-q31.(Farndon et al., 1992) The human 
homologue of Drosophila PTCH was then identified as the likely candidate for BCNS 
and sporadic BCC.(Gailani et al., 1996, Johnson et al., 1996) Moreover, Knudson’s two 
hit hypothesis was suggested to apply to the all components of BCNS, however, 
hemizygosity is enough for the craniofacial malformations, but homozygosity is required 
for cancer development.(Levanat et al., 1996) PTCH1 is essentially a tumour suppressor 
gene as it role is to maintain the Hh pathway in the off state when no ligand is present. 
Loss of this repression will lead to uncontrolled and continuous activation of the pathway. 
The heterozygous mutation is sufficient to induce the skeletal defects during 
embryogenesis, however, the genesis of BCC requires a second hit (the Knudson’s two-
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hit hypothesis). An environmental insult is thought to cause the mutation in the second 
allele (such as UV light damage), however, the majority will be compound heterozygous 
(same gene, but not exactly the same location). This implicates that dysregulation in the 
hedgehog (Hh) signalling pathway is an early event in the development of BCC. Inherited 
BCC only account for 1-2% of the BCC workload and the vast majority arise sporadically. 
Sporadic BCC have shown heterozygous PTCH 1and PTCH2 mutations, however, it is 
not universal.(Jayaraman et al., 2014) Nonetheless, other parts of the Hh signalling 
pathway have been mutationally affected such as smoothened (SMO).(Otsuka et al., 
2015, Pricl et al., 2015) 
 
 
Disease Defective gene Cytogenetic locality 
Albinism Tyrosinase (TYR) 
Oculocutaneous Albinism II (OCA2) 
Tyrosinase-Related Protein 1 (TYRP1) 
Solute Carrier Family 45, Member 2 (SLC45A2) 
Hermansky-Pudlak Syndrome 1 (HPS1) 







BCNS Patched receptor 1 (PTCH1) 
Patched receptor 1 (PTCH2) 
9q22.32 
1p34.1 
Bazex’s syndrome Unknown Xq24-q27 
Rombo syndrome Unknown: Possibly a DNA repair or cell cycle regulation 
gene 
Unknown 
Xeroderma pigmentosa Excision Repair Cross-Complementation Group 4 (ERCC4) 16p13.12 
Table 1.8 Syndromes associated with BCC highlighting genetic heterogeneity 
 
1.7 Sebaceous gland carcinoma genetics 
 
The genetics of sebaceous gland carcinoma is essentially unknown. Muir-Torre syndrome 
is where alterations in the DNA mismatch repair genes MSH2 located on Chromosome 2 
(2p21) or MLH1 located on Chromosome 3 (3p22.5) lead to cutaneous and visceral 
tumours.(Schwartz and Torre, 1995) These cutaneous tumours include sebaceous 
adenoma, keratocanthoma, BCC, and visceral include colorectal adenocarcinoma and 
genitourinary malignancies. It resembles a hereditary non-polyposis colorectal cancer 
syndrome (HNPCC), and is autosomal dominant in nature. HNPCC involves changes to 
DNA microsatellites. These microsatellites are short repeats of DNA that are often read 
incorrectly by DNA polymerase. Proof reading mechanisms (also known as mismatch 
repair mechanisms) have to compare the newly synthesized (sense) strand to the template 
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strand to pick these incorrect reads made by the DNA polymerase and repair them. Failure 
of these mismatch repair (MMR) gene products to pick this up, leads to HNPCC. There 
are six MMR genes and listed in Table 1.9. MSH2 is the most frequent change seen in 
HNPCC. Although commonly associated with sebaceous gland carcinoma, its true 
association is actually rare (sebaceous adenoma is the true association): a case series of 
60 revealed only one case of Muir Torre syndrome, highlighting that this (SGC) is 
unlikely to be a syndrome condition.(Shields et al., 2004, Svajdler et al., 2015) Moreover, 
sebaceous adenoma does not seem to convert into sebaceous carcinoma (i.e. it is not a 
premalignant step to the development of SGC).(Lazar et al., 2007) Nevertheless, in up to 
40% of cases in MTS, the sebaceous adenoma predates the internal malignancy and so it 
is still recommended to screen for mismatch repair gene products. Furthermore, 
immunostaining of the sebaceous adenoma for MLH1 and MSH2 proteins is a valid tool 
to help diagnose MTS.(Jagan, 2014) 
 
Periocular SGC has not been readily investigated. Kim et al carried out some 
immunostaining comparing metastatic with non-metastatic SGC to find that the 
metastatic group demonstrated higher expression levels of sonic hedgehog (SHH), wnt 
and ATP-Binding Cassette, Sub-Family G, Member 2 (ABCG2).(Kim et al., 2013d) A 
retrospective study looked at 16 cases and using immunostaining identified increased 
expression of b-catenin, cellular retinoic acid binding protein 2 (CRABP2) and fatty acid-
binding protein 5 (FABP5) compared to controls.(Tsai et al., 2015) Over expression of 
ZEB2 by immunostaining was associated with lymph node metastasis and poorer 
prognosis in a 65 case study.(Bhardwaj et al., 2015) Fluorescence in situ hybridization 
highlighted extra copies of two epidermal growth factor (EGF) receptors, namely 
epidermal growth factor receptor (EGFR) and Erb-B2 Receptor Tyrosine Kinase 2 
(ERBB2) along with fibroblast growth factor receptor 1 (FGFR1) 3-6 of 49 SGC 
cases.(Lee et al., 2015) 
  
Gene Cytogenetic locality 
MutS Homolog 6 (MSH6) 2p16.3 
MutS Homolog 2 (MSH2) 2p21 
PMS1 Postmeiotic Segregation Increased 1 (S. Cerevisiae) (PMS1) 2q32.2 
MutL Homolog 1 (MLH1) 3p22.5 
PMS2 Postmeiotic Segregation Increased 2 (S. Cerevisiae) (PMS2) 7p22.1 
MutL Homolog 3 (MLH3) 14q24.3 
Table 1.9 Mismatch repair genes and their cytogenetic location 
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1.8 Cancer signalling pathways 
 
Genes are functional units of DNA. This functional code produces a transcript (primary 
RNA) in the nucleus, becomes modified by splicing the introns out to produce a 
messenger RNA (mRNA) that moves into the cytoplasm.  The primary structure of RNA 
is similar to DNA except that it is single stranded with ribose instead of deoxyribose and 
thymine (T) is replaced by uracil (U). MRNA is composed of trinucleotide repeats 
(codons) which produce 64 combinations; of these 3 encode stop codons (UGA, UAG, 
and UAA) and the other 61 encode 20 amino acids. Interestingly, the genetic code is 
universal across all species - the same codons specify the same amino acids in all of life. 
Aminoacyl-transfer RNA (tRNA) reads the mRNA cipher within the ribosome to align 
the correct amino acids to form the polypeptide chain. The polypeptide undergoes many 
post-translational modification steps including folding, chemical modification and 
transportation before forming a protein. Moreover, one gene can code for more than one 
protein as a result of splicing out different parts of the primary RNA. Furthermore, genes 
are switched on and off depending on the state of the cell. Some genes code for pathways 
that are essential for embryogenesis, but are switched off in most adult cells. Hh, EGF 
and wingless-type MMTV (wnt) are examples of such pathways that are highly active 
during embryogenesis, but most of the time lay dormant in adult cells. These embrogenic 
pathways promote growth and the laying down of new tissues, hence in cancer these 
proliferative pathways are reactivated. 
 
1.8.1 Hedgehog signalling pathway 
 
Hh is a critical embryonic pathway whose role is essential for temporal and positional 
development of tissue such as the appendages. It is switched off in the majority of adult 
cells bar transient expression in hair follicles, reproductive organs and parts of the brain 
along with a role in stem cell maintenance.(Petrova and Joyner, 2014, Sahin et al., 2014, 
Morales et al., 2009) Three Hh protein homolog’s bind to PTCH1, a cell membrane 
receptor, to initiate the canonical Hedgehog (Hh) pathway. SHH, indian hedgehog (IHH) 
and desert hedghog (DHH) are the three homologs. SHH is involved in polarising limb 
buds and notocord organisation; IHH controls cartilage and bone development; DHH is 
required for germ cell development and nerve sheath construction.(Briscoe and Therond, 
2013) In the absence of the ligand, PTCH1 represses the activation of SMO, a receptor 
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on the membrane of intracellular endosomes, effectively keeping it in the off position. 
Binding of the ligand removes PTCH1 repression allowing the translocation of SMO 
from the endosome to the primary cilium where it activates the Glioma-associated 
oncogene (Gli) zinc finger transcription factors 1,2 and 3 (Figure 1.10). Gli then enter the 
nucleus to activate or repress target genes. Gli1 is mainly described as an activator, Gli3 
a suppressor, and Gli2 as having dual function.(Briscoe and Therond, 2013) 
 
 
Figure 1.10 Canonical Hedgehog signalling pathway. Orange circle denotes available therapeutic agents, 
namely SMO inhibitors. Blue circle denotes newer therapies being developed for more downstream 
inhibition of the Hh pathway (Adapted from KEGG pathway) 
 
SMO promotes the dissociation of the Supressor-of-fused (SUFU)-Gli complex. Three 
kinases regulate Gli processing within the primary cilia: protein kinase A (PKA), casein 
kinase 1a (CK1) and glycogen synthase kinase 3b (GSK3B). Kinesin Family Member 7 
(KIF7) partly controls movement around the primary cilia. All Gli have C-terminal 
activation domains, but only Gli2 and 3 have N-terminal repressor domains. The 
activating C-terminal domain undergoes phosphorylation and partial proteolytic cleavage 
Introduction	
	 52 
in the ‘off state’ allowing the N-terminal and DNA blinding sites to translocate to the 
nucleus to repress transcription. ‘On state’ (binding of the Hh ligand) inhibits 
phosphorylation and proteolytic cleavage, allowing C-terminal activator domains to 
become functional.(Briscoe and Therond, 2013)  
 
1.8.2 Hedgehog activation in cancer 
 
Pathological activation of Hh signalling occurs in a variety of cancers, including inherited 
BCC, prostate cancer, upper gastrointestinal tumours, a subset of small cell lung 
carcinoma and pancreatic ductal adenocarcinoma; the role being different in each: 
initiation of tumour, excess ligand being essential for tumour growth, cancer cell survival, 
maintenance of malignant phenotype, and both early and late regulation of tumorigenesis 
respectively.(Berman et al., 2003, Watkins et al., 2003, Thayer et al., 2003, Dahmane et 
al., 1997, Sanchez et al., 2005) BCNS highlights the cancer initiator role of the Hh 
pathway, presumably by its role in stem cell maintenance of the hair follicle and Purkinje 
cells where BCCs and medulloblastomas are thought to arise respectively. Gli-1 over 
expression is seen in both inherited and sporadic BCCs.(Dahmane et al., 1997) The 
diversity of Hh involvement reflects it varied function, but also means there is no simple 
solution or modification of the Hh pathway that would help all tumours as reflected by 
discouraging results seen by cancer trials with Hh pathway inhibitors.(Gonnissen et al., 
2015) Where no Hh pathway mutation is found, the role of Hh in such cases could be to 
promote the Warburg glycolytic metabolism, to help support tumour development or 
promote tumour microenvironment possibly via a stromal paracrine signalling 
effects.(Teperino et al., 2012, Yauch et al., 2008)  
 
Much excitement has surrounded the development of SMO inhibitors to treat Hh pathway 
associated cancers. Vismodegib was shown to successfully in patients with BCNS: it 
reduced the burden of skin BCCs clinically and showed a 90% reduction in Gli-1 mRNA 
levels at one month post-treatment.(Sekulic et al., 2012) Unfortunately, 54% discontinued 
drug usage due to side effects including loss of taste, hair, weight and muscle cramps. 
Good initial responses are seen with the drug, but secondary resistance has been 
noted.(Pricl et al., 2014, Pricl et al., 2015) Vismodegib has also been used in metastatic 
pancreatic adenocarcinoma with less success, although at a molecular level it showed 
reduced levels of Gli-1 and PTCH1, the pool of cancer stem cells remained and at a 
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clinical level, survival was inferior to a more traditional chemotherapy drug 
Gemcitabine.(Kim et al., 2014) 
 
1.8.3 Epidermal Growth factor (EGF) pathway 
 
EGF pathway is an essential pathway for cell growth, differentiation and proliferation 
both in the developing embryo and adult. A family of tyrosine kinase receptor mediates 
its action, namely EGFR, ERBB2, erb-B2 receptor tyrosine kinase 3 (ERBB3) and erb-
B2 receptor tyrosine kinase 4 (ERBB4) or more commonly known as human epidermal 
receptor (HER)-1, HER2, HER-3 and HER-4. A number of different ligands can bind to 
each receptor that resides on the plasma membrane. Dimerisation of the receptor occurs 
to trigger a cascade of events depending on the ligand/receptor involved. Events comprise 
of protein synthesis, glycolysis and via nuclear localization, gene regulation, kinase 
function and protein interactions. EGF receptors can even translocate to the 
mitochondrion to activate cytochrome c oxidase subunit II; a critical pathway of oxidative 
phosphorylation.(Boerner et al., 2004) The commonest ligands are EGF, heparin-binding 
EGF-like growth factor and transforming growth factor-a. Activated EGFR can signal 
via a kinase-dependent or kinase-independent route. The former signals phospholipase-
Cγ/protein kinase C (PLC-g/PKC); rat sarcoma viral oncogene homolog/rapidly 
accelerated fibrosarcoma kinase/mitogen activated protein kinase kinase/mitogen 
activated protein kinase (Ras/Raf/MEK/MAPK); phosphatidylinositol 3-kinase/ RAC-
alpha serine-threonine-protein kinase/ Mechanistic Target Of 
Rapamycin (PI3K/AKT/mTOR); Janus Kinase 2/ Signal Transducer And Activator Of 
Transcription 3 (JAK2/STAT3) and STAT3 (independent of JAK2). The latter signals 
MAPK, AKT pathway, Solute Carrier Family 5 (Sodium/Glucose Cotransporter), 
Member 1 (SLC5A1) and BCL2 Binding Component 3 (BBC3) usually by direct 
interaction with proteins. 
 
1.8.4 EGF pathway in cancer 
 
Several cancers have demonstrated increased activity of EGF pathways via mutation of 
the EGFR, upregulation of the EGFR or via a receptor independent route. EGFR mediated 
carcinogenesis is summarised in Table 1.10. Mutations are seen in the tyrosine kinase 
portion of the EGFR in a subtype of lung cancer, non-small cell lung cancer 
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(NSCLC).(Bunn and Franklin, 2002) Being on the plasma membrane, targeted therapy 
using antibodies and tyrosine kinase small molecule inhibitor. Erlotinib and Gefitinib are 
the first-generation tyrosine kinase inhibitors. Erlotinib versus carboplatin-gemcitabine 
chemotherapy in NSCLC demonstrated progression free survival (PFS) rates of 13.1 
months versus 4.6 months respectively.(Zhou et al., 2011) Gefitinib versus carboplatin-
paclitaxel chemotherapy demonstrated PFS rates at 12 months of 25% versus 7% 
respectively.(Mok et al., 2009) Subsequently, similar EGFR changes were noted in 
certain types of breast, colorectal cancer and pancreatic cancer, where the drugs have 
been used. 
 
Pathways do not act in isolation, and cross talk between pathways is likely to constantly 
be happening. This adds a layer of complexity when trying to dissect out important driver 
pathways.  An example of crosstalk in BCC was demonstrated by an over expressing Gli1 
(Hh signalling) cell line model of nodular BCC, that repressed  MAPK1 (EGF signalling) 
which kept the cell nodular like colonies in an epithelial phenotype preventing 
migration.(Neill et al., 2008)  
 
Receptor Pathway and action 
EGFR Ras/Raf/MEK/MAPK pathway: cell proliferation 
FAK pathway: tumour migration 
STAT3 pathway: gene transcription 
PI3K pathway: cell survival 
ERBB2 HER1/HER2 - MAPK pathway: cell proliferation 
HER2/HER3- PI3K  pathway: aggressive phenotype 
HER2/HER3-may confer drug resistance 
Note: there is no known ligand that binds to HER-2, nevertheless, HER-2 is the preferred 
dimerisation partner with the other receptors 
ERBB3 HER2/HER3- PI3K signalling pathway: aggressive phenotype 
HER2/HER3-may confer drug resistance 
Note: HER-3 can bind multiple ligands but cannot carry out kinase activity, requiring dimerisation 
with another ligand, commonly HER2, to function 
ERBB4 Tissue differentiation 
Binds multiple ligands 
 







1.9 Stromal milieu in cancer 
 
Cancer behaviour is not restricted to the tumour borders delineated on microscopy; the 
surrounding apparent normal tissue, termed stroma, has been shown to play a key role in 
local spread.(Davidson et al., 2014) During embryogenesis, communication between 
epithelial tissue and surrounding stroma occurs by Hh signalling in order to promote 
growth and differentiation of the stroma: urogenital epithelium utilises Hh signalling to 
promote surrounding tissue to develop into the prostate gland.(Podlasek et al., 1999) 
Reactivation of this paracrine phenomenon of Hh signalling has been shown in prostate 
cancer stroma and the tumour regulates the proliferation of adjacent non-malignant 
epithelium.(Wilkinson et al., 2013) Studies in ovarian cancer have highlighted the 
importance of the changes in the stroma that confer a poorer prognosis and the promotion 
of local invasion in morphoeic BCC has been demonstrated by modulating the stromal 
milieu.(Marsh et al., 2008, Davidson et al., 2014, Kataoka et al., 2012)  
 
Preliminary in vitro and in vivo work in the lab highlighted that local invasion seen in the 
morphoeic subtype was promoted by the integrin beta 6 (ITGB6) through activation of 
transforming growth factor-beta 1 (TGFB1) that modulates the surrounding 
stroma.(Marsh et al., 2008) Furthermore, TGFB1 may be the culprit of the 
myofibroblastic phenotype that is seen surrounding the morphoeic tumours.  
 
1.10 Hypothesis and aims of study 
 
Periocular malignancy represents an increasing burden and currently requires disfiguring 
surgery in attempt to cure patients. Basal cell carcinoma is the commonest cancer 
worldwide and morphoeic BCC is an aggressive subtype requiring more intensive 
surgical excision. Sebaceous gland carcinoma is a rare, but life threatening condition that 
often requires blinding surgery to prevent mortality. The genetic and molecular 
characteristics of these tumours have not been studied in detail. For BCC, exome 
sequencing of 10 BCC elucidated some candidate genes, however, the subtypes were not 
mentioned which means the majority or all were nodular as these are the most common. 
The genetics of the aggressive subtype has not been looked at. As mentioned, pilot studies 
in the Philpott lab on human cell lines have suggested a difference in the Hh expression 
levels account for the varied phenotype or behaviour between nodular and morphoeic 
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subtypes. Furthermore, modification of the surrounding apparent normal stromal tissue 
to promote local spread. Immunostaining has been the mainstay of SGC investigation and 
recent studies have excess SHH ligand implicating the Hh signalling pathway in SGC 
carcinogenesis. A two-stage approach was taken to elucidate tumorigenesis. Firstly, a 
discovery approach identifying the mutational burden along with driver mutations was 
undertaken. Secondly, a functional analysis of the transcriptome and protein was 
performed to implicate pathways, including Hh, involved and relate them to the 
mutational burden.  
 
Hypothesis: The interplay between Hedgehog and other pathway signalling in BCC and 
SGC, along with differences in tumour and stromal expression underlies the pathogenesis 
of different histological subtypes and their degree of invasiveness.  
   
Two main approaches were taken to study this: 
i) Mutational burden analysis to discover new driver mutations 
ii) Transcriptome and protein investigation to identify known and novel pathways and 
relate this to the mutational discovery 
 
In order to answer this hypothesis, the following aims were formulated: 
1) Obtain ethical approval across multi-site to recruit as many patients as possible over 
the 3 years 
2) Create a multi-specialty collaboration between ophthalmology, dermatology, 
pathology, molecular genetics, molecular biology, bioinformatics 
3) Obtain funding for the project 
4) Devise protocol for nucleic acid extraction from patient’s blood and tumour as well 
as transfer to the lab 
5) Perfect laser capture microdissection to obtain pure tumour 
6) Ensure correct bioinformatics pipeline for next generation sequencing analysis 
7) Mine data to identify driver mutation, transcriptome changes in relation to known 
and unknown pathways 
8) Carry out verification and validation of data 
9) Present and publish data. 






METHODS AND MATERIALS 
 
2.1 Human tissue 
 
2.1.1 Ethical approval for the use of human tissue 
 
Prospective approval 
The concept, design, and ethical approval was all performed by myself in the preceding 
two years of the PhD. A new collaboration was forged between Moorfields Eye Hospital 
(MEH), Institute for Ophthalmology (IoO), Blizard Institute and Barts cancer Institute 
(BCI). Expansion of ethical approval and collaboration with Guys and St Thomas’ NHS 
Trust (GSTFT) occurred during the PhD.  
 
Ethical approval was granted to acquire prospectively tissue samples of human nodBCC, 
mBCC and SGC along with blood samples over 3 years from patients attending MEH. 
MEH Biobank research ethic committee (REC), reference 10/H0106/57-2012ETR28, 
established the approval. Following informed consent (Figure 2.1) from the patient, a 
small part of surplus tumour was taken for research during the routine scheduled eyelid 
cancer surgery, the margins were not compromised and the remaining tissue sent for 
routine histopathological examination at the IoO. The patient’s normal treatment was not 
affected in any way. Several Moorfield’s patients went onto to have Mohs micrographic 
excision at St Thomas’ Hospital (acting as a tissue collection centre) and further surplus 
tissue was collected if required. Permission for St Thomas’ hospital to become a tissue 
collection centre was gained from GSTFT research and development team and given the 
local number RJ113/N155.  
 
A proportionate REC amendment was sort to convert St Thomas hospital from a tissue 
collection centre for MEH patients only into a full recruitment centre for the 
aforementioned tumours. National Research Ethics Service (NRES) Committee North 
West - Greater Manchester South conferred a favourable opinion and coded the study as 
follows 14/NW/1080. Thus, the project recruited in similar fashion patients attending the 
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Dermatological Surgery and Laser Unit at St Thomas’ Hospital for Mohs micrographic 
surgery directly without a prior visit to Moorfields Eye Hospital.  
 




St John’s Institute of Dermatology 
Guy's Hospital 
Great Maze Pond 
London SE1 9RT 
Telephone: 020 718 86273 / 86277 / 89142  
Fax 020 718 86113  
Email: stru@gstt.nhs.uk 
Version 2.2, 1/6/14 




SUBJECT INFORMATION SHEET and INFORMED CONSENT FORM 
Title of Study: Identification of genetic factors involved in morphoeic basal cell (mBCC) 
and sebaceous gland carcinoma (SGC) of human eyelid tumours with a view to identifying 
potential treatment targets. 
Version and Date of Subject Information Sheet/Informed Consent: 1/6/14 Version 2.2 
Ethics Committee Code: Ethics Committee Code: 14/NW/1080 
 
Name of Researcher: Dr John Bladen       Please initial box 
 
1. I confirm that I have read and understand the information sheet dated 1/6/14 (version 2.2) 
       for the above study and have had the opportunity to ask questions. 
 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time,  
 without giving any reason, without my medical care or legal rights being affected. 
 
 
3. I understand that sections of any of my medical notes may be looked at by responsible  
 individuals of the sponsor or research site and from regulatory authorities where it is  
       relevant to my taking part in research. I give permission for these individuals to have  
       access to my records. 
 
4.   I agree that my tissue samples (tumour sample and DNA extracted from my blood) will be  
      sent to the Blizard Institute at Barts and the London School of Medicine where it will be 
      anonymised and stored for the duration of the study, then stored at MEH Biobank. 
 
5.   I agree to being recalled in the future (up to 5 years) if you need further clinical information 
 and Biological samples from me.  I understand that this part of the study is entirely optional. 
 
 
6. I agree to take part in the above study.    
 
 
________________________ ________________ ____________________ 
Name of Patient Date Signature 
 
 
_________________________ ________________ ____________________ 
Name of Person taking consent Date Signature 
(if different from researcher) 
 
 
_________________________ ________________ ____________________ 




Archival tissue stored at the Moorfields Biobank was given approval for use by the 
Biobank REC under the same prospective reference (10/H0106/57-2012ETR28).  
 
2.1.2 Funding and Sponsorship 
 
Fight For Sight UK 
Fight For Sight (FFS) is an eye charity that awarded me with a clinical fellowship to carry 
out the three year PhD with a grant of £189,957 (reference number 1327/28). Their ethos 
is to prevent and treat eye conditions. Part of the fellowship involved patient and public 
engagement in order to promote their research portfolio. This included carrying out 
lectures for the speakers network designed to engage with not only eye professionals, but 
also allied organisations including those involved in the eye trade (selling glasses/contact 
lenses) and those in non-eye related primary care. In addition, the FFS website provides 
a wealth of educational information on eye conditions accessible to the public.  
 
National Institute for Health Research Clinical Research 
The National Institute for Health Research (NIHR) clinical research network (CRN) 
comprises of 15 local clinical research networks working together to record and support 
clinical studies. The study was registered onto the national portfolio of studies in an 
anonymised fashion. This is accessible to members of the public who can learn about the 
project and see how many people have been recruited. Access to the portfolio is via the 
following link: www.crn.nihr.ac.uk/can-help/funders-academics/nihrcrn-portfolio. 
Furthermore, NIHR Moorfields Biomedical Research Centre provided an award 
amounting to £18,120 to help with consumable costs during the final PhD year. 
  
Sponsor 
Queen Mary University of London (QMUL) was the acting Sponsor of the study as 
defined in the Research Governance Framework for Health and Social Care Act 2005 and 
filed under ReDa reference 008621 QM. Furthermore, the study was insured by Arthur J 






2.1.3 Informed Consent 
 
Informed consent was obtained from all patients with the help of a specially designed 
peer-reviewed patient information sheet (Figure 2.2). The inclusion criteria for patients 
into the study included those aged between 18-90; both male and female; tissue diagnosis 
of SGC, mBCC or nodBCC using predetermined definitions as laid out in the RCPath 
datasets; first presentation; previous non-cancerous surgery to eyelid. Exclusion criteria 
included previous chemotherapy or radiotherapy; recurrence; children under 18; 
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St John’s Institute of Dermatology 
Guy's Hospital 
Great Maze Pond 
London SE1 9RT 
Telephone: 020 718 86273 / 86277 / 89142  






SUBJECT INFORMATION SHEET and INFORMED CONSENT FORM 
Title of Study: Identification of genetic factors involved in morphoeic basal cell (mBCC) 
and sebaceous gland carcinoma (SGC) of human eyelid tumours with a view to identifying 
potential treatment targets. 
Version and Date of Subject Information Sheet/Informed Consent: 3/7/14 Version 2.3 





You have been invited to participate in a study to look for the genes that may cause your eyelid tumour. Please 
take your time to decide whether you would like to participate. Discuss it with your friends and family. Please ask 
the study doctor or nurse to explain anything you do not understand. 
 
WHAT IS THE PURPOSE OF THE STUDY? 
 
This study is part of a PhD research project on eyelid cancer undertaken by Dr John Bladen (specialised registrar 
in Ophthalmology) and is designed to answer the following questions (which may or may not be relevant to you): 
 
1) Why do some people develop eyelid cancer and some people don’t? 
2) Why do some people get more aggressive forms of cancer and some patients don’t? 
3) Why do some patients respond to their treatments and some don’t? 
4) Is there any way we can predict whether your eyelid tumour will get better or worse over time? 
5) Can we develop tests to aid in the diagnosis of the aggressive cancer subtypes? 
6) Can we use this information to develop better treatments? 
 
WHAT WILL THE STUDY ENTAIL? 
 
1) Donation of the removed cancer tissue sample that is taken as part of your normal treatment and 
routinely destroyed. Importantly, no extra tissue will be removed and your operation will not be 
modified in any way. In addition, it does not affect your diagnosis or subsequent treatment. 
2) A member of the study team will look at your medical notes 











2.1.4 Sample retrieval 
 
Material transfer and storage of tissue and blood 
Both archival and fresh tissue samples, along with blood samples, were sent to Blizard 
Institute, Barts and the London School of Medicine, QMUL, 4 Newark Street, E1 2AT. 
Samples were be collected and personally couriered by myself and stored in the 
aforementioned Institute under the care of Professor Mike Philpott. At the end of the 
study, all samples were returned for storage at Moorfields Eye Hospital Biobank or 
destroyed. 
 
Data collection, handling and record keeping 
All tumour samples were anonymised at the point of retrieval.  No patient identifiable 
details were collected. Anonymised data were kept on specific password protected, and 
encrypted computers. Excel software was used to collate results. In addition, the collated 
results were loaded onto the NIHR CRN portfolio as mentioned. Records will be kept for 
5 years after completion of the project then erased. In addition, the project adhered to the 
Data Protection Act 1998 and Caldicott principles. 
 
Fresh sample retrieval 
Surplus fresh cancer tissue was removed, ensuring that the borders remained intact, from 
the patient prior to placement in formalin and embedded in paraffin for histological 
examination. During Mohs micrographic excision, the debulking tissue was taken for 
research. The research sample was placed into a nuclease free, UV treated 2 µl 
microcentrifuge tube. Marking of the skin surface during retrieval using a surgical 
marking pen allowed for correct tissue orientation for subsequent cryosectioning. Once 
the tube was labelled with the randomised number, the sample was placed into dry ice for 
snap freezing and transported to store in the -80°C freezer. Thickness of the sample rarely 
exceeded 5mm in the thinnest dimension and this allowed for successful rapid freezing 
using dry ice alone. An initial test comparison was made using liquid nitrogen for snap 
freezing and tissue integrity was similar in both as long as the sample remained small. At 
worst, a thick sample would show ice crystal formation with slight loss of tissue 
architecture on H+E staining, however, this did not affect the integrity of nucleic acid for 
extraction, including RNA. In addition, the use and transport of liquid nitrogen between 
tissue collection sites and the lab was prohibitive. 
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2.2 Preparation of tissue for nucleic acid extraction 
 
2.2.1 Preparation and cutting of fresh tissue  
 
Tissue was transferred to the cryostat-microtome (Leica CM3050S) machine on solid 
carbon dioxide (dry ice or CardiceÒ). Cutting of tissue was done at -23ºC (both the 
specimen and chamber temperature). Tissue was orientated so that transverse cross-
sections were obtained with the epithelial surface on top and the subcutaneous layer at 
the bottom aided by the marking made at the time of surgery. Once correctly orientated, 
the tissue was embedded into a bead of optimal cutting temperature medium (OCT: 
Tissue-Tek® Sakura® polyethylene glycol and polyvinyl alcohol <11%) for DNA 
extraction or 0.1% DiEthylPyroCarbonate (DEPC, Sigma-Aldrich®) water for RNA 
placed on a chuck at -23°C. Tissue was cut at a thickness of either 10 µm onto a laser 
capture microdissection slide for nucleic acid extraction or 7 µm onto a plain glass slide 
(Shandon Colorfrostä Plus, Thermo scientific) for histology. 
 
2.2.2 Preparation and cutting of formalin fixed paraffin embedded (FFPE) 
 
At the time of tissue collection, the rest of the sample was sent for histological analysis 
to ensure the borders are clear by fixing the tissue in formalin. The specimen was taken 
to the Institute of Ophthalmology (IoO) where it was cut and embedded into paraffin. 
Borders were then reported on to determine clearance for the patient. Once the clinical 
examination was completed and specimen reported on, the surplus FFPE tissue blocks 
were used for research purposes. Excess paraffin was trimmed off and research sections 
were cut 10 µm thick using a clean blade rinsed in DNAZap™ (Life technologies™) and 
RNaseZap® (Applied Biosystems®, Life technologies™) on a Leica microtome 
RM2255. The blocked was cooled to aid cutting and prevent shredding. Tissue sections 
were floated on 0.1% DEPC water (Sigma-Aldrich®). 
 
2.2.3 Laser capture microdissection of fresh tissue 
 
Slide pretreatment 
Tissue was placed onto a laser capture microdissection (LCM) slide covered with 
polyethylene naphthalate (PEN)-membrane (Carl Zeiss MembraneSlide 1.0 PEN) and 
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pretreated with UV light at 254 nm for 45 minutes. The UV rays convert and the relatively 
hydrophobic PEN membrane into a more hydrophilic structure that allowed for better 
adherence of the sections to the slide. Furthermore, the UV lights breaks down any 
potentially contaminating nucleic acids that may be on the surface of the slide. Tissue of 
10 µm thick was placed onto the slide using the cryostat-microtome (Leica CM3050S) 
and the box immediately put onto dry ice. 
 
Staining of nuclei using methyl green to determine area of interest 
The LCM slides were removed from the box on dry ice and allowed to defrost briefly. 
When the tissue turn from opaque (frozen) to clear (just defrosted) a drop of methyl green 
was placed onto the tissue and washed off using DNase, RNase, and nuclease-free, 
deionised water (Qiagen® nuclease-free water) after 5 seconds only. The slide was air 
dried momentarily before being placed into the box on dry ice. Despite the rapid staining, 
this was more than adequate to visualize tumour tissue from normal structures (Figure 
2.3). The glass bottle used to make the meythl green was cleaned using DNAZap™ (Life 
technologies™) and RNaseZap® (Applied Biosystems®) Moreover, the Qiagen® 
nuclease-free water was used to make up the solution. 
 
 






The PALM microBeam (version-1105) Carl Zeiss LCM device was used to cut and 
collect the specimens. The machine was cleaned before use to avoid contamination and 
one slide at a time was used with the rest kept cool in a box containing dry ice. The 
settings for LCM were speed at 15%, focus 79 with delta 2 at x10 magnification and cut 
energy of 35 J. At x5 magnification, cut speed was 30%, focus at 78 with delta 2 and cut 
energy was at 53 J. Two techniques were employed for removal of tissue from the slide 
depending on the size of the material of interest. Sizes smaller than 1mm utilized the laser 
pressure catapulting (LPC) mode where the circumference is ablated and the cut area 
subsequently catapulted into an opaque AdhesiveCap (Carl Zeiss). Tissue greater than 
1mm was removed using two sterile, 25 gauge needles and placed into a 1.5 µl 
microcentrifuge tube containing 180 µl of buffer ALT and 30 µL of proteinase K 
(Qiagen® QIAamp® DNA micro kit). Tissue collected in the AdhesiveCap (Carl Zeiss) 
was inverted into 40 µl buffer ALT containg 20 µl proteinase K (Qiagen® QIAamp® 
DNA micro kit).  
 
2.2.4 Laser capture microdissection of formalin fixed paraffin embedded (FFPE) 
 
LCM slides were pretreated as per fresh tissue, but no staining with methyl green was 
carried out. Comparison with haematoxylin and eosin (H&E) staining of a preceding 
section at the time of laser allowed for accurate excision of target tissue (Figure 2.4). The 
PALM Microlaser settings for FFPE LCM were speed at 25%, focus 79 with delta 2 at 
x5 magnification and cut energy of 50 J. The two tissue removal techniques as described 






Figure 2.4 Laser Capture Microdissection (LCM) (A) H&E template used for LCM that is not stained 
(B) LCM of FFPE sample. 
 
2.3 Extraction of nucleic acids 
 
2.3.1 Total DNA extraction from fresh tissue 
 
Tissue samples were placed into buffer ALT with proteinase K (Qiagen® QIAamp® 
Micro kit) with the amounts depending on tissue size as mentioned above, and mixed 
with pulse vortex for 15 seconds. The mixture was then incubated overnight for a 
minimum of 15 hours at 56ºC for efficient lysis. Subsequently, 200 µl AL buffer was 
added and pulse vortexed for 15 seconds, then 200 µl absolute ethanol put in, pulse 
vortexed for 15 seconds and incubated for 5 minutes at room temperature followed by 15 
seconds of centrifuge at 6000g. The entire lysate was spun through a QIAamp® MinElute 
column (which had been stored at 4ºC prior to use) for 1 minute at 6000g. A new 
collection tube (CT) was used and 500 µl buffer AW1 added, and then spun for 1 min at 
6000g. A clean CT was placed and 500 µl buffer AW2 placed, and then spun for 1 min 
at 6000g. Using a clean CT, the QIAamp MinElute was spun at full speed for 3 minutes 
to dry the silica membrane. Two elutions were carried out, both with 50 µl of buffer AE 
and incubated for 5 minutes. Finally, the column was spun to elute into a 1.5 µl 







2.3.2 Total DNA extraction from FFPE tissue 
 
Tissue was placed initially placed into 320 µl of deparaffinization solution (Qiagen®), 
pulse vortexed for 10 seconds and briefly centrifuge for 15 seconds at 6000g. The mixed 
solution was incubated on a heat block at 56ºC for 3 minutes. On cooling to room 
temperature, the mixture was observed to see if it remains as a solution or solidifies. If 
the latter occurred, more deparaffinization solution (Qiagen®) was added in aliquots of 
160  µl, the combination reheated to 56ºC for 3 minutes then cooled until the mixture 
remains a solution on cooling. Buffer ATL was added (180 µl), pulse vortexed for 15 
seconds and centrifuged for 1 min at 11,000g to form a clear lower phase and murky 
supernatant (Qiagen® QIAamp® DNA FFPE Tissue kit). Thirty microlitres of proteinase 
K was added to the clear lower phase and mixed by pipetting only, then incubated 
overnight (minimum 15 hours) at 56ºC to ensure complete lysis.  Partial reversal of the 
formaldehyde modification of nucleic acids was attempted by heating to 90ºC for 1 hour. 
Droplets formed on the top of the lid were removed by spinning at 6000g for 30 seconds. 
The clear lower phase was transferred to a new 1.5 microcentrifuge tube, allowed to cool 
to room temperature and 2 µl of RNase A was added for 2 minutes. Subsequently, 200 µl 
AL buffer was added and pulse vortexed for 15 seconds, then 200 µl absolute ethanol put 
in, pulse vortexed for 15 seconds and incubated for 5 minutes at room temperature 
followed by 15 seconds of centrifuge at 6000g. The entire lysate was spun through a 
QIAamp® MinElute column (which had been stored at 4ºC prior to use) for 1 minute at 
6000g. A new collection tube (CT) was used and 500 µl buffer AW1 added, and then 
spun for 1 min at 6000g. A clean CT was placed and 500 µl buffer AW2 placed, and then 
spun for 1 min at 6000g. Using a clean CT, the QIAamp® MinElute was spun at full 
speed for 3 minutes to dry the silica membrane. Two elutions were carried out, both with 
50 µl of buffer AE and incubated for 5 minutes. Finally, the column is spun to elute into 
a 1.5 µl microcentrifuge tube and stored at -20ºC. 
 
2.3.3 Total DNA extraction from blood 
 
Fresh blood was drawn from the antecubital fossa, and subsequently the DNA extracted 
within hours of removal by utilising the Qiagen® DNeasy® Blood and Tissue kit, and 
excess blood stored at -80ºC. Thirty microlitres of proteinase K was placed into a 1.5 
microcentrifuge and 200 µl of whole blood added along with 200 µl buffer AL, followed 
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by pulse vortexed for 15 seconds. Incubation occurred for 10 minutes at 56ºC and the 
lysate spun to removed droplets for the top of the lid before adding 200 µl of absolute 
ethanol, pulse votexed for 15 seconds and placed into a DNeasy® Mini spin column. The 
mixture was spun for 1 minute at 6000g, follow-through discarded and clean CT place. 
Five hundred microlitres of buffer AW1 was placed and centrifuged for 1 minute at 
6000g. Subsequently, 500 µl of buffer AW2 was put in and spun at full speed for 3 
mintues. The CT was replaced with a clean one and spun for a further minute at full speed 
to prevent buffer AW2 carry over. Two elution’s were carried out using 200 µl of AE 
buffer into a 1.5 microcentrifuge tube and incubation times of 5 minutes. The resultant 
elute was stored at -20ºC. 
 
2.3.4 Determination of DNA fragmentation 
 
Gel electrophoresis was used to run to determine the integrity of the DNA extracted. 
Agarose gel at 1% was made (0.3 g agarose dissolved in 30 ml of x1 TAE buffer) and set 
with 15 µl of GelRedä nucleic acid gel stain (Biotium) and a comb placed at one end. 
The solidified gel was subsequently placed in 1X TAE running buffer. Loading buffer (1 
µl) was mixed with 5 µl of DNA (at less than 0.5 ng/µl per lane) and placed into the wells. 
A 1kb Plus DNA ladder (invitrogen™ by Life technologies™) was inserted as a 
reference. The electophoresis was set at 100 mV for 45 minutes with the negatively 
charged DNA moving towards the positive electrode. Intact, high quality DNA was 
defined as large fragments greater than 50 kb (Fig 2.5). Purified DNA or cDNA should 





Figure 2.5 DNA electrophoresis. Purified DNA is run to see if it runs as a single band 
on gel electrophoresis. Lane one is the ladder. No bands are detected on lane 2 and 5. 
Lane 4 contains the highest concentration of DNA.  
 
2.3.5 Total RNA including miRNA extraction from fresh tissue 
 
RNA was extracted from fresh, LCM tissue using a modified Qiagen® RNeasy® Micro 
kit protocol. Tissue was placed into a 1.5 microcentrifuge tube containing 350 µl buffer 
RLT and 3.5 µl of b-mercaptoethanol (Sigma-Aldrich®), then pulse vortexed for 30 
seconds. Three hundred and fifty microlitres of 70% ethanol, mixed with moderate 
pipetting for 15 seconds and the entire sample transferred into a RNeasy® MinElute spin 
column (which had been stored at 4ºC prior to use). Following, the column was spun at 
8000g for 15 seconds, follow-through discarded and CT reused. Buffer RW1 was added 
at a volume of 350 µl, column spun at 8000g, the follow through discarded and CT reused. 
On column digestion of DNA occurred using 10 µl DNase1 solution mixed (by tube 
inversion only) with 70 µl Buffer RDD for 15 minutes at room temperature. A further 
wash with 350 µl Buffer RW1 occurred, centrifuging for 15 seconds at 8000g and 
discarding both the follow-through and CT. The column was placed into a new CT, 500 
µl Buffer RPE added, spun for 15 seconds at 8000g and follow-through discarded, but 
the CT reused. Subsequently, the column was washed with 80% ethanol and spun for 2 
minutes at 8000g. With the follow-through and CT discarded, the column was dried by 
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spinning for 5 minutes at full speed. Two elutions were carried out by placing 15 µl of 
nuclease free water directly onto the membrane and incubating for 5minutes before 
spinning at full speed for 1 minute into a 1.5 microcentrifuge tube. The resultant RNA 
was stored at -80ºC. 
 
2.3.6 Total RNA including miRNA extraction from formalin fixed paraffin 
embedded tissue 
 
Tissue was placed initially placed into a 2 µl microcentrifuge tube containing 320 µl of 
deparaffinization solution (Qiagen®), pulse vortexed for 10 seconds and briefly 
centrifuge for 15 seconds at 6000g. The mixed solution was incubated on a heat block at 
56ºC for 3 minutes. On cooling to room temperature, the mixture was observed to see if 
it remains as a solution or solidifies. If the latter occurred, more deparaffinization solution 
(Qiagen®) was added in aliquots of 160 µl, the combination reheated to 56ºC for 3 
mintues until the mixture remains a solution on cooling. RNeasy® FFPE kit from 
Qiagen® was used to extract the RNA. Buffer PKD was added at 240 µl volume and 
pulse vortexed for 15 seconds, and then centrifuged for 1 minute at 11,000g. Twenty 
microlitres of proteinase K was added to the lower phase and mixed by gentle pipetting. 
Initial incubation occurred at 56ºC for 15 minutes for proteinase K tissue digestion, 
followed by immediate incubation at 80ºC to partially reverse the formaldehyde induced 
cross links. The lower phase was transferred into a new 2 µl microcentrifuge tube and 
placed onto ice for 3 minutes before centrifuging for 15 minutes at full speed to create a 
pellet of insoluble tissue debris including crosslinked DNA. The supernatant was 
removed without disturbing the pellet and placed into a new 2 µl microcentrifuge tube. 
DNA digestion occurred with 25 µl of DNase booster buffer and 10 µl DNAse1 for 15 
minutes at room temperature. Binding conditions were improved by adding 500 µl Buffer 
RBC, pulse vortexed and 1200 µl of absolute ethanol added using pipetting, then 
transferred into a RNeasy® MinElute spin column. The column was spun for 15 seconds 
at 8000g. The flow-through was discarded and CT reused. Buffer RPE was subsequently 
washed through the column twice, firstly 500 µl which is spun for 15 seconds at 8000g 
and secondly, 500 µl centrifuged for 2 minutes. Next, the RNeasy® MinElute spin 
column was dried by centrifuging for 5 minutes at full speed. Following, two elutions 




2.3.7 Determination of nucleic acid concentration and purity 
 
To ascertain larger quantities of nucleic acid, the NanoDrop™ 1000 Spectrophotometer 
(Thermo Fisher Scientific, Inc) was used to determine the concentration in ng/µl by 
testing 1.5 µl of undiluted sample. Although the concentration detection range of the 
spectrophotometer is from 2-3700 ng/µl for double stranded DNA and 2-3000 ng/µl 
RNA, any sample measuring less than 10 ng/µl were analysed using the Qubit® 2.0 
Fluorometer (invitrogen™ by Life technologies™). The spectrophotometer was set to 
nucleic acid application mode and to either DNA-50 (double stranded DNA) or RNA-40 
(total RNA). Up to 1.5 µl of sample was placed onto the unit and on activating the system, 
an absorbance curve was produced along with the concentration and purity ratios. A target 
purity ratio relating to protein contamination of 260 nm to 280 nm (A260/A280) used for 
DNA was ~1.8 and ~2.0 for RNA. A target purity ratio relating to organic compound 
contamination of 260 nm to 230 nm (A260/A230) was >2.0. For smaller concentrations the 
spectrophotometer became inaccurate and a benchtop fluorometer, Qubit® 2.0 
Fluorometer (invitrogen™ by Life technologies™), was used in conjunction with the 
Qubitä high sensitivity assay kit (DNA range 10 pg/µl to 100 ng/µl and RNA range 250 
pg/µl to 100 ng/µl). A working solution is made using 1 µl of fluorescent reagent to 199 
µl of buffer per sample including two standards. Thin walled 0.5 µl PCR tubes were used 
for accurate readings. The working solution and the test sample were vortexed and 
readings were taken after 2 minutes of incubation. 
  
 
2.3.8 Determination of RNA Integrity Number (RIN)  
 
Total RNA underwent RIN analysis using an Agilent 2100 bioanalyzer instrument 
(Agilent technologies, Inc). LCM samples yielded very low concentrations of RNA, 
hence an Agilent RNA 6000 pico kit was employed whose range was 50-5000 pg/µl. The 
electropherogram was observed to look at 18S and 28S fragments along with the presence 








Figure 2.6 RNA RIN Electropherograms  (A) RNA extracted from fresh tissue with a RIN of 8.6 and 
(B) RNA extracted from FFPE with a lower RIN of 2.6. 
 
2.4 Polymerase chain reaction (PCR)  
 
2.4.1 PCR primer design 
 
Primers were devised against cDNA sequence taken from university of California Santa 
Cruz (UCSC) using GRCh38 and designed to be 18-30 nucleotides in length, have similar 
melting temperatures (Tm), a GC content of 50-60% where possible, and calculated using 
the following formula; Tm = 2°C x (A+T) + 4°C x (G+C). In order to avoid amplification 
from any contaminating genomic DNA, primers were constructed to span exons. 
Furthermore, the primer pair was separated by an intron between 1000-1000,000 bp long 
with the final product length between 90 to 200 bp and any unintended products being 
greater than 1000bp as confirmed by primer basic local alignment search tool (BLAST) 
from the National Centre for Biotechnology Information (NCBI, 
http://www.ncbi.nlm.nih.gov/tools/primer-blast). Possible primers were crosschecked 
against primer design websites Primer3web version 4.0 (http://primer3.ut.ee/) and the 
primer basic local alignment search tool (BLAST). Specificity of primers was checked 
again using the BLAST from Ensembl (http://www.ensembl.org/Multi/blastview). 
Moreover, OligoAnalyser3.1 was used to analyse homo- and hetero-dimer potential. The 
primer sequences designed for use are summarised in Table 2.1.  
 
Customised oligonucleotides for micoRNA were designed (Table 2.2) in conjunction 
with Invitrogen™  (Life technologies™) to use Taqman advanced technology qPCR. This 





Gene Forward (5’>3’) 
Reverse (5’>3’) 






























Table 2.1 Primer design for mRNA. Primers designed for use in real time quantitative PCR from 
messenger RNA derived cDNA; Tm, melting temperature; self comp, self complimentary binding. 
 
 
Mature miRNA Accession number TaqMan oligo 
hsa-miR-16-5-p MIMAT0000069 UAGCAGCACGUAAAUAUUGGCG 
hsa-miR-34a-5p MIMAT0000255 UGGCAGUGUCUUAGCUGGUUGU 
hsa-miR-205-5p MIMAT0000266 UCCUUCAUUCCACCGGAGUCUG 
hsa-miR-150-5p MIMAT0000451 UCUCCCAACCCUUGUACCAGUG 
hsa-miR-199a-3p MIMAT0000232 ACAGUAGUCUGCACAUUGGUUA 
miR-26a-5p (control) MIMAT0000082 
 
UUCAAGUAAUCCAGGAUAGGCU 
Table 2.2 Primer design for microRNA. Customised primers for Taqman® real time quantitative PCR 
from microRNA derived cDNA. MiRNA were chosen from Nanostring® nCounter® human v2 MicroRNA 
expression assay. 
 
2.4.2 Reverse transcriptase polymerase chain reaction (RT-PCR) 
 
Messenger RNA to copy DNA (cDNA) 
Input RNA for reverse transcription (RT) had been treated with DNase 1 to ensure 
minimal genomic DNA was present in the sample. Concentrations of RNA were within 
the recommended range of 2 – 200 ng/µl and dissolved in nuclease/RNase free water. 
Quality nondenatured RNA was used as determined by the Agilent 2100 bioanalyzer 
instrument (Agilent technologies, Inc). SuperScript™ III First-Strand Synthesis 
SuperMix (invitrogen™ by Life technologies™) was used for cDNA synthesis. It also 
contains RNaseOUT™ to protect against degradation of RNA input template. Reaction 
mixture consisted of 2 µl of RT enzyme mix, 10 µl 2X RT reaction mix, variable volume 
of input RNA depending on concentration and made up to 20 µl with DEPC-treated water 
in a PCR tube. The tube was mixed gently and heated to 25ºC for 10 minutes followed 
by 30 minutes at 50ºC. Termination of the reaction occurred at 85ºC for 5 minutes then 
the tube was placed on ice. Two units of RNase H (1 µl) from E.Coli was added to remove 
RNA template from the RNA:cDNA hybrid molecule after first strand synthesis and 
incubated for 20 minutes at 37ºC. Template cDNA quality was examined using 
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spectrophotometry and agarose gel electrophoresis as described in 2.3.4 and 2.3.8 
respectively.  
 
Copy DNA library preparation from MicroRNA including amplification 
A four step process (poly(A) tailing, ligation, reverse transcription and miR-
amplification) was undertaken to create a library of cDNA from isolated miRNA (2.3.8) 
using TaqMan® Advanced miRNA cDNA synthesis kit. An input range of 1-10 ng of 
total RNA containing enriched miRNA was used. Poly(A) tailing cocktail of 0.5 µl 10X 
poly(A) buffer, 0.5 µl ATP, 0.3 µl poly A enzyme, 1.7 µl RNase-free water was prepared 
in a 1.5 ml microcentrifuge tube and combined with 2 µl of input RNA by vortexing and 
centrifuged to remove bubbles. The mixture was placed into a thermal cycler and 
incubated at 37°C for 45 mins of polyadenylation followed by 65°C for 10 mins to stop 
the reaction. A ligation cocktail of 3 µl 5X DNA ligase buffer, 1.5 µl RNA ligase, 4.5 µl 
50% PEG 8000, 0.6 µl 25X ligation adapter, 0.4 µl RNAse-free water was made and after 
mixing, all 10 µl was added to the poly(A) tailing reaction. The vortexed mixture was 
placed into a thermal cycler and incubated at 16°C for 60 mins of ligation. A RT cocktail 
of 6 µl 5X RT buffer, 1.2 µl dNTP (25 mM each), 20X universal RT primer, 3 µl 10XRT 
enzyme, 3.3 µl RNase-free water was made and after mixing, all 15 µl was added to the 
ligation product. The vortexed mixture was placed into a thermal cycler and incubated at 
42°C for 15 mins of reverse transcription followed by 85°C for 5 mins to stop the reaction. 
An amplification cocktail of 25 µl 2X miR-Amp master mix, 2.5 µl 20X miR-Amp primer 
mix, 17.5 µl RNase-free water was made and after mixing, all 45 µl was added to a 5 µl 
aliquot of RT product. The rest of the RT product was stored for up to 2 months at -20°C. 
The amplification mixture was run according to conditions in Table 2.1. The product was 
then immediately used for qPCR or stored at -20°C. 
 
Step Temperature Duration Cycle 
Enzyme activation 95°C 5 min 1 
Denaturation 95°C 3 sec  
X14 Annealing/Extension 60°C 30 sec  
Stop 99°C 20 min 1 
Hold 4°C hold 1 
Table 2.3 Step 4 microRNA to cDNA formation. Amplification thermocycling conditions as part of the 





2.4.3 Real time quantitative PCR (RL-qPCR) 
 
Two detection systems were used to carry out RL-qPCR; Probe based (TaqMan® Assay, 
Life technologiesä) and dye based (SYBR®, invitrogen™ by Life technologies™, 
Thermofisher) assays. The Applied Biosystems 7500 RT PCR system was used for both 
RL-qPCR techniques. 
 
Probe based assay 
High specificity minor-groove binding (MGB) Taqman® probes were used for genetic 
validation of the miRNA data. The main advantage is the enhanced specificity from the 
custom probe designed against the exact sequence. A 1:10 dilution of cDNA was made 
by combining 5 µl miR-Amp amplification product with 45 µl 0.1 TE buffer. A cocktail 
of 10 µl 2X Fast advanced mastermix, 1 µl 20X Taqman® advanced miRNA assay, 4 µl 
RNase-free water were vortexed and placed into a PCR well. Subsequently, 5 µl of diluted 
cDNA template was added to each well and sealed with an adhesive cover. In addition, 
an endogenous control gene, hsa-miR-26a-5p, was chosen as it is relatively constant and 
abundant within tissues. A minimum of three replicates for each reaction was performed 
and the endogenous control placed on every well appropriate intraplate analysis. No 
sample library and PCR mix control were also on each plate. Normalisation of the gene 
of interest was performed against this control gene in a similar fashion to mRNA analysis. 
Thermocycling settings are set out in Table 2.4. 
 
Step Temperature Duration Cycle 
Enzyme activation 95°C 20 sec 1 
Denaturation 95°C 3 sec  
X40 Annealing/Extension 60°C 30 sec  
Hold 4°C hold 1 
Table 2.4 Taqman® RL-qPCR settings. Taqman® advanced miRNA assay settings using the Applied 
Biosystems 7500 RT PCR system. 
 
Analysis involved the use of ExpressionSuite™ Software to view the amplification plots 
and set both the baseline and threshold values. Calculation of the relative expression used 
the comparative formula c=2-DDCt where c represents the fold difference and Ct 
represents the average threshold cycle of the triplicate samples. DCt refers to the 
difference between the gene of interest and the housekeeping gene hsa-miR-361-5p. DDCt 
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represents the difference between the DCt cDNA of the tumour compared to the DCt 
cDNA of the tarsal plate. 
 
Dye based assay 
SYBR® green dye-based assay was used to analyse mRNA extracted from tumour and 
surrounding reference stroma. A minimum of three replicates of each reaction was 
performed and the standard thermocycling mode was used. For volumes of 20 µl per well, 
the plate contained 10 µl SYBR® Select mastermix 2x, variable concentration of forward 
and reverse primers (<200nM in standard thermocycling mode) and variable 
concentration of cDNA template in RNAse free water. The mixture was centrifuged 
removed air bubbles and bring the contents down. A standard thermocycling reaction was 
setup up and individualise by matching the annealing temperature to the melting points 
(Tm) of the primers (Table 2.6). Negative control sample omitted the template cDNA. A 
post-amplification dissociation (melt) curve was performed to detect primer-dimer 
artefact and reaction specificity by observing a single peak. Amplification plots were 
analysed to determine the threshold cycles (CT) for each curve by setting the threshold 
above the baseline, background fluorescence signal but within the exponential growth 
phase of the amplification curve. The relative mRNA expression values were calculated 
using the formula c=2-DDCt where c represents the fold difference and Ct represents the 
average threshold cycle of the triplicate samples. DCt refers to the difference between the 
gene of interest and the housekeeping gene GAPDH. DDCt represents the difference 
between the DCt cDNA of the tumour compared to the DCt cDNA stroma. 
 Primer Tm ≥ 60°C  Primer Tm < 60°C 
Step Temperature Duration Cycles  Temperature Duration Cycles 
UDG activation 50°C 2 min   50°C 2 min  
DNA Poly 95°C 2 min   95°C 2 min  
Denaturation 95°C 15 sec  
X40 
 95°C 15 sec  
X40 Annealing 60°C 1 min  50-60°C 15 sec 
Extension 60°C with annealing  72°C 1 min 
End and dissociation       
Table 2.5 Standard RL-qPCR. Standard cycling mode for mRNA derived cDNA, real time quantitative 







2.5 Nucleic acid decipherment  
 
2.5.1 Whole exome sequencing 
 
Next generation whole exome sequencing was carried out on DNA extracted from fresh 
tumour samples. In addition, blood was extracted from the same patient and sent for 
whole exome sequencing for paired tumour-normal (blood) analysis. Gene encoding 
regions covering 1.5% of the human genome are sequenced. A minimum of 1.5 µg of 
DNA was required for library preparation and determined using a Qubit® 2.0 
Fluorometer (invitrogen™ by Life technologies™) which had the advantage of detecting 
double stranded DNA. Intact, high quality DNA (defined as large fragments greater 50 
kb) was confirmed using agarose gel electrophoresis. Library preparation using Agilent 
SureSelectä (51Mb) version 5 capture products and whole exome sequencing on an 
Illumina® HiSeqä2000 100bp paired end analysis with a minimum 100X mean coverage 
was carried out by Oxford Gene Technology (OGT). Output files in FASTQ format were 
processed through our bioinformatics pipeline (section 2.7.1). 
 
2.5.2 RNA sequencing 
 
Extraction of high quality RNA, as determined by the bioanalyzer ,was required for RNA 
sequencing.  Due to the small sample sizes and meticoulous LCM, low concentrations of 
RNA were obtained for some samples. To allow for an impartial comparison, a low input 
library preparation protocol (SMARTer® Universal low input RNA kit from Clontech®) 
capable of a range between 200 pg to 10ng was employed for all samples regardless of 
total yield. Amplification of the low input samples only would have introduced bias when 
comparing against the standard library preparation. Despite the low input range, samples 
were greater than 100ng total yield. Moreover, RNa was poly-A tail selected. Synthesised 
and adapter ligated copy DNA (cDNA) was then sequenced using 100 bp paired-ended 
reads on an Illumina® HiSeqä2000 averaging 13 million paired end reads per sample 
(12 samples in 1 lane) by OGT. Output FASTQ files were then processed in out RNA 






2.5.3 Nanostring® nCounter® human v2 MicroRNA expression assay for SGC RNA 
 
Total RNA was extracted from FFPE tissue and a minimum of 100 ng in 10 µl was 
required for assay analysis. Total RNA typically comprises of only a small amount of 
micro RNA (miRNA) and varies between tissues. (Liang et al., 2007) Sensitivity of the 
hybridisation reaction was previously shown to be good for FFPE tissue and contains 
unique oligonucleotide tags for 800 human miRNA based on the miRBase version 18. 
Output files were represented in the nCounter analysis system to obtain expression levels 
and these results were put through our miRNA pipeline. 
 
2.5.4 AffymetrixäGeneChip® Human Genome U133 Plus 2.0 Array for SGC RNA 
 
FFPE total RNA from SGC samples along with tarsal plate controls from a different 
individual were sent for AffymetrixäHuman Gene U133 plus 2.0 array analysis by the 
University College London (UCL) genome centre. The total number of transcripts 
covered were 47,000 representing 38,500 well characterised genes and 6500 new ones. 
Sequence clusters were created from the UniGene database (Build 133, 20th April, 2001) 
including the ‘plus’ element of 6500 genes (Build 159, 25th Jan, 2003). A minimum of 50 


















2.6 Nucleic acid analysis 
 
2.6.1 DNA cancer pipeline and bioinformatics 
 
FASTQ files were received from OGT and underwent a specific validated pipeline in 
conjunction with the QMUL bioinformatics unit which has been published (Okosun et 
al., 2013). All data underwent three main stages, 1) pre-calling scrutiny, 2) somatic 
(cancer) variant calling and 3) copy number analysis (Figure 2.7).  Pre-calling involved 
quality control of FASTQ files, followed by read alignment against human genome 19 
(hg19) using the backward search with Burrows-Wheeler transform, a second generation 
alignment (BWA) tool.(Li and Durbin, 2009) The resultant sequence alignment map 
(SAM) output file was converted into a compressed binary version (BAM file) that 
underwent sorting and removal of PCR duplicate paired-end reads using the Picard tool 
(version 1.86). The latter was to prevent false positive single nucleotide variant (SNV) 
calls. As a consequence, a BAM file with mapped data and a HTML file with the number 
of reads discarded was produced. Local realignment around indels, recalibration of 
quality scores and base quality recalibration using Genome Analysis ToolKit (GATK) 
unified genotyper was carried out (version 2.3.9). Variant calling of single nucleotide 
variants (SNVs) and short insertions/deletions (indels) occurred with the genotyper. The 
output variant call format (vcf) file could then be viewed as text in an excel format 
(Microsoft) or an integrative genomics viewer (IGV, Broad Institute). Simultaneous 
analysis of tumour–germline (blood) paired sequence analysis was carried out using 
Strelka pipeline. This has been shown to be particular good in cancer where tissue 
samples may have low tumour cell purity (down to 5%). This provided a lower false 
positive variant number than doing an initial independent analysis of the tumor and 
germline data, followed by a comparison. A study by Cai et al compared the four most 
popular tumour-germline programs (namely Strelka, Varscan, Somaticsniper and 
Mutect2) and ran data on 32 WES samples: it gave Strelka and Mutect2 the highest score 
for sensitivity and accuracy.(Cai et al., 2016) Known limitations of the program is that it 
requires a matched normal sample, paired end reads and should be a minimum of half the 
tumour depth. A variant was only considered as a possible significant change if a read 
depth greater than 20 was seen in the tumour. Subsequently, an attempt to determine any 
potential biological action of SNVs and small indels occurred by undertaking variant 
annotation. This included variant location, effect, evolutionary conservation and 
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regulatory effect. Lastly, copy number analysis was analysed using three different 
approaches. ASCAT assessed the genotyping information of identified variants between 
normal and tumour. VarScan2 (version 2.3.5) and DNACopy (R Bioconductor package 
version 2.12) used the number of aligned reads for exons as markers between normal and 
tumour.(Koboldt et al., 2012) Consequently, gene annotation took place in conjunction 
with RNA data for the formulation of potential pathways or molecular milieu specific to 
the tumour types. WES data was deposited to the European Genome-phenome Archive 





Figure 2.7 Whole exome sequencing pipeline. Process from DNA extraction to the determination of 
significant driver genes and copy number analysis. SAM, sequence alignment map; BAM, binary 





Driver gene predictive tools
IntoGgen oncodriveFM q<0.05 (database) MutSigCV raw p<0.05 (database) Randomised comparison testing of signifcant genes
CNV analysis (3 programmes)
Varscan2 (read data only) DNAcopy (read data only) ASCAT (genotyping information, LOH is possible)
Strelka pipeline simultaneous analysis of tumour and blood
Good for low tumour purity >20 read depth deemed significant
Mapping reads (SAM ->BAM)
hg 19 (UCSC) Picard tool (remove PCR duplciates paired end reads) GATK (local realigment around indels)
Pre-calling FASTQ Quality control check
Illumina HiSeq 2000
100 bp paired end reads 100X depth
Ilumina library prep 51Mb v5
DNA extraction (Tumour with blood matched control) 1.5 ug dsDNA minimum
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Predictive functional databases 
Sorting intolerant from tolerant (SIFT) 
Predicting the effects of non-synonymous variants found in coding regions of DNA on 
protein function.(Sim et al., 2012) 
 
Polymorphism phenotyping version 2 (Polypen-2) 
Another tool that predicts the functional effects of non synonymous human single 
nucleotide variants.(Adzhubei et al., 2010)  
 
dbSNP 
Single nucleotide polymorphisms are the most common genomic variation that can occur 
every 1200bp with the vast majority (99%) being a single nucleotide substitution.(Sherry 
et al., 2001) dbSNP is a database that catalogues genetic variation. 
  
Catalogue of somatic mutations in cancer (COSMIC) 
This database is continually updated with new somatic mutations in cancer and attempts 
to collate the data into a user friendly format and splits it into five sections.(Bamford et 
al., 2004, Forbes et al., 2011) Initially, it focused on somatic (cancer) point mutations 
within coding regions, however, with the advent of whole genome sequencing, non 
coding regions are included along with structural rearrangements and gene fusions. 
Access to the database is at http://www.sanger.ac.uk/cosmic. All mutations held in the 
database area assigned a Cosmic Somatic Mutation identifier (COSM id) to allow external 
database such as emsembl to access the correct record within COSMIC. Moreover, these 
COSM id remain as stable between the updating of the database. Further integration with 
external databases, acquisition of the huge sequencing data that is being carried out and 
curating individual driver genes as has been done with TP53. 
 
DriverDB 
The annotation databases mentioned above are incorporated with driver mutation 
bioinformatic algorithms driver and exome sequencing data to identify clinically 






Integrative Oncogenomics Cancer Browser (IntOGen) 
This portal combines data from The Cancer Genome Atlas (TCGA), International Cancer 
Genome Consortium (ICGC) and data from cancer journals. Currently, it contains data 
from 6792 WES samples from 48 projects and 28 cancer types (May 2016), but is 
constantly been updated. Driver mutations are placed into two broad categories, high-
confidence driver (HCD) that is seen in the in the TCGA and candidate driver (CD) with 
an expectedly higher false-positive rate. The limitations is that it does not take into 
account the background mutation rate of the tumour and skin tumours including BCC 
have high levels which can increase the false positive for SNV calls. In addition, there 
are no WES samples relating to BCC which means that the driver mutation call are 
relating to different cancers, thus may not be as relevant and their significance is unknown 
for BCC.   
 
Mutation significance (MutSig) 
A software programme for the Broad Institute that was originally set up to look at 
background mutation rates (bmr) across the genome, it has evolved to analyse exome data 
to see if a gene is mutated more often than expected by chance.(Lawrence et al., 2013) It 
corrects for variation by using patient specific mutation frequency, spectrum and gene 
specific background mutation rates by incorporating expression levels and replication 
times. For example, melanoma has bmr of 100/megabase of DNA versus 5/megabase for 
a paediatric tumour and so corrects for the predicted noise. It takes into account the non-
synonymous:synonymous SNV ratio for a particular gene, identifies hotspots within the 
samples given (10 mBCC) plus comparing to known hotspots using its database. The 
limitation is that it performs better with larger sample sizes and in this study the samples 
size is relatively small. 
 
Identification of mutational driver genes and significantly mutated pathways 
We used two methods to identify different positive selection signals that occurred in 
driver mutations: OncodriveFM(Gonzalez-Perez et al., 2012), implemented in the 
IntOGen software(Gonzalez-Perez et al., 2013) (Gonzalez-Perez et al. Nature Methods 
2013), and MutSigCV(Lawrence et al., 2013) (Lawrence et al. Nature 2013). We applied 
the two algorithms in mBCC and nodBCC samples separately. For OncodriveFM, we 
used corrected p-values q < 0.05 for significance. For MutSigCV, due to the small sample 
size, p-values could not be adjusted, so raw p < 0.05 was applied. Overlapped genes that 
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were identified being significant by both methods were further selected. Significantly 
mutated pathways were also identified using OncodriveFM (q < 0.05). These identified 
pathways were further compared between mBCC and nodBCC groups. 
 
Randomisation comparison test 
To identify mBCC and nodBCC specific driver genes, we focused on genes significantly 
mutated in one subtype but not so much in the other based on OncodriveFM and 
MutSigCV results, e.g., genes within OncodriveFM q < 0.05 in one group but q > 0.1 in 
the other group. We then applied a randomisation procedure, where the pool of 20 total 
BCC samples was randomly split into two groups of equal size (n=10). We then applied 
OncodriveFM and MutSigCV on the two groups and recorded the significance values for 
our subtype specific candidate genes. We repeated the randomisation procedure 100 times 
and calculated the transformed p-values from OncodriveFM and MutSigCV, which 
generally followed a normal distribution for each gene. We next calculated the probability 
that the observed significance in mBCC or nodBCC group was stronger than that 
expected by chance for each candidate. Significant subtype genes from the randomisation 
test (two-tail p < 0.05) were further identified and regarded as the true mBCC or nodBCC 
specific genes, based on OncodriveFM and MutSigCV significance values, respectively. 
We also applied this procedure to identify specific mutated genes to eyelid nodBCC and 
nodBCC elsewhere. 
 
2.6.2 RNA sequencing cancer pipeline 
 
FASTQ output files underwent data quality check using FastQC, raw reads were aligned 
to the reference genome hg19 using Tophat2.(Kim et al., 2013a, Andrews) The number 
of uniquely aligned reads (mapping quality score q > 10) to the exonic region of each 
gene were counted using HTSeq based on the Ensembl annotation (version 75).(Anders 
et al., 2015, Cunningham et al., 2015) Genes that were expressed in a low level across all 
samples were excluded. For the 6 BCC tumour and stroma samples, only genes that 
achieved at least one count per million (cpm) mapped reads in at least 6 samples were 
kept, leading to 19,101 filtered genes in total. An abundance estimation was made looking 
at fragment per kilobase exon (FPKM). Normalisation for read counts took into account 
the length of the transcript, as longer transcript tend to be sequenced more than shorter 
transcripts. After applying scale normalization, read counts were converted to log2-cpm 
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using the voom function with associated weights ready for linear modeling.(Law et al., 
2014) Differential expression analysis was then performed using the limma R 
package, using tumour-stroma paired analysis with an additive model design adjusting 
for baseline differences between patients.(Ritchie et al., 2015) A double threshold of raw 
p value <0.01 and an absolute fold change > 2 were used to define significantly 
differentially expressed (DE) genes. Gene Set Enrichment Analysis (GSEA) was 
performed for mBCC and nodBCC tumour-stroma comparisons using the GSEA tool to 
identify the dysregulated canonical pathways from the Molecular Signatures Database 
(MSigDB-C2, version 5.0) (Subramanian et al., 2005). Common and specific pathways 
between mBCC and nodBCC were further identified. GSEA performed for SGC used two 
pathway databases, KEGG and REACTOME in order to identify common pathways 
specific to SGC. RNAseq data has been deposited to the Gene Expression Omnibus using 
accession number GSE937997. 
 
Heatmap representation of RNA seq data 
Hierarchical clustering analysis was performed in R. This groups similar values into 
clusters then produces a dendogram that shows a hierarchy of clustering, but in an 
unsupervised way i.e. without taking into account the experimental variables such as 
tissue type. Samples were grouped into columns and gene expression into rows. These 
genes underwent a Z-score which soothes logFC, which allows event those genes with 
small changes to be seen on the plot. Z = (expression in tumour sample – mean expression 
in normal reference stromal tissue)/SD of expression in normal reference. A Z=0 means 
the gene expression is the same as the mean, or to put it another way the mean score for 
the gene becomes 0 with a maximum standard deviation=1. Thus, the gene expression in 
each sample is compared to 0 and is assigned a colour whether it is up (red) or down 
(blue) regulated. The viewer can interpret the colour as a standard deviation of the mean 
and has an intuitive idea of variation of that gene.s 
 
Geneset enrichment analysis (GSEA) 
This tool focuses on a geneset defined as a group of genes that share biological function, 
chromosome location or regulation). These genesets are taken from MSigDB-C2, KEGG 
and REACTOME which collects unbiased published expression profiles. Looking at the 
significance of a single gene may miss certain pathway activation especially where genes 
don’t reach significance due to mutational noise and having a list of significant genes 
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without biological theme can be confusing. Looking at a geneset and noticing just a small 
increase in expression (for example 10% increase in expression across many genes in the 
geneset) can be more significant that a large over expression of just one gene. 
Significance cut off include false discovery rate (FDR) q-value 0.10 (whereby 9 out of 
10 times the result is valid), p-value <0.05 (enrichment score for a single gene set without 
taking into account the multiple hypothesis gene testing, taking into account geneset size 
and comparing against the empirical null distribution as FDR rate, thus the value is less 
than FDR). Thus, an enrichment score (ES) was calculated to see to which a geneset is 
correlated to ta particular pathway. ES was plotted against the gene list rank, with those 
closest to the y-axis more strongly correlated to the pathway. In addition, normalised ES 
was used to take into account for the difference in geneset size. 
 
2.6.3 SGC MicroRNA cancer pipeline 
 
MiRNA expression raw and normalised data were first generated from Nanostring 
nCounter Digital Analyzer. Filtered data were log2 transformed and further normalised 
using the quantile normalisation method in R, to make sure values across samples were 
comparable. DE analyses were performed using the limma R package.(Ritchie et al., 
2015) The pairwise comparisons of nodular versus control and pagetoid versus control 
were first conducted, followed by the one-way ANOVA amongst the three groups. 
Common DE miRNAs between nodular and pagetoid against control, as well as unique 
DE miRNAs to the nodular and pagetoid groups specifically were identified. 
 
2.6.4 AffymetrixäSGC RNA pipeline 
 
Raw data from sebaceous gland carcinoma samples from the Affymetrix Human Gene 
2.0 array were analysed using R. Expression data was normalised with guanine cytosine 
robust multiarray average (GCRMA) preprocessing algorithm which converts the raw 
expression data taking into account the GC content.(Wu Z, 2004) Data was then filtered 
using standard deviation to select the most variable probes and reduce the dimensionality. 
P values were adjusted using the Benjamini-Hochberg method to obtain a q-value.(Wu 
Z, 2004) DE probes between control samples and those taken from a pagetoid and 
between control samples and those taken from a nodular SGC were identified using the 
limma R package.  
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Haematoxylin and eosin (H&E) 
H&E staining was performed using standard methods. FFPE tissue were dewaxed using 
xylene for two changes of 2 minutes each, alcohol for two changes of 2 minutes each and 
washed in tap water for 5 minutes. Subsequently, they were placed into haematoxylin for 
5 minutes, followed by a wash with tap water for 3 minutes. Aqueous blueing solution 
(Scott’s tap water substitute) was used followed by a further 3 minutes was in water. Two 
dips in 1% acid alcohol are performed and a ensuing wash in tap water for 3 minutes. 
Eosin staining of sections was performed for 5 minutes, a wash in tap water for 5 minutes 
and lastly a dehydrating step using increasing alcohol concentration. Fresh frozen tissue 
could be placed straight into haematoxylin for the allotted time, although a fast 
haematoxylin stain only was used for LCM orientation. Sections were sealed and covered 
using mounting medium (Sigma-AldrichÒ) by hand or using the automated Thermo 
Clearview Coverslipper (Thermo Fisher Scientific, Inc). 
 
3-3’-diaminobenzidine (DAB) 
DAB immunostaining of 5 µm formalin-fixed, paraffin-embedded (FFPE) tissue sections 
was performed for the Hh pathway proteins including PTCH1, SMO, Gli1 and Gli2 
(Abcam). Tissue sections were mounted on slides, deparaffinised in xylene then alcohol, 
followed by treatment with the DAKO EnVisionÔFLEX+ System (Dako). Antigen 
retrieval was performed using the DAKO PT LINK machine at 97°C for 20 minutes under 
alkaline (pH 9.0) or acidic (pH 6.0) conditions. Endogenous peroxidase activity was 
blocked using EnVisionÔFLEX peroxidase-blocking reagent. Tissue was incubated with 
primary antibody for 30 minutes, followed by incubation with a secondary antibody 
(EnvisionÔFLEX/HRP LINKER; 20 mins) and then visualisation of the primary-
secondary reaction with EnVisionÔFLEX substrate working solution containing buffer 
and DAB (10 mins). Positive control tissue included breast, brain, testes and intestine for 
PTCH1, SMO, Gli1 and Gli2 respectively. Negative controls involved all steps excluding 
the primary antibody. Finally, sections were counterstained with haematoxylin using the 
Gemini autostainer (Thermo Fisher Scientific, Inc). Sections were sealed and covered 
using the automated Thermo Clearview Coverslipper (Thermo Fisher Scientific, Inc). 
Methods	and	Materials	
	 87 
Expression levels were assessed according to the chromagen signal using a simple 
immunoreactivity scoring system: 0 no expression, 1 (25-50% cells positive), 2 (50-75% 




Immunofluorescence was used for semi quantitative analysis of Hh pathway expression 
in SGC in comparison to nodBCC. FFPE sections were cut (5 µm) and antigen retrieval 
carried out as described above. Blocking of the sections occurred with 5% goat serum for 
one hour followed by primary antibody staining as mentioned. Secondary antibody 
staining utilised AlexaFluor-568 (Invitrogen™ by Life technologies™). Nuclei were 
counterstained with 4’,6-diamidino-2-phenylindole dihydrochloride (DAPI; Sigma-
AldrichÒ) at 1:1000 dilution to highlight the number of cells present and aid accurate 
semi-quantification. Coverslips were placed using VECTASHIELDÒ mounting medium 
(Vector Laboratories). Negative controls omitted the primary antibody and were essential 
for removal of background fluorescent noise to allow for accurate signal quantification 
and prevention of false positive acquisition. 
 
Confocal Microscopy and fluorescence signal quantification 
Immunofluorescence sections were examined using the Zeiss LSM710 Meta confocal 
laser microscope (Carl Zeiss Microscopy GmbH) and a ZEN configuration tool (Carl 
Zeiss Microscopy GmbH) which is a digital image processing software that produced an 
output TIFF image. Negative control slides were used to remove background 
fluorescence and set up the acquisition conditions that subsequently remained constant 
throughout the imaging process. Images were taken at 200 X magnification. Output TIFF 
images were analysed using ImageJ (http//imagej.nih.gov/ij) to quantify antibody 
expression. For semi-quantification of antibody expression, fluorescence intensity was 
determined in regions of interest (ROIs), ensuring a standardised area size whilst 
containing the same number of nuclei as determined by the DAPI staining. Furthermore, 
3 separate ROI were taken for each area in each sample (such as 3 tumour ROI and 3 
stroma ROI in nodBCC or SGC samples) to obtain a mean signal for comparison. 
Statistical analysis 
Immunofluorescence data are expressed as mean± standard error of the mean (SEM) of a 
given number of observations. Comparison between groups was made using the Student 
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t-test. A p-value of less than 0.05 was considered to be significant. Figures show the mean 
with error bars representing SEM. 
 
2.7.3 Protein extraction from cell models and Western blotting 
 
Protein extraction 
Cells were harvested at ≥ 70% confluence using 50 mM sodium hydroxide at 100°C. 
Following a wash with phosphate buffered solution (PBS), 220 µl of heated protein lysis 
buffer (50 mM Tris-HCL, 2% sodium dodecyl sulphate (SDS) at pH 8.0) were added to 
the cells ensuring the cell surface was covered in its entirety before cells were removed 
with the cell scraper. Removed cells were placed in a 1.5 µl microcentrifuge tube and 
heated to 95° for 2 minutes. Passing the lysate through a needle and syringe reduced 
viscosity and 20 µl of lysate was removed for quantification using the Bio-RadDC Protein 
Assay detection kit (Bio-Rad). A mixture of 20 µl protein, 98 µl solution A (alkaline 
copper tartrate) and 2 µl solution S (SDS) was developed for 3 minutes before 800 µl of 
solution B (Folin) was added. Any protein binds to copper tartrate which in turn reduces 
Folin thereby turning the solution blue. The intensity of the blue correlates with the 
amount of protein present. The blue mixture was transferred to a 1 ml clear plastic cuvette 
and the protein absorbance (AU) measured using a spectrophotometer at a wavelength of 
655 nm. A standard curve was obtained from known concentrations of bovine serum 
albumin provided and the protein concentration calculated in µg/µl. Samples were then 
stored at -80°C. 
 
Western blot 
Pre-cast Any kDÔSDS-polyacrylamide gel (Bio-Rad Laboratories, Inc) was used to 
separate proteins.  SDS interacts with protein to enable it to have a negative charge that 
is attracted to the cathode of the electric current. Twenty micrograms of protein was 
heated for 5 minutes at 95°C and mixed with 5X loading dye (100 mM Tris-GCL pH 6.8, 
4% SDS. 200 mM dithiothreitol, 0.2% bromophenol blue and 20% glycerol). Exact 
volume varied in order to get 20 µg of protein per lane which was quantified using the 
Bio-RadDC Protein Assay detection kit (Bio-Rad Laboratories, Inc). DualColor 
Prestained Protein Ladder (Bio-Rad Laboratories, Inc) was used for the identification of 
protein size. The gel was placed into a mini-PROTEAN tetra cell system (Bio-Rad 
Laboratories, Inc) and run for 1 hour and 30 minutes at 60 volts in 1x Nupage MES SDS 
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running buffer (Life technologies™). Protein was transferred onto an Immun-BlotTM 
PVDF membrane (Bio-Rad Laboratories, Inc) using a Trans-Blot SD  semi-dry transfer 
cell (Bio-Rad Laboratories, Inc) and Nupage Transfer Buffer (Life technologies™) at 
~8V for 1 hour . Subsequently, the membrane was blocked overnight at 4ºC in blocking 
solution (0.4% PBS/Tween (PBST), 5% dry milk). The following morning, the membrane 
was washed five times in PBST and then incubated for 2 hours at room temperature with 
the antibody of interest (1:500 anti-PTCH, 1:200 anti-SMO, 1:1000 anti-Gli1 and 1:500 
anti-Gli2). The membrane was then washed five times in PBST for 5 minutes, and 
incubated with 1:10 000 conjugated secondary anti-rabbit IgG horseradish peroxidise 
(HRP) (Dako) for 1 hour at room temperature. A further five washes of PBST for 5 
minutes before the use of a ECLTM Prime western blotting detection system kit (GE 
Healthcare) which produces a chemiluminescent signal on binding to HRP. Signal was 
detected using the ChemiDoc MP Imaging system (Bio-Rad Laboratories, Inc) and 
ImageLab software (Bio-Rad Laboratories, Inc). Membranes were stripped of primary 
antibody using RestoreTM Western Blot Stripping Buffer (Life technologies™) at 55ºC 
for 30 minutes, washed five times for 5 minutes in PBST and reprobed with 1:5000 
polyclonal anti-β-actin antibody (Sigma-Aldrich®) as a loading control for each sample. 
 
2.8 Cancer cell lines 
 
2.8.1 LNCaP-Gli1 cancer cell line 
 
This cancer cell line that ectopically expresses Gli1 was previously created in our lab by 
Dr Sandeep Nadendla and details on the methodology and validation are discussed 
elsewhere.(Nadendla et al., 2011) In summary, amphotropic viral particles containing 
pBABE-PURO-Gli1 were generated using the Phoenix packaging cell line (Nolan 
laboratory, Stanford, USA). Parental LNCaP cells (obtained from Sigma-Aldrich®) were 
exposed to viral particles with polybrene and centrifuged at 300g at 32°C for 1 hour. An 
elapse of 72 hours occurred prior to selection using puromycin to allow for the control, 







2.10 General solutions and media 
 
Methyl green PBS (pH 7.3) Tris-HCL, 1M 
0.1M Sodium Acetate Buffer, pH4.2 137mM Nacl 121g Tris base in 800ml 
H20 
1.36g Sodium acetate, trihydrate (MW 136.1) 2.7mM KCL HCL to adjust pH 
100ml dH20 4.3 mM Na2HPO4.7H20 d H20 to make 1L 
Mix to dissolve and adjust pH to 4.2 using 
glacial acetic acid 
1.4 mM KH2PO4  
Methyl Green Solution (0.5%)  
0.5g methyl green (ethyl violet from Sigma) 
  
Dissolve in 100ml 0.1M sodium acetate buffer 
pH 4.2 
  
   
Agarose Gel DNA runs(large) 50X TAE  
300mls x1 TAE buffer 242g Tris base  
4.5grams Agarose 57.1ml glacial acetic acid  
15ul gel red 37.2g Na2EDTA.2H20  
 dH20 to 1L  
   
Antibody Concentration Ag retrieval 
PTCH1 1 in 1500 High pH 9, 20mins 97°C 
SMO Ab72130 1 in 200 High pH 9, 20mins 97°C 
Gli1 Ab134906 1 in 250 High pH 9, 20mins 97°C 
Gli2 Ab26056 1 in 150 Low pH 6, 20 mins 97°C 
Alexa Fluro 568 A11011 1 in 500 ------ 
GPC3 Ab66596 1 in 200 Low pH 6, 20 mins 97°C 
HIST1H2BM Ab1790 1 in 1000 Low pH 6, 20 mins 97°C 





GENETIC VARIANTS IN BASAL CELL CARCINOMA (BCC) 
 
3.1 Aims of the BCC study 
 
The main aim of the study was to identify the genetic makeup of sporadic, periocular 
BCC, specifically in reference to the different histological subtypes that confer a 
dissimilar prognosis. Although malignant, the nodular subtype is an indolent tumour that 
is readily amenable to curative surgical excision, however, the defect often requires 
reconstruction. In contrast, the morphoeic subtype is more locally aggressive, requires 
more mutilating surgery and in the worst case, requires the removal of a normal seeing 
eye (exenteration) to save life. Deciphering the genetic makeup of the more aggressive 
subtype by comparing it to its more benign counterpart was the initial objective. BCC 
from the so-called H zone on the face are classed as high risk, possible due to the delicate 
local structures preventing wide excision margins or due to their genetic makeup being 
different. Up to a third of tumours arise in non-UV exposed areas and so BCC elsewhere 
(elseBCC; defined as non-periocular BCC with intermittent exposure to UV light) may 
be genetically different and speculated to show a reduced UV light induced mutational 
signature and overall mutation burden. Thus, nodBCC from non-periocular sites were 
included in the study to see if they differ from those in the periocular region. It is 
hypothesised that H zone periocular tumours will have a higher UV burden than elseBCC 
and that the morphoeic subtype will have even more than nodBCC taken from any 
location. In addition, histological samples from the same individual can demonstrate both 
nodular and morphoeic subtypes and it is possible that morphoeic in this case is a 
subsequent development or evolved branching of the nodular subtype. Thus, a greater 
mutational burden with a more differential expressed transcriptome is expected. A 
discovery approach (Figure 3.1) using whole exome sequencing of 10 periocular mBCC 
(including 1 stroma) and 10 nodular BCC comprising of 5 periocular nodBCC and 5 non-
periocular nodBCC (elseBCC) was carried out to address these issues. WES findings are 
summarised in this chapter. After looking at candidate genes, further examination using 
RNA sequencing (Chapter Four) of 3 periocular nodular and 3 morphoeic subtypes was 
performed to corroborate the exome sequencing data. The surrounding normal stromal 
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tissue was used as the reference, but also to see if the morphoeic stroma milieu possessed 
any changes that may explain its locally aggressive infiltrative nature by comparing it to 
the nodular stroma. On light microscopy, it has been long suspected that the surrounding 
stroma of the morphoeic subtype was different as a strong inflammatory reaction 
containing fibroblasts is seen (Figure 1.6). In light of the nucleic acid analysis, supportive 
evidence from protein expression (Chapter Four) was sought, especially in the hedgehog 




Figure 3.1 BCC project. Overview of the BCC project highlighting the stepwise progression starting with 
genetic variant detection in the DNA, followed by genetic expression using RNAseq and validation using 
quantitative PCR plus protein expression. Resultant treatment targets are summarised at the end of chapter 













3.2 Whole exome sequencing in basal cell carcinoma (BCC) 
 
Whole exome sequencing (WES) has massively increased the wealth of information on 
the mutational burden of cancer, but it can also add to the confusion. Large collaborations, 
for example the cancer gene atlas (TCGA), have got together to pool data in the hope that 
the larger numbers would allow the driver mutations to become more prominent with the 
background passenger mutations fading away. However, the large accumulation of 
sequencing data has not increased the sensitivity (number of driver mutations) and 
specificity (from passenger mutations) as desired. Despite correction for length and low 
false discovery rates being applied, very large genes such as TTN and MUC16, genes 
spanning long introns (for example CSMD) and those with unexplained biological 
significance like the olfactory receptors consistently come out on top.(Lawrence et al., 
2013) Taking this awareness into account, the WES data is presented in a number of 
formats and different databases were consulted to look for potential driver mutations. 
Therefore, simple data such as frequency noted in the tumour is still shown and genes 
with odd biological function included. Genes of interest are described with a paragraph 
to introduce their known function and their relation to cancer given. Pathway grouping 
was another method of linking biologically similar mutations, however, tumours can act 
through non-canonical pathways (for example KRAS in pancreatic cancer). Cancer is 
heterogeneous and ultimately each patient is likely to be given personalised treatment 
according to their own mutational burden and expression in the future. 
 
3.2.1 Clinical and histological features of BCC patients 
 
The clinical and histological features of the BCC patient cohort used in the study are 











Sample Age Gender Location 
M1 85 M RLL 
M2 47 F LLL 
M3 78 F LLL 
M4 71 M LMC 
M5 83 F LMC 
M6 61 M RLL 
M7 71 F RMC 
M8 78 F RUL 
M9 62 F RUL 
M10 87 F RMC 
Sample Age Gender Location 
Nod1 70 M LLL 
Nod2 80 M RLL 
Nod3 71 M RMC 
Nod4 72 F LLL 
Nod5 46 F RLL 
Else1 74 M Chest 
Else2 89 M Chest 
Else3 83 M Forearm 
Else4 87 M Forearm 
Else5 52 M Shin 
 
Table 3.1 Clinical features of BCC patients. Summary of the clinical features for each BCC histological 
subtype that underwent whole exome and RNA sequencing. M, morphoeic BCC, Nod, nodular BCC, Else, 
non-periocular nodular BCC found outside the H-zone; LLL, left lower eyelid; RLL, right lower eyelid, 






Figure 3.2 BCC patients recruited into the study. Histological collage of BCC samples presented as 
Haematoxylin and Eosin stained sections (H&E). All samples were initially processed as fresh tissue with 
fast H&E staining to identify tumour for laser capture. A few cases went on to FFPE processing with further 
H&E, hence the difference in quality between the samples. M, morphoeic BCC, N, nodular BCC, E, nodular 










3.2.2 Read level quality control metrics  
 
Whole exome sequencing was performed on the Illumina HiSeq2000 platform. Read files 
(FASTq) were generated from the sequencing platform and read level quality control 
metrics provided by FastQC, a Babraham bioinformatics quality control tool for high 
throughput sequencing data (http://www.bioinformatics. 
babraham.ac.uk/projects/fastqc/). Raw data from the platform is summarised in Figure 
3.3. Quality control metrics are presented including mean read base quality (Phred score) 
(Figure 3.4), per sequence quality (Figure 3.5) and GC content per base (Figure 3.6). The 
Phred score is a measure of the quality of the identification of the base by the Illumina 
platform. A score of 30 indicates a 1 in 1000 probability of an incorrect base call 
conferring a base call accuracy 99.9%. Throughout the read the Phred score is 
approximately 32. The per sequence quality represents the quality of each read with the 
count representing the number of sequences. As for the individual base, a mean sequence 
quality (Phred) of greater than 30 indicates a good average quality per read. In addition, 
the graph highlights any subset of the sequences with that have poor quality by having a 
small peak below 20 which is not demonstrated on these samples. The per base GC 
content should reflect the organism’s genome under investigation and is between 42-48 












Figure 3.4 Mean Phred score for mBCC. Plot of the mean read base quality (Phred score) at each position 
of a read (cycle) for all ten mBCC samples. Mean quality decreases towards the end of the read as expected.  
 
 
Figure 3.5 Per sequence quality in mBCC. Counts of the mean sequence quality (Phred score) for all 









Figure 3.6 Per base GC content for mBCC. (A) Plot of percentage GC content at each position of a read 
(cycle) for all ten mBCC samples. It reflects the GC content for humans (B) between 42-48 percent. Figure 
3.6B adapted from Romiguier et al. (Romiguier et al., 2010) 
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3.2.3 Mutational profile of BCC 
 
A general overview of the WES data was performed to see how many variants were 
detected in each of the BCC subtypes giving an overall mutational burden within the 
tumour. Subsequently, UV signature analysis was performed to see how many variants 
were UV induced and whether this varied across the different subtypes.  
 
Mutational burden 
The total number of somatic coding mutations filtered for at least x20 depth for all ten 
nodular BCC was 18,446 and for mBCC 9564 (Table 3.2). Nodular elsewhere had a total 
burden of 10,368 compared to periocular nodBCC total of 8078. Periocular mBCC 
displayed a marginally reduced mutational burden to nodBCC (P=0.085) refuting the 
hypothesis that the more aggressive tumour would contain a greater number of mutations. 
Interestingly, the burden of mutation burden on normal eyelid skin alone is just under 
1000, which highlights that a large number of the changes detected within these tumours 
are passenger mutations that are gathered in the skin. (Martincorena et al., 2015) Thus, it 
makes it harder to decipher the meaningful driver mutations. 
 
Sample Total  Non-syn Syn 
M1 3107 1817 1018 
M2 958 560 327 
M3 1025 603 325 
M4 445 249 137 
M5 611 375 180 
M6 166 93 53 
M7 935 556 284 
M8 89 58 28 
M9 1132 702 340 
M10 1096 615 378 
Sample Total  Non-syn Syn 
Nod1 1936 1165 771 
Nod2 609 363 185 
Nod3 2393 1402 991 
Nod4 1378 789 589 
Nod5 1762 1059 703 
Else1 1728 1017 527 
Else2 605 368 161 
Else3 213 133 50 
Else4 4123 2348 1321 
Else5 3699 2196 1124 
 
Table 3.2 Mutational burden in BCC. Overall mutational burden, non-synonymous single nucleotide and 
synonymous single nucleotide variants for each sample that underwent WES after filtering for a minimum 
of x20 depth. M, morphoeic BCC, Nod, nodular BCC, Else, nodular BCC no in the H-zone; non-syn, non-






UV burden and signature 
Ultraviolet light can be genotoxic to DNA, producing cyclobutane pyrimidine dimers 
(CPD) and pyrimidine (6-4) pyrimidone photoproducts (64PPs) at dipyrimidine 
sites.(Ikehata and Ono, 2011) A specific type of base substitution occurs, a cytosine to 
thymine (C>T) at dipyrimidine sites. This especially occurs when the cytosine is preceded 
by another pyrimidine (in a CpC or TpC context) as this makes it easier for the dimer 
production to occur, as the dipyrimidine is not just nearby, but adjacent (CX or XC, where 
X= C or T). Moreover, these changes occur more frequently on the non-transcribed 
strand, as there is preferential nucleotide excision repair on the transcribed DNA strand 
(transcription coupled repair). Another, less common change is a tandem base substitution 
where two neighbouring cytosine (dinucleotide) are replaced by thymine (CC>TT). 
Methylated cytosine’s at CpG islands seem to be more susceptible to CPD formation, 
especially from UVA and UVB light. The UV signature of normal skin is 55% and the 
majority tend to be a dinucleotide change (CC>TT).(Martincorena et al., 2015) The UV 
signature across all subtypes showed a similar change at 85% for mBCC, 88% for 
nodBCC and 85% for elseBCC (Figures 3.7 and 3.8). This refutes the hypothesis that the 
aggressive nature of mBCC is related to both UV burden and locality. It was thought that 
those on the face (within the high-risk H-zone) would be more exposed to sunlight over 
the course of time than those that are covered most of the time, hence would show an 
increase in UV signature along with tumour total mutation burden. mBCC 10 was an 
outlier and only demonstrated a UV signature percentage of 45% reflecting normal skin 
burden percentage, but a greater number of potentially pathological changes compared to 
normal skin. The lack of UV signature may represent an early stage in the cancers 
development, the UV induced genes may not beneficial to the cancer and therefore not 
positively selected.  
 
In addition, the mBCC histological subtype is a proven risk factor for recurrence and 
being a UV associated tumour, it was thought the aggressive nature would be related to 
more UV induced mutations, but this was not the case. (Mosterd et al., 2008) 
Nevertheless, it was postulated by Martincorena et al that every sun exposed skin cell 
acquires a new mutation in its genome for everyday of its life.(Martincorena et al., 2015) 
Moreover, it has been shown that as little as three driver mutations are required for the 
onset of lung and colorectal cancer.(Tomasetti et al., 2015) Thus, the normal skin 





Figure 3.7 Mutational burden of basal cell carcinoma. Somatic coding single nucleotide variant (SNV) 
burden for each BCC WES sample with the blue portion of the bar representing non-synonymous SNVs 
and the red synonymous SNVs 
 
 
Figure 3.8 Pathological mutations and signature in BCC. Somatic single nucleotide variants are shown 
for each BCC sample with the percentage of each possible transition/transversion shown. M, morphoeic 
BCC; N, nodular BCC; E, non-periocular nodular BCC located elsewhere. Key: Pyrimidine transition, 





3.2.4 Driver mutations in periocular morphoeic BCC 
 
The ten mBCC samples were analysed together using two different mutational 
significance algorithms, namely MutSigCV and Intogen, resulting in 38 (Table 3.4, 3.5 
and 3.6) and 17 (Table 3.7, 3.8) significant genes respectively. The striking result is that 
they shared just one gene, namely PTCH1, albeit the most reassuring one that confirms 
our samples were genuine BCC (Figure 3.9). Genes from both lists are explored in more 
detail in relation to their biological function and cancer association. Genes are then 







Figure 3.9 Driver genes in mBCC. Venn diagram highlighting the significant driver genes in mBCC using 
two algorithms, MutSigCV and Intogen, with shared genes within the cross over region. Q, false discovery 








3.2.4.i Shared driver mutation using MutSigCV and Intogen 
Only one gene, PTCH1 was identified using both algorithms (Figure 3.9). This may 
reflect the heterogeneity of the tumour whereby a multitude of different genes can lead to 
a morphoeic phenotype. Table 3.3 summarises the PTCH1 variants that were found in the 
mBCC cohort with the predicted outcome for the variant using SIFT and Polypen. 
 
Sample Genomic / DNA level Protein level SIFT Poly Cos id 
M1 c.988T>C p.Thr230Ala 0.7, T 0.99, PD  
M2 g.98244414A>T (Intronic) p.? (Splice distance 2)    
M3 c.1885T>A p.Lys529*   144245 
M4 c.3077C>G p.Trp926Ser 0, D,H 1, PD  
M5 c.3419_3427delinsA p.(Ser1040fs)    
M6 c.3059_3060insAGAAAGC p.(Tyr920fs)    
M7 c.3549_3550insCA p.(Val1083fs)    
M8 c.2536T>A p.Lys746*    
Table 3.3 PTCH1 mutations seen in mBCC cohort. The mutation DNA location and protein change are 
highlighted. * Stop/gain; fs, non-synonymous frameshift:stop/gain. Analysis from SIFT (D=damaging, T=tolerated, 










3.2.4.ii Drivers identified using MutSigCV algorithm 
Four driver mutations were discovered using the MutSigCV algorithm with a P<0.02 
(Figure 3.9). However, due to only one gene being shared across the Intogen and 
MutSigCV, the data is presented in an alternative format to highlight any other potential 
driver genes. The algorithm is weighted to non-silent variants, but also taking into account 
silent variants (Table 3.4). If genes were organised using non-silent changes then they 
would be ordered differently and C6 becomes significant (Table 3.5). However, it also 
takes into account the size of the gene and its function otherwise TTN would come out as 
the most important gene (Table 3.6). Selected potential drivers are explored in more detail 





Gene Non-silent Silent P Value 
PTCH1 8 1 1.61E-07 
CCDC108 4 2 0.011 
FBXO15 2 0 0.013 
POM121L12 6 1 0.015 
OR5H2 2 0 0.018 
KRTAP12-3 1 0 0.02 
 
Table 3.4 Drivers in mBCC using MutSigCV silent and non-silent mutations. Top six driver genes 




Gene Non-silent Silent P Value 
PTCH1 8 1 0.000000161 
C6 7 0 0.040 
POM121L12 6 1 0.013 
CCDC108 4 2 0.015 
 
Table 3.5 Drivers in mBCC using MutSigCV non-silent mutations. Top six driver genes using 







Silent P value 
TTN 52 15 9.99E-01 
MUC16 17 4 1.00E+00 
CSMD3 13 2 8.72E-01 
SYNE1 10 5 9.61E-01 
CSMD1 9 2 9.99E-01 
PCDH15 9 5 1.00E+00 
PTCH1 8 1 1.61E-07 
ANK2 8 2 4.96E-01 
BAI3 8 1 9.92E-01 
C6 7 0 4.02E-02 
EPHA3 7 0 1.05E-01 
Gene Non-
silent 
Silent P value 
GPR112 7 1 2.80E-01 
TEX15 7 1 3.69E-01 
RYR1 7 0 5.10E-01 
RP1 7 1 7.62E-01 
LRP1B 7 2 9.23E-01 
DNAH8 7 2 9.70E-01 
GPR98 7 2 1.00E+00 
POM121L12 6 1 1.46E-02 
PKD1L2 6 1 1.69E-01 
COL11A1 6 0 3.07E-01 
 
Table 3.6 Most mutated mBCC genes using MutSigCV ignoring size and function. Top 20 genes 
arranged according to the number of non-silent gene mutations in MutSigCV ignoring size and function.  
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3.2.4.iii Drivers identified using Intogen algorithm 
WES data was put through the Intogen algorithm too and the potential driver genes listed 
in the Table 3.7 using a false discovery rate (q-value) of < 0.05. TTN is included, as it is 
not removed in the same way as MutSigCV, however, although it contains many variants, 
it is not attributed driver status by Intogen program. A list of known drivers that were 
detected is listed in Table 3.8 but many are not significant. A more stringent q value was 
used for the Venn diagram (Figure 3.9) to narrow the number of potential drivers. These 
among other selected genes are discussed in more detail below the tables. 
 
 
Gene Freq Driver q-value 
PTCH1 8 HCD 1.06E-10 
FLNB 5  1.51E-8 
TTN 8  4.44E-8 
USP4 4  7.71E-4 
CHD3 2 CD 1.39E-3 
EPHA3 3 CD 0.007 
Gene Freq Driver q-value 
NFS1 3  0.038 
EFTUD2 2 CD 0.038 
HECTD4 4  0.038 
SMARCA4 4 HCD 0.038 
FNIP1 2   0.042 
CHKB 2  0.043 
 
Table 3.7 Intogen derived drivers in mBCC. Top 12 driver genes arranged using Intogen and an fm-bias 





Gene Freq q-value 
PTCH1 8 <0.001 
CHD3 2 0.001 
EFTUD2 2 0.039 
ARHGAP35 4 0.039 
CREBBP 3 0.066 
Gene Freq q-value 
AHNAK 2 0.192 
MED12 2 0.346 
ARID4B 3 0.346 
ATR 2 0.487 
PLXNA1 2 0.487 
Table 3.8 Known Intogen drivers found in mBCC.  Top 10 known driver genes using Intogen arranged 









3.2.5 Morphoeic BCC molecular pathway analysis using WES data  
 
Potentially pathological variants were collated according to pathway involvement to try 
and identify any associations. Intogen was used to collated the variants and list the most 
significant altered pathways according a q <0.05 (Table 3.9). In doing so, four pathways 
came out on top namely the hedgehog, BCC, pathways in cancer and Wnt signalling 
pathways (Table 3.9). The mutational burden of four biologically significant pathways 
were picked for further assessment to see which genes were changed and included Hh, 
NK cell, Wnt and FC epsilon RI signalling pathway (Tables 3.10 – 3.13). The later 
pathway was just non-significant at a q value of 0.06; however, it is a potential candidate 
pathway as it is involved in the release of inflammatory mediators and cytokines (Figure 
3.9). Another potential pathway (axonal guidance) not picked using Intogen q<0.05, but 
has been associated with pancreatic cancer and is altered in our RNAseq analysis is 
mentioned below in more detail. 
 
 
Table 3.9 Driver pathways in mBCC. Intogen pathway prediction highlighting altered pathways using 













Gene Freq Driver 
PTCH1 8 Driver, Rec 
SMO 1 Driver, Dom 
Gli1 1  
Gli2   
Gli3 1  
STK36 2  
LRP2 2  
WNT8A   
CREBBP 2 Driver 
HHIP   
SIN3A 1  
BMP4 1  
CSNK1A1 1  
Gene Freq Driver 
CSNK1E 1  
PRKACB   
PRKX 1  
WNT2   
PRKACA 1  
SUFU 1 Driver, Rec 
WNT5B 1  
BMP5 1  
PTCH2 1  
WNT10A 1  
BMP6 1  
WNT3A 1  
SHH 1  
 
Table 3.10 Hedgehog pathway and related genes in mBCC. Mutational burden in 10 mBCC tumours 
with respect to the Hedgehog signalling pathway (hsa04340). Specific variants are highlighted as possible 
driver mutations according to the Intogen algorithm along with their either dominant or recessive effect. 





Gene Freq Driver 
ARAF 1  
FCER1G 1  
FCGR3A 2  
FYN 1  
HRAS 1 HCD, Dom 
IFNA10 2  
IFNA16 2  
IFNA2 1  
IFNA4 1  
IFNA7 2  
PIK3CD 1  
PIK3CG 1 HCD 
 
Table 3.11 Natural Killer pathway in mBCC. Mutational burden in 10 mBCC tumours with respect to  
the NK pathway (hsa04650). Specific variants are highlighted as possible driver mutations according to the 
Intogen algorithm along with their either dominant or recessive effect. Freq, frequency; Rec, recessive; 









Gene Freq Driver 
CREBBP 2  
NFATC2 2  
NFAT5 2  
RHOA 2 HCD 
TBL1X 2  
PPP3R1 2  
MAPK9 1  
LRP6 1  
PRKACA 1  
EP300 1 HCD, Rec 
CHD8 1 HCD 
NFATC4 2  
CSNK2A1 1  
PORCN 1  
AXIN1 1  
FZD3 1  
SFRP4 2  
DVL1 1  
MAPK8 1  
WNT5B 1  
FZD10 1  
PPP2R5D 1  
CSNK1A1 1  
Gene Freq Driver 
ROCK2 1  
APC 1 HCD,Rec 
WNT10A 1  
PPP2R1B 2  
PPP3CA 1  
TP53 2 HCD,Rec 
SMAD4 1 HCD,Rec 
TCF7L2 1 HCD,Dom 
PLCB3 4  
WNT3A 1  
CTBP1 1  
DVL3 1  
PRICKLE2 1  
SOX17 1 HCD 
PRKCB 1  
SMAD3 1  
RAC3 1  
VANGL1 1  
RUVBL1 1  
PRKX 1  
FZD9 2  
CSNK2B 2  
CSNK1E 1  
 
Table 3.12 Wnt signalling and related genes in mBCC. Mutational burden in 10 mBCC tumours with 
respect to the Wnt signalling pathway (hsa04310). Specific variants are highlighted as possible driver 
mutations according to the Intogen algorithm along with their either dominant or recessive effect. Freq, 















Gene Freq Driver 
INPP5D 2  
FYN 1  
GAB2 1  
MAP2K3 1  
MAPK9 1  
SOS2 1  
PIK3R2 2  
PIK3CG 1 HCD  
MAPK8 1  
MAPK14 1  
AKT3 1  
Gene Freq Driver 
VAV1 1  
PIK3R1 1 HCD, Rec 
MS4A2 1  
FCER1G 1  
PRKCB 1  
RAC3 1  
PIK3CD 1  
HRAS 1 HCD, Dom 
PLA2G6 1  
PLCG2 2  
LAT 1  
 
Table 3.13 Fc epsilon RI signalling in mBCC. Mutational burden in 10 mBCC tumours with respect to 
the Fc epsilon RI signalling pathway (hsa04664s). Specific variants are highlighted as possible driver 
mutations according to the Intogen algorithm along with their either dominant or recessive effect. Freq, 
frequency; Rec, recessive; Dom, dominant. 
 
As mentioned the Fc epsilon RI signalling pathway was only just non-significant, but 
looking at the Kegg pathway in terms of flow you can see that alteration of the known 






















Figure 3.10 FC epsilon RI signalling pathway adapted from Kegg (hsa04664). Orange circles represent 





Axonal guidance pathway 
Another possible novel pathway in mBCC is the axonal guidance pathway (Figure 3.11). 
Each gene is summarised in Figure 3.11 which visually summarises the pathway burden 
for each of the 10 mBCC samples. Although not within q <0.05 Intogen analysis, it is 
sufficiently affected to suspect potential involvement, especially as it is significantly 
modified at the RNA level too (see section 3.4.2). A Kegg pathway diagram (Figure 3.12) 





Figure 3.11 Axonal guidance in mBCC. Heatmap representing the axonal guidance pathway (genes along 









Figure 3.12 Axonal guidance pathway adapted from Kegg (hsa04664). Orange circles represents genes 
identified using Intogen that were mutated in mBCC. Also shown are the Hh and Wnt signalling pathways 

















3.2.6 Driver mutations in nodular BCC  
 
Ten nodular BCC, 5 from the periocular region and 5 from elsewhere, were analysed 
together using two different mutational significance algorithms, MutSigCV and Intogen. 
This resulted in 78 and 176 (22 drivers) significant (P<0.05) genes using respectively. 
Restricting the significance cut-off to P<0.01 for the MutSigCV genes reduced the total 
to 8 genes (Table 3.14). Using a q-value (adjusted p-value taking into account the false 
discovery rate, FDR) of less than 0.05, the Intogen total reduced to 23 (7 drivers) top 
genes listed in Table 3.15. When comparing the two, the shared significant (P<0.05) 
mutations were found in six genes: PTCH1, TP53, FADS1, PPM1D, TAF4B, TRIP4 
(Figure 3.13). Genes from both algorithms are explored in more detail in relation to their 





Figure 3.13 Drivers in nodBCC. Venn diagram highlighting the significant driver genes identified in 
nodBCC using two algorithms, MutSigCV (p<0.02) and Intogen (q<0.02) with shared genes in the cross 







3.2.6.i Shared driver mutations using MutSigCV and Intogen 
 
Six genes were found to be potential drivers using both algorithms including PTCH1, 
TP53, FADS1PPM1D, TAF4B, TRIP4 and are discussed in more detail below (see 3.3.4). 
  
 
3.2.6.ii Drivers identified using MutSigCV algorithm 
 
Eleven genes were identified using MutSigCV and a P<0.02. The number of silent and 
non-silent variants are listed for the top 8 mutations in Table 3.14. Six of the genes shared 





Gene Non-silent Silent P Val 
TP53 13 2  
PTCH1 9 1  
GABRA6 5 1  
OR52J3 4 0  
Gene Non-silent Silent P Val 
TSGA13 3 0  
TRIM39 3 0  
C10orf82 3 0  
FADS1 2 0  
 
Table 3.14 Drivers in nodBCC using MutSigCV silent and non-silent mutations. Top 8 potential driver 
mutations MutSigCV genes taking into account silent and non-silent genes ordered according to P value 

















3.2.6.iii Drivers identified using Intogen algorithm 
Twenty-three genes were identified using a q<0.05 and are summarised in Table 3.15. 
Several of the variants were also noted in databases such as COSMIC and an example of 
their identifying numbers is also mentioned. PTCH1 changes were replicated in 26 




Gene F Dr Database ID 
PTCH1 7 1 * (4) COSM96959 
TP53 7 1 
* (26) COSM10662 
 * (2) rs28934573 
COL4A4 3 0  
TRIP4 4 0 rs144077712 
ARHGAP35 3 1  
MTR 3 0 rs142250261 
TTN 9 0 
*(8)COSM286164;  
* (5)rs145185269 
MYCN 4 1  
NARS 2 0 ESP_18_55274765 
PAM 4 0  
ZEB1 4 0  
Gene F Dr Database ID 
ITGAL 4 0  
NHSL1 4 0  
SYNE1 8 0 rs201346604 
RAB14 2 0  
IGSF10 3 0  
KANSL1 2 0  
PPM1D 2 1  
FADS1 3 0 rs142276858 
TAF4B 2 0  
ARID1A 2 1 COSM51453 
IRF2 2 1  
TANC1 3 0  
 
Table 3.15 Intogen drivers in nodBCC Top 23 genes sorted using Intogen using a fm-bias q value <0.05 
*(total number) multiple known variants were identified in the following databases COSMIC, dbSNP and 















3.2.7 Nodular BCC molecular pathway analysis using WES data 
 
Intogen pathway prediction was performed on nodBCC WES data across the ten samples. 
Forty-two pathways are significantly altered using a q<0.05 and the ones with a q value 
less than 0.02 are summarised in Table 3.16. Specific pathway variants for Hh, TGF-beta 
and TP53 are shown in Tables 3.17, 3.18 and 3.19 respectively.  
 
 
Table 3.16 Driver pathway in nodBCC. Intogen pathway prediction highlighting altered pathways using 
WES data from 10 nodBCC tumours. 
 
Gene Freq Driver 
PTCH1 8 Driver, Rec 
SMO 1 Driver, Dom 
Gli1 1  
Gli2   
Gli3 1  
STK36 2  
LRP2 2  
WNT8A   
CREBBP 2 Driver 
HHIP   
SIN3A 1  
BMP4 1  
CSNK1A1 1  
Gene Freq Mutation 
CSNK1E 1  
PRKACB   
PRKX 1  
WNT2   
PRKACA 1  
SUFU 1 Driver, Rec 
WNT5B 1  
BMP5 1  
PTCH2 1  
WNT10A 1  
BMP6 1  
WNT3A 1  
SHH 1  
Table 3.17 Hedgehog pathway in nodBCC. The mutational burden in 10 nodular BCC with respect to the 
Hedgehog signalling pathway is highlighted. Specific variants are highlighted as possible driver mutations 
according to the Intogen algorithm along with their either dominant or recessive effect.. 
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Gene Freq Driver 
ACVR1C 1  
ACVRL1 1  
AMH 3  
AMHR2 1  
BMP4 1  
BMP6 3  
CHRD 1  
DCN 1  
Gene Freq Driver 
MAPK3 2  
RBL1 1  
ROCK1 3  
SMAD3 1  
SMAD4 2  
TGFB1 1  
TGFB2 1  
 
Table 3.18 TGF-beta pathway in nodBCC. Highlighting the mutational burden in 10 nodular BCC 





Gene Freq Driver 
APAF1 3 D 
ATM 2 D 
ATR 2 D 
BAI1 3  
CASP8 3 D 
CCNB3 2  
Gene Freq Driver 
CCND3 1  
CCNG2 1  
CDK4 1 D 
TP53 7 D 
ZMAT3 1  
 
Table 3.19 TP53 pathway in nodBCC. Highlighting the mutational burden in 10 nodular BCC with 
respect to TP53 pathway.  
 
 
3.2.8 Locality and subtype specific drivers 
 
Next, we performed the randomisation analysis (see Methods section 2.6.1) to identify 
significantly mutated genes that were related to a specific subtype or locality (Figures 
3.14-3.16). MutSigCV mBCC specific gene included CCDC108, and nodBCC specific 
included GABRA6, OR52J3, TRIM39 and ADAM29 (Figure 3.14). Intogen mBCC 
specific genes included HECTD4 and FLNB and nodBCC specific were ZEB1 and 
TP53 (Figure 3.15).  Locality nodBCC genes include SIPA1L1 and SYNE1 whereas 
elseBCC revealed ANK2 and HIVEP1 (Figure 3.16). TP53 and PTCH1 were shared 






Figure 3.14 Randomised comparison of MutSigCV drivers in BCC. Drivers identified using 
MutSigCV were compared across the two subtypes, morphoeic and nodular BCC, and a randomised 
comparison test performed to discover those drivers that are more likely to be noteworthy than being 
randomly picked by chance during WES discovery. Genes close to an axis are specific for that subtype. 
Genes in the middle are shared between the two. The size of the circle indicates the confidence that the 














Figure 3.15 Randomised comparison of Intogen drivers to identify subtype specific genes in BCC. 
Drivers identified using Intogen were compared across the two subtypes, morphoeic and nodular BCC, 
and a randomised comparison test performed to discover those drivers that are more likely to be 
noteworthy than being randomly picked by chance during WES discovery. Genes close to an axis are 
specific for that subtype. Genes in the middle are shared between the two. The size of the circle indicates 
















Figure 3.16 Randomised comparison of Intogen drivers to identify location specific genes in 
nodBCC. Drivers identified using Intogen were compared across the two localities, periocular and 
elsewhere, and a randomised comparison test performed to discover those genes that are more likely to 

















3.2.9 Stromal morphoeic BCC 
 
Epithelial cancer behaviour is not restricted to the tumour borders delineated on 
microscopy; the surrounding stroma has been shown to play a key role in local 
spread.(Davidson et al., 2014) mBCC has long been associated with snake-like 
projections of cancer cells with surrounding inflammatory reaction containing 
fibroblast cells (Figure 3.17). This stromal soup could be beneficial to the tumour or 
simply be the body’s immune response. Removal of the tumour alone is tricky and 
hence Mohs surgery is advocated to ensure histological removal, however, the leaving 
behind of the stromal reaction has not thought to be an issue. Local recurrence is a risk 
with mBCC and as this tumour rarely metastasis, one would think that this is due to the 
leaving behind of mutated cells. If the stroma contains mutations then this too may have 
to be removed along with tumour cells in future Mohs surgery. 
 
 
Figure 3.17 Histopathology of BCC subtypes. H&E staining of (A) Morphoeic BCC M4 highlighting 
the varied strands of tumour interdigitated in cellular stroma. (B) Nodular BCC for comparison 
demonstrating a well circumscribed tumour with relatively few cells in the surrounding stroma. 
 
WES was carried out on both the tumour and histologically normal surrounding stroma 
of one microdissected mBCC sample. This revealed 150 shared nonsynonymous 
mutations (76.5% of all stromal mutations) including mutations in ATR, EPHA3 and 
Gli3. Interestingly, the majority of the potentially pathological mutations revealed 
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identical variants (Table 3.20). The overall variant allele frequency (VAF), however, 
was low at 0.12 for the tumour at peak density and 0.04 for the stroma equating to a 
tumour purity of 24% and 8% respectively if assuming heterozygous change throughout 
the tumour (Figure 3.18). The highest VAF gene was ROS1, a proto-oncogene tyrosine 
kinase receptor and is discussed below. 
 
 TUMOUR STROMA 
Gene F q/p Driver Stroma mBCC SIFT Poly 
TTN 8  I c.57578 C>T 
c.22301 p.G19118E C>T p.G5759E 
  
EPHA3 3  I,CD c.862 C>T p.P213S  0.00, D,L 0.96, P 
ATR 2 0.487 I, HCD c.4218 G>A pP1336S 0.17, T,H 0.85, P 
C6 7 0.040 Mut c.772 C>T pE170K 0.0, D,H 0.99, P 
Gli3 1   c.2688 G>A p.S868L 0.01, D,H  0.999, P 
ROS1 5  Dom c.5628 G>A p.S1810F.  0.00, D, H 0.988, P 
EPHA3 3  I,CD c.862 C>T p.P213S  0.00, D,L 0.96, P 
EPHB1 2   c.463 G>T p.E31D 0.36, T,H 0.98, P 
 
Table 3.20 Driver mutations in mBCC tumour and stroma. Driver mutations in morphoeic  tumour 
assessed for presence in the stroma underwent Intogen, SIFT and Polypen analysis. The top 12 genes 
were arranged using tumour Intogen using a fm-bias value <0.05. The mutations detailed above were the 
same one seen in the microdissected tumour. F=frequency, q=q-value, p=p-value, I=Intogen, 
Mut=MutSigCV, P=Probably, D=Damaging, T=Tolerated, L=low, H=High, SIFT, Poly=Polypen. 
 
 
Figure 3.18 VAF in mBCC tumour and stroma. Variant Allele frequency (VAF) for non-synonymous 
(NS) mutations in morphoeic BCC M4 highlighting (A) peak density of mutational burden and (B) 150 
shared mutations between stroma and tumour with the corresponding VAF.  
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3.2.10 Stromal morphoeic BCC molecular pathway analysis from WES data 
 
Pathways that were altered in the tumour were also analysed to see if they were altered 
in the stroma too. Only 3 pathways contained variants and are listed in Table 3.23, 
however, these growth pathways do act in concert during embryogenesis so they may 
also be important in promoting the stroma milieu to encourage tumorigenesis.   
 
Pathway Gene Variant SIFT Polpen 
Hedgehog  Gli3 c.2688G>A / p.Ser868Leu 0.01, D, H 0.999, PD 
     
Axonal G EPHA3 c.862C>T / p.Pro213Ser 0.36 T, H 0.975, PD 
 EPHB1 c.463G>T / p.Glu31Asp 0, D, L 0.996, PD 
 SLITRK3 c.1762C>T / p.Glu494Lys   
     
Wnt TBL1X 
 
c.1446C>T / p.Ser269Phe 
c.1447C>T / p.Ser269Ser 
  
 PPP3CA c.2159 G>A / p.Ser492Phe 0.04, D, L 0.001, B 
 
Table 3.21 Altered driver pathways in mBCC stroma. G=guidance; F=frequency, q=q-value, p=p-






















3.3 Whole exome sequencing in basal cell carcinoma (BCC) 
 
3.3.1 PTCH1 is shared mBCC driver using MutSigCV and Intogen 
 
Patched 1 (PTCH1)– chromosome 9q22.32 
As mentioned in the introduction, this is an inhibitory receptor of the Hh signalling 
pathway that represses smoothened (SMO) when no ligand is bound. On binding of the 
ligand, PTCH1 repression is released and SMO goes on to activate downstream targets 
such as Gli transcription factors. Inactivating mutations in PTCH1 result in a variety of 
pathologies and its discovery in basal cell naevus syndrome paved the understanding 
of BCC tumorigenesis. Loss of PTCH1 (by deletion or methylation) also occurs in 
oesophageal basaloid squamous cell carcinoma, keratocystic odontogenic tumours, 
cervical, colorectal, gastric and ovarian tumours to name a few.(Saito et al., 2015, Qu 
et al., 2015, Chung and Bunz, 2013, Zuo and Song, 2013, Musani et al., 2013, 
Chakraborty et al., 2015) Eight out of 10 morphoeic tumours contained PTCH1 
mutations and the majority were frame shift as summarised by Table 3.3. WES of BCC 
by Jayaraman et al revealed 9 out 12 tumours had a PTCH1 mutation and they were 
mainly nonsense mutations, however, they failed to state the subtype of BCC 
analysed.(Jayaraman et al., 2014) 
 
3.3.2 Drivers in mBCC identified using MutSigCV algorithm 
 
Coiled-Coil Domain Containing 108 (CCDC108)– chromosome 2q35 
This is a poorly defined protein that is highly expressed in the testis.(Imsland et al., 
2012) SCOC (Short Coiled-Coil Protein), however, is involved in axonal growth in 
C.elegans and axonal growth may be a driver pathway in BCC.(Su et al., 2006) Coiled-
coil interaction is an important component of DNA methylation-driven gene silencing 
and disruption of this coiling interaction can prevent methyl-CpG binding domain 
protein 2 (MBD2)-containing nucleosome remodelling and deacetylation (NuRD) 
complex (MBD2/NuRD) ability to silence genes.(Gnanapragasam et al., 2011) DNA 
methylation plays a role in cancer through transcriptional silencing of gene regulators. 
Nevertheless, it is not clear if CCDC108 has any relation to these coiling processes.  
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F-Box Protein 5 (FBXO15)– chromosome 18q22.3 
FBXO15 contains an ubiquitin E3 ligase complex that is involved in the ubiquitination 
of p-glycoprotein/ABCB1 present on cancer cell surfaces that confers drug 
resistance.(Katayama et al., 2013) F-Box proteins also play an oncogenic role in 
colorectal cancer and loss of FBXO15 enhances vincristine resistance in fibrosarcoma 
cells.(Gong and Huo, 2015, Okita et al., 2007) 
 
POM121 Transmembrane Nucleoporin-Like 12 (POM121L12)– chromosome 7p12.1 
Little is known about this 1283 base pair gene. It is expressed in numerous cancers with 
a predilection for squamous cell carcinoma of the head and neck.(Bamford et al., 2004) 
 
Olfactory Receptor, Family 5, Subfamily H, Member 2 (OR5H2)– chromosome 3q12.1  
The largest family in the genome are the olfactory receptors whose role is in olfactory 
signalling and odorant binding.(Persuy et al., 2015) Although they are frequently 
detected in cancer their biological role may not be relevant.(Xu et al., 2015)  
 
Keratin Associated Protein 12-3 (KRTAP12-3)– chromosome 21q22.3 
Keratin associated proteins are large genes that play an essential role in the maintenance 
of the ridged hair shaft. An association with cancer has not been made, although in this 
case the origin of BCC may be the hair follicle where these proteins are expressed.   
 
Complement component 6 (C6) – chromosome 5p13.1 
The C6 protein is part of the complement cascade and is an integral part of the 
membrane attack complex (MAC) that causes cell lysis. Activation of the complement 
system is via three pathways, the classical, alternative and lectin pathways, however, 
they all converge at C3 that leads onto the final common pathway with the formation 
of the MAC via C5b-C9. Deficiency in C6 induces a susceptibility to Neisseria 
meningitides infection.(Moya-Quiles et al., 2013) Complement activation occurs in 
breast, gastric, lung and brain cancer.(Mamidi et al., 2015) Loss of this final pathway 
will interfere with the body’s cancer defence, and induce complement resistance to 
monoclonal antibody immunotherapy mediated MAC attack.(Di Gaetano et al., 2003) 
Cancer clearing cells such as NK or T-cells are less efficient when complement 




SYNE1 – Chromosome 6q25.2 
SYNE1 is a large gene that codes for several isoforms including the large (>1000KDa) 
protein nesprin-1, a nuclear membrane protein involved in structural cellular 
organisation in muscle and the central nervous system, especially Purkinje cells.(Gros-
Louis et al., 2007) Its role within the nuclear membrane may have a determining 
function for embryonic stem cell differentiation with an increase in facilitation for cells 
to differentiate.(Smith et al., 2011) Mutations in SYNE1 results in neurodegenerative 
disease, cerebellar ataxia and motor neuron disease.(Izumi et al., 2013, Noreau et al., 
2013) SYNE1 is methylated in lung cancer and mutated in colorectal cancer.(Papadia et 
al., 2014, Tessema et al., 2008, Sjoblom et al., 2006) A non-synonymous SNV 
(rs2295190) in SYNE1 is associated with an increased risk of invasive ovarian 
cancer.(Doherty et al., 2010) 
 
3.3.3 Drivers in mBCC identified using Intogen algorithm 
 
Patched 1 (PTCH1)– chromosome 9q22.32 
See details written above in section 3.3.1 and Table 3.3 for specific mutations. 
 
Filamin B (FLNB)– chromosome 3p14.3 
The filamin family trio are non-muscle actin-binding cytoplasmic proteins involved in 
scaffolding, but also interact with a variety of signalling proteins highlighting their 
importance beyond 3D structure.(Nakamura et al., 2011) They carry out cell signalling 
during embryogenesis and FLNB is involved in bone morphogenesis whereby 
mutations result in bone defects seen in spondylocarpotarsal syndromes.(Feng and 
Walsh, 2004) FLNB interacts with histone deacetylase (HDAC) to regulate vascular 
endothelial growth factor (VEGF) induced expression of HDAC7 target genes such as 
matrix metallopeptidase 10 (MMP10) and nuclear receptor subfamily 4, group A, 
Member 1 (NR4A1).  Loss of FLNB inhibits vascular permeability, and in ovarian 
cancer cells, promotes MMP9-mediated tumour invasion and VEGFA-mediated 
vascular growth.(Su et al., 2013) In contrast, FLNB overexpression is related to spindle 
type extracellular cancer invasion seen in 3D collagen models.(Iguchi et al., 2015) Five 
out of ten samples contained a missense variant in the gene. The RNAseq data shows 
FLNB as being non-significantly (p=0.48) downregulated (-0.2 log2FC, expression 
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7.3), which may suggest a loss of function mutation being more likely in the morphoeic 
subtype. 
 
Titin (TTN)– chromosome 2q31.2 
TTN codes for cardiac and skeletal muscle protein and is the largest known protein. 
Mutations in this gene are seen in cardiomyopathy and autoimmune diseases, however, 
it is important to point out that virtually everybody has a variant in their TTN 
gene.(Chavanas et al., 2008) Despite this, it is still reported as associated with many 
cancers including the most common, breast and colorectal, and as mentioned, is one of 
the most mutated genes found in cancer.(Lips et al., 2015, Kim et al., 2015, Kim et al., 
2013c) 
 
Ubiquitin Specific Peptidase 4 (Proto-Oncogene) USP4– chromosome3p21.31 
USP4 has been shown to counteract aberrant Wnt activation and therefore acts as a 
tumour suppressor gene. Its location on chromosome 3 is often lost in epithelial tumours 
where Wnt is dysregulated such as lung, breast, kidney and ovarian cancer.(Zhao et al., 
2009) Overexpression, although less commonly reported, has been seen in 
adrenocortical cancer and can be involved in the aggressive nature of hepatocellular 
carcinoma cancer, which may mean USP4 has a cell specific role.(Velazquez-
Fernandez et al., 2005, Heo et al., 2014) USP4 has recently been shown to suppress p53 
and tumour necrosis factor-α (TNFα)-induced NF-κB activation preventing 
transcriptional, pro-apoptotic functions and inflammation respectively by 
deubiquitating HDAC2.(Li et al., 2015d) A novel role for USP4 is in its promotion of 
DNA repair by homologous recombination and deranged repair often occurs in cancer 





Chromodomain Helicase DNA Binding Protein 3 (CHD3)– chromosome17p13.1 
CHD3 is part of a protein complex called CHD3/nucleosome remodelling and 
deacetylase (NuRD) that carries out two distinct enzymatic chromatin organising 
functions, namely a remodelling ATPase and histone catalytic deacetylase subunits 1,2 
(HDAC1/HDAC2). In addition, there are non-enzymatic subunits as part of the 
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complex that includes metastasis associated 1-3 (MTA1-3), retinoblastoma-binding 
protein 4 and 7 (RBBP4,7), and CpG binding domains 2 and 3.(Lai and Wade, 2011) It 
was initially described in the autoimmune connective tissue disorder dermatomyositis, 
which is a paraneoplastic condition, and this association with cancer prompted 
investigation into its role in oncogenesis. HDAC1/HDAC2 interacts with RB1, 
repressor element-1 silencing transcription factor Corepressor 1 (RCOR1) and SIN3 
Transcription Regulator Family Member A (SIN3A) suggesting it has a key suppressor 
role in the cell cycle.(Denslow and Wade, 2007) More recently, it has been shown to 
maintain the silencing of tumour suppressor genes by occupying their promoters and 
functionally maintaining their hypermethylated, inactive state.(Cai et al., 2014) For 
example, the CHD3/NuRD complex recruits DNA methyltransferases and Chromobox 
Homolog 5 (CBX5) in the epigenetic repression of Cyclin-Dependent Kinase Inhibitor 
1A (CDKN1A) by DNA methylation.(Choi et al., 2013) It is an essential cofactor in 
TWIST1 mediated repression of E-cadherin promoter, a hallmark of EMT, and 
TWIST1 mediated migration, invasion and metastasis.(Fu et al., 2011) HDAC1 
inhibitors have been developed but possess significant side effects with minimal 
success.(Laugesen and Helin, 2014)  
 
Erythropoietin-producing hepatocellular carcinoma (EPH) Receptor A3 (EPHA3)– 
chromosome 3p11.1 
EPH receptors are members of the tyrosine kinase family and interact with two classes 
of ligands, A and B. Unlike other tyrosine kinase receptors that undergo dimerisation, 
EPH receptors require a minimum of four (tetramer) to form clusters, thus only a 
heterozygous loss would act in a dominantly negative fashion.(Janes et al., 2014) It 
preferentially binds the ligand ephrin-A5 and this complex interacts with 
metalloproteinase ADAM10. During embryogenesis, it plays a key role in patterning 
of the vascular and nervous system including axonal guidance. EPHA3 is the most 
frequently mutated gene in lung adenocarcinoma and is a loss of function change.(Ding 
et al., 2008) Mutations are not only restricted to tumour tissue, but are also found in the 
surrounding stroma indicating a possible role in the tumour microenvironment.(Vail et 
al., 2014). EPHA3 was shown to be a tumour suppressor gene in head and neck SCC 
and mutations have been identified in a variety of cancers including pancreatic, 
colorectal, and breast cancer.(Lee et al., 2010) In contrast, EPHA3 overexpression 
promotes aggressive behaviour and self-renewal in glioblastomas.(Day et al., 2013) 
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Depending on cellular context along with their bidirectional potential, it is important to 
determine their tissue specific role before embarking on therapeutic modification. 
Activating and inhibiting monoclonal antibodies have been designed against the 
EPH/ephrin system and antibodies can be radiolabelled to help imaging or targeted 
radiotherapy.(Barquilla and Pasquale, 2015) A recombinant, de-fucosylated human 
immunoglobulin G1κ (IgG1κ), KB004 (KaloBios Pharmaceuticals, California, USA), 
causes sustained EPHA3 activation resulting in tumour cell contraction and apoptosis 
and is currently being tested in phase 1 plus 2 clinical trials for haematological 
malignancies.(Boyd et al., 2014) Three out of ten samples had a variant, two missense 
and one nonsense. 
 
NFS1 Cysteine Desulfurase (NFS1)– chromosome 20q11.22 
Iron-sulphur clusters are part of proteins that are involved in a variety of cellular 
functions including respiration and gene expression.(Fosset et al., 2006) For the 
creation of iron-sulphur cluster, a complex involving NFS1-LYR Motif Containing 4 
LYR (LYRM4) - Iron-Sulfur Cluster Assembly Enzyme (ISCU) is required.(Parent et 
al., 2015) The role it plays in cancer is not clear and is something that needs to be 
discerned.  
 
Elongation Factor Tu GTP Binding Domain Containing 2 (EFTUD2)– chromosome 
17q21.31 
EFTUD2 is a GTPase component of a spliceosome complex that removes introns from 
pre-messenger RNA to form mature mRNA.(Staley and Woolford, 2009) It plays a 
fundamental role in embryogenesis and mutations in this gene cause mandibulofacial 
dysostosis with microcephaly.(Luquetti et al., 2013) EFTUD2 is also involved in the 
regulation of the innate immune system through alternative splicing of Myeloid 
Differentiation Primary Response 88 (MYD88) mRNA, a toll-like receptor signalling 
adaptor.(De Arras et al., 2014) In addition, it modifies the growth regulators (possible 
tumour suppressor genes) retinoic acid inducible gene 1 (RIG-1/DDX58) and 
melanoma differentiated protein 5 (MDA5/IFIH1) expression, which are positively 
correlated with EFTUD2.(Zhu et al., 2015, Tsai et al., 2009)  
 




HECTD4 is a ubiquitin ligase family member that are involved in a plethora of cellular 
functions and they have been implicated in tumour growth and metastasis. 
Overexpression of E3 ubiquitin ligase promotes cell proliferation and survival via 
erythroblastic leukaemia viral oncogene homolog 2 (ErbB2) and epithelial growth 
factor receptor (EGFR) in breast and prostate cancer.(Chen et al., 2008) An intronic 
SNV in this gene (rs11066280) has been associated with a poorer outcome in 
oesophageal squamous cell carcinoma in a genome wide association study (GWAS), 
possibly due to alternative splicing creating a more potent transcript.(Zhang et al., 
2015a, Pagani and Baralle, 2004) Four out of ten samples contained a variant, 2 
missense and 2 nonsense.  
 
Switch (SWI)/Sucrose Non-Fermentable (SNF) Related, Matrix Associated, Actin 
Dependent Regulator of Chromatin, Subfamily A, Member 4 (SMARCA4) – 
chromosome 19p13.2 
Chromatin modelling can be regulated by complexes that either modify the histone tail 
or nucleosomes in an ATP fashion. These complexes play an essential role in gene 
expression and SMARCA4 is a member of the ATP dependent chromatin 
remodeler.(Wilson and Roberts, 2011) In addition, it plays a role in actin cytoskeleton 
with loss of function contributing to loss of actin cytoskeleton, loss of CD44, loss of 
ROCK1 expression and subsequent increase in invasion and motility.(Asp et al., 2002) 
Heterozygous knockout in mice (smarca4 +/-) are prone to epithelial tumours and 
highlights its role as a tumour suppressor gene.(Bultman et al., 2000, Rodriguez-Nieto 
and Sanchez-Cespedes, 2009) Frequent inactivating mutations are seen in lung cancer, 
rhabdoid tumours, pancreas, prostate and breast cancer.(Wong et al., 2000, Medina et 
al., 2005, Dal Molin et al., 2012). Furthermore, restoration of SMARCA4 reversed 
malignant phenotype in cell lines and inhibited growth.  Loss of SMARCA4 causes a 
compensatory increase in expression of SMARCA2 as part of a complex, which has 
oncogenic properties.(Wilson et al., 2014) Mutations have been found in 
medulloblastoma, a tumour with similar associated aberrant signalling pathways and 
underscored by their occurrence in Gorlin syndrome, although this was only in 4 cases 
out of 92.(Dahlin et al., 2015, Pugh et al., 2012) SMARCA4 was present in 4 out of ten 
samples so possibly has a higher frequency in mBCC. Immunostaining for SMARCA4 
in BCC samples demonstrated a reduced protein expression along with SCC, but not a 
reduced RNA expression in SCC; BCC RNA levels were not reported.(Bock et al., 
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2011) Furthermore, the BCC subtype was not mentioned. Four missense variants were 
found in four samples. 
 
Folliculin Interacting Protein 1 (FNIP1)– chromosome 5q31.1 
FNIP1 interacts with folliculin (FLN) and AMP kinase, both regulators of metabolism. 
Germline loss of function mutations in FLN results in an inherited kidney cancer 
syndrome (Birt-Hogg-Dube syndrome) defined by cutaneous fibrofolliculomas, 
pulmonary cysts, and kidney cancer. FNIP1 deficiency in mice (fnip1-/-) blocks B cell 
development resulting in immunodeficiency.(Park et al., 2012, Hasumi et al., 2015) 
Folliculin acts as a tumour suppressor gene via FNIP1-AMPK binding.(Baba et al., 
2006) Activation of AMPK increases glycolysis and oxidative phosphorylation along 
with decreasing rapamycin mTOR driven cell growth.  
 
Choline Kinase Beta (CHKB)– chromosome22q13.33 
Two choline kinase enzymes (CHK A and B) catalyse the phosphorylation of choline 
in the biosynthesis of phospholipid phosphatidylcholine.(Wu and Vance, 2010) CHKB 
is a large gene of 22 Kb and plays an important role in bone embryogenesis and muscle 
function. Loss of function results in bone deformation and muscular 
dystrophy.(Mitsuhashi and Nishino, 2013, Sher et al., 2006, Li et al., 2014c) 
Transcription of CHKB is regulated by the protein kinase C pathway which represses 
the CHKB promoter.(Kuan et al., 2014) Dysregulated choline metabolism occurs in 
many cancers, but this has been mainly attributed to overexpression of CHKA with 
little known about the role of CHKB.(Glunde et al., 2015) More recently, it has been 
shown that the relative balance of CHKA to CHKB is more important for cancer cell 
survival: if CHKA is knocked out alone, mitosis can be halted and apoptosis occurs, 
but if both isoforms are knocked out, then cells no longer undergo cell death.(Gruber et 
al., 2012) Thus, the loss of CHKB confers an anti-apoptotic survival of cancer cells. 
 
Rho GTPase Activating Protein 35 (ARHGAP35) – chromosome 19q13.32 
The main action of ARHGAP35 is to convert Rho-GTP to Rho-GDP thereby 
inactivating the Rho pathway. By binding to p120, it forms a complex which positively 
regulates the Ras pathway by converting Ras-GTP to Ras GDP.(Arthur and Burridge, 
2001) It also acts as a substrate for breast tumour kinase (brk) and phosphorylated 
ARHGAP35 plays an essential role in mediating the migratory and proliferative effects 
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of brk through Ras (activation) and Rho (inactivation).(Shen et al., 2008) 
Phosphorylated ARHGAP35 is regulated by the EGFR pathway in lung 
adenocarcinoma and involves invasion (via Ras) where is presence is associated with 
an aggressive phenotype.(Notsuda et al., 2013) Deliberate overexpression in the mouse 
model of pancreatic cancer resulted in a reduction of tumour invasion and 
metastasis.(Kusama et al., 2006)  
 
CREB (c-AMP response element binding protein) binding protein (CREBBP) – 
chromosome 16p13.3 
CREBBP binds specifically to phosphorylated CREB and acts as a transcriptional co 
activator. In addition, it has a histone acetyltransferase (HAT) domain, however, it does 
acetylate both histone and non-histone proteins. It is vital during embryogenesis and 
autosomal dominant loss of function mutations within this gene result in broad thumb-
hallux syndrome (Rubinstein-Taybi syndrome). Increased frequency of tumours has 
been seen in this syndrome, in particular leukaemia and brain tumours. (Hutchinson 
and Sullivan, 2015) CREBBP mutations are seen in relapsed acute lymphoblastic 
leukaemia and in particular found within the HAT domain.(Mullighan et al., 2011)  
 
3.3.4 Shared nodBCC drivers using MutSigCV and Intogen 
 
Patched 1 (PTCH1)– chromosome 9q22.32 
See section 3.3.1 for description of the gene in BCC. Six out of the ten-nodBCC 
samples had potentially pathological mutations in PTCH1. Two were frameshifts, two 
were nonsense and two were missense. In Gorlin syndrome, the majority of variants 
(65%) tend to be nonsense change, 16% missense, 13% splice site and 6% frameshift.  
 
Tumour protein p53 (TP53) –chromosome 17p13.1 
The archetypal tumour suppressor gene, TP53 has a major role in the stress response 
by carrying out DNA repair, cell arrest, senescence and apoptosis, all of which are 
defence mechanisms against tumour activity. TP53 plays a cardinal role in transcription 
and is a master regulator of the cell cycle. It is not restricted to suppressing tumour 
initiation, but has activity in all stages of cancer progression, aggressiveness and 
metastasis highlighting the multistep process of malignant transformation. Loss of 
function is typically seen in many different cancer types by affecting the ability of the 
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TP53 protein to bind to DNA to activate transcription. A gain of aberrant advantageous 
tumour signalling function could also be happening and more difficult to decipher. 
Single nucleotide variant changes are most commonly seen and occur throughout the 
TP53 coding sequence. Predilection occurs for exons 4 to 9, the area of the gene that 
codes for the protein DNA binding site domain. Furthermore, most mutations are 
heterozygous, meaning that both wildtype and mutant protein are present, however, 
they don’t compete equally. Normal functioning TP53 requires the formation of a 
tetramer to carry out transcription which one mutant protein can disrupt, thereby acting 
in a dominantly negative fashion. Loss of heterozygous provides the final insult by 
inactivating any wildtype TP53 allele. There is no denying that loss of wildtype or gain 
of oncogenic mutant function TP53 is a driver gene, but it is not clear what stage of 
tumorigenesis the effect is having. Inactivation of TP53 has been shown to occur in late 
adenoma early carcinoma transition for colorectal cancer; however, loss of the short 
arm of 17p has been shown in early adenoma. In pancreatic cancer, loss of TP53 occurs 
late. Ductal carcinoma in situ (early breast cancer) has demonstrated TP53 loss as has 
premalignant lesion Barrett oesophagus where the diploid cell is primed with loss of 
TP53. Environmental insults can induce TP53 mutations with smoking inducing a G to 
T transversion occurring at codons 154, 157, 158, 245, 248, and 273. UV induced skin 
cancers show early TP53 change each with their own individual hotspots. Normal 
eyelid skin accumulates TP53 mutations suggesting a constant background mutational 
presence that may be normal for skin. Seven out of the ten samples had pathological 
TP53 mutations, the same frequency as PTCH1.  
 
Fatty acid desaturase 1 (FADS1) – chromosome 11q.22 
The biosynthesis of unsaturated fatty acids requires the expression of dietary fat genes 
such as FADS1 which code for enzymes that add a double bond to a fatty acid 
chain.(Lee and Park, 2014) Genome wide association study has shown that the 
FADS1/2 locus is associated with long chain fatty acid, which in turn is risk to 
health.(Dorajoo et al., 2015) Furthermore, dysfunctional adipose tissue has been shown 
to be involved in carcinogenesis and cancer progression.(van Kruijsdijk et al., 2009) A 
large epidemiological study has identified FADS1 locus as a risk factor for colorectal 
cancer and decreased expression poses a poorer prognosis in oesophageal 
cancer.(Zhang et al., 2014, Li et al., 2015b) FADS1 mediates the formation of 
inflammatory mediators and is found to be downregulated in the tissue surrounding 
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prostate cancer, which is thought to aid local tumour invasion.(Ribeiro et al., 2012) 
FADS1 is downregulated (-0.6 log2FC, exp 5.3) in nodBCC but just non-significantly 
(P=0.09). 
 
Protein Phosphatase, Mg2+/Mn2+ Dependent, 1D (PPM1D) – chromosome 17q23 
This protein is a negative regulator of the cell stress response and is part of the PP2C 
family. It is an oncogene by the fact that is inhibits tumour suppressor pathways 
including TP53 via dephosphorylation.(Lu et al., 2005) PPM1D potentiates the Wnt/b-
catenin pathway, which in turn increased the migration and invasion behaviour of 
pancreatic cancer cells.(Wu et al., 2016a) Increasing expression levels are seen in 
higher grades of meningioma suggesting it is more prevalent in aggressive 
tumours.(Fukami et al., 2016) Overexpression has been reported in hepatocellular, 
breast, ovarian, neuroblastoma and pancreatic cancer.(Ogasawara et al., 2015) Novel 
inhibitors have been developed against PPM1D including peptide and small chemical 
inhibitors. SL-176 inhibits PPM1D, which in turn suppresses proliferation of a breast 
cancer cell line via activation of TP53.(Ogasawara et al., 2015) Nevertheless, SL-176 
also reduces growth in p53 null cells suggesting it suppresses division in a TP53 
independent manner. As 7 out of 10 samples have a presumed loss of function TP53, if 
PPM1D is a gain of function change, then SL-176 could a frontrunner as a p53 
independent inhibitor of cell growth in PPM1D overexpressed cancer states. Two out 
of ten had a PPM1D variant. However, RNA sequencing data shows PPM1D is non-
significantly (P=0.9) downregulated (-0.1 log2FC, expression 3.2). 
 
TAF4b RNA Polymerase II, TATA Box Binding Protein (TBP)-Associated Factor 
(TAF4B) – chromosome 18q11 
TATA-box binding protein associated factors (TAFs) are part of fundamental 
transcription machinery and there are around 14 variants. TAF4 inactivation in the 
epidermis leads to hyperplasia in the mouse model and inhibits embryonic stem cell 
proliferation.(Fadloun et al., 2007) In contrast, TAF4B supports embryonic stem cell 
proliferation in cooperation with transcription factor POU Class 5 Homeobox 1 
(POU5F1).(Bahat et al., 2013) TAF4B requirement for stem cell development and self-
renewal has been elucidated in spermatogenesis (Oatley and Brinster, 2008) It is, 
however, part of the fundamental transcription machinery and shown to be aberrant in 
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several cancers. It is abnormal in 26% of high-grade ovarian cancer mainly as a gain of 
function or amplification.(Ribeiro et al., 2014) Knockdown, however, promotes 
migration of colon cancer.(Kalogeropoulou et al., 2010) Expression of TAF4B is 
induced by MYC in a non-canonical fashion along with their co-expression in leukemic 
cells.(Teye et al., 2008) TAF4B is non-significantly (P=0.7) down regulated (-0.2 
log2FC, exp 3.0) in nodBCC.  
 
Thyroid Hormone Receptor Interactor 4 (TRIP4) – chromosome 15q22 
This is a transcription coactivator that interacts with many transcription factors 
including cAMP-response element binding protein, binding protein (CREBBP), E1A 
Binding Protein P300 (EP300) and Nuclear Receptor Coactivator 1(NCOA1). The 
driver gene EP300 is altered in 2 out of 10 nodular and NCOA1 is altered in one tumour. 
In concert with its binding protein, Activating Signal Cointegrator 1 Complex Subunit 
1 (ASCC1), it may have a role in putative cross talk with JUN and NF kappa B linking 
inflammatory which may be important in oesophageal cancer.(Orloff et al., 2011) 
Ufmylation (by Ubiquitin-Fold Modifier, UFM1) of TRIP4 is an essential step in the 
development of oestrogen receptor positive breast cancer. TRIP4 is non-significantly 
(P=0.9) up regulated (0.1 log2FC, exp 5.1) in nodBCC. 
 
3.3.5 Drivers identified using MutSigCV algorithm 
 
Gamma-Aminobutyric Acid (GABA) A Receptor, Alpha 6 (GABRA6) - chromosome 
5q34 
This is a receptor that mediates inhibitory action of GABA and is mainly associated 
with brain. Altered genetic function is therefore associated with schizophrenia, 
epilepsy, panic disorders and other behavioural changes.(Hirose, 2014) However, it is 
also involved in AKT/PK3B and apoptosis pathways. It prevents neural apoptosis via 
the JNK3 pathway, but has been described to have actions outside the central nervous 
system by preventing apoptosis in pancreatic islet cells.(Prud'homme et al., 2014) It 
also has inhibitory action via NF-kB, an activator of the immune response.(Prud'homme 
et al., 2013). Both these actions would confer an advantage to the tumour. GABA A 
receptors have shown to stimulate basal-like breast cancer in cell lines, promote growth 
of hepatocellular cancer and the growth of pancreatic cancer.(Li et al., 2012c, Sizemore 
et al., 2014, Takehara et al., 2007)  
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Olfactory Receptor, Family 52, Subfamily J, Member 3 (OR52J3) – chromosome 
11p15.4 
OR52J3 is an odorant receptor involved in smell transmission. It is part of a large group 
of proteins that biologically (with the evidence known) should not have any relation to 
cancer. A polymorphism in this gene, rs17350764, has been associated with asthma in 
a genome-wide association study (GWAS), however, they do admit it is difficult to 
understand the functional significance.(Song and Lee, 2013)  
 
Testis specific, 13 (TSGA13) – chromosome 7q32.2 
TSGA13 is abundantly found in testis; however, it is also expressed in normal tissue 
including spleen, stomach, bladder, and thyroid. In addition, it is a gene that undergoes 
genomic imprinting, a process whereby one of the parental copies are silenced in the 
germline, so that there is only monoallelic expression in somatic cells. This 
phenomenon, which only occurs in around 100 genes in humans, makes it particularly 
venerable to genomic alterations such as those seen in cancer and more likely to have a 
functional effect. These genes tend to be conserved across species and are thought to 
have vital roles especially during embryogenesis. Reduced expression has been shown 
in liver, breast and stomach cancers and so it is possible that loss of function in this 
gene confers a benefit to the tumour.(Zhao et al., 2015a)  
 
Tripartite Motif Containing 39 (TRIM39) – chromosome 6p22.1 
It has shown to be an important factor for inflammatory signalling and negatively 
regulates the NFkappaB pathway, a pivotal player in cell survival, immunity, 
inflammation, carcinogenesis and cell growth.(Suzuki et al., 2016) Cell survival action 
occurs through the regulation of the cell cycle through p21 and this interaction has been 
shown in hepatocellular carcinoma.(Zhang et al., 2012) TRIM39 stimulates the innate 
immune system and provides protection against virus.(Wang et al., 2016b) 
 
Chromosome 10 Open Reading Frame 82 (C10orf82) – chromosome 10q25.3 
Malignant melanomas, testicular cancer and a sample of BCC have shown high 
expression of C10orf82.(Uhlen et al., 2015) 
 
Fatty acid desaturase 1 (FADS1) – chromosome 11q.22 
See section 3.2.6i 
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3.3.6 Drivers identified using Intogen algorithm 
 
Collagen, Type IV, Alpha 4 (COL4A4) – chromosome 2q36.3 
Basement membranes are ubiquitous across the body, however, this gene codes for 
collagen IV in only a subset of basement membranes making it more tissue specific. 
Mutations in this gene are found in hereditary glomerulonephropathy (Alports 
syndrome) and familial benign haematuria. Patients with Alports syndrome and loss of 
the 5-prime end of the COL4A4 gene can develop leiomyomatoma, a smooth muscle 
tumour that is essentially indolent, transforming to a malignant tumour in only 0.1%) 
(Zhang et al., 1996) Downregulation of COL4A4 was shown to occur in oesophageal 
cancer. 
  
Rho GTPase Activating Protein 35 (ARHGAP35) – chromosome 19q13.3 see section 
3.2.3, p92 
This driver gene was also mutated in the mBCC subtype and so is a common driver 
(trunk mutation) that may be important in early tumorigenesis. 
5-Methyltetrahydrofolate-Homocysteine Methyltransferase (MTR) – chromosome 
1q43  
The final step in the synthesis of methionine is catalysed by MTR. There has been some 
interest in folate levels and polymorphisms in MTR; however, no relationship was seen 
with MTR variations in breast cancer, non-Hodgkin’s lymphoma, or bowel cancer.(He 
et al., 2015, He et al., 2014, Taflin et al., 2014) 
 
v-myc Avian Myelocytomatosis viral oncogene Neuroblastoma Derived Homolog 
(MYCN) – chromosome 2p24.3 
MYCN codes for a nuclear protein that requires dimerisation in order to activate DNA 
transcription. As the name suggests it is commonly found in neuroblastoma. MYCN is 
frequently mutated in medulloblastoma, another Hh pathway driven tumour, however, 
a gene risk study on 243 children with medulloblastoma did not show an increased risk 
for a particular MYCN SNV.  
 
Asparaginyl-TRNA Synthetase (NARS) – chromosome 18q21.31 
Although this is traditionally known as a tRNA enzyme responsible for esterification 
of a cognate amino acid to its tRNA as part of protein synthesis, it has also been 
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associated with growth promoting function. FGF2 induced NARS promotes the 
survival of osteoblasts through PI3K/Akt signalling.(Park et al., 2009).  
 
Other driver genes picked from Intogen analysis 
Protein Phosphatase, Mg2+/Mn2+ Dependent, 1D (PPM1D) – chromosome 17q23 
See section 3.2.5  
 
AT Rich Interactive Domain 1A (SWI-Like), (ARID1A) – chromosome 1p36  
This gene is part of the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin 
remodelling complex and plays a role in regulating transcription of gene, which are 
repressed by surrounding chromatin. As a consequence, it is thought to be a tumour 
suppressor gene its loss could potentially be a prognostic marker. Histone H2B is a 
main component of chromatin and thought to be a target of ARID1A.(Li et al., 2010, 
Wu et al., 2016b) Loss of ARID1A leads to hypermethylation of MLH1 mismatch 
repair gene among others. In addition, ARID1A negatively regulates telomerase reverse 
transcriptase (TERT), hence loss of function confers a survival advantage to cancer 
cells.(Suryo Rahmanto et al., 2016) Mutations are most commonly seen in ovarian clear 
cell carcinoma, endometrial cancer, renal clear cell carcinoma and gastric 
carcinoma.(Takeda et al., 2016, Sato et al., 2016) Gastric cancer cases with partial or 
reduced loss had a minimal disease free survival effect, but complete loss had a worse 
disease free survival conferring a hazard ratio of 1.7. (Kim et al., 2016) Low levels were 
seen in 71% of 432 cases of breast cancer and were an independent predictor of poor 
disease free and overall survival.(Cho et al., 2015) In colorectal cancer, loss of function 
was seen in 8% of cases and although it was associated with poor differentiation, 
lymphovascular invasion and higher tumour stage, it did not correlate with 
prognosis.(Lee et al., 2016) Similar findings occurring in hepatocellular cancer where 
low expression correlated with larger tumour size, but not prognosis.(Zhao et al., 
2015b) Two out of ten samples have a variant in the gene. ARID1A is non-significantly 
(P=0.5) down regulated (-0.2 log2FC, expression 7.4) in nodBCC. 
 
Interferon Regulatory Factor 2 (IRF2) – chromosome 4q35 
As a member of the transcription regulatory family it can both inhibit and activate 
transcription factors. Originally described to regulate the beta interferon gene, 
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downregulation of IRF2 on human leukemic cells resulted in arrested growth 
highlighting its oncogene properties.(Choo et al., 2008) 
 
3.3.7 Drivers compared to external BCC cohort  
 
A genomic analysis of a large cohort of 293 BCC revealed 7 significantly mutated genes 
using MutSigCV on 121 of the samples with a q-value of <0.1. (Bonilla et al., 2016). 
However, the majority underwent targeted sequencing; 38 nodular WES and 8 
morphoiec BCC only. These seven genes were assessed in our cohort of patients to 
identify any commonality (Table 3.22). 
 
 
Bonilla et al MBCC NodBCC Total our cohort (%)  
PTCH1 (73%) 8 7 15 (75%) 
TP53 (61%) 2 7 9   (45%) 
SMO (20%) 1 2 3   (15%) 
MYCN (30%) 1 4 5   (25%) 
PTPN14 (23%) 1 1 2   (10%) 
RPL22  1 3 4   (20%) 
PPIAL4G 1 1 2   (10%) 
 
Table 3.22 Presence of external BCC drivers within our cohort. Seven significant driver mutations 
with a q value of <0.1 using MutSigCV on a 293 cohort (sporadic, inherited, Vismodegib naïve and 
treated, all histological subtypes including unknown) that underwent WES and target sequencing 
compared to our cohort of 20 BCC. 
 
 
The Bonilla cohort was further scrutinised to select for sporadic, morphoeic subtype 
BCC analysed using WES (as opposed to a cancer gene panel of a selected number of 
genes). After filtering the mutation summary table of 293 cases (supplementary table 
1b of Bonilla et al) for WES, Vismodegib naïve and sporadic BCC revealed only 8 
morphoeic and 38 nodular samples.(Bonilla et al., 2016) It may therefore be prudent  to 
state that the aforementioned 7 BCC driver mutations reflect a nodBCC makeup as 





3.3.8 Drivers within morphoeic stroma 
 
GLI Family Zinc Finger 3 (GLI3) – chromosome 7p13    
Gli3 is part of the Hh signalling pathway and often called a transcriptional repressor. 
An autosomal dominant loss of function mutation in Gli3 leads to Grieg’s 
cephalopolysyndactyly syndrome, a variable syndrome resulting in abnormal 
development of the limbs or head. Wnt activity controls Gli3 expression via b-
catenin/Tcf pathway with the Gli3 gene revealing Tcf binding sites as part of its 
code.(Alvarez-Medina et al., 2008) Reducing the expression of Gli3 inhibits colonic 
cancer cell growth suggesting an antagonist of Gli3 would be beneficial to suppress 
cancer.(Trnski et al., 2015) Moreover, Gli3 expression is associated with cyclopamine 
(SMO inhibitor) resistance in pancreatic cancer cells and is tumorigenic as per colonic 
cancer cells.(Steg et al., 2010) Gli3 is non-significantly (P=0.6) upregulated (log2FC 
0.4, exp 5.8) in morphoeic stromal tissue. The VAF in the stroma was low at 8%, 
however, it was low in the tumour at 26%. 
 
Erythropoietin-producing hepatocellular carcinoma (EPH) Receptor A3 (EPHA3)– 
chromosome 3p11.1 
See section 3.2.3. EPHA3 is non-significantly (P=0.5) upregulated (log2FC 0.8, exp 
1.8) in morphoeic stromal tissue. 
 
ATR Serine/Threonine Kinase (ATR) – chromosome 3q23 
This belongs to the phosphatidylinositol 3-kinase (PI3K) family and ATR plays a vital 
role in the cell cycle by phosphylating checkpoint kinase 1 (CHK1), checkpoint proteins 
RAD17/9 and BRCA1 tumour suppressor gene. It is particularly activated during times 
of genotoxic UV light exposure where it causes arrest of the cell cycle, DNA repair and 
apoptosis.(Al-Khalaf et al., 2012) It shares a similar function with Ataxia 
Telangiectasia Mutated Serine/Threonine Kinase (ATM), however, is generally 
activated during single strand DNA damage whereas ATM is involved in double strand 
breaks. An autosomal dominant germline mutation in ATR can lead to Familial 
Cutaneous Telangiectasia and Oropharyngeal Predisposition Cancer 
Syndrome.(Tanaka et al., 2012) Interestingly, Imiquimod treatment of BCC activates 
TP53 dependent apoptosis by ATR pathway, thus it is important that the gene is 
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functioning for this medication to be effective.(Huang et al., 2016b) ATR is non-
significantly (P=0.9) down regulated (log2FC -0.02, exp 5.7) in morphoeic stromal 
tissue. 
 
Complement component 6 (C6) – chromosome 5p13.1 
See section 3.2.4ii. Seven out of 10 mBCC tumour contain a variant. 
 
ROS proto-oncogene 1 (ROS1) – chromosome 6q22 
This is a tyrosine kinase receptor member of the insulin receptor superfamily. IT has 
been identified in cancer states, but its wild type function remains elusive. 
Chromosomal rearrangement with the formation of aberrant fusion genes have been 
reported with ROS1 in gastrointestinal, lung adenocarcinoma and inflammatory 
myofibroblastic tumours.(Davies and Doebele, 2013, Bergethon et al., 2012) The latter 
has similar characteristics to mBCC with an inflammatory fibroblastic response, local 
recurrence potential and minimal risk of metastasis. TFG-ROS1 and YWHAE-ROS1 
tend to occur in ALK negative myofibroblastic tumours. ROS1 fusions seem to 
congregate to a particular subset of NSCLC, adenocarcinoma. Furthermore, there 
seems to be a loss of the non-rearranged ROS1 allele too. The ROS1 mutation with the 
mBCC tumour and stroma is also named in COSMIC (id 139667). Treatment of ALK 
positive NSLC with specific antibodies has been developed including Crizotinib 
(Xalkori®, Pfizer) and some have activity against ROS1. Resistance can occur to these 
drugs, particularly in the tyrosine kinase section of the oncogene.  Interestingly, these 
drugs have affinity for ROS1 rearrangements too.  
 
EPH Receptor B1 (EPHB1)- chromosome 3 
This is an ephrin receptor and also part of the axonal guidance pathway. See section 
3.2.4. Four out of 10 mBCC tumour contain a variant. 
 
The mutational load of the morphoeic stroma is significantly high with 196 potentially 
pathogenic non-synonymous changes, ten of which are stop-gain changes. Eighty-one 
were probably damaging using the Polypen and SIFT algorithms. Shared potentially 
pathogenic variants using the two algorithms were 54 including ROS1, ORSC1, 
PCDHBG1, ZNF381 and VPS13C that were also found in COSMIC.  Potential drivers 
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within the stroma were determined using knowledge of their biological along with their 
cancer association (Table 3.22). 
 
Gene Protein Variant Cancer association Freq 
PTPN22 p.Trp244* Uterine leiomyomas, CLL 1 
ARHGEF28 p.Tyr1232*  3 
ASAP1 p.Gln318* Invasive phenotype of laryngeal SCC, ovarian  2 
SFMBT2 p.Gln596* Regulation of prostate cancer cell growth 1 
MYBPC1 p.Arg318*  2 
XPO4 p.Gln412* Tumour suppressor gene. Lost in liver cancer 1 
CPNE7 p.Gln122* Inflammation amplifier 1 
CDH20 p.Trp684* Early stages of tumorigenesis 3 
 
Table 3.23 Potential drivers in stromal mBCC. Top 8 stop-gain non-synonymous changes. * stop/gain; 
F=frequency, q=q-value, p=p-value, I=Intogen, Mut=MutSigCV; Freq, frequency of gene variant in the 




3.4 Summary of genetic variants in BCC 
 
BCC contains a large number of mutations many of which are not significant to tumour 
initiation, growth, progression or metastasis. Normal skin contains many mutations too 
and to identify the driver genes within the tumour required several approaches. WES 
underlined the huge tumour burden with the vast majority of NSSNV being UV induced 
(UV signature). Interestingly the location of the tumour was not related to tumour 
burden nor was the UV signature profile. Morphoeic is a more aggressive tumour, but 
it did not display any greater mutational burden than nodBCC nor did it have a greater 
UV signature. Driver genes within mBCC revealed a large number with little 
correlation between the two algorithms (Intogen and MutSigCV) except for PTCH1. 
This may represent the heterogeneous nature of this tumour and that it is fairly 
uncommon to find pure mBCC on histology without nodBCC or another subtype being 
present too. Pathway WES analysis revealed the importance of Hh signalling, which 
was supported by the RNAseq and protein expression (See chapter 4). Other 
significantly changed pathways includes up regulation of the axonal guidance pathway, 




In contrast, nodBCC algorithm analysis revealed six common drivers and TP53 is an 
integral change in tumour development. Pathway WES analysis places BCC pathway 
as number one and is the only upregulated pathway along with mismatch repair pathway 
on RNAseq analysis; Hh pathway was not feature on RNAseq analysis (see Chapter 
Four).  
  
The skin stroma lies beneath the epithelium and consists of a superficial lymphoid and 
deep fibrous layer. WES of mBCC stroma shared 150 genes with its tumour counterpart 
including the identical mutation in ATR, EPHA3 and Gli3, although the overall VAF 
was low in both samples. EPHA3 is thought to act as a tumour suppressor gene and is 
the most frequently mutated gene in lung adenocarcinoma as a loss of function 
change.(Ding et al., 2008) Mutations are not only restricted to tumour tissue, but are 
also found in the surrounding stroma indicating a possible role in the tumour 
microenvironment.(Vail et al., 2014). The highest mBCC stromal VAF gene was a 
ROS1, a proto-oncogene tyrosine kinase receptor. This could be true stromal mutational 
burden or just undetectable cancer cells intermixed in the stromal soup that are being 
analysed. Either way it is clinically relevant when it comes to excision whereby the 
removal of this inflammatory material during Mohs micrographic surgery should be 
considered, as this may be the reason for local recurrence.  
 
The vast majority of mutations in cancer are heterozygous, but this does not mean that 
they no effect if the wildtype allele is present.(Rentoft et al., 2016) However, 
knowledge of the copy number aberration would help to improve the interpretation of 
the potential driver gene and allow the focus on those which may have undergone LOH 
or amplification. In addition, functional studies to determine their true nature is required 
and allow the identification of drug targets; potential drug targets highlighted in this 












GENE EXPRESSION IN BASAL CELL CARCINOMA 
 
4.1 Further aims of the BCC study 
 
Genetic variants alone are not enough to discern the effects that are ensued by the tumour 
although a wealth of information that hints to possible biologically relevant changes has 
been documented in the last chapter. Looking at the gene expression in terms of RNA and 
protein is outlined in this chapter (Figure 4.1) to see if it complements the variance data, 
but also to identify those pathways that are modified but don’t possess a mutation.  
 
 
Figure 4.1 BCC project part 2. Overview of the BCC project highlighting the stepwise progression 
starting with genetic variant detection in the DNA, followed by genetic expression using RNAseq and 
validation using quantitative PCR plus protein expression. The orange box highlights the focus of chapter 








4.2 RNA sequencing in periocular BCC 
 
4.2.1 Clinical and histological features of periocular BCC patients 
Six BCC patients who underwent WES also had RNA sequencing of their tumour. This 
was compared against normal tissue at a large distance away from the cancer. Three were 
morphoeic and three were nodular BCC (Table 4.1). Each sample underwent fresh, frozen 
laser capture microdissection to ensure purity of sample. All 12 samples (6 tumours and 
6 normal stoma) were run on a single lane (13 million reads each) and underwent the 
same processing conditions such as library preparation. 
 
Tumour Age Gender Location 
M1 85 M RLL 
M2 47 F LLL 
M3 78 F LLL 
Nod3 71 M RMC 
Nod4 72 F LLL 
Nod5 46 F RLL 
Table 4.1 Clinical features of RNAseq samples. Samples used where also ones that underwent WES. M, 
morphoeic BCC; Nod, nodular BCC. 
 
4.2.2 Periocular morphoeic BCC RNA expression 
Raw reads counts were derived from processing high-throughput sequencing data through 
HTSeq (Python library) against Ensembl annotation.(Anders et al., 2015) A paired 
analysis of morphoeic tumour versus morphoeic stroma using limma R/Bioconductor 
software package (voom function) was preformed using raw p value less than 0.01 and 
log2FC greater than 1 or less than -1.(Ritchie et al., 2015) Downregulation in the tumour 
is defined as log2FC<-1 and upregulation in the tumour as log2FC > 1. Paired analysis 
of morphoeic tumour versus stroma revealed 288 differentially expressed genes using a 
P value < 0.01 and log2FC >1 or <-1. Log2FC ranged from -7.1 to 5.0 and expression 
levels between -1.8 to 9.1. A heatmap of the findings is summarised in Figure 4.2 and 
almost 60% (169 genes, blue colour) were downregulated and the vast majority, 143, 






Fig 4.2 Heatmap of mBCC tumour and stroma. Genes and samples were clustered based on Pearson's 
correlation. The scaled expression of each gene, denoted as the row Z-score, is plotted in red–blue colour 
scale with red indicating high expression and blue indicating low expression. 
 
4.2.2.i Upregulated genes in morphoeic BCC 
Genes found to be significantly upregulated were organised according to their Log2FC 
(Table 4.2) and then according to the highest expressed (Table 4.3). Selected genes of 
interest are further discussed in terms of their biological relevance and cancer association. 
Genes equally expressed in both tumour and stroma may not be picked up. 
 
Gene Exp Log2FC P-val 
AMER2 2.2 2.9 <0.001 
ALK 3.8 2.8 <0.001 
HSD11B1 3.2 2.8 0.002 
PADI3 2.1 2.8 0.006 
TSHR 3.9 2.7 0.004 
STAC2 6.0 2.4 <0.001 
Gene Exp Log2FC P-val 
HHIP 3.7 2.3 <0.001 
EDN2 3.3 2.3 <0.001 
CALCB 3.3 2.2 <0.001 
GPC3 4.2 2.1 0.001 
BOK 3.1 2.0 0.003 
MAGEA4 2.1 1.9 <0.001 
Table 4.2 Highest Log2FC upregulated genes in mBCC. Top 10 differentially expressed RNA are 







Gene Exp Log2FC P-val 
STAC2 6.0 2.4 <0.001 
GPC3 4.2 2.1 0.001 
TSHR 3.9 2.7 0.004 
ALK 3.8 2.8 <0.001 
HHIP 3.6 2.3 <0.001 
Gene Exp Log2FC P-val 
CALCB 3.3 2.2 <0.001 
EDN2 3.3 2.3 <0.001 
HSD11B1 3.2 2.8 0.003 
BOK 3.1 2.0 0.003 
AMER2 2.2 2.9 <0.001 
Table 4.3 Most upregulated genes in mBCC arranged according to expression levels. Top 10 
differentially, highest expressed, upregulated RNA with a log2FC of greater than 2.0. Exp=expression, P-
val=P-value.  
 
4.2.2.ii Downregulated genes in morphoeic BCC 
As mentioned, the majority of genes are downregulated in mBCC. Genes found to be 
significantly downregulated were organised according to their Log2FC (Table 4.4) and 
then according to the highest expressed (Table 4.5). Selected genes of interest are further 
discussed in terms of their biological relevance and cancer association. 
 
 
Gene Exp Log2FC P-val 
KRT13 3.1 -7.1 0.007 
KRT4 3.0 -5.8 <0.001 
TGM2 2.5 -5.0 0.009 
CXCL17 2.5 -4.9 0.004 
PIGR 3.3 -4.7 0.009 
Gene Exp Log2FC P-val 
IGLV1-40 2.9 -4.2 <0.001 
IGKV3-11 2.9 -4.2 0.007 
TMPRSS4 3.8 -4.1 0.003 
IGLC2 5.3 -4.0 P<0.001 
IGHA1 5.7 -4.0 0.002 
Table 4.4 Log2FC downregulated genes in mBCC. Top 10 differentially expressed RNA are arranged 
according to the lowest log2FC with an average expression greater than 2.0. Exp=expression, P-val=P-
value. 
 
Gene Exp Log2FC P-val 
S100A8 8.7 -3.1 0.005 
IGHG1 8.4 -2.7 <0.001 
KRT6A 7.9 -2.5 0.001 
FABP5 7.9 -2.7 0.002 
IGLC3 7.0 -3.5 <0.001 
Gene Exp Log2FC P-val 
SERPINB1 6.8 -2.3 0.004 
SLPI 6.5 -3.6 0.008 
IGJ 6.4 -3.3 <0.001 
IGHA1 5.6 -4.0 0.002 
IGHG4 5.3 -3.2 <0.001 
Table 4.5 Most downregulated genes in mBCC arranged according to expression levels. Top 10 




4.2.3 Periocular nodular BCC RNA expression 
 
Two hundred and eighty-eight genes were differentially expressed when nodular and 
stromal tissue were compared. Raw reads counts were derived from processing high-
throughput sequencing data through HTSeq (Python library) against Ensembl 
annotation.(Anders et al., 2015) A paired analysis of nodular tumour versus nodular 
stroma using limma R/Bioconductor software package (voom function) was performed 
using raw p value less than 0.01 and log2FC greater than 1 or less than -1.(Ritchie et al., 
2015) Downregulation in the tumour is defined as log2FC<-1 and upregulation in the 
tumour as log2FC > 1. A heatmap of the findings is summarised in Figure 4.3 and just 
under half (145) of the differentially expressed genes were down regulated and the range 
of log2FC was from -5.5 to 4.8 with expression levels between -2 to 11. 
 
 
Fig 4.3 Heatmap of nodBCC tumour and normal stroma. Genes and samples were clustered based on 
Pearson's correlation. The scaled expression of each gene, denoted as the row Z-score, is plotted in red–









4.2.3i Upregulated genes in nodular BCC 
Genes found to be significantly upregulated were organised according to their Log2FC 
(Table 4.6) and then according to the highest expressed (Table 4.7). Selected genes of 
interest are further discussed in terms of their biological relevance and cancer association. 
 
 
Gene Exp Log2FC P val 
CAPN6 2.7 3.7 0.008 
miR-3117 2.2 3.5 0.009 
ZNF418 2.1 3.3 0.009 
TLL1 2.0 3.2 0.003 
RP11-119F7.5 2.2 3.0 0.002 
Gene Exp Log2FC P val 
RP11-996F15.2 2.0 3.9 0.006 
WIPF3 4.2 2.9 0.004 
ZNF737 2.8 2.7 0.004 
TSHR 3.9 2.7 0.001 
SHISA2 5.1 2.3 0.005 
Table 4.6 Highest Log2FC upregulated genes in nodBCC. Top 10 differentially expressed RNA are 
arranged according to the highest log2FC with an average expression greater than 2.0. Exp=expression, P-
val=P-value 
 
Gene Exp Log2FC P val 
ABI3BP 8.3 2.2 <0.001 
STAC2 6.0 2.2 0.002 
LMO3 5.3 2.0 <0.001 
SOX11 5.3 2.3 <0.001 
SHISA2 5.1 2.3 0.005 
Gene Exp Log2FC P val 
SLITRK2 4.9 2.2 0.001 
PLAG1 4.8 2.3 0.002 
WIPF3 4.2 2.9 0.004 
ZNF251 3.9 2.6 0.001 
TSHR 3.9 2.7 0.001 
Table 4.7 Highest expressed genes in nodBCC. Top 10 differentially, highest expressed, upregulated 















4.2.3ii Downregulated genes in nodular BCC 
Genes found to be significantly downregulated were organised according to their Log2FC 
(Table 4.8) and then according to the highest expressed (Table 4.9). Selected genes of 
interest are further discussed in terms of their biological relevance and cancer association. 
 
 
Gene Exp Log2FC P val 
SLC39A2 2.4 -4.6 <0.001 
DGKQ 2.1 -3.8 0.005 
KRT6A 7.9 -3.7 0.003 
CYTH4 2.9 -3.6 0.006 
CD2 4.5 -3.6 0.002 
Gene Exp Log2FC P val 
HDC 2.6 -3.6 0.002 
FAM65C 2.6 -3.5 <0.001 
GBP6 2.2 -3.5 0.009 
GNLY 2.9 -3.5 0.003 
CD1C 2.4 -3.5 0.005 
Table 4.8 Log2FC downregulated genes in nodBCC. Top 10 differentially expressed RNA are arranged 
according to the lowest log2FC with an average expression greater than 2.0. Exp=expression, P-val=P-
value. 
 
Gene Exp Log2FC P val 
KRT6A 7.9 -3.7 0.003 
FABP5 7.9 -3.4 0.001 
KRT6B 7.1 -2.1 0.006 
SERPINB1 6.8 -2.2 0.005 
CCL21 6.7 -2.4 0.005 
Gene Exp Log2FC P val 
KRT16 6.5 -2.9 0.004 
LYPD3 6.4 -2.8 0.004 
CCL5 6.4 -2.8 0.005 
LAD1 5.3 -2.2 0.003 
IGHG4 5.1 -2.5 <0.001 
Table 4.9 Most downregulated genes in nodBCC arranged according to expression levels. Top 10 




4.2.4 Comparison of BCC subtypes 
 
A total of 128 differentially expressed genes were seen when comparing tumour subtypes 
only. The heatmap below (Fig 4.4) gives an overview of the over and under expressed 
genes seen within each subtype when compared against each other. Log2FC ranged from 
-6.1 to 8.0 with the majority being up regulated in morphoeic tumour and only 31 genes 





Fig 4.4 Heatmap comparing mBCC and nodBCC tumour. Genes and samples were clustered based on 
Pearson's correlation. The scaled expression of each gene, denoted as the row Z-score, is plotted in red–
blue colour scale with red indicating high expression and blue indicating low expression. 
 
4.2.4i Upregulated in morphoeic compared to nodular BCC 
Genes found to be significantly upregulated were organised according to their Log2FC 
(Table 4.10) and then according to the highest expressed (Table 4.11). Selected genes of 
interest are further discussed in terms of their biological relevance and cancer association. 
 
Gene Exp Log2FC P-val 
KRT77 2.8 5.9 0.007 
OASL 2.1 4.9 0.006 
DGKQ 2.1 4.7 0.001 
CD1C 2.4 4.5 0.003 
NAB2 3.2 4.0 0.004 
Gene Exp Log2FC P-val 
ZNF697 2.7 4.0 0.004 
ITGA11 3.7 3.7 0.004 
PKP1 7.4 3.1 0.002 
GPC1 4.5 3.0 0.010 
DOK4 3.0 2.9 0.004 
 
Table 4.10 Highest Log2FC upregulated genes in mBCC compared to nodBCC. Top 10 differentially 








Gene Exp Log2FC P-val 
PKP1 7.4 3.1 0.002 
APCDD1 7.0 2.0 0.001 
LAMB3 6.4  2.3 0.006 
WDR46 5.2 2.5 0.006 
EPHB3 5.2 2.7 0.003 
Gene Exp Log2FC P-val 
USP5 5.1 2.6 0.004 
UNC5B 4.8 2.8 0.007 
SLC38A5 4.6 2.4 0.008 
ACTR1B 5.6 2.5 0.010 
GPC1 4.5 3.0 0.007 
Table 4.11 Most upregulated genes in mBCC compared to nodBCC and arranged according to 
expression levels. Top 10 differentially, highest expressed, upregulated RNA with a log2FC of greater than 
2.0. Exp=expression, P-val=P-value. 
 
4.2.4ii Downregulated genes in morphoeic compared to nodular BCC 
Genes found to be significantly downregulated were organised according to their Log2FC 
(Table 4.12) and then according to the highest expressed (Table 4.13).  
 
Gene Exp Log2FC P-val 
Hsa-miR-3117 2.2 -3.7 0.003 
SAMD12 3.9 -2.8 0.004 
NT5DC3 4.5 -2.7 0.002 
MAN1C1 4.0 -2.5 0.006 
TNFAIP2 6.6 -2.4 <0.001 
Gene Exp Log2FC P-val 
CBWD5 4.0 -2.1 0.003 
NCAM1 4.5 -1.9 0.009 
TMTC1 5.7 -1.6 0.003 
TJP1 6.6 -1.6 <0.001 
RND3 6.6 -1.4 0.005 
 
Table 4.12 Log2FC downregulated genes in mBCC compared to nodBCC. Top 10 differentially 
expressed RNA are arranged according to the lowest log2FC with an average expression greater than 2.0. 
Exp=expression, P-val=P-value. 
 
Gene Exp Log2FC P-val 
Hsa-miR-3117 2.2 -3.7 0.003 
SAMD12 3.9 -2.8 0.004 
MAN1C1 4.0 -2.5 0.006 
CBWD5 4.0 -2.1 0.003 
NT5DC3 4.5 -2.7 0.002 
Gene Exp Log2FC P-val 
TNFAIP2 6.6 -2.4 <0.001 
NCAM1 4.5 -1.9  
TMTC1 5.7 -1.6  
TJP1 6.6 -1.6  
RND3 6.6 -1.4  
 
Table 4.13 Most downregulated genes in mBCC compared to nodBCC and arranged according to 
expression levels. Top 6 differentially, highest expressed, downregulated RNA with a log2FC of less than 






4.2.4iii Shared genes present in both morphoeic and nodular tumour 
Further analysis was done to take into expression across both tumour subtypes and their 
corresponding normal tissue (Figure 4.5). The shared genes between the two numbered 
44 and were plotted to reveal closer concordance with the upregulated genes (Figure 4.6). 
Explanations of a selected shared gene are mentioned below noting their biological 




Fig 4.5 RNA expression between morphoeic and nodular BCC subtypes. All filtered genes that were 
tested are represented as log2FC expression in the above graph with a line that best fits. Selection of the 44 
shared genes are shown below in Figure 4.6. 
 
Fig 4.6 Shared differentially expressed genes across both morphoeic and nodular BCC subtypes. The 
Venn diagram shows each subtype with 288 differentially expressed (DE) genes and 44 were shared 
between the two. These genes are then represented as a Log2FC expression with a line that best fits. The 
genes that are upregulated show greater concordance than the downregulated genes, 
Gene	expression	in	basal	cell	carcinoma	
	 155 
4.2.5 Morphoeic normal stroma RNA expression 
Following from the discovery of DDR1 expression, the normal stromal tissue from both 
subtypes were compared against each other to see if the mBCC normal stroma had any 
abnormally expressed genes. This raises the possibility that the surrounding tissue of the 
mBCC tumour is not entirely normal and as suggested by the WES stroma findings (see 
section 3.2.9). In total, there are 37 differentially expressed genes seen in the morphoeic 
stroma compared to the nodular stroma using p < 0.01 and log2FC > or <1. The heatmap 
highlights that all but three genes were upregulated in morphoeic stroma (Figure 4.7). 
 
 
Fig 4.7 Comparison of stromal expression mBCC and nodBCC. Genes and samples were clustered 
based on Pearson's correlation. The scaled expression of each gene, denoted as the row Z-score, is plotted 














4.2.5i Upregulated genes in morphoeic stroma 
DDR1 was discussed above a gene present in both the morphoeic tumour and normal 
stroma. Comparing morphoeic tumour with nodular normal stroma, the expression was 
7.2, log2FC 1.8 and P 0.0005. When comparing the morphoeic stroma with nodular 
stroma the expression was 7.2, log2FC 0.9 and P = 0.04. Genes found to be significantly 
upregulated were organised according to their Log2FC (Table 4.14) and then according 
to the highest expressed (Table 4.15).  
  
Gene Exp Log2FC P-val 
GSTM1 1.2 7.6 <0.001 
ACVR1C 0.5 4.9 0.022 
AC009237.8 2.0 4.6 0.012 
CD1B 0.5 4.2 0.007 
RSPH4A 0.9 4.0 0.008 
Gene Exp Log2FC P-val 
CCR2 2.1 3.5 0.005 
SIM2 0.9 3.4 0.008 
ZNF446 1.1 3.1 0.009 
LPXN 4.1 2.1 0.007 
ABHD5 4.3 1.5 0.007 
Table 4.14 Highest Log2FC upregulated genes in the stroma of mBCC compared to nodular stroma. 
Top 10 differentially expressed RNA are arranged according to the highest log2FC with an average 
expression greater than 2.0. Exp=expression, P-val=P-value. 
 
Glutathione S-Transferase Mu 1 (GSTM1) is a detoxification enzyme that is 
overexpressed in morphoeic stroma suggesting an environment undergoing oxidative 
stress. Other genes of interest include Activin A Receptor Type 1C (ACVR1C), a TGFB 
receptor, a pathway that may be BCC pathway and it binds SMAD transcription 
regulators. CD1b Molecule (CD1B) is an antigen binding protein that triggers T-cell and 
NK cells. C-C Motif Chemokine Receptor 2 (CCR2) is a chemokine that attracts 
monocytes, particularly in the inflammatory response to tumours. Single-Minded Family 
BHLH Transcription Factor 2 (SIM2) is a master gene for CNS development and may 
either be irrelevant or be related to the axonal guidance that seems to be upregulated in 
mBCC. Leupaxin (LPXN) contributes to the regulation of cell migration, adhesion and 











Gene Exp Log2FC P-val 
ABHD5 4.4 1.5 0.007 
LPXN 4.1 2.1 0.07 
CCR2 2.1 3.5 0.005 
ACOO9237.8 2.0 4.6 0.001 
GSTM1 1.2 7.6 <0.001 
Gene Exp Log2FC P-val 
ZNF446 1.1 3.1 0.009 
RSPH4A 0.9 4.0 0.008 
SIM2 0.9 3.4 0.008 
CD1B 0.5 4.2 0.007 
ACVR1C 0.5 4.9 0.002 
 
Table 4.15 Most downregulated genes in mBCC stroma compared to nodBCC stroma and arranged 
according to expression levels. Top 10 differentially, highest expressed, upregulated RNA with a log2FC 
of greater than 2.0. Exp=expression, P-val=P-value. 
 
 
4.2.5ii Downregulated genes in morphoeic stroma 
As mentioned, only three genes were downregulated and they had minimal expression. 
DMRT Like Family A1 (DMRTA1) is probably involved in transcription and may be 
associated with type 2 DM. Little is known about the other two. 
 
 
Gene Expression Log FC P value 
DMRTA1 0.4 -5.2 0.005 
RP13-15M17.1 1.8 -4.1 0.008 
CTD-2257D19.6 1.5 -3.5 0.007 
Table 4.16 Log2FC downregulated genes in the stroma mBCC. Top 3 differentially expressed RNA are 
arranged according to the lowest log2FC with an average expression greater than 2.0. No other genes were 















4.2.6 RNA pathway analysis 
 
RNA sequencing expression was assessed using GSEA to identify significantly altered 
genesets. Pathway expression was first assessed on an individual tumour basis by 
comparing tumour with the stroma followed by a comparison between the two subtypes. 
Significant pathway alteration was determined using a FDR q-value ≤ 0.10. Following, 
subtypes are compared at an individual gene level for selected pathways of interest (see 
Appendix 1). 
 
4.2.6i Morphoeic BCC expression 
Eleven pathways were shown to be upregulated when analysing RNAseq gene-set data 
(Table 4.17) The ribosome pathway came out as the most upregulated, with BCC and Hh 
pathway close behind. The TGF beta pathway is also significantly involved and may act 
in concert with the other pathways. More pathways were downregulated, with 34 
significantly reduced (Table 4.18) A lot of these are immune pathways such as the NK, 
antigen presenting, complement cascades and Fc epsilon, suggesting that a localised 
immunodeficiency assists local mBCC behaviour. 
 
MSigDB pathway NES Geneset size q-val P-val 
Ribosome 2.65 85 <0.001 <0.001 
Basal_cell_carcinoma 2.30 46 <0.001 <0.001 
Hedgehog_signaling_pathway 2.17 42 8.5E-04 <0.001 
Spliceosome 1.92 125 0.009 <0.001 
Base_excision_repair 1.91 31 0.009 <0.001 
Dna_replication 1.69 35 0.062 0.003 
Basal_transcription_factors 1.67 31 0.064 <0.001 
Arrhythmogenic_right_ventricular_cardiomyopathy_arvc 1.62 67 0.088 <0.001 
Cysteine_and_methionine_metabolism 1.62 29 0.079 0.016 
Tgf_beta_signaling_pathway 1.58 75 0.099 <0.001 
 
Table 4.17 Upregulated mBCC pathways using GSEA. Upregulated MSigDB pathway expression in 
morphoeic tumour versus stroma. Arranged according to NES with a false discovery rate (q-value)  <0.10. 








MSigDB pathway NES GS size q-val P-val 
Allograft_rejection -2.38 29 <0.001 <0.001 
Graft_versus_host_disease -2.36 30 <0.001 <0.001 
Hematopoietic_cell_lineage -2.23 67 <0.001 <0.001 
Autoimmune_thyroid_disease -2.22 31 <0.001 <0.001 
Antigen_processing_and_presentation -2.20 56 <0.001 <0.001 
Primary_immunodeficiency -2.18 28 <0.001 <0.001 
Natural_killer_cell_mediated_cytotoxicity -2.13 98 1.2E-04 <0.001 
Complement_and_coagulation_cascades -2.13 46 1.0E-04 0.002 
Asthma -2.10 21 9.2E-05 <0.001 
Type_1_diabetes_mellitus -2.10 33 8.3E-05 <0.001 
Intestinal_immune_network_for_iga_production -2.07 35 1.5E-04 <0.001 
Cytokine_cytokine_receptor_interaction -2.03 186 2.8E-04 <0.001 
Leishmania_infection -2.02 62 3.9E-04 <0.001 
Chemokine_signaling_pathway -1.90 159 0.001 <0.001 
Cell_adhesion_molecules_cams -1.89 116 0.002 <0.001 
T_cell_receptor_signaling_pathway -1.89 99 0.002 <0.001 
Abc_transporters -1.86 40 0.003 <0.001 
Glycosphingolipid_biosynthesis_lacto_and_neolacto_series -1.83 22 0.004 0.003 
B_cell_receptor_signaling_pathway -1.79 70 0.006 <0.001 
Viral_myocarditis -1.72 67 0.014 0.002 
Rig_1_like_receptor_signaling_pathway -1.71 51 0.014 0.003 
Arachidonic_acid_metabolism -1.62 44 0.031 0.008 
Systemic_lupus_erythematosus -1.60 69 0.039 0.004 
Proximal_tubule_bicarbonate_reclamation -1.59 15 0.040 0.030 
Toll_like_receptor_signaling_pathway -1.59 81 0.039 0.004 
O_glycan_biosynthesis -1.59 22 0.039 0.025 
Neuroactive_ligand_receptor_interaction -1.58 126 0.040 0.001 
Nod_like_receptor_signaling_pathway -1.56 59 0.046 0.011 
Cytosolic_dna_sensing_pathway -1.55 40 0.050 0.021 
Retinol_metabolism -1.53 34 0.056 0.033 
Leukocyte_transendothelial_migration -1.52 101 0.062 0.018 
Fc_epsilon_ri_signaling_pathway -1.50 66 0.073 0.020 
Apoptosis -1.48 76 0.082 0.021 
Phosphatidylinositol_signaling_system -1.45 71 0.098 0.023 
Allograft_rejection -2.38 29 <0.001 <0.001 
Graft_versus_host_disease -2.36 30 <0.001 <0.001 
Hematopoietic_cell_lineage -2.23 67 <0.001 <0.001 
 
Table 4.18 Downregulated mBCC pathways using GSEA. Downregulated MSigDB pathway expression 
in morphoeic tumour versus stroma. Arranged according to NES with a false discovery rate (q-value)  <0.10 
MSigDB, molecular signature database; NES, normalised enrichment score; Q-value, false discovery rate; 
P-val, P-value MSigDB, molecular signature database; NES, normalised enrichment score; GS size, gene-




4.2.6ii Nodular BCC 
Only two pathways are upregulated significantly in nodBCC when assessing RNAseq 
GSEA (Table 4.19). BCC pathway is upregulated, but most notably the Hh pathway does 
not feature. In contrast, 40 pathways are down regulated in nodBCC including immune 
pathways such as NK, Toll like receptor, complement cascades, but there are many others 
such as type 1 diabetes mellitus, asthma and Parkinson’s disease whose biological 
significant seems unrelated (Table 4.20).  
 
MSigDB pathway NES Geneset size q-val P-val 
Mismatch_repair 1.84 22 0.069 0.002 
Basal_cell_carcinoma 1.82 46 0.041 <0.001 
Table 4.19 Upregulated nodBCC pathways using GSEA. Upregulated MSigDB pathway expression in 
morphoeic tumour versus stroma. Arranged according to NES with a false discovery rate (q-value)  <0.10. 

























MSigDB pathway NES GS size q-val Pval 
Ribosome -2.86 85 <0.001 <0.001 
Hematopoietic_cell_lineage -2.63 67 <0.001 <0.001 
Antigen_processing_and_presentation -2.61 56 <0.001 <0.001 
Graft_versus_host_disease -2.57 30 <0.001 <0.001 
Allograft_rejection -2.46 29 <0.001 <0.001 
Type_1_diabetes_mellitus -2.43 33 <0.001 <0.001 
Oxidative_phosphorylation -2.41 108 <0.001 <0.001 
Cytokine_cytokine_receptor_interaction -2.33 186 <0.001 <0.001 
Autoimmune_thyroid_disease -2.32 31 <0.001 <0.001 
Systemic_lupus_erythematosus -2.24 69 <0.001 <0.001 
Intestinal_immune_network_for_iga_production -2.22 35 <0.001 <0.001 
Asthma -2.21 21 <0.001 <0.001 
Parkinsons_disease -2.13 105 1.7E-04 <0.001 
Primary_immunodeficiency -2.13 28 1.6E-04 <0.001 
Leishmania_infection -2.13 62 1.5E-04 <0.001 
Toll_like_receptor_signaling_pathway -2.04 81 6.9E-04 <0.001 
Cell_adhesion_molecules_cams -2.01 116 9.4E-04 <0.001 
Natural_killer_cell_mediated_cytotoxicity -1.96 98 0.002 <0.001 
Complement_and_coagulation_cascades -1.95 46 0.002 <0.001 
Alzheimers_disease -1.95 147 0.002 <0.001 
T_cell_receptor_signaling_pathway -1.94 99 0.002 <0.001 
Nod_like_receptor_signaling_pathway -1.92 59 0.002 <0.001 
Proteasome -1.88 42 0.003 0.002 
Huntingtons_disease -1.87 158 0.003 <0.001 
Prion_diseases -1.82 29 0.005 0.004 
Chemokine_signaling_pathway -1.81 159 0.006 <0.001 
Pantothenate_and_coa_biosynthesis -1.77 15 0.009 0.004 
B_cell_receptor_signaling_pathway -1.71 70 0.016 0.002 
Cardiac_muscle_contraction -1.69 61 0.019 0.008 
Viral_myocarditis -1.67 67 0.021 0.004 
Jak_stat_signaling_pathway -1.67 111 0.021 <0.001 
Snare_interactions_in_vesicular_transport -1.61 38 0.034 0.006 
Tyrosine_metabolism -1.61 32 0.033 0.008 
Cytosolic_dna_sensing_pathway -1.56 40 0.049 0.022 
Arachidonic_acid_metabolism -1.54 44 0.054 0.026 
PPAR_signaling_pathway -1.54 51 0.053 0.011 
Rig_1_like_receptor_signaling_pathway -1.51 51 0.063 0.024 
 
Table 4.20 Downregulated nodBCC pathways using GSEA. Downregulated MSigDB pathway 
expression in morphoeic tumour versus stroma. Arranged according to NES with a false discovery rate (q-
value)  <0.10 MSigDB, molecular signature database; NES, normalised enrichment score; Q-value, false 
discovery rate; P-val, P-value MSigDB, molecular signature database; NES, normalised enrichment score; 




4.2.6iii Morphoeic versus Nodular tumour 
The two tumour subtypes were then compared in terms of pathway analysis and it 
demonstrates a shared expression of BCC and several immune pathways (Figure 4.8) 
Pathways that were more expressed in morphoeic than nodular are shown in Table 4.21 
and include extracellular matrix interaction and cell adhesion; which fits mBCC 
phenotype. In addition, notch and axonal guidance signalling seem to play a role in 




Figure 4.8 Pathway comparison between morphoeic and nodular BCC. Pathways identified using 
gene-set enrichment analysis (GSEA) of RNAseq data for morphoeic and nodular BCC are represented. A 
selection of shared pathways are highlighted in red. Blue represents those significantly altered pathways in 
nodular BCC and those pathways in orange represent morphoeic specific pathways. nodBCC, nodular BCC; 





MSigDB pathway NES Geneset Size q-val P-val 
Ribosome 2.58 85 <0.001 <0.001 
Ecm_receptor_interaction 1.98 76 0.003 <0.001 
Systemic_lupus_erythematosus 1.98 69 0.002 <0.001 
Intestinal_immune_network_for_iga_production 1.82 35 0.024 <0.001 
Antigen_processing_and_presentation 1.81 56 0.019 0.0012 
Asthma 1.75 21 0.036 0.004 
Type_1_diabetes_mellitus 1.73 33 0.042 0.007 
Vasopressin_regulated_water_reabsorption 1.72 38 0.041 0.004 
Allograft_rejection 1.66 29 0.072 0.009 
Cell_adhesion_molecules_cams 1.63 116 0.087 <0.001 
Hematopoietic_cell_lineage 1.63 67 0.080 0.001 
Autoimmune_thyroid_disease 1.60 31 0.105 0.016 
Notch_signaling_pathway 1.59 43 0.103 0.015 
Graft_versus_host_disease 1.58 30 0.105 0.017 
Pantothenate_and_coa_biosynthesis 1.58 15 0.103 0.033 
Axon_guidance 1.56 115 0.107 0.002 
 
Table 4.21 Upregulated mBCC pathways compared to nodBCC using GSEA. MSigDB Pathway 
expression when comparing morphoeic tumour versus nodular tumour. All pathways are upregulated in 
morphoeic tumour and arranged according to NES with a false discovery rate (q-value)  <0.10. MSigDB, 
molecular signature database; NES; FDR false discovery rate. 
 
 
4.2.7 RNA sequencing validation 
 
Validation of two genes (PDGFA and DDR1) was performed using SYBR RT-qPCR. 
RNA from 3 morphoeic and 3 nodular samples were analysed against normal eyelid tissue 
from a non-cancerous eye. PDGFA was found to be one of the 44 shared genes in the 
RNAseq analysis and may contribute to extracellular matrix modification of the tumour. 
On the other hand, DDR1 expression using RNAseq was only found in the morphoeic 
tumour and stroma. 
 
Relative expression levels (x20) of PDGFA demonstrated increased expression in both 
mBCC and nodBCC when compared to normal eyelid tissue (Fig4.9). There was a trend 
to increased expression in mBCC compared to nodBCC, however this was non-
significant. As a potent mitogen of mesenchymal cells this confirms the shared gene 






Fig 4.9 PDGFA q-rtPCR expression in mBCC and nodBCC. Relative PDGFA levels in both mBCC 
and nod BCC compared to normal eyelid whilst each were normalised to housekeeping gene B-actin. N=3 
for each sample type. *P<0.01 compared to normal eyelid 
 
In contrast, DDR1 levels were shown to be less than normal eyelid tissue for both 
subtypes (Fig 4.10). Interestingly, there is a slight difference between levels in the mBCC 
and nodBCC, being more in the former, which is what the RNAseq data suggested, 
however, the fact that the expression is less than normal eyelid implies it may not be 
important. Nevertheless, the RNAseq data highlighted its presence in the mBCC stroma 
and the normal eyelid sample contains tarsal plate, skin and stroma, thus it may be better 
to compare normal stroma with mBCC stroma in the future to see if it has a significant 
role in this microenvironment. 
 
 
Fig 4.10 DDR1 q-rtPCR expression in mBCC and nodBCC. Relative DDR1 levels in both mBCC and 
nod BCC compared to normal eyelid whilst each were normalised to housekeeping gene B-actin. No P 










4.3 Correlated WES and RNA sequencing data 
 
4.3.1 Individual driver genes with RNA changes in BCC 
 
Driver genes identified using WES data were assessed in terms of their expression. mBCC 
driver genes (see section 3.2.4) are listed in Table 4.22. Correlation of RNAseq and WES 
data revealed increased expression for PTCH1 as the only significantly changed using a 
P <0.05. A trend towards down regulation for HECTD4 and up regulation for SMARCA4 
is noted. The reverse trend could be expected if HECTD4 is involved in tumorigenesis 
and SMARCA4 acts as a tumour suppressor gene. However, the log2FC was rather low 
so on an individual gene basis it is not clear what could be happening on a functional 
level. PTCH1 is upregulated presumably in an attempt to suppress the overactive Hh 
pathway, so it may be better to look at an overall pathway picture rather than an individual 
gene level change for both SMARCA4 and HECTD4. Loss of function in the gene cannot 
be ruled out as a cause of low expression or log2FC. 
 
Driver  Exp Log2FC P-val 
PTCH1 5.7 1.2 0.01 
FLNB 7.3 -0.16 0.63 
TTN 8.3 -0.58 0.21 
USP4 6.6 -0.04 0.91 
CHD3 5.8 0.09 0.81 
EPHA3 1.8 -0.50 0.64 
NFS1 3.9 0.03 0.96 
EFTUD2 6.5 -0.10 0.81 
HECTD4 5.1 -0.09 0.09 
Driver  Exp Log2FC P-val 
SMARCA4 5.6 0.50 0.10 
FNIP1 6.1 -0.1 0.85 
CHKB - - - 
CCDC108 - - - 
FBXO15 0.8 0.3 0.6 
POM121L12 3.3 -0.3 0.7 
OR5H2 - - - 
KRTAP12-3 -1.0 2.0 0.24 
 
Table 4.22 Driver gene expression in mBCC. WES drivers selected using Intogen and MutSigCV with a 
q<0.02 and p<0.02 respectively.  
 
 
Driver genes identified using WES for nodBCC (see section 3.2.6) were assessed for their 
RNA expression in Table 4.23. Correlation of WES and RNAseq data revealed two genes, 
PTCH1 and COL4A4. Increased expression in PTCH1 is seen as in mBCC presumably 
for the same reasons. COL4A4 is greatly reduced in expression suggesting a loss of 
function. Loss of the 5-prime end of COL4A4 results in the development of 
leiomyomatoma which behave in an indolent fashion rather like nodBCC and full loss of 






Driver Exp Log2FC P-val 
PTCH1 5.7 1.8 0.002 
TP53 7.0 0.3 0.377 
FADS1 5.3 -0.6 0.091 
PPM1D 3.2 -0.1 0.861 
TAF4B 3.0 -0.3 0.72 
TRIP4 5.1 0.1 0.846 
COL4A4 2.0 -2.0 0.033 
ARGAP35 - - - 
Driver Exp Log2FC P-val 
MTR 6.2 -0.3 0.388 
MYCN 4.4 0.8 0.182 
NARS 7.4 -0.3 0.921 
GABRA6 - - - 
TSGA13 0.8 0.8 0.528 
OR52J3 - - - 
TRIM39 4.0 0.8 0.248 
C10orf82 1.0 0.7 0.463 
 
Table 4.23 Driver gene expression in nodBCC. WES drivers selected using Intogen and MutSigCV with 
a q<0.02 and p<0.02 respectively. 
 
 
Potentially important genes within the morphoeic stroma were assessed at a RNA 
expression level, however, none were significantly expressed (Table 4.24). 
 
Gene Exp Log2FC P-val 
PTPN22 2.2  1.4  0.13 
ARHGEF28 4.2 1.0  0.19 
ASAP1 6.2 0.16 0.73 
C5 2.4 1.0 0.33 
SFMBT2  2.0 -0.52 0.62 
Gene Exp Log2FC P-val 
MYBPC1 1.7 1.3 0.70 
XPO4 4.8 0.1 0.78 
CPNE7 1.0 2.8 0.07 
CDH20 0.2 0.6 0.73 
 
Table 4.24 Correlation of stromal mBCC WES and RNAseq pathway analysis. Top ten loss/gain 

















4.3.2 Pathway link of DNA and RNA analysis 
 
In a similar fashion to the driver genes, significantly modified pathways detected using 
WES data was compared to pathways picked up using RNAseq. Comparison for mBCC 
data is summarised in Figure 4.11 and Table 4.25. Upregulation of Hh signalling is 
significant for both WES and RNAseq analysis and loss of function in NK and FC epsilon 
pathways seem important. Axonal guidance is not altered in terms of WES analysis, but 
significantly overexpressed using RNAseq pathway detection (Figure 4.12). As 




Figure 4.11 Pathways in morphoeic BCC. WES and RNAseq pathway data are compared. Red pathways 
are significantly changed in DNA and RNA analysis using a q=0.05. Orange pathways represent pathways 
altered in WES data only and blue pathways are RNAseq expressed pathways; mBCC, morphoeic BCC; 




 WES   RNAseq       










08 9 2.30 46 <0.001 <0.001 
Axon_guidance Hsa04360 0.53 8 1.56 115 0.107 0.002 
        
Natural_killer_cell_mediated_cytotoxicity Hsa04650 0.042 8 -2.13 98 
1.2E-
04 <0.001 
Fc_epsilon_ri_signaling_pathway Hsa04664 0.07 6 -1.50 66 0.073 0.020 
 
Table 4.25 Correlation of mBCC WES and RNAseq pathway analysis. Intogen pathway prediction 
highlighting altered pathways using WES data from 10 mBCC tumours. MSigDB Pathway expression 
when comparing morphoeic tumour versus nodular tumour. MSigDB, molecular signature database; Kegg 
ID, KEGG pathway identification number; q-val, q-value;  F, frequency of mutations within tumour sample; 




Figure 4.12 Axonal guidance pathway in mBCC. Overall enrichment plot for the 115 genes within the 
axonal guidance pathway demonstrating an increased normalised enrichment score compared to nodBCC. 




Nodular BCC revealed three pathways expressed in both WES and RNAseq pathway 
analysis (Figure 4.13). Hh pathway seems only to be altered at a mutational level and not 
overexpressed on a RNA level. Overexpression of BCC pathway and loss of PPAR 
highlights nodBCC activity (Table 4.26). 
 
 
Figure 4.13 Pathways in nodular BCC. WES and RNAseq pathway data are compared. Red pathways 
are significantly changed in DNA and RNA analysis using a q=0.05. Orange pathways represent pathways 
altered in WES data only and blue pathways are RNAseq expressed pathways. nodBCC, nodular BCC; 










 WES   RNAseq       
MSigDB pathway ID Q-val F NES GS size q-val P-val 
Mismatch repair Hsa03430  5 1.84 22 0.069 0.002 
Basal_cell_carcinoma Hsa05217 2.25E-09 9 1.82 46 0.041 <0.001 
        
TGFB Hsa04350 1.2E-0.4 9 1.03 75 0.846 0.379 
P53 Hsa04115 1.2E-0.4 10 -1.09 65 0.448 0.310 
PPAR hsa03320 0.005 9 -1.54 51 0.053 0.011 
Oxidative phosphorylation Hsa00190 0.04 9 -2.41 108 <0.001 <0.001 
 
Table 4.26 Correlation of nodBCC WES and RNAseq pathway analysis. Intogen pathway prediction 
highlighting altered pathways using WES data from 10 nodBCC tumours. MSigDB Pathway expression 
when comparing morphoeic tumour versus nodular tumour. MSigDB, molecular signature database; Kegg 
ID, KEGG pathway identification number; q-val, q-value;  F, frequency of mutations within tumour sample; 

























4.4 Protein expression in BCC 
 
4.4.1 Clinical features of BCC patients 
 
 Number Mean Age Sex (M/F) 
mBCC 15 71 (9/6) 
nodBCC 15 64 (4/11) 
Table 4.27 Clinical details of protein expression study in BCC. nodBCC, nodular BCC; mBCC, 




4.4.2 Hedgehog expression in periocular BCC 
 
Signalling of the Hh pathway is known to be a fundamental component of BCC initiation 
and growth as blocking of it using SMO inhibitors has shown to cause an impressive 
reduction in tumour size or temporary resolution. It is not clear if the pathway is different 
between the subtypes and the WES analysis places it as the top pathway in mBCC and 
the second most important pathway in nodBCC. GSEA showed Hh to be the third 
upregulated pathway in mBCC, but was not up regulated in nodBCC.  Protein expression 
was therefore sort to see if the there was a difference in expression at a protein level and 
to see if the canonical pathway was activated. Expression was noted in all four parts of 
the canonical Hh pathway for both subtypes although nodBCC expressed less than 
expected especially in Gli1 (Fig 4.14). Semi-quantification using immunofluorescence 
revealed an increase in all components of the Hh pathway in mBCC tumour compared to 
nodBCC tumour and positive control tissue (Fig 4.15A). NodBCC showed a trend to an 
increase in Gli2 expression but the rest of the pathway was less than the positive control 
tissue, nevertheless still present. Interestingly, the stroma of mBCC demonstrated Hh 
expression (Fig 4.15B) and the RNAseq expression data showed a trend towards  this 





Fig 4.14 Hh protein expression in BCC. Representative pictures of Hedgehog pathway expression 
proteins using immunofluorescence in positive control tissue (A-D), nodBCC (E-H) and mBCC (I-L). 
Secondary antibody staining utilized AlexaFluor-568 and the colour converted into green using Image J for 
pictorial purposes. Scale bar represents 250 µm and all images are at 200 X magnification. Antibody stains 
for PTCH1 (A,E,I), SMO (B,F,J), Gli1 (C,G,K) and Gli2 (D,H,L). PTCH1=Patched 1; SMO=smoothened; 
















Fig 4.15 Semi-quantification of Hh expression in BCC. Semi-quantification of antibody expression (x-
axis) within (A) mBCC tumour, nBCC tumour, control tissue and (B) stroma of mBCC, nBCC, control 
tissue using fluorescence intensity (y-axis) was determined in regions of interest as delineated by 
microscopy, ensuring a standardized area size whilst containing the same number of nuclei as determined 
by DAPI staining. Each tumour sample had an average of three readings. Each bar represents mean values 
± SEM taken from 15 nodBCC, 15 mBCC and control tissue samples for each Hh protein. *P<0.01, ** 
P<0.05 compared to control tissue. PTCH1=Patched 1; SMO=smoothened; Gli1=Glioma-associated zinc 
transcription factor1; Gli2= Glioma-associated zinc transcription factor2=Gli2. 
 
RNAseq trend supports protein expression 
 Nodular   Morphoeic   M 
Stroma 
  
Gene Exp Log2FC  P-val Exp Log2FC  P-val Exp Log2FC  P-val 
PTCH1 5.7 1.8 0.002 5.7 3.2 0.04 5.7 2.0 0.20 
SMO 4.5 0.2 0.63 4.8 2.0 0.03 4.5 0.8 0.39 
Gli1 4.9 1.8 0.006 4.9 3.6 0.02 4.9 1.6 0.34 
Gli2 5.1 0.9 0.09 5.1 4.2 0.03 5.1 2.9 0.12 
Table 4.28 Hh pathway RNA expression in BCC. RNAseq data supporting protein expression findings 
of an increased Hh pathway expression in morphoeic tumour compared towards nodular tumour and a trend 
towards increased stromal expression, especially Gli2. 
Gene	expression	in	basal	cell	carcinoma	
	 174 
4.4.3 Glypican 1 expression in periocular BCC 
 
 
Fig 4.16 Glypican expression in BCC. GPC1 expression in mBCC (B-D) compared to nodBCC (F-H) 
with duodenum as control tissue (A and E). Scale is 100um. GPC1, Glypican 1.  
 
 
Glypicans have already been mentioned as important in morphoeic tumours, specifically 
GPC3 and GPC1. The latter was shown to be unique to mBCC and hence was investigated 
at a protein level.  Increased staining is seen in mBCC tumour compared to nodBCC, 
although there is some staining in both cancers. GPC1 is thought to inactivate the G1/S 
checkpoint and stimulate DNA replication with its mitogenic activity described in glioma 
and pancreatic cancer. Moreover, it acts as a co-receptor in SHH activity and therefore, 














4.4.4 Validation of hedgehog pathway antibodies 
 
Western blot of LNCaP-Gli1 cells, a known hyper-expressed Hh pathway cancer cell line, 
demonstrated good specificity of each antibody with a clear band for the appropriate sized 





Fig 4.17 Validation of Hh antibodies. Western blot analysis of LnCaP-Gli1 and human wildtype 
fibroblasts demonstrating good specificity of each antibody with a clear band for the appropriate sized 
protein. 1=LnCaP-Gli1; 2=Human wildtype fibroblasts; PTCH1=Patched 1; SMO=smoothened; 



























4.5 RNA sequencing in periocular BCC 
 
4.5.1 Upregulated genes in morphoeic BCC 
 
Adenomatous Polyposis Coli membrane recruitment protein 2 (AMER2) – chromosome 
13q12.13 
During embryogenesis, AMER2 is a key negative regulator of the canonical Wnt 
signalling pathway during neuroectodermal patterning.(Pfister et al., 2012b) Its structure 
contains binding sites for the tumour suppressor, adenomatous polyposis coli (APC), and 
interacts with other critical components of the b-catenin destruction complex.(Boutet et 
al., 2010) Loss of AMER2 induces overexpression of the Wnt/b-catenin pathway. 
Another function is the recruitment of microtubule-associated protein RP/EB family 
member (MAPRE1) and knockout of AMER2 reduces cell migration, highlighting its 
effect on cell migration.(Pfister et al., 2012a) One of the hallmarks of the morphoeic 
subtype is the widespread cell migration arranged in lines and in skip lesions. It is possible 
that overexpression of AMER2 contributes to this migratory pattern especially as high 
expression levels are seen neuron migration during the development of the growing 
brain.(Comai et al., 2010)  Furthermore, excessive AMER2 could be a compensatory 
response to aberrant Wnt pathway expression. 
 
Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK)- chromosome 2p23.1 
This gene is a tyrosine kinase member of the insulin receptor superfamily and has an 
important function in the genesis and differentiation of the nervous system. The role of 
ALK in cancer has been extensively documented since it was first found to promote 
tumour growth by chromosomal rearrangement and fusing to other genes almost 20 years 
ago.(Ladanyi, 1997) In the case of anaplastic large cell lymphoma there is a 
nucleophosmin (NPM)/ALK fusion. NPM was highly expressed (expression 10) in 
morphoeic, but non-significantly up regulated (P=0.27, log2FC 0.4). Fusion of 
echinoderm microtubule-associated protein-like 4 (EML4)/ALK occurs in a sub group of 
non-small cell lung cancer (NSCLC) leading to the production of an oncogenic 
EML4/ALK tyrosine kinase that promotes cell proliferation and is anti-apoptotic.(Rossi 
et al., 2014) Other oncogenic genetic rearrangements seen in ALK include multiple copies 
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or a sequence variation that results in constitutive activation. Germline point mutations 
can occur in ALK causing heritable neuroblastoma.(Mosse et al., 2008) ALK 
overexpression is seen in breast cancer and related to a more aggressive subtype.(Siraj et 
al., 2015) ALK overexpression is also seen in inflammatory myofibroblastic tumours and 
these tumours have some similarity to mBCC under the microscope, namely the florid 
inflammatory and fibrotic response.(Zhou et al., 2013, Pierry et al., 2015) This data 
supports the work of Ning et al who demonstrated ALK overexpression in BCC and 
furthermore, showed that infiltrative (morphoeic) has a higher fold change compared to 
nodBCC.(Ning et al., 2013) In addition, nodBCC ALK was slightly less upregulated (3.8 
expression, 2.1 log2FC and P=0.006) reflecting a similar trend. Moreover, there is likely 
to be an association with activation of the Hh pathway and Gli1 overexpression.(Singh et 
al., 2009) There are several ALK inhibitors on the market which might  provide an 
alternative therapeutic modality.(Crescenzo and Inghirami, 2015) 
 
Hydroxysteroid (11-Beta) Dehydrogenase 1 (HSD11B1) – chromosome 1q32.2 
This gene codes for an enzyme that interconverts cortisol to cortisone the active/inactive 
glucocorticoid respectively. Despite being bidirectional, it mainly functions to generate 
active glucocorticoid and excess is attributed to type 2 diabetes mellitus, obesity, 
Alzheimer’s disease, rheumatoid arthritis and glaucoma.(Longley et al., 2003) Steroid 
surplus in the skin, as demonstrated by Cushing’s syndrome, impairs healing, causes 
degradation of extracellular matrix proteins and impaired fibroblast function, all of which 
would confer a benefit for the tumour. A constitutive activating variant (rs932335) in the 
HSD11B1 gene poses a risk factor for colorectal cancer in the Chinese population.(Wang 
et al., 2013a) Overexpression has been shown in colorectal cancer with increasing levels 
relating to neoplastic transformation. A different variant (rs11807619) is associated with 
an increased risk of breast cancer. There is therapeutic potential, as several HSD11B1 
inhibitors are being developed for type 2 diabetes mellitus and some have been tested 
with success on human subjects.(Byun et al., 2015, Hong et al., 2015, Wright et al., 2013) 
Expression was not seen in nodBCC where it was non-significantly downregulated 
(expression 3.2, log2FC -0.2 and P=0.74) and its presence may confer a more aggressive 






Peptidyl Arginine deiminase type III (PADI3) – chromosome 1p36.13 
Expression of this enzyme that converts arginine into citrulline is restricted to the granular 
layer of the epidermis and the inner root sheath of the hair follicle.(Dong et al., 2006) 
Protein citrullination regulates physiological pathways such as gene transcription and in 
cancer this can be altered. Isoenzyme 4 has been shown to be over expressed in cancer, 
for example in breast, lung, hepatocellular and ovarian carcinoma.(Chang et al., 2009) 
Due to the alteration in cancer, rheumatoid arthritis and multiple sclerosis to name a few, 
the development of PADI3 inhibitors has started.(Knuckley et al., 2010)  
 
Thyroid Stimulating Hormone Receptor (TSHR) – chromosome 14q31.1 
TSHR transmits the activity of the thyroid-stimulating hormone (thyrotropin) onto the 
thyroid gland to release thyroxine and triiodothyronine. Gain of function mutations or 
hyper expression is seen in thyroid cancer with TSHR mRNA levels acting as a biomarker 
for malignancy and it can predict metastasis or residual disease.(Chia et al., 2007) Over-
expression has been shown to occur in the more aggressive form of breast cancer and may 
be associated with a poorer prognosis.(Yuan et al., 2014) TSHR mutations and 
overexpression is seen in some cases of lung cancer.(Kim et al., 2012)  
 
SH3 And Cysteine Rich Domain 2 (STAC2) – chromosome 17q12 
STAC2 is present in the nervous system and involved in skeletal muscle 
contraction.(Polster et al., 2015, Legha et al., 2010) No association with cancer has been 
made. 
 
Hedgehog Interacting Protein (HHIP) – chromosome 4q31.21 
HIPP regulates sonic hedgehog ligand signalling by binding to SHH on the cell surface. 
It is upregulated in response to SHH signalling and plays a role in sequestering the ligand 
in order to prevent autonomous cell and nearby neighbour cells (termed non-cell 
autonomous) from undergoing Hh signalling. This allows for a graded Hh signal which 
is essential for neural tube patterning seen in embryogenesis.(Kwong et al., 2014) 
Reduced HHIP expression is seen in combination with SHH over expressed cancer states 
such as pancreatic cancer, gastric cancer and medulloblastoma whereby the promoter 
region of HHIP undergoes methylation.(Martin et al., 2005, Song and Zuo, 2014, Shahi 
et al., 2011) High levels seen in the morphoeic subtype may reflect the attempt at tackling 
an aberrant Hh signalling pathway. HHIP is also significantly (P=0.02) overexpressed 
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(3.7 expression, log2FC 1.4) in nodular tumours and so reflects a common initiator or 
trunk change on the proviso that mBCC is an extension of nodBCC. Nevertheless, both 
subtypes rarely metastasis and this may in part be due to the anti-angiogenic effect of 
HHIP.(Olsen et al., 2004)  
 
Endothelin 2 (EDN2) – chromosome 1p34.2 
EDN2 belongs to a family of potent vasoconstrictors, but has also shown to have a role 
as a chemokine, inhibiting neutrophils in high concentrations and plays a role in the 
hypoxic environment seen in tumours.(Ling et al., 2013) EDN2 expression has been noted 
in nodular (and superficial) BCC before and the authors went on to suggest that it is a 
downstream target of Hh signalling.(Tanese et al., 2010) NodBCC also has significantly 
(P=0.002) overexpressed (expression 3.3, log2FC 2.5) EDN2, and this data supports the 
aforementioned study. EDN2 has been shown to be an inflammatory factor that promotes 
demyelination in the central nervous system.(Yuen et al., 2013) Increased expression has 
been noted in breast and renal cancer.(Grimshaw et al., 2002, Bot et al., 2012)  
 
Calcitonin-Related Polypeptide Beta (CALCB) – chromosome 11p15.2 
In contrast to EDN2, CALCB is a vasodilator.(Franco-Cereceda et al., 1987) However, it 
does play a role in the central nervous system as a possible neurotransmitter. This family 
of hormones has been associated with acute leukaemia and thyroid carcinoma.(Schifter 
et al., 1986, Pfluger et al., 1988) 
  
Glypican 3 (GPC3) – chromosome Xq26.2 
This is a cell surface proteoglycan which plays an important role in growth as highlighted 
by the loss of function mutation in GPC3 causing Simpson–Golabi– Behmel overgrowth 
syndrome.(Pilia et al., 1996) Moreover, GPC3 binds SHH and inhibits Hh signalling. The 
GPC3-shh complex then undergoes endocytosis, mediated by low-density-lipoprotein 
receptor-related protein-1 (LRP1), which is non-significantly (p=0.07) overexpressed in 
morphoeic tumour (log2Fc 1.7, expression 6.1). This suggests that GPC3 has a tumour 
suppressor effect in cancer, and is decreased in breast and ovarian cancer.(Lin et al., 1999, 
Peters et al., 2003) However, it is over expressed in other cancers, including 
hepatocellular and lung, especially in the squamous subtype.(Lin et al., 2012, Du et al., 
2011, Yu et al., 2015b) The mechanism of its role in tumorigenesis is not clear, but 
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thought to relate to binding to Wnt, resulting in its subsequent activation.(Lin et al., 2012) 
GPC3 is significantly (p=0.01) expressed (expression 4.2, log2Fc1.1) in nodBCC too. 
 
BCL2-Related Ovarian Killer (BOK) – chromosome 2q37.3 
As a member of the BCL-2 family, it has pro-apoptotic behaviour by mediating p53-
apoptosis.(Bartholomeusz et al., 2006) For example, it has an important role in foetal and 
adult ovarian tissue, inducing apoptosis during follicle maturation.(Jaaskelainen et al., 
2010) It has shown to be induced after DNA damage and be an essential mediator of p-
53 dependent apoptosis in neuroblastoma and breast cancer.(Yakovlev et al., 2004) Over 
expression in morphoeic tissue probably represents a response to the excessive DNA 
damage seen in the tumour. Downregulation has been noted in colorectal cancer and 
confers an advantage to the tumour.(Zeilstra et al., 2011)  
 
Melanoma Antigen Family A4 (MAGEA4) – chromosome Xq28 
MAGE antigens are uniquely present on tumour and germ cells, but not on normal 
somatic adult cells. Its expression in cancer varies and its presence is associated with a 
poorer clinical outcome in melanoma, NSCLC and multiple myeloma.(Caballero and 
Chen, 2009) MAGE-A4 is not significantly (p=0.13) expressed in nodular subtype 
(expression 2.1, log2FC 1.3) and supports data that its expression is related to a more 
aggressive subtype. Despite this, the presence of a cancer unique antigen, if recognised 
by the body, can promote tumour cell death by the body’s own immune system. This had 
led to the potential for immunotherapy and the development of vaccines against the 
antigen.(Gunda et al., 2013, Shirakura et al., 2012)  
 
4.5.2 Downregulated genes in morphoeic BCC 
 
Keratin 13, Type I (KRT13) – chromosome 17q21.2 
Expression normally occurs in epithelial cells and in disease, it is associated with white 
plaques in the oral mucosa known as white sponge naevus syndrome. KRT13 was shown 
to be downregulated in oral/oesophageal squamous cell carcinoma and bladder cancer. 
(Worst et al., 2014, Hartanto et al., 2015) It is thought to be a marker of epithelial 
differentiation, whereby mild dysplastic tissue or well differentiated tumours retain 
KRT13 expression whereas, when tumours that become poorly differentiated they lose 
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expression. (Bloor et al., 2001) KRT13 is non-significantly (p=0.12) reduced (expression 
3.1, log2FC -3.0) in nodBCC. 
 
Keratin 4, Type II (KRT4) – chromosome 12q13.3 
KRT13 and KRT4 are co-expressed in the same differentiated epithelial layers and 
unsurprisingly are both downregulated.(Sakamoto et al., 2011) Both are down regulated 
in squamous cell carcinoma of the larynx. (Nair et al., 2015) KRT4 is non-significantly 
(p=0.15) downregulated (expression 3.0, log2FC-2.1) in the nodular subtype. This 
biologically confirms the view seen on microscopy that morphoeic subtype is more 
poorly differentiated compared to the nodular subtype. 
 
Transglutaminase 2 (TGM2) – chromosome12q11.23 
Although originally described as having enzyme function in the extracellular matrix, it 
also plays a role in cell survival and signalling by binding to guanosine triphosphate 
(GTP). In breast cancer, TGM2 can induce epithelial to mesenchymal transition (EMT) 
and is involved in cancer stem cell traits.(Agnihotri et al., 2013) Overexpression confers 
a poor prognostic outlook and is associated with chemoresistance.(Leicht et al., 2014) 
This would support the low risk of metastasis seen in BCC. NodBCC demonstrates no 
change in TGM2 (P=0.89, expression 2.4 and log2Fc 0.2). In addition, TGM2 activates 
ROCK kinase, thus its deficiency promotes protein kinase B (AKT) signalling and 
adipogenesis.(Myneni et al., 2015) In addition, ROCK is involved in the axonal guidance 
pathway, a novel BCC pathway, and lack of ROCK has been shown to permit the survival 
of stem cells.(Watanabe et al., 2007)  
 
Chemokine (C-X-C Motif) Ligand 17 (CXCL17) – chromosome 19q13.2 
CXCL17 is a chemokine that attracts monocytes, dendritic cells and promotes 
angiogenesis.(Pisabarro et al., 2006) Monocytes are attracted by ERK1/2 as well as p38, 
and release proangiogenic factors including VEGF A. In contrast to other chemokines, it 
plays an anti-inflammatory role in LPS activated macrophages.(Lee et al., 2013) MBCC 
is often encased with a florid inflammatory reaction, and the loss of CXCL17 may 
augment this inflammatory response. Upregulation occurs in breast cancer and it confers 
a poorer prognosis in hepatocellular cancer.(Weinstein et al., 2006, Li et al., 2014a) 
CXCL17 has no significant change (p=0.91) in expression (expression 2.5, log2FC 0.1) 
in nodBCC, which lacks any surrounding inflammatory response. 
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Polymeric Immunoglobulin Receptor (PIGR) – chromosome1q32.1 
PIGR is an important defence mechanism of mucosal surfaces that binds immunoglobulin 
(Ig) M and IgA, the latter being secreted as part of the innate immune system. 
Furthermore, the Ig/PIGR complex is secreted together to act as a free scavenger to attack 
microbes.(Phalipon and Corthesy, 2003) PIGR expression is reduced in colon cancer, an 
area where it is normally highly expressed as part of the colonic epithelial 
defence.(Traicoff et al., 2003) Reduced expression signifies tumour progression and 
poorer prognosis in pancreatic adenocarcinoma, more advanced tumour stage (but not 
metastasis) in gastric adenocarcinoma and less favourable prognosis in ovarian 
cancer.(Fristedt et al., 2014a, Fristedt et al., 2014b, Berntsson et al., 2014) Higher 
expression confers a protective effect as it inhibits the pro-inflammatory cytokine IL-8 
which in turn activates polymorphonuclear neutrophils (PN) that are anti-tumorigenesis. 
(Dong et al., 2005) In addition, PN are known to activate matrix metalloproteinase 2 
(MMP2) which aids local tumour invasion, a trait characteristic of morphoeic 
tumours.(Hadler-Olsen et al., 2013) NodBCC demonstrates non-significant (p=0.612) 
expression (log2FC 0.8, expression 3.3) of PIGR. 
 
Immunoglobulin Lambda Variable 1-40 (IGLV1-40) – chromosome 22q11.22 
Neoplastic plasma cells can produce an excess number of Ig light chains in conditions 
like myeloma. Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal 
gammopathy, and Skin changes syndrome (POEMs) is a rare disease of the plasma cell 
that preferentially releases light chain Ig. IGLV1-40 is also significantly (p=<0.001) 
downregulated (expression 2.9, log2FC -2.3) in nodBCC.  
 
Immunoglobulin Kappa Variable 3-11 (IGKV3-11) – chromosome 2p11.22 
IGKV3-11 is also significantly (P<0.001) downregulated (expression 1.7, log2FC -2.8) 
in nodBCC. 
 
Membrane-Type Serine Protease 2 (TMPRSS4) – chromosome 11q23.3 
This belongs to the family of serine proteases which are found throughout all cells and 
whose role is to cleave peptide bonds within proteins. Highly expressed TMPRSS4 
induces invasion and migration in colon, pancreatic and gastric cancer.(Wallrapp et al., 
2000, Kebebew et al., 2005) Moreover, high levels increases cell adhesion, migration and 
induce EMT via ZEB2 induction.(Jung et al., 2008a) Activation of invasiveness and 
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migration occurs via integrin alpha-5 (ITGA5) to trigger downstream pathways include 
FAK/MAPK, ERK, PI3K/Akt, Src and Rac1, with activation of the former two also being 
responsible for invasiveness and EMT.(Kim et al., 2010b) This has led to the development 
of TMPRSS4 inhibitors derived from 2-hydroxydiarylamide that has shown promise in 
colorectal cancer cells.(Kang et al., 2013) In contrast, lower levels (as seen in mBCC) 
were seen in metastatic melanoma: Riker et al compared melanoma profile to non-
metastatic RNA profile of SCC and BCC. Although they did not state the subtype of BCC 
that were included in the study, they noted that all 15 had  high expression of 
TMPRSS4.(Riker et al., 2008) However, TMPRSS4 was non-significantly (p=0.386) 
downregulated (expression 3.8, log2Fc -1.3) in nodBCC and so this also conflicts with 
Riker’s findings. 
 
Immunoglobulin Lambda Constant 2 (Kern-Oz- Marker) (IGLC2) – chromosome 
22q11.22 
Loss of heterozygosity (presumed reduce function) was noted in eight out of 11 
intracranial meningioma and thought to play a pathogenic role.(Kim et al., 1993)  
 
Immunoglobulin Heavy Constant Alpha 1 (IGHA1) – chromosome14q32.33 
Differential expression has been noted in gastric cancer, but the authors did not mention 
if it was up or down-regulated.(Rajkumar et al., 2010)  
 
Secretory Leukocyte Peptidase Inhibitor (SLPI) – chromosome 20q13.12 
As the name suggest, SLPI protects epithelial cell surfaces from proteolytic enzymes 
(serine proteases) and is involved in the immune response, including being present in 
many secretions. Higher expression levels of SLPI induces cell proliferation and invasion 
in pancreatic ductal adenocarcinoma.(Zhang et al., 2015c) SLPI increases cell adhesion, 
Grb2, Ras and ERK1/2 phosphorylation.(Jeong et al., 2015) In addition, it is an anti-
inflammatory molecule and inhibits the degradation of connective tissue by preventing 
the release of MMP2 and MMP9 by monocytes.(Zhang et al., 1997) Morphoeic BCC 
cells induce a significant inflammatory response and the loss of SLPI may contribute to 
this. MMP2 is non-significantly (p=0.43) expressed (expression 8.1, logFc0.6) in 





4.5.3 Upregulated genes in nodular BCC 
 
Calpain 6 (CAPN6) – chromosome Xq23 
Calpains are a large, ubiquitously expressed family of calcium dependent cysteine 
proteases, however, CAPN6 is mainly expressed in the placenta.(Dear et al., 1997) It is 
involved in microtubule stability and cytoskeletal organisation in embryo.(Tonami et al., 
2007) Loss of CAPN6 promoted skeletal muscle differentiation, suggesting that it has an 
inhibitory role in skeletal muscle development.(Tonami et al., 2013) Increased expression 
is seen in uterine sarcoma and hepatocellular cancer.(Lee et al., 2007, Liu et al., 2015e)  
CAPN6 ability to inhibit apoptosis, via the PI3K-Akt pathway, may be the advantageous 
role it plays within the cancer.(Liu et al., 2011c)  
 
Hsa-miR-3117– chromosome 1p31.3 
Over-expression has been seen in colorectal cancer, more so in the primary tumour rather 
than metastatic tumour, and in melanoma.(Neerincx et al., 2015, Stark et al., 2010) This 
suggests it has a role in primary tumorigenesis and less so in the tumours ability to 
metastasis.  
 
Zinc Finger Protein 418 (ZNF418) – chromosome 19q13.43 
Krüppel or Cys2His2 zinc finger proteins are the largest class of transcription factors and 
ZNF418 acts as transcriptional repressor of the MAPK signalling pathway.(Li et al., 
2008a) Overexpression of ZNF418, may therefore confer a disadvantage to the tumour.  
 
Tolloid like-1(TLL1) – chromosome 4q32.3 
During development, TLL1 is necessary for the correct position of the heart.(Clark et al., 
1999) It is often co-expressed with BMP1 and when both are down-regulated, brittle 
bones (osteogenesis imperfecta) arise in the mouse model.(Muir et al., 2014) Expression 
of BMP1 enhances the migration of NSCLC cancer by releasing MMP2 and 9 via 
TGFB.(Wu et al., 2014) BMP1 is significantly (P=0.015) down regulated (log2Fc -2.5, 
expression 4.0) in nodBCC, but non-significantly (p=0.765) changed (log2FC 0.45, 






(RP11-119F7.5) – chromosome 10q22.1 
This is a 2295 base pair, long non-coding RNA. Down-regulation of RP11-119F7.5 
occurs in gastric cancer and is correlated with histological type and grade, but not survival 
prediction.(Sun et al., 2015) 
 
(RP11-996F15.2) – chromosome 12p11.22 
RP11-996F15.2 has 7 exons at 2380 base pair in length and has been associated with 
lymphoma. 
 
Wiskott Aldrich Syndrome (WAS/WASL) Interacting Protein Family, Member 3 
(WIPF3) – chromosome 7p14.3 
WIPs play an important role in maintaining actin cytoskeleton integrity, cell adhesion, 
migration, chemotaxis and axonal growth.(Zettl and Way, 2002, Anton et al., 2002, 
Banon-Rodriguez et al., 2013, Lanzardo et al., 2007) WIP responds to B1 integrin to form 
complexes with CDC42 for fibroblast chemotaxis.(King et al., 2011) WIPF3 plays a role 
in spermatogenesis and the formation of a blood testis barrier.(Fu and Xiang, 2012) In 
cancer, it is found to have a role in breast cancer invasion probably via actin 
reorganisation.(Garcia et al., 2014)  
 
Zinc Finger Protein 737 (ZNF737) – chromosome 19p12 
ZNF737 resides in a cluster of genes on chromosome 19 whose expression is higher in 
human T-lymphocytes.(Bellefroid et al., 1993) 
 
Thyroid Stimulating Hormone Receptor (TSHR) – chromosome 14q31.1 
TSHR transmits the activity of the thyroid stimulating hormone (thyrotropin) onto the 
thyroid gland to release thyroxine and triiodothyronine. Gain of function mutations or 
hyper-expression is seen in thyroid cancer; with the mRNA levels acting as a biomarker 
for malignancy and can predict metastasis or residual disease.(Chia et al., 2007) Over 
expression has been shown to occur in the more aggressive form of breast cancer and may 
be associated with a poorer prognosis.(Yuan et al., 2014) TSHR mutation and over-






Shisa family member 2 (SHISA2) – chromosome 13q12.3 
SHISA2 regulates the Wnt and FGF pathways by modifying the number of frizzled and 
FGF receptors respectively.(Hedge and Mason, 2008) Both pathways play a role in 
gradient somitogenesis, which is promoted by SHISA2.(Nagano et al., 2006) It is up-
regulated in breast, prostate and hepatocellular cancer cell lines and specifically related 
to more invasive behaviour.(Cheishvili et al., 2015) 
 
4.5.4 Downregulated genes in nodular BCC 
 
Solute Carrier Family 39 (Zinc Transporter), Member 2 (SLC39A2) – chromosome 
14q11.2 
SLC39A2 normal function involves the homeostasis of iron, zinc and calcium in 
developing embryos and is specifically expressed in keratinocytes, hepatocytes and 
dendritic cells.(Peters et al., 2007) SLC39A2 carries out contact inhibition of epithelial 
cells and so acts as a tumour suppressor. Damaging polymorphisms occur in this gene are 
related to bladder cancer.(Karagas et al., 2012) Low or undetectable levels have been 
noted in prostate and breast cancer.(Franklin et al., 2003) Zhang et al showed that breast 
cancer growth can be inhibited by increasing levels of Zn transporter LIV-1, but not 
SLC39A2, using flaxseed (the richest source of the plant lignin, secoisolariciresinol 
diglycoside).(Zhang et al., 2008) 
 
Diacylglycerol Kinase, Theta 110kDa (DGKQ) – chromosome 4p16.3 
The family of diacylglycerol kinases metabolise 1,2 diacylglycerol to produce 
phosphatidic acid. Expression of DGKQ is primarily seen in the nervous system where it 
plays a major role in synaptic transmission, gene expression, nerve growth factors and 
trafficking via various signalling pathways.(Tu-Sekine et al., 2013, Tabellini et al., 2004) 
Localised mainly in the nucleus, DGKQ attenuates protein kinase C (PKC) activity by 
removing diacylglycerol PKC activation and prevents progression of the cell 
cycle.(Sakane and Kanoh, 1997) Inhibitors to DCKs are being developed, but not 
specifically for the DGKQ isoforms, however these non-specific inhibitors have shown 
some promise.(Purow, 2015, Tu-Sekine et al., 2013) 
 
Keratin 6A, Type II (KRT6A) – chromosome 12q13.3 
The keratin family are fibrous structural proteins responsible for cytoskeleton integrity. 
Keratin filaments are present in epithelial cells and especially prominent on the surface 
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of skin and found in nails, hair and hard palate of the mouth. Autosomal dominant 
mutations in the KRT6A gene result in pachyonychia congenita type1 (MIM 167200), a 
condition characterised by hypertrophic nail dystrophy, palmoplantar keratoderma, 
follicular keratosis and oral leucokeratosis.(Bai et al., 2008)  KRT6A forms heterodimers 
with KRT16 and 17. The former is down-regulated (-2.9 log2FC, expression 6.5) 
significantly (p=0.004) in nodBCC and in mBCC (-1.6 log2FC, expression 6.5 p=0.005). 
KRT17, however, is non-significantly (p=0.28, 0.9 log2FC, 2.4 expression) changed in 
nodBCC whereas it is significantly (p=0.03) upregulated (log2Fc 1.3, expression 2.4) in 
mBCC. KRT6A negatively regulates the proto-oncogene tyrosine-protein kinase (SRC) 
and loss of expression enhances keratinocyte migration.(Rotty and Coulombe, 2012)  
 
Cytohesin 4 (CYTH4) – chromosome 22q13.1 
Cytohesins are a small family of four and a type of guanine nucleotide-exchange protein 
(GEP).(Moss and Vaughan, 2002) They mediate phosphoinositide (PI) 3-kinase regulated 
ADP ribosylation factor (Arf) signalling.(Jackson et al., 2000) CYTH4 expression is 
localised to leucocytes, especially monocytes (CD33+) and absent from most other 
tissue.(Ogasawara et al., 2000) The lack of CYTH4 may reflect the tumours ability to 
evade the monocyte innate immune system and their progeny of macrophages and 
dendritic cells. 
 
CD2 Molecule (CD2) – chromosome1p13.1 
All peripheral blood T-lymphocytes possess a surface antigen CD2 along with some 
natural killer cells. In cutaneous melanoma, CD2 cell number has a prognostic role, with 
fewer cells being a higher risk of recurrence or death.(Harcharik et al., 2014) A similar 
result was seen in T-cell acute lymphoblastic leukaemia whereby CD2-negative patients 
had a poorer outcome.(Uckun et al., 1996) MBCC is more aggressive than nodBCC, but 
the down-regulation of CD2 is less (log2FC -1.3, expression 4.5), but still significant 
(P=0.05). Nevertheless, it does highlight the fact the adaptive immune system is also 
dysregulated in BCC.  
 
Histidine Decarboxylase (HDC) – chromosome 15q21.2 
This is the sole enzyme that provides histamine in the body by converting L-histidine into 
histamine, hence is a biomarker for histamine synthesis. It is a well-known inflammatory 
mediator, but also involved in neurotransmission, secretions and smooth muscle tone. 
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Increased expression is seen in colorectal, pancreatic, small cell lung cancer and 
melanoma.(Masini et al., 2005, Tanimoto et al., 2004, Matsuki et al., 2003, Haak-
Frendscho et al., 2000) Histamine released from mast and non-mast cells induce tumour 
angiogenesis.(Li et al., 2008b) In addition, it seems to augment an autocrine tumorigenic 
loop in cholangiocarcinoma by enhancing local histamine synthesis.(Francis et al., 2012). 
It is non-significantly (P= 0.19) down-regulated (-1.7 log2FC, expression 2.6) in mBCC 
too and therefore histaminergic tumorigenesis does not seem to play a part in BCC. 
 
Family with Sequence Similarity 65, Member C (FAM65C) – chromosome 20q13.3 
Over-expression has been seen in cervical, pancreatic, renal, large bowel and urinary tract 
cancer, with the latter in over 10% of cases.(Forbes et al., 2011) 
 
Guanylate Binding Protein Family, Member 6 (GBP6) – chromosome 1p22.2 
Common interferon stimulated genes include the guanylate binding proteins as part of the 
innate immune system. Loss of GBPs result in defective macrophage activity.(Pilla et al., 
2014) GBP1 expression is associated with a better prognosis and inhibits proliferation, 
invasion and migration of colorectal cancer cells, therefore, GBP6 may act as a tumour 
suppressor gene.(Britzen-Laurent et al., 2013) 
 
Granulysin (GNLY) – chromosome 2p11.2 
T-lymphocytes and natural killer cells contain cytotoxic granules called granulysin as part 
of the innate immune system which is lytic to tumour cells.(Stenger et al., 1999) Increased 
expression conferred a favourable outcome in gastric cancer, colorectal cancer and large 
B-cell lymphoma.(Li et al., 2012b, Tosolini et al., 2011, Park et al., 2011) It induces 
apoptotic cell death in haematological tumours and its anti-tumour properties could be 
exploited as a form of immunotherapy.(Aporta et al., 2014) 
 
CD1c Molecule (CD1C) – chromosome 1q23.1 
Four transmembrane glycoproteins for the family of CD1 molecules that are involved in 
the major histocompatibility complex and the presentation of lipid antigens to T-
lymphocytes. CD1C is known to be involved in antigen presentation in relation to 
Mycobacterium tuberculosis.(Matsunaga and Sugita, 2012) It traffics through all cell 
compartments unlike the other isoforms and presents a wide range of antigens to T-cells 
including endogenous antigens, hence may play a role in cancer cell priming of the body’s 
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T-cell defence.(Adams, 2013) CD1C is a marker of professional antigen presenting cells 
such as the dendritic cell and encouraging its ability to present cancer cell lipids as another 
form of immunotherapy. 
 
4.5.5 Upregulated in morphoeic compared to nodular BCC 
 
Plakophilin 1 (PKP1) chromosome 1q32.1 
Being an armadillo-related protein, it has a dual role in cell-to-cell contact and 
cytoplasmic/nuclear signalling altering gene expression. PKP1 acts both in the 
extracellular matrix (PKP1a) to support desmosome structure and as a transcription factor 
in the nucleus (PKP1b variant) to promote eukaryotic initiation factor 4A1 (eIF4A1) 
activity.(Wolf et al., 2010) Deficiency in PKP1 was first noted in the dysplasia-skin 
fragility syndrome whereby an autosomal recessive mutation leads to skin fragility, 
palmoplantar hyperkeratosis, onychodystrophy, perioral fissuring and non-cicatricial 
alopecia due to lack of protein production.(Hernandez-Martin et al., 2013) A shortage of 
PKP1 results in a reduction in the number of desmosomes and increased migration.(South 
et al., 2003) Plakophilin expression in breast cancer demonstrates overexpressed PKP3, 
but not PKP1 or 2.(Demirag et al., 2012) Gastric cancer showed a loss of PKP3, but no 
change in PKP1 or 2.(Demirag et al., 2011) Oesophageal adenocarcinoma shows 
methylated PKP1 (therefore reduce PKP1) resulting in increased cell motility.(Kaz et al., 
2012) Cervical cancer demonstrates a reduced expression of PKP1.(Schmitt-Graeff et al., 
2007) Conversely, increased expression is seen in squamous cell carcinoma, especially 
in those at low risk of  metastasis. (Villaret et al., 2000) Differing plakophilin expression 
may be due to them having a dual role as either an oncogene or tumour suppressor gene 
depending on the cancer cell of origin.(Bass-Zubek et al., 2009) Moreover, cytoplasmic 
PKP1 may act as a post-transcriptional regulator of gene expression. (Fischer-Keso et al., 
2014) PKP1 immunostaining of BCC and SCC have been heterogeneous, with a trend 
towards less intensity in poorly differentiated (and invasive) tumours.(Moll et al., 1997) 
In contrast, PKP1 in nodBCC is significantly (p=0.002) downregulated (expression 7.3, 
log2Fc -1.6).  
 
Laminin, Beta 3 (LAMB3) – chromosome 1q32.2 
The laminins are a family of extracellular proteins involved in a diverse number of 
functions depending on the organ. In skin they are involved in cohesion of the dermal-
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epidermal junction and mutations in LAMB3 (homozygous loss of function) result in 
blistering skin disorders such as epidermolysis bullosa.(Laimer et al., 2010) Laminins 
have been shown to be involved in cancer and may aid local spread or invasion. (Sroka 
et al., 2010) 
 
Glypican 1 (GPC1) – chromosome 2q37.3 
There are six glypicans within the family and two main subgroups based on sequence 
homology. GPC1, 2, 4, 6 are in one subgroup and 3, 5 in the other. As mentioned, they 
have an important role in developmental morphogenesis and interact with Hh, Wnt, FGF 
and BMP.(Filmus et al., 2008) GPC 1 regulates Hh signalling by acting as a co-receptor 
in Shh-dependent induction of commissural axon guidance.(Wilson and Stoeckli, 2013) 
Its responsibility in cancer is less well documented than its family member GPC3, 
however, it is overexpressed in pancreatic cancer, and is part of the  stromal soup of 
MMP, growth factors that promotes invasion of cancer cells.(Korc, 2007) It is also 
overexpressed in ameloblastoma, glioma and breast cancer.(Bologna-Molina et al., 2015, 
Qiao et al., 2013, Matsuda et al., 2001) GPC1 inactivates the G1/S checkpoint and 
strongly stimulates DNA replication in glioma cells, possibly via the S-phase kinase-
associated protein 2 (SKP2) autoinduction loop.(Qiao et al., 2013) In pancreatic cells, 
GPC1 is essential for the mitogenic effect of FGF2 and HB-EGF.(Kleeff et al., 1998) 
 
 
EPH (Ephrin) Receptor B4 (EPHB4) – chromosome 7q22.1 
Ephrins mediate developmental processes, especially in the nervous system. Both EPHB3 
and EPHB4 are significantly upregulated (the latter log2FC 2.0, expression 3.6 and 
P<0.003). EPHB4 is a receptor tyrosine kinase that coordinates cell migration during 
embryogenesis and although ubiquitous in adult tissue, is expressed at low levels. 
Overexpression has been detected in lung, colorectal, breast, thyroid, prostate, cervix, 
ovarian and skin cancers. EPHB4 promotes proliferation, cell motility and migration 
which is enhance by binding of the ligand ephrinB2.(Ferguson et al., 2014) The receptor 
binds all ephrin-B ligans and EFNB1 is significantly (P=0.007) overexpressed (1.2 
log2FC, expression 4.7) in mBCC, but non-significantly (p=0.559) altered (0.3 log2FC, 
expression 4.7) in nodBCC. Mechanism of action include targeting Rho GTPases, 
directly promoting angiogenesis by action on endothelial cells and affecting the 
extracellular matrix by modulating integrins such as Integrin beta 8 (ITGB8) to aid cell 
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migration.(Yang et al., 2006, Mertens-Walker et al., 2015) Inhibitors of EPHB4 are in the 
pipeline and clinical trials have already started with the use of EPHB4-fusion protein and 
small molecules in combination with standard chemotherapy for solid 
tumours.(Duggineni et al., 2013) 
 
Unique to morphoeic tumour and normal stroma 
The above-mentioned genes are DE when comparing tumour subtypes only. When 
looking at all four compartments (two tumour subtypes and two normal stroma) we can 
look for genes that are shared (see 4.2.4iii below) and those that are present in some of 
the compartments. DDR1 was found to be expressed in both the morphoeic tumour and 
normal stroma, but not the nodBCC tumour or the corresponding normal stroma. For 
example, comparing morphoeic tumour with nodular normal stroma, the expression was 
7.2, log2FC 1.8 and P 0.0005. This raises the possibility of the normal surrounding stoma 
in the morphoeic tissue being different to true, normal tissue and DDR1 is discussed 
further below. In order to look at this further, the morphoeic normal stroma was compared 
to the nodular normal stroma to identify any other interesting genes. 
 
Discoidin Domain Receptor Tyrosine Kinase 1 (DDR1) - chromosome 
DDR1 is a tyrosine kinase receptor that binds collagen to induce cell migration, 
proliferation and extracellular matrix modification. Pathway activation is dependent on 
cell type as it can activate or inhibit ERK pathway.(Curat and Vogel, 2002, Lu et al., 
2011) Within the extracellular matrix it can activate integrins, TGFB and notch1.(Kim et 
al., 2011) Overexpression has been shown in pancreatic, NSCLC, breast, ovarian and 
hepatocellular cancer.(Huo et al., 2015, Shen et al., 2010b) DDR1 Has been shown to 
mediate MMP invasion in breast cancer cells and regulates embryonic stem cell self-
renewal in the mouse.(Castro-Sanchez et al., 2011, Suh and Han, 2011) Inhibitors of 
DDR1 have been developed that reduce tumorigenesis and repel metastatic cells from 









4.5.6 Shared genes present in both morphoeic and nodular tumour 
 
SH3 And Cysteine Rich Domain 2 (STAC2) chromosome 17q12 
STAC2 is part of a membrane trafficking adapter protein family and one of three isoforms 
(STAC 1-3).  It is found in skeletal muscle, spine, cerebellum and forebrain.(Nelson et 
al., 2013) In skeletal muscle, it increases calcium influx and subsequent 
contraction.(Polster et al., 2015) STAC2 is also expressed during post-natal development 
of dorsal root ganglion neurons and promotes their expansion.(Legha et al., 2010) 
Potentiating growth may be the role that it plays in cancer. 
 
Versican (VCAN) – chromosome 5q14.2 
The extracellular matrix within the developing embryo provides a permissive 
environment for growth and VCAN is a proteoglycan that forms a part of this complex. 
In addition, it is found in large amounts in adult tissue with particular prominence in soft 
tissue.(Wight, 2002) Protein Tyrosine Kinase 2 (PTK2), PDGF and VCAN all work 
together to expand the extracellular matrix for proliferation of cells.(Wight, 2002) PTK2 
is non-significantly (p=0.27/0.19) downregulated (-0.5/0.6 log2FC, expression 5.8/5.8) 
in morphoeic/nodular respectively, but PDGFA is overexpressed (see below). It is 
proinflammatory by allowing sustained recruitment of leukocytes and release of 
inflammatory chemokines and helps to create a setting for cell proliferation and 
migration. VCAN is upregulated by PDGF and TGFB1, both known mitogens, and it is 
possible that VCAN itself is a mitogen by acting through EGF.(Wight, 2002) It terms of 
cell migration, it has been extensively studied in relation to the movement of neural crest 
cells during embryogenesis.(Perissinotto et al., 2000) Increased expression has been seen 
in a variety of cancers including breast, prostate, ovarian and confers an inverse 
relationship with prognosis.(Ween et al., 2011, Du et al., 2013) Specifically, it plays a 
role in the local stromal microenvironment in association with hyaluronan (HA) and 
CD44.(Ricciardelli et al., 1997) Immunostaining for VCAN in BCC demonstrated 
stromal expression, but not within the tumour; HA and CD44 showed very low tumour 
cell signal.(Karvinen et al., 2003) Promising results have been shown by the inhibition of 
VCAN with the tyrosine kinase drug Genistein, asthma drugs Montelukast and 





Platelet-Derived Growth Factor Alpha Polypeptide (PDGFA) – chromosome 7p22.3 
Platelet-derived growth factors are potent mitogens of mesenchymal cells and essential 
in embryogenesis, cell survival, chemotaxis, migration and proliferation. Overexpression 
is seen in cholangiocarcinoma, glioma, mantle cell lymphoma, pancreatic and ovarian 
cancer. (Martinho et al., 2009, Boonjaraspinyo et al., 2012) It has been demonstrated by 
immunohistochemistry that stromal PDGFA expression is necessary for BCC 
growth.(Ponten et al., 1994) Activation of PDGFA by SOX11 has been shown to regulate 
angiogenesis in mantle cell tumours with SOX11.(Palomero et al., 2014) Furthermore, 
SOX11 itself promotes angiogenesis in mantle cell tumours and effective tumour growth 
by activating AKT and MAPK. Sox11 is significantly (P=0.001/P<0.001 overexpressed 
(1.8/2.3 log2FC, expression 5.3/2.3) in morphoeic/nodular respectively. Clinical trials 
have been undertaken with anti-PDGFA, however, it has not shown to be potent as a 
single agent, rather, used in combination with chemotherapy.(Raymond et al., 2008) 
 
Basonuclin 2 (BNC2) – chromosome 9p22.2 
BNC2 is virtually ubiquitous to the nucleus of all cell types and highly expressed in 
reproductive tissue.(Winham et al., 2014) It has been shown to regulate male mouse stem 
cells, allowing for meiosis progression in spermatogenesis.(Vanhoutteghem et al., 2014) 
In oesophageal cancer it has been suggested to be a tumour suppressor gene, based on 
expression of BNC2 causes growth arrest in vitro.(Akagi et al., 2009) Basonuclin 1 has 
been shown to be overexpressed in BCC and upregulated by Hh/Gli (especially Gli2) 
signalling, however, despite the similarity of name, the protein function is vastly different 
to BNC2.(Vanhoutteghem and Djian, 2006, Cui et al., 2004) Moreover, BNC1 is not over 
or under expressed in either nodBCC or mBCC.  
 
Glypican 3 (GPC3) – chromosome Xq26.2 
Please refer to section 4.2.2i 
 
Adenomatous Polyposis Coli membrane recruitment protein 2 (AMER2) – chromosome 
13q12.13 






Shared progressive gene 
CTSV was found to be present in all four compartments (i.e. both the normal stroma and 
tumour of the two subtypes), but had increased in its expression in a progressive fashion 
starting with the lowest expression in normal nodular tissue, then increasing in the 
nodBCC tumour, morphoeic normal tissue and highest within the mBCC tumour. It is 
discussed in further detail below. 
 
Cathepsin V (CTSV) – chromosome 9q22.3 
Cathepsins form a large family proteases, and CTSV is a cysteine proteinase involved in 
collagen degradation, keratinocyte differentiation and angiogenesis.(Zeeuwen et al., 
2007) The pathogenesis of fibrosis, vasculopathy and altered keratinocyte function seen 
in systemic sclerosis has been attributed to loss of CTSV expression.(Noda et al., 2013) 
Expression of CTSV is under the control of Fli1, and this is just non significantly (P=0.06) 
downregulated (log2FC-1.11, expression 4.3) in nodBCC, but significantly (p=0.02) 
downregulated (log2FC -1.4, expression 4.3) in mBCC.(Noda et al., 2013) Cathepsin K, 
also a cysteine proteinase, was expressed in BCC and Bowen’s disease, and cathepsins in 






















4.6 Summary of gene expression in BCC 
 
Basal cell carcinoma (BCC) is the most common cancer in the world and a large 
proportion (60%) affect the face.(Flohil et al., 2013) In particular, BCCs within the H 
zone, including periocular region, have a higher risk of recurrence, behave more 
aggressively and pose a risk to sight (see Figure 1.6).(Mosterd et al., 2008) Compounding 
this is a histological diagnosis of morphoeic BCC (mBCC), which is a high risk factor for 
recurrence and often requires Mohs micrographic surgery to ensure complete histological 
resection.(Malhotra et al., 2004) mBCC comprises of irregular, spiky strands of cells 
accompanied by a florid surrounding inflammatory fibrosis of the stroma (Figure 1.7A) 
In contrast, the more common, indolent nodular BCC (nodBCC) consists of regular nests 
of cells, a pseudocapsule and no surrounding stromal inflammation (Figure 1.7B).  
 
Whole exome sequencing (WES) of 10 periocular mBCC were compared to 10 nodBCC; 
5 periocular and 5 below the head to allow for histological and site specific evaluation. 
BCCs in the periocular region were hypothesised to have a greater mutational burden and 
higher UV burden than BCC elsewhere (elseBCC) with mBCC being the most genetically 
altered. Overall mutational burden was marginally (p=0.08) less in mBCC than nodBCC 
(Table 3.2), but locality had no effect (P=0.6) with normal skin burden be a confounding 
factor. (Martincorena et al., 2015)  
 
Driver mutations in mBCC using the Intogen algorithm (q < 0.1) revealed 18 significantly 
mutated genes, including two known drivers PTCH1 and SMARCA4, four Intogen cancer 
drivers CHD3, EFTUD2 and ARHGAP35, and additional genes shown to be connected 
to a driver, such as FLNB, EPHA3 and CHKB (Table 3.4). MutSigCV identified only one 
known driver PTCH1 (q < 0.05), with additional top mutated genes being CCDC108, 
FBX015, POM121L12 and OR5H2 (raw p < 0.02) (Table 3.14). Shared genes across the 
two algorithms revealed PTCH1 only (Figure 3.9). 
 
In contrast, in nodBCC exomes Intogen highlighted 23 significantly mutated genes (q < 
0.05), including four known drivers PTCH1, TP53, MYCN, ARID1A and five Intogen 
drivers ARHGAP35, IRF2, and PPM1D (Table 3.15). MutSigCV revealed 11 top mutated 
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genes (p < 0.02) with the top two being TP53 and PTCH1 (Table 3.14). Shared genes 
across the two algorithms uncovered six drivers, PTCH1, TP53, FADS1, PPM1D, TAF4B 
and TRIP4 (Figure 3.13).  
 
Next, we performed the randomisation analysis (see Methods) to identify significantly 
mutated genes that were related to a specific subtype or locality. Intogen mBCC specific 
genes included HECTD4 and FLNB and nodBCC specific were ZEB1 and TP53 (Figure 
3.17). MutSigCV mBCC specific gene included CCDC108, and nodBCC included 
GABRA6, OR52J3, TRIM39 and ADAM29 (Figure 3.14). Locality nodBCC genes include 
SIPA1L1 and SYNE1 whereas elseBCC revealed ANK2 and HIVEP1 (Figure 3.18). TP53 
and PTCH1 were shared across both locations for nodular BCC. 
 
Bonilla et al recent article revealed seven driver mutations in their large collection of 
BCCs containing mixed histological subtypes and we demonstrated a similar burden in 
our 20 cases PTCH1 (75%), TP53 (45%), SMO (15%), MYCN (25%), PTPN14 (10%), 
RPL22 (20%) and PPIAL4G (10%) although these mutations may reflect a nodBCC 
makeup which comprises the bulk of Bonilla’s cases.  
 
Tumour-stroma paired gene-set enrichment analysis (GSEA) on RNAseq expression was 
performed and compared to Intogen pathway prediction on WES data. Four common 
mBCC dysregulated pathways (q < 0.05 for both WES and RNAseq) were; ‘hedgehog 
(Hh) signalling pathway’,‘BCC’,‘Natural killer cell mediated cytotoxicity’ and ‘Fc 
Epsilon RI signalling pathway’ (Figure 4.11).  In nodBCC, the ‘BCC’, ‘PPAR signalling’ 
and ‘oxidative phosphorylation’ were commonly dysregulated (Figure 4.13). 
Interestingly, Hh, TGF-beta and p53 signalling demonstrated significant mutational 
burden that was not reflected in the differential expression (DE) profile in nodBCC. The 
comparison between mBCC and nodBCC WES only data revealed a significant novel 
shared pathway as ‘Wnt signalling’, in addition to ‘BCC’, ‘Hh signalling’, ‘pathways in 
cancer’ and ‘cell cycle’. Comparison of nodBCC and mBCC GSEA only revealed 
multiple shared immune-related pathways including ‘Natural killer cell mediated 
cytotoxicity’ (Figure 4.8). However, significant upregulation in ‘Hh signalling’, 
‘spliceosome’ and ‘base excision repair’, and downregulation in ‘ABC transporters’ and 
‘glycosphingolipid biosynthesis’ were observed to mBCC only.  Pathway analysis by 
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Bonilla et al again reflected more nodBCC specific features with the presence of p53 and 
TGF-B signalling, something revealed by mutational burden only in our data.  
Epithelial cancer behaviour is not restricted to the tumour borders delineated on 
microscopy; the surrounding stroma has been shown to play a key role in local 
spread(Davidson et al., 2014) (Figure 1.7). WES of one mBCC microdissected tumour-
stroma pair revealed 150 shared nonsynonymous mutations (76.5% of all stromal 
mutations) including mutations in ATR, EPHA3 and Gli3 (Figure 3.20), although the 
overall variant allele frequency (VAF) was low in both samples, reflecting the low tumour 
purity. EPHA3 is thought to act as a tumour suppressor gene and mutations have been 
found within the surrounding stroma.(Boyd et al., 2014, Vail et al., 2014) The highest 
mBCC tumour VAF genes include ROS1, a proto-oncogene tyrosine kinase receptor and 
Gli3, a Hh protein involved in cancer progression.(Wen et al., 2014) This raises the 
question of whether this is true stromal mutational burden or just histologically 
undetectable cancer cells intermixed within the stromal soup. Either way it is clinically 
relevant when it comes to surgical excision whereby the removal of this inflammatory 
material along with tumour should be considered, as failure to do so may be the reason 
for the local recurrence seen in mBCC.  
 
Protein overexpression of Hh was seen in mBCC tumour compared to nodBCC tumour 
supporting the aforementioned RNAseq data  (Figure 4.14). Stromal Hh protein 
expression was significantly up regulated too in mBCC whereas nodBCC was similar or 
less than control tissue (Figure 4.15). Activation of stromal Hh pathway could be a local 
paracrine effect from the morphoeic tumour or related to the altered cells in the stroma 
itself. Moreover, thirty-seven DE genes (raw p < 0.01) were seen in mBCC stroma 
compared to normal eyelid. GSTM1, a detoxification enzyme associated with BCC, was 
most significantly, upregulated in mBCC stroma with almost absent expression in 
nodBCC stroma. GSEA analysis revealed the most upregulated pathways in mBCC 
stroma were immune related, such as ‘primary immunodeficiency’ and ‘T-cell receptor 
signalling’. Analysis of Hh signalling expression in RNAseq also demonstrated a trend 
towards increased expression in mBCC stroma, although it was not significant compared 
to nodBCC stroma. 
 
The driver mutational profile is different in mBCC compared to its indolent nodular 
counterpart. Loss of function PTCH1 is common to both subtypes; however, their 
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markedly different behaviour may also be reflected by differing expression of the Hh 
pathway especially within the surrounding stroma tissue. Removal of both mBCC tumour 
and stroma may be required to prevent recurrence.  
 
4.7 Potential treatment targets 
 
The overarching aim to all of this research is to identify potential treatment targets for 
patients with BCC and after deciphering the data there are targets where there is a 
currently available treatment in humans:  
 
Smoothened (SMO) inhibitor 
Development of SMO inhibitors occurred after observations were made with the 
Veratrum californicum plant extract cyclopamine. Cyclopamine itself has a poor 
pharmacokinetic profile and too toxic for humans.  Great promise was shown during one 
of the first trials in Gorlin syndrome whereby a 58% response rate was seen in advanced 
BCC on 150mg PO Vismodegib daily, nevertheless 25% reported serious side effects 
including 7 deaths.(Sekulic et al., 2012) Safety outcome reporting at 12 months since the 
trial demonstrated no more death adverse events but similar side effects of muscle spasm 
(72%), alopecia (66%) dysgeusia (54%), weight loss (50%), nausea (33%) and lethargy 
(41%).(Sekulic et al., 2015) Periocular mBCC tumours have been treated with 
Vismodegib, and a small case series of 7 advanced mBCC (post Mohs clearance relapse): 
Two achieved complete clearance, one continued to progress with the others partially 
responding, however, 86% experienced side effects as mentioned above, and the 
development of cutaneous squamous cell carcinoma in two cases.(Gill et al., 2013) 
Resistance to the Vismodegib has also been shown and this is thought to involve 
upregulation of PI3K. To combat resistance, combination therapy is currently 
being assessed with PI3K inhibitors in advanced/metastatic BCC (NCT02303041; 
Buparlisib + Sonidegib) and advanced solid tumours (NCT01576666). 
 
Glioma-associated oncogene (Gli) zinc finger transcription factors 1/2 (Gli1/2) 
Hh is an important signalling pathway in many cancers and as confirmed in our study, 
plays a pivotal. Although initial responses with SMO inhibitors were promising, 
resistance has now been observed, recurrence when stopping the treatment. Resistance 
was shown in advance BCC and medulloblastoma.(Yauch et al., 2009) Re-growth was 
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shown in 20% of patients whilst on SMO treatment.(Chang and Oro, 2012) The antifungal 
Iitraconazole (antifungal) was found to inhibit Hh downstream of SMO and thought to 
prevent Gli transcription.(Kim et al., 2010a) Furthermore, a clinical trial is recruiting at 
the national cancer institute, USA comparing the effects of Iitraconazole versus placebo 
(NCT02735356). Gli antagonists (GANT) have shown promise across a spectrum of 
animal cancer models including pancreas, lung, prostate and rhabdomyosarcoma. GANT 
are thought to act in a multitude of ways that are tumour suppressive (Fig 3.34). In acute 
myeloid leukaemia (AML) cells it causes growth arrest and apoptosis, further, in 
combination with a mTOR inhibitor (Rapamycin) it has shown synergistic potential.(Pan 
et al., 2012) Similar actions were detected in treating rhabdomyosarcoma, along with 
reduction in EMT transition vai AKT/mTOR signalling.(Srivastava et al., 2014) On a 
head to head with the SMO inhibitor Vismodegib, GANT61 was found to suppress 
tumour growth more effectively.(Benvenuto et al., 2016) This highlights the importance 
of targeting the downstream part of the signalling pathway, especially if there is suspected 




Fig 4.18 Action of Gli antagonists. Summary of proposed anti-cancer actions by Gli antagonists (GANT). 







Versican (VCAN) inhibitor 
Induction of VCAN has shown to benefit cancer progression, migration, invasion and 
associated with a poorer outcome. Genistein is a phenolic compound present in soy based 
foods and shown to have a wide variety of anti-cancer effects.(Spagnuolo et al., 2015) 
Nevertheless, it has been shown to increase proliferation of breast cancer cells at high 
doses, so there may be a narrow therapeutic window outside of which may be 
dangerous.(Russo et al., 2016) Leukotriene inhibitors reduce versican and are shown to 
reduce the risk of cancer development in asthma sufferers.(Tsai et al., 2015) In colonic 
cancer cells CysLT1R antagonists (for example Montelukast and ZM198,615) have been 
shown to reduce proliferation and colony formation.(Savari et al., 2013) 
 
Wnt signalling targets 
Protein-serine O-palmitoleoyltransferase porcupine (PORCN) interacts with 
wnt1,3,3A,4,5A,5B,6,7A,7B to carry out palmitoylation, a step required for ligand 
secretion. Small molecule, Wnt974 inhibitor (Novartis), has been developed that binds to 
PORCN and inhibits the enzyme. Initial findings in Wnt driven rodent tumour models, 
and in loss of function NOTCH signalling where cross talk occurs with Wnt, showed 
promising results.(Liu et al., 2013) The molecule has moved into clinical trial for 
pancreatic adenocarcinoma and BRAF mutated colorectal cancer. It is possible other 
tumours with variants in upstream Wnt signalling could be responsive. Monoclonal 
antibodies have been developed against the FZD receptor including Vanituctumab which 
binds to five of the ten frizzled receptors (FZD 1,2,5,7,8). It has shown promise in 
pancreatic and breast cancer cells, but works better in combination with chemotherapy 
and is currently undergoing a phase 1 clinical trial in the aforementioned cancers in 
humans. Cancer like stem cells (CSC) self-renewal depends of Hh ,Wnt, and notched 
signalling and they possess specific markers CD133, CXCR1, and CD44. CSC actions 
are attributed to relapse and metastasis via the c-met/FZD8 axis. An antibody specific to 
FZD8, omp-54 F28, has been used in humans but causes significant side effects in over 
20% of patients including bone fractures. The latter complication would prevent it being 
a practical drug in metastatic bone disease where fractures are common, however it has 
progressed into phase 1b study as an adjunct in ovarian, hepatocellular and pancreatic 
cancer. Antagonists of the cAMP response element binding protein (CREB)-binding 
protein (CBP)/catenin prevent the interaction of the two proteins and in turn eliminate 
cancer initiating cells. By preventing their combination, it has been shown to reduce the 
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formation of drug resistance. These have gone on to phase 2 clinical trials in combination 
with avastin for metastatic colon cancer. Aberration of Wnt within cancer occurs at 
different levels of the pathway, for example, modification of FZD receptor function 
would not be helpful in APC colorectal cancer where the aberration arises lower down in 
the pathway. Traf2- and Nck-interacting protein kinase (TNIK) is an essential regulator 
of the β-catenin and T-cell factor 4 (TCF4) complex, the final component of Wnt 
signalling. Aminothiazole is a small molecule inhibitor of TNIK and shown to reduce 
Wnt signalling as have some other molecules in the preclinical setting.(Masuda et al., 
2015) It does have a role in AKT pathway, autophagy and EMT so the effect of blocking 
these is unknown. 
 
Histone deacetylase 1 (HDAC1) inhibitor 
This inhibitor has been used in the past as a mood stabiliser and antiepileptic. Vorinostat 
was one of the first inhibitors on the market and licensed in 2006 against cutaneous T cell 
lymphoma. Panobinostat is one of the latest licensed HDAC inhibitor in 2015 and had 
been used in patients with haematological and solid cancers. Route of administration has 
been oral and intravenous although there is a wide variability between patients in active 
drug getting to the tissue of interest despite administered the same dose.(Srinivas, 2016)  
 
Erythropoietin-producing hepatocellular carcinoma (EPH) Receptor A3 (EPHA3)–  
inhibitor 
EPHA3 has large body of evidence that it is associated with cancer, even more that it is 
a driver mutation. It has a role in both the Wnt and axonal guidance pathway that are 
altered in mBCC. In nodBCC, only Wnt is altered. Its role is cellular specific and is 
deleted in some cancers and overexpressed in others. A monoclonal antibody IIIA4 
triggers EPHA3 activation, preferentially enters tumour cells and a humanised version, 
KB004 (Kalabios Pharmaceuticals Inc, USA), causes apoptosis of EPHA3 leukaemia 
stem cells from acute myeloid leukaemia patients. In a phase 1 trial it reduced blast counts 
in blood and bone marrow cells.  
 
EPH (Ephrin) Receptor B4 (EPHB4) inhibitor 
As mentioned, antibodies have been developed against EPHB4 and promising results 
have been shown using monomeric soluble EphB4 fused to human serum albumin 
(EphB4-HSA) against human mesothelioma cells established with human mesothelioma 
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cells.(Savari et al., 2013) Phase 1 trial has been carried out in ovarian cancer using JI-
101, a multi-kinase inhibitor against EPHB4, PDGFRB and VEGFR-2 in ovarian 
cancer.(Werner et al., 2015)  
 
Anaplastic Lymphoma Receptor Tyrosine Kinase (ALK) inhibitor 
Crizotinib (PF-02341066) is an oral inhibitor of ALK along with MET, ROS1 and RON 
kinase. It has been trialled in MET and ALK activated tumours  
 
Hydroxysteroid (11-Beta) Dehydrogenase 1 (HSD11B1) inhibitor 
Local tissue levels of active cortisol are controlled by 1β-hydroxysteroid dehydrogenase 
type 1 and 2 with production of cortisol, forward reaction by the former. Various 
compounds are under development primarily for the treatment of type 2 diabetes where 
it is thought that high levels of cortisol in adipose tissue cause visceral obesity and insulin 
resistance.(Hong et al., 2015)  
 
Peptidyl Arginine deiminase type III (PADI3) inhibitor 
Peptidylarginine deiminases are involved in the deamination of the amino acid arginine 
into citrulline within a protein, a process also known as citrullination. This process is 
believed to take part in various chronic inflammatory diseases such as rheumatoid 
arthritis, psoriasis fibrosis and Alzheimer’s disease.(Gudmann et al., 2015) Proteins that 
undergo citrullination undergo degradation more quickly and in terms of tumour, may 
make the microenvironment more conducive to local spread. Analogues of 
benzoylarginine amide are the best PAD inhibitors.(Knuckley et al., 2010, Jones et al., 
2009) Cl-amidine and F-amidine have been shown to reduce cancer cell viability and 
sarcoma growth in murine models.(Slack et al., 2011, Wang et al., 2012b) 
 
ROS proto-oncogene 1 (ROS1) – chromosome 6q22 
Treatment of ALK positive NSLC with specific antibodies has been developed including 
Crizotinib (Xalkori®, Pfizer) and some have activity against ROS1.. 
 
Melanoma Antigen Family A4 (MAGEA4) – chromosome Xq28 
The development of vaccines against this antigen has occurred .(Gunda et al., 2013, 





CHAPTER FIVE  
 
RESULTS IN SEBACEOUS GLAND CARCINOMA (SGC) 
 
5.1 Aims of the SGC study 
 
Sebaceous gland carcinoma is an aggressive, potentially fatal cancer that has predilection 
for the periocular region. Currently, the only treatment is surgical excision and this 
requires removal of a normal seeing eye to protect life, especially in the pagetoid 
histological subtype. By understanding the genetic factors, it is hoped that novel therapies 
can be developed to prevent blinding treatment. A discovery approach using WES of five 
SGCs was carried out to identify driver mutations, followed by transcriptome analysis 
with RNAseq. It is hypothesised that its predilection to the periocular region may be 
associated with UV exposure and a high mutational UV signature would be seen in these 
tumours. Continuing the transcriptome approach, a histological subtypes analysis was 
taken to tease out the differences between the nodular (localised) versus pagetoid 
(spreading) SGC. RNA from 5 pagetoid and 5 nodular subtypes were compared to tarsal 
plate control tissue and then with each other to differentiate those genes that could be 
attributed to poor or favourable outcome. Changes at a DNA and RNA level are not the 
sole changes in cancer, with changes also occurring at an epigenetic and miRNA level 
that shape the cancer’s phenotype. MiRNA from 3 pagetoid were compared to 3 nodular 
along with 3 normal tarsal plate controls. Any changes were then related back to the 
mutational and RNA data in an attempt to construct pathway data. Validation of miRNA 
array data occurred using Taqman real time quantitative PCR. Protein expression was 







Fig 5.1 SGC Project. Overview of the SGC project highlighting the stepwise progression starting with 
WES of SGC DNA, RNA sequencing, then different SGC samples undergoing mRNA array, microRNA 
array and validation using Taqman real time quantitative PCR plus protein expression by 
immunohistochemistry. Resultant treatment targets are summarised at the end. T, SGC tumour; B, SGC 
blood match control; S, stromal tissue; P, pagetoid SGC; N, nodular SGC; C, tarsal plate control;*control 
 
4.2 Whole exome sequencing in sebaceous gland carcinoma (SGC) 
 
WES was carried out on five SGC patients and in a similar fashion to the BCC project, 
posing similar limitations as mentioned in 3.2.  
 
4.2.1 Clinical and histological features of SGC patients 
 
The clinical and histological features are features in Table 5.1 and Figure 5.2. 
 
Sample Age M/F Side Location/histological subtype Surgical and adjuvant treatment 
SGC1 67 M L LUL well differentiated tumour Localised 
SGC2 72 M R Invasive and lymph node positive  Exenteration and local radiotherapy 
SGC3 69 F R RUL Poorly differentiated and in situ disease Localised 
SGC4 57 M R Intraepithelial spread Exenteration 
SGC5 61 M L Intraepithelial spread Exenteration 
 
Table 5.1 Demographics of 5 SGC patients who underwent whole-exome and RNA sequencing. 
Summary of the clinical features for each SGC sample that underwent whole exome and RNA sequencing. 





Fig 5.2 SGC samples recruited into SGC Project. Histological collage of SGC samples stained with 
haematoxylin and eosin (H&E). All samples were initially processed as fresh tissue with fast H&E staining 
to identify tumour for laser capture. A few cases went on to FFPE processing with further H&E, hence the 






5.2.2 Read level quality control metrics 
 
Raw WES data is summarised in the tables (Figure 5.3 – 5.6) below without any filtering 
for depth. Quality control metrics are presented including mean read base quality (Phred 
score) (Fig 5.4), per sequence quality (Fig 5.5) and GC content per base (Fig 5.6). 
 
Fig 5.3 All variants in SGC. Metrics of all variants identified in WES including those from the single 
nucleotide polymorphism database (dbSNP) release 138. 
 
Fig 5.4 Mean Phred score for SGC. Plot of the mean read base quality (Phred score) at each position of 




Fig 5.5 Per sequence quality in SGC. Counts of the mean sequence quality for all individual sample’s 
reads. Mean sequence quality is just greater than 30 for all samples, indicating good quality. 
 
Fig 5.6 Per base GC content for SGC. (A) Plot of percentage GC content at each position of a read (cycle) 












5.2.3 Mutational profile of SGC 
 
The overall mutational burden of potentially pathogenic variants is summarised in Table 
5.2. In contrast to BCC, there are a low number of variants reflecting a visceral cancer-
like profile rather than a skin tumour. Thus, it seems that SGC is not a tumour arising 
from skin tissue, but from deeper structures such as the meibomian gland.  
 
Sample Total  Non-syn Syn Ratio of Non-Syn:Syn 
RSGC1 50 34 12 2.8 
SGC2 615 375 190 2.0 
SGC3 265 181 64 2.8 
SGC4 259 174 66 2.6 
SGC5 296 163 109 1.5 
 
Table 5.2 Mutational burden in SGC. Overall mutational burden, non-synonymous single nucleotide and 
synonymous single nucleotide variants for each sample that underwent WES after filtering for a minimum 
of x20 depth. SGC, sebaceous gland carcinoma; Non-syn, non-synonymous single nucleotide variant; syn, 
synonymous single nucleotide variant. 
 
UV signature and burden 
As mentioned in chapter 3, UV signature contains a specific type of base substitution that 
occurs at dipyrimidine sites, and is a cytosine to thymine (C>T/G>A) change. SGC2 is 
the only sample with a C>T change at over 90%. At first glance, this may reflect a UV 
signature in SGC2. The rest are more reflective of a visceral cancer and show only some 
C>T change. SGC2 is the most aggressive of all five tumours with local lymph node 
spread and the cancer was present in the sun exposed bulbar conjunctiva along with the 
tarsal conjunctiva (non-sun exposed). This may explain the larger number of mutations 
and higher UV burden; at this stage, the control mechanism are all but defunct, thus the 
usual UV protection is no longer present at the tumour location.  
 
There is a large proportion of G>T (C>A) changes within SGC. This traditionally 
represents a tobacco signature whereby polycyclic aromatic hydrocarbons are converted 
to epoxides via liver enzymes which in turn form alkylated guanine adducts that lead to 




Putting the two findings together, G>T (C>A) occurring in the presence of a fair presence 
of C>T at NpCpG sites is more characteristic of signature 6, a marker of a cancer with 
defective DNA mismatch repair.(Alexandrov et al., 2013) 
 
The transitions and transversion were also assessed according to VAF to see if the 
percentage grouping below was reflecting in both low and high VAF. If these changes 
were mainly enriched for the mutations with low VAF, they could be artefact from 
oxidative DNA damage during preparation.(Costello et al., 2013) However, the 
percentages were similar across several VAF categories highlighting these signatures as 
being more genuine. For example, G>T/C>A changes for SGC3 was 30% at a higher 
VAF (greater than VAF 0.10) and for SGC4, 90% at the same higher VAF. 
 
 
Figure 5.7 Pathological mutations and signature in SGC. Tumour single nucleotide variants are shown 














5.2.4 Driver mutations in periocular SGC 
 
The five SGC samples were analysed together using two different mutational significance 
algorithms, namely MutSigCV and Intogen, resulting in 14 (Table 5. 4) and 11 (Table 






Fig 5.8 Driver genes in SGC. Venn diagram highlighting the significant driver genes in SGC using two 
algorithms, MutSigCV and Intogen, with five shared genes within the cross over region. q; false discovery 
rate; p, p-value. 
 
 
5.2.4.i Shared driver mutations using MutSigCV and Intogen 
Fiver genes are shared between the two algorithms, namely TP53, RB1, REPIN1, 
ZNF37A and FRA10AC1. As mentioned in section 3.3.4, TP53 is the archetypal tumour 
suppressor gene. It is ubiquitously mutated in all five samples (Table 5.3) with four out 
of five damaging (in the binding site), but none were G>T (smoking signature). A 
mutation in TP53 is seen in 3-5% of normal eyelid skin so it may be a passenger in SGC4 
where it is predicted to be benign, although the VAF was 0.07 (14% of the sample) so it 
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may have started to be selected as a driver, despite its benign prediction. (Martincorena 
et al., 2015) 
Sample DNA Protein SIFT Polypen COS id/dbSNP 
SGC1 c.715_716insTA p.(Asn239fs) --- ---  
SGC2 c.582_583insAG p.(Ile194fs) --- ---  
SGC3 c.932G>A p.Arg248Trp 0, D,H 1, P 10656 / rs121912651 
SGC4 c.310C>A p.Met40Ile 0.22, T,H 0, B  
SGC5 c.582_583insAG p.(Ile194fs) --- ---  
 
Table 5.3 TP53 variants seen in SGC cohort. The DNA location and protein change are highlighted. Fs, 
non-synonymous frameshift:stop/gain; Analysis from SIFT (D=damaging, T=tolerated, L=low probability, H=high 
probability); Poly=Polypen (P=probably damaging, B=benign) and Cos id=COSMIC identifier; dbSNP,  
 
 
5.2.4.ii Drivers identified using MutSigCV algorithm 
 
Gene NS S P Value 
TP53 5 1 6.79E-05 
REPIN1 2 2 3.39E-03 
IBSP 2 0 5.30E-03 
FRA10AC1 2 1 6.69E-03 
RB1 2 0 1.13E-02 
ZNF37A 2 0 1.69E-02 
C16orf87 1 0 2.33E-02 
Gene NS S P Value 
IL12RB2 2 0 2.92E-02 
GPX3 1 0 3.52E-02 
RPTN 7 1 3.77E-02 
GJD3 1 0 3.94E-02 
DLX6 2 0 4.60E-02 
GNG2 1 0 4.94E-02 
GPR31 1 0 4.97E-02 
 
Table 5.4 Drivers in SGC using MutSigCV silent and non-silent mutations. 14 driver genes using 
MutSigCV taking into account silent and non-silent genes, and ordered according to P value with a P<0.05. 
S, silent; NS, non-silent. 
 
5.2.4.iii Drivers identified using Intogen algorithm 
Gene Freq Driver P-value 
TP53 5 1 0.001 
RB1 2 1 0.002 
REPIN1 2 0 0.002 
DNAH14 2 0 0.002 
TTN 3 0 0.007 
Gene Freq Driver P-value 
ZNF37A 2 0 0.011 
PRPF31 2 0 0.018 
CUBN 2 0 0.025 
SYNE1 2 0 0.028 
FRA10AC1 2 0 0.050 
 
Table 5.5 Intogen derived drivers in SGC. 10 driver genes arranged using Intogen, p-value < 0.05 and 
an fm-bias (q-value) value <0.05. 1, known driver gene; 0, driver status unknown; Freq, frequency. 
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Dynein Axonemal Heavy Chain 14 (DNAH14) – chromosome 1q42.12 
Heavy chains of axonal dynein are encoded by a family of similar functioning genes 
including DNAH14. Their exact function is not clear; however, murine studies 
demonstrate abnormal sister chromatids segregation when mutations occur in the leftright 
dynein gene. This suggests that DNAH family may be involved in positioning of mitotic 
spindles, microtubules and chromosomal dynamics. Biallelic mutations of DNAH11 have 
been seen in primary ciliary dyskinesia.(Knowles et al., 2012) Germline polymorphisms 
of DNAH14, for example rs1857623 in ovarian cancer, plays a role in overall cancer 
survival and prognosis.(Braun et al., 2013) DNAH2, 5 and 10 genetic aberrations were 
associated with renal cell carcinoma as were the spindle assembly and chromosome 
separation pathways.(Arai et al., 2015) Other members of the dynein family were also 
mutated (Table 5.6) 
 
Sample Gene Chr Genome / DNA level Protein level Change /S P T 
Depth 
VAF 
SGC1 DNAH2 17 c.5838_5839insTTG p.Phe1941_Gly1942insVal pepshift 88 0.33 
SGC2 DNAH11 7 c.794C>T p.Gln255* Stop-gain 128 0.11 
SGC3 DNAH14 1 c10903G>T p.Gly3635* Stop-gain 151 0.05 
 DNAH11 7 c.10002G>A p.Arg3324His O,D,H;0.9,P 188 0.26 
 DNAH17 17 c.3807C>A p.Asp1228Tyr 1T,H;0.94 P 43 0.12 
SGC4 DNAH14 1 c.12089C>A p.Ser4030* Stop-gain 73 0.10 
 DNAH7 2 c.7794C>A p.Glu2565* Stop-gain 35 0.14 
SGC5 DNAH11 2 g.196759699C>T  p.? (Intronic) --- 62 0.34 
 DNAH5 5 c.223A>C p.Leu40Val 0.57 T,H; B 337 0.17 
 
Table 5.6 SGC Dynein gene variants. Non-synonymous changes detected in the Dynein family from all five WES 
SGC samples and undergoing SIFT (S) and Polypen (P) analysis. Chr, chromosome; AA, amino acid; S, SIFT; 
P, Polypen; T, tumour; VAF, variant allele frequency.  
 
5.2.5 Periocular SGC WES molecular pathway analysis 
 
Intogen pathway prediction was performed on WES data across the five SGC samples. 
Fifteen pathways were significantly affected using a p-value < 0.05. This included 7 
cancer pathways: pancreatic cancer, chronic myeloid leukaemia, non-small cell lung 
cancer, melanoma, colorectal cancer, glioma and small cell carcinoma. Using a q-value 




Identifier Description Geneset size Q-value Freq 
Hsa04110 Cell cycle 124 0.026 5 
Hsa04120 Ubiquitin mediated proteolysis 137 0.034 4 
Hsa05212 Pancreatic cancer 70 0.091 5 
Hsa04310 Wnt signalling pathway 152 0.091 5 
Hsa04728 Dopaminergic synapse 130 0.091 5 
 
Table 5.7 Driver pathways in SGC. Intogen pathway prediction highlighting altered pathways using WES 
data from 5 SGC tumours and using a q value<0.10. Freq, frequency. 
 
 
5.3 Chromosomal instability in SGC 
 
Single nucleotide changes represent damage to a single strand of DNA and these single 
base changes underpin mutational instability. Damage to two strands of DNA or 
unplanned double stranded breaks leads to chromosomal instability with subsequent 
homologous or non-homologous end joining. Large loss of chromosome regions can 
inactivate tumour suppressor genes and the short arm of chromosome 17 is lost in SGC1 
where TP53 is located (Figure 5.9). Amplification of chromosomal regions can promote 
tumorigenesis by activation a proto-oncogene and chromosome 8 is significantly 
amplified where the MYC resides in SGC2 and even more so in SGC1.  A large-scale 
shattering of the chromosomes in a single cellular event is termed chromothripsis 
whereby the DNA repair machinery joins segments in an erroneous fashion leading to 


















5.4 RNA sequencing in periocular SGC 
 
5.4.1 Clinical features of periocular SGC patients 
 
All five WES samples were sent for RNAseq with normal stroma acting as the reference 
control (Table 5.1). Two had intraepithelial (pagetoid) spread, two were poorly 
differentiated tumours with invasion and one was a well-differentiated tumour. The latter 
underwent local excision and the former three underwent exenteration. 
 
5.4.2 SGC RNA Expression 
 
One tumour sample (SGC4) Phred score tailed off after the 15 cycle and failed quality 
control, thus was excluded from further analysis. A paired analysis of SGC tumour versus 
SGC stroma using limma R/Bioconductor software package (voom function) was 
preformed using raw p value less than 0.01 and log2FC greater than 1 or less than -
1.(Ritchie et al., 2015) Downregulation in the tumour is defined as log2FC<-1 and 
upregulation in the tumour as log2FC > 1. Paired analysis of SGC tumour versus normal 
stroma revealed 949 differentially expressed genes using a q-value < 0.05 and log2FC >1 
or <-1. Log2FC ranged from -6.1 to 5.1 and expression levels from -1.6 to 11.5. A 
heatmap of the 949 DE findings is summarised in Figure 5.10 and almost 72% (679 genes, 
blue colour) were downregulated with the vast majority (449) being -2 log2FC or more.  
 
Fig 5.10 Heatmap of SGC tumour and stroma. Genes and samples were clustered based on Pearson's 
correlation. The scaled expression of each gene, denoted as the row Z-score, is plotted in red–blue colour 




5.4.2i Upregulated genes in SGC 
Genes found to be significantly upregulated were organised according to their Log2FC 
(Table 5.8) and then according to the highest expressed (Table 5.9). ON 28% of DE genes 
were upregulated. Selected genes of interest are further discussed in terms of their 
biological relevance and cancer association. 
 
 
Gene Log2FC Exp P val 
SPRR2A 4.3 2.9 8.6E-03 
SERPINB4 3.6 4.5 7.6E-05 
AARD 3.5 2.6 0.02 
SYCP2 3.4 3.8 8.1E-05 
SPRR2D 3.3 3.1 2.7E-04 
Gene Log2FC Exp P val 
S100A8 3.2 9.3 0.03 
S100P 3.1 4.4 0.05 
SERPINB3 2.9 5.6 6.1E-04 
HIST1H4H 2.9 2.2 6.7E-03 
EPCAM 2.9 6.6 4.8E-03 
 
Table 5.8 Highest Log2FC upregulated genes in SGC. Top 10 differentially expressed RNA are arranged 





Gene Log2FC Exp P val 
S100A8 3.2 9.3 0.03 
FABP5 2.2 9.3 0.001 
STMN1 2.1 9.0 8.1E-04 
FXYD3 2.8 8.6 2.7E-03 
S100A2 2.2 8.5 0.04 
Gene Log2FC Exp P val 
MGST1 2.3 8.4 2.14E-05 
KRT16 2.2 8.0 7.2E-03 
S100A7 2.8 7.7 9.2E-03 
CHCHD7 2.1 7.7 0.01 
EPCAM 2.9 6.6 4.8E-03 
 
Table 5.9 Highest expressed genes in SGC. Top 10 differentially, highest expressed, upregulated RNA 











5.4.2.ii Downregulated genes in SGC 
As mentioned, the majority of genes are downregulated in SGC. Genes found to be 
significantly downregulated were organised according to their Log2FC (Table 5.10) and 
then according to the highest expressed (Table 5.11). Selected genes of interest are further 
discussed in terms of their biological relevance and cancer association. 
 
 
Gene Log2FC Exp P-val 
PYGM -6.1 5.6 
1.6E-
03 
MYH4 -5.6 3.7 
3.9E-
03 
PVALB -5.5 3.5 
1.4E-
03 
ATP2A1 -5.5 6.6 
2.6E-
03 
MYH1 -5.4 6.6 
9.4E-
03 
Gene Log2FC Exp P-val 
CHGB -5.3 4.8 
4.1E-
03 
RP11-755O11.2 -5.3 2.9 
4.3E-
03 
SRL -5.2 3.4 
8.5E-
04 
CKM -5.2 8.3 0.02 




Table 5.10 Downregulated genes with highest Log2FC in SGC. Top 10 differentially expressed RNA 




Gene Log2FC Exp P-val 
IGHG1 -2.5 11 0.01 
CD74 -2.5 10 0.01 
GSN -2.3 10 4.3E-05 
COL1A2 -2.1 10 6.3E-03 
TPM2 -3.7 9.6 1.4E-03 
Gene Log2FC Exp P-val 
COL3A1 -2.3 9.6 4.7E-03 
TTN -3.4 9.4 0.05 
APOE -2.2 9.4 0.03 
COL1A1 -2.1 9.4 0.02 
DCN -2.8 9.2 1.3E-03 
 
Table 5.11 Highest expressed, down regulated genes in SGC. Top 10 differentially, highest expressed, 









5.4.3 RNAseq pathway analysis in SGC 
 
RNA sequencing expression was assessed using GSEA to identify significantly altered 
genesets. Pathway expression was first assessed on an individual tumour basis by 
comparing tumour with the stroma followed by a comparison between the two subtypes. 































5.4.3.i SGC expression using KEGG genesets 
Twenty-seven pathways were shown to be upregulated when analysing RNAseq gene-set 
data (Table 5.12). Upregulation occurred in 4 DNA repair pathways; mismatch repair, 
homologous recombination, nucleotide excision repair and base excision repair. 
 
KEGG pathway NES GS Size Q-val P-val 
Ribosome 4.0 86 <0.001 <0.001 
Spliceosome 3.2 125 <0.001 <0.001 
DNA_replication 3.0 36 <0.001 <0.001 
Cell_cycle 2.8 121 <0.001 <0.001 
Proteasome 2.7 41 <0.001 <0.001 
Oxidative_phosphorylation 2.6 107 <0.001 <0.001 
Mismatch_repair 2.5 23 <0.001 <0.001 
Pyrimidine_metabolism 2.4 89 <0.001 <0.001 
RNA_degradation 2.4 56 <0.001 <0.001 
Nucleotide_excision_repair 2.4 43 <0.001 <0.001 
Homologous_recombination 2.2 28 <0.001 <0.001 
Protein_export 2.2 24 <0.001 <0.001 
Terpenoid_backbone_biosynthesis 2.2 15 <0.001 <0.001 
Rna_polymerase 2.1 28 1.1E-04 <0.001 
Huntingtons_disease 2.0 156 8.9E-04 <0.001 
Steroid_biosynthesis 2.0 15 0.001 <0.001 
Parkinsons_disease 2.0 103 0.001 <0.001 
Basal_transcription_factors 1.9 30 0.002 <0.001 
Butanoate_metabolism 1.8 27 0.005 <0.001 
Glycosylphosphatidylinositol_GPI_anchor_bisynthesis 1.8 24 0.007 0.018 
Base_excision_repair 1.8 33 0.008 0.004 
Oocyte_meiosis 1.7 103 0.011 <0.001 
Systemic_lupus_erythematosus 1.7 78 0.018 0.005 
P53_signaling_pathway 1.6 67 0.019 0.005 
One_carbon_pool_by_folate 1.6 16 0.021 0.028 
Alzheimers_disease 1.6 147 0.021 <0.001 
Peroxisome 1.5 74 0.047 0.0262 
 
Table 5.12 Upregulated SGC pathways using GSEA on KEGG genesets. Upregulated KEGG pathway 
expression in SGC tumour versus stroma. Arranged according to NES with a false discovery rate (q-value)  
<0.05. NES, normalised enrichment score; Q-value, false discovery rate; P-val, P-value 
More pathways were downregulated (Table 5.13) with the most downregulated in extracellular matrix 
receptor interaction and 2 others involved in cell adhesion; focal adhesion and cell adhesion molecules. 






KEGG pathway NES GSS Q-val P-val 
ECM_receptor_interaction -2.3 75 <0.001 <0.001 
Dilated_cardiomyopathy -2.3 79 <0.001 <0.001 
Focal_adhesion -2.2 191 <0.001 <0.001 
Viral_myocarditis -2.2 67 <0.001 <0.001 
Hypertrophic_cardiomyopathy_HCM -2.2 74 <0.001 <0.001 
Vascular_smooth_muscle_contraction -2.2 98 <0.001 <0.001 
Cell_adhesion_molecules_cams -2.2 121 <0.001 <0.001 
Complement_and_coagulation_cascades -2.1 48 <0.001 <0.001 
Calcium_signaling_pathway -2.1 139 <0.001 <0.001 
JAK_STAT_signaling_pathway -2.1 107 <0.001 <0.001 
Hematopoietic_cell_lineage -2.1 69 <0.001 <0.001 
Intestinal_immune_network_for_IGA_production -2.0 38 8.3E-05 <0.001 
MAPK_signaling_pathway -2.0 230 1.5E-04 <0.001 
Graft_versus_host_disease -2.0 29 2.8E-04 <0.001 
Autoimmune_thyroid_disease -2.0 31 3.3E-04 <0.001 
Cytokine_cytokine_receptor_interaction -2.0 194 4.2E-04 <0.001 
Axon_guidance -2.0 119 4.5E-04 <0.001 
Arrhythmogenic_right_ventricular_cardiomyopathy_ARVC -1.9 66 4.8E-04 <0.001 
Lysosome -1.9 116 0.001 <0.001 
Allograft_rejection -1.9 29 0.001 0.002 
Inositol_phosphate_metabolism -1.9 52 0.002 0.001 
Leishmania_infection -1.8 64 0.003 <0.001 
Glycosaminoglycan_degradation -1.8 19 0.003 0.003 
Chemokine_signaling_pathway -1.8 164 0.004 <0.001 
Neuroactive_ligand_receptor_interaction -1.8 137 0.004 <0.001 
Glycosaminoglycan_biosynthesis_chondroitin_sulfate -1.8 21 0.005 0.005 
Long_term_depression -1.8 57 0.005 <0.001 
T_cell_receptor_signaling_pathway -1.8 97 0.005 <0.001 
Phosphatidylinositol_signaling_system -1.8 73 0.006 0.002 
 
Table 5.13 Downregulated SGC pathways using GSEA on KEGG genesets. Downregulated KEGG 
pathway expression in SGC tumour versus stroma. Arranged according to NES with a false discovery rate 












5.4.3.ii SGC expression using REACTOME genesets 
 
A second algorithm, REACTOME, was used to assess SGC pathway. Upregulated 
pathways mainly involve replication (Table 5.14). Downregulated pathways using 
REACTOME also demonstrated reduction in extracellular matrix pathways (Table 5.15) 
 
REACTOME pathway NES GSS Q-val P-val 
Influenza_viral_RNA_transcription_and_replication 3.8 101 <0.001 <0.001 
SRP_dependent_cotranslational_protein_targeting_to_membrane 3.8 109 <0.001 <0.001 
Influenza_life_cycle 3.8 135 <0.001 <0.001 
Peptide_chain_elongation 3.8 85 <0.001 <0.001 
Translation 3.8 147 <0.001 <0.001 
3_UTR_mediated_translational_regulation 3.7 106 <0.001 <0.001 
Nonsense_mediated_decay_enhanced_by_the_exon_junction_complex 3.7 106 <0.001 <0.001 
Metabolism_of_mRNA 3.6 207 <0.001 <0.001 
Metabolism_of_RNA 3.6 252 <0.001 <0.001 
Mitotic_M_M_G1_phases 3.5 163 <0.001 <0.001 
DNA_replication 3.5 183 <0.001 <0.001 
Formation_of_ternary_complex_and_subsequently_the_43s_complex 3.4 49 <0.001 <0.001 
Cell_cycle_mitotic 3.3 303 <0.001 <0.001 
Cell_cycle_checkpoints 3.3 110 <0.001 <0.001 
S_phase 3.3 105 <0.001 <0.001 
G1_S_transition 3.3 106 <0.001 <0.001 
Activation_of_the_mrna_upon_binding_of_the_cap_binding_complex 3.3 57 <0.001 <0.001 
Synthesis_of_DNA 3.3 89 <0.001 <0.001 
Cell_cycle 3.3 364 <0.001 <0.001 
G1_G1_S_phases 3.3 130 <0.001 <0.001 
M_G1_transition 3.2 77 <0.001 <0.001 
Telomere_maintenance 3.1 48 <0.001 <0.001 
 
Table 5.14 Upregulated SGC pathways using GSEA on REACTOME genesets. Upregulated 
REACTOME pathway expression in SGC tumour versus stroma. Arranged according to NES with a false 
discovery rate (q-value)  <0.01. NES, normalised enrichment score; GSS, Geneset size; Q-value, false 











REACTOME pathway NES GS Size Q-val P-val 
Striated_muscle_contraction -2.4 26 <0.001 <0.001 
Muscle_contraction -2.3 45 <0.001 <0.001 
Extracellular_matrix_organization -2.3 77 <0.001 <0.001 
Integrin_cell_surface_interactions -2.2 73 1.8E-04 <0.001 
NCAM1_interactions -2.2 35 1.4E-04 <0.001 
Collagen_formation -2.1 56 1.2E-04 <0.001 
Formation_of_fibrin_clot_clotting_cascade -2.1 15 1.0E-04 <0.001 
Glycosaminoglycan_metabolism -2.1 96 1.9E-04 <0.001 
Nitric_oxide_stimulates_guanylate_cyclase -2.0 24 8.4E-04 <0.001 
Gpcr_downstream_signaling -2.0 313 0.001 <0.001 
Degradation_of_the_extracellular_matrix -2.0 21 0.001 <0.001 
Myogenesis -2.0 24 9.9E-04 <0.001 
Signaling_by_PDGF -2.0 113 0.00144768 <0.001 
Platelet_homeostasis -2.0 67 0.001 <0.001 
Axon_guidance -2.0 223 0.002 <0.001 
Chondroitin_sulfate_dermatan_sulfate_metabolism -1.9 45 0.002 <0.001 
Platelet_activation_signaling_and_aggregation -1.9 171 0.004 <0.001 
Signaling_by_RHO_gtpases -1.9 109 0.004 <0.001 
NCAM_signaling_for_neurite_out_growth -1.9 59 0.003 <0.001 
Phospholipase_C_mediated_cascade -1.9 42 0.006 0.001 
Signaling_by_GPCR -1.9 396 0.006 <0.001 
G_alpha_S_signalling_events -1.9 74 0.006 <0.001 
IL_3_5_and_gm_csf_signaling -1.8 38 0.007 <0.001 
Nuclear_receptor_transcription_pathway -1.8 38 0.007 <0.001 
Smooth_muscle_contraction -1.8 23 0.008 0.001 
Synthesis_of_pips_at_the_plasma_membrane -1.8 29 0.008 0.001 
Developmental_biology -1.8 338 0.01 <0.001 
 
Table 5.15 Downregulated SGC pathways using GSEA on REACTOME genesets. Downregulated 
REACTOME pathway expression in SGC tumour versus stroma. Arranged according to NES with a false 
discovery rate (q-value) <0.006. MSigDB, molecular signature database; NES, normalised enrichment 












5.5 Correlated SGC WES and RNA sequencing data 
 
5.5.1 Individual driver genes with RNA changes in SGC 
 
Driver genes identified using WES data were assessed in terms of their expression. SGC 
driver genes (see section 5.2.4) are listed in Table 5.16. Retinoblastoma gene was 
downregulated, as were REPIN1, CUBN, SYNE1, GPX3 and GNG2. Individual TP53 
showed a possible trend to downregulation, but at a pathway level is significantly 
upregulated (Table 5.12). DNAH14 is upregulated.  
 
 
Driver Log2FC Exp P-val 
TP53 -0.2 5.0 0.598 
RB1 -0.9 5.2 0.010 
REPIN1 -0.7 6.0 0.024 
ZNF37A -0.5 4.8 0.239 
FRA10AC1 0.2 4.7 0.588 
DNAH14 2.0 3.1 0.002 
TTN -3.4 9.4 0.046 
PRPF31 0.01 6.4 0.966 
CUBN -1.6 1.1 0.011 
SYNE1 -2.3 5.4 0.002 
Driver Log2FC Exp P val 
IBSP --- --- --- 
C16orf87 1.0 4.3 0.041 
IL12RB2 0.4 2.0 0.661 
GPX3 -2.0 7.2 <0.001 
RPTN --- --- --- 
GJD3 -1.3 0.8 0.08 
DLX6 2.0 0.2 0.13 
GNG2 -2.6 4.4 0.005 
GPR31 --- --- --- 
 
Table 5.16 Driver gene expression in SGC. Shared and individual driver genes selected by Intogen and 















5.5.2 Pathway link of SGC DNA and RNA analysis 
 
In a similar fashion to the driver genes, significantly modified pathways detected using 
WES data was compared to pathways picked up using RNAseq. Comparison for SGC 
data is summarised in Table 5.17. Upregulation of the cell cycle and ubiquitin-mediated 
proteolysis was seen at a DNA and RNA level, as was Wnt signalling. Downregulation 
of the melanoma pathway is seen, but of unknown significance. 
 
 WES    RNAseq      
Identifier Description GS q-val F NES GS q-val P-val R/K 
Hsa04110 Cell cycle 124 0.026 5 2.8 121 <0.001 <0.001 K 
Hsa04120 Ubiquitin mediated proteolysis 137 0.034 4 2.6 46 0 0 R 
Hsa05212 Pancreatic cancer 70 0.091 5 - - - - - 
Hsa04310 Wnt signalling pathway 152 0.091 5 2.5 61 0 0 R 
Hsa04728 Dopaminergic synapse 130 0.091 5 - - - - - 
Hsa05218 Melanoma 71 0.13 5 -1.7 59 0.009 0.001 K 
 
Table 5.17 Correlation of SGC WES and RNAseq pathway analysis. Intogen pathway prediction 
highlighting altered pathways using WES data from 5 SGC tumours. Pathway expression when comparing 
SGC tumour versus stroma utilising both KEGG and REACTOME genesets. Kegg ID, KEGG pathway 
identification number; q-val, q-value;  Fr, frequency of mutations within tumour sample; NES, normalised 


















5.6 SGC RNA subtype analysis  
 
A second method of RNA analysis was performed on a separate, larger cohort of SGC 
patients whose details are below. These are labelled sebaceous cell carcinoma (SCC) 
rather than SGC to avoid confusion between tissue samples used for RNA validation and 
miRNA analysis, and the five used for sequencing. This served two purposes: firstly, to 
carry out a histological subtype analysis to decipher any differences between nodular 
SGC and the more aggressive pagetoid subtype. Secondly, it provides a source of 
validation of the RNAseq data by identifying any common genes that are differentially 
expressed using both modalities. RNA expression from 4 nodular (SCC1-4) and 4 
pagetoid (SCC 7,9-11) SGC samples were compared to 4 normal tarsal plate control with 
a subsequent cross comparison. A differential expression (DE) analysis using a threshold 
of P <0.01 identified 1625 DE probe sets (Fig 5.11), 590 in nodular, 796 in pagetoid and 
239 shared and visually represented as a heatmap (Fig 5.12). Using a threshold of false 
discovery of <0.05, it narrowed the search to 9 nodular, 9 pagetoid and 4 shared genes. 
(Fig 5.13) 
 
Microarray analysis was performed to assess the RNA and microRNA (section 5.7) of 
the two histological subtypes. Probes on an array have the problem that they often detect 
more than one gene. The Affymetrix and Nanostring array chips used employ short 
oligonucleotides to reduce the likely of detecting more than one gene, however, it is still 
possible. Some of the array oligonucleotides are transcript specific, but some primary 
transcripts undergo alternative splicing depending on the cell status and these alternative 
transcripts can have opposing mechanism of action. Furthermore, closely related genes 
may cross hybridise with a probe despite having the ‘perfect match oligonucleotide’. 
Moreover, tumours contain novel splice variants and duplicated genes that either may not 









Fig 5.11 Differential expression of RNA in Pagetoid versus Nodular SGC. Log2 fold change between 




5.6.1 Clinical and histological features of SCC patients 
 
A different set of SGC patients underwent RNA subtype analysis and coded as SCC rather 
than SGC to differentiate from the WES/RNAseq cohort (Table 5.18). 
 
Sample Age Gender L Subtype 
SCC1 70 F RE Pagetoid 
SCC2 71 F LUL Pagetoid 
SCC3 64 F RE Pagetoid 
SCC4 66 M RE Pagetoid 
SCC6 59 F RUL Pagetoid 
Sample Age Gender L Subtype 
SCC7 66 F RUL Nodular 
SCC8 72 F LLL Nodular 
SCC9 78 M LUL Nodular 
SCC10 65 F LUL Nodular 




Fig 5.12 Heatmap of RNA in Tarsal plate control, Pagetoid SGC and Nodular SGC. Log2 fold change 
between (pagetoid vs. control) and (nodular vs. control) for all 1625 differentially expressed  probe sets p 
<0.01. Genes and samples were clustered based on Pearson's correlation. The scaled expression of each 
gene, denoted as the row Z-score, is plotted in red–blue colour scale with red indicating high expression 














5.6.2 Nodular SGC messenger RNA 
 
Nodular SGC had 590 DE genes and the top nodular specific are listed in Table 5.19. 
Selected individual genes are discussed in more detail below. 
 
 Nodular vs. Control Pagetoid vs. Control 
Gene LC Exp P-val LC Exp P val 
RNU7-141P 5.8 8.4 <0.001 2.4 5.1 0.001 
Y_RNA 3.6 6.6 <0.001 2.7 5.6 0.001 
SYCP2 3.3 6.2 <0.001 2.0 4.9 0.002 
SNORD51 3.2 6.4 <0.001 0.7 3.9 0.124 
SCARNA8 2.8 7.5 <0.001 0.7 5.4 0.144 
RNU7-57P 2.4 5.5 <0.001 0.6 3.7 0.113 
SCARNA1 2.4 5.8 <0.001 1.2 2.0s 0.005 
 
Table 5.19 Nodular specific RNA. Differentially expressed genes present in nodular SGC only when 
normalised to tarsal plate control and using a false discovery rate <0.05 and Log2FC fold change >1.5. 
Pagetoid readings included to highlight the difference between subtypes. LC, Log2FC; Exp, average 






















5.6.3 Pagetoid SGC messenger RNA 
 
Pagetoid SGC demonstrated 796 DE genes with the top pagetoid specific listed in Table 
5.20. Individual genes are explored below in more detail. 
 
 Pagetoid vs. Control Nodular vs. Control 
Gene LC Exp P-val LC Exp P-val 
IGKJ3 6.2 10 <0.001 3.4 7.2 0.005 
CXCL9 3.8 7.3 <0.001 0.2 3.6 0.789 
IGKV1-5 3.8 6.0 <0.001 -0.2 2.0 0.635 
CXCR4 3.0 8.3 <0.001 -0.5 4.7 0.344 
DBF4P1 3.0 6.2 <0.001 1.6 4.8 0.006 
RP11-44K6.2 3.0 4.5 <0.001 0.2 1.7 0.727 
HIST1H2BM 2.8 8.0 <0.001 1.7 6.9 0.003 
CKS2 2.8 6.1 <0.001 1.4 4.6 0.002 
NUSAP1 2.3 5.7 <0.001 1.9 5.3 <0.001 
C2orf47 2.0 5.3 <0.001 0.9 4.3 0.015 
CDKN3 2.0 4.1 <0.001 1.6 4.4 <0.001 
SMCHD1 1.8 6.5 <0.001 1.0 7.2 0.003 
 
Table 5.20 Pagetoid specific RNA. Differentially expressed genes present in pagetoid SGC only when 
normalised to tarsal plate control and using a false discovery rate <0.05 and Log2FC fold change >1.5. 
Nodular expression is included in order to highlight the difference between subtypes. LC, Log2FC; Exp, 


















5.6.4 Comparison of pagetoid and nodular SGC 
 
Shared genes between the two subtypes numbered 239 using P < 0.01, however, this was 
reduced to 22 DE genes using a q-value <0.05 (Fig 5.13A). Of these 4 were common to 




Fig 5.13 Heatmap of shared RNA between pagetoid SGC and nodular SGC. (A) Log2 fold change 
between (pagetoid vs control) and (nodular vs control) for all 22 differentially expressed genes using a 
threshold of false discovery rate <0.05. Genes and samples were clustered based on Pearson's correlation. 
The scaled expression of each gene, denoted as the row Z-score, is plotted in red–blue colour scale with 
red indicating high expression and blue indicating low expression. (B) Venn diagram highlighting only four 
genes are shared between nodular and pagetoid subtype .DE, differential expression; C, tarsal plate control; 
P, pagetoid SGC; N, nodular SGC. 
  
 Nodular vs. Control Pagetoid vs. Control 
Gene LC Exp P-val LC Exp P-val 
TYMS 2.6 6.8 <0.001 2.8 7.0 <0.001 
HIST1H2BD 2.4 6.4 <0.001 3.2 7.0 <0.01 
SNHG1 2.4 6.0 <0.001 2.5 6.0 <0.001 
Y_RNA -3.9 2.8 <0.001 -3.4 3.3 <0.001 
 
Table 5.21 Shared nodular and pagetoid SGC RNA. Differentially expressed genes present in both 
nodular and pagetoid SGC when normalised to tarsal plate control and using a false discovery rate <0.05 








5.7 SGC Micro RNA subtype analysis  
 
MiRNA expression in three This had led to the potential for immunotherapy and the 
development of vaccines against the antigen.(Gunda et al., 2013, Shirakura et al., 2012) 
pagetoid (SCC1,2,3) were compared to three nodular (SCC7,8,9) to decipher the 
differences between the two subtypes.  
 
5.7.1 Clinical and histological features of SGC patients 
 
Six of the RNA microarray patients also went on to have their miRNA analysed (Table 
5.22). 
Sample Age Gender L Subtype 
SCC1 70 F RE Pagetoid 
SCC2 71 F LUL Pagetoid 
SCC3 64 F RE Pagetoid 
Sample Age Gender L Subtype 
SCC7 66 F RUL Nodular 
SCC8 72 F LLL Nodular 
SCC9 78 M LUL Nodular 
Table 5.22 Demographics of SGC samples undergoing miRNA analysis. SCC, sebaceous gland carcinoma; 



















5.7.2 Nodular SGC microRNA  
 
Seventy-five differentially expressed genes were found to be unique to nodular SGC 
compared to control and pagetoid using a P value <0.05 (Fig 5.14). The majority of these 
were downregulated with 27 up regulated. Log2FC ranged from -4.8 to 3.0. Expression 
ranged from 0.9 to 9.9. The top 5 nodular specific miRNA are listed in Table 5.23 and 
selected miRNA discussed further below. 
 
Fig 5.14 Nodular SGC specific microRNA. Seventy-five significant differentially expressed microRNA 
unique to nodular SGC using a p <0.05 threshold. 
 
 Nodular vs. Control Pagetoid vs. Control  
miRNA LC Exp P-Val LC Exp P-Val Gene Target 
150 3.0 6.4 0.018 0.62 6.4 0.572 ZEB1 in SGC; MMP14; P2X7; HER2; MUC4 
142-3p 2.8 9.1 <0.001 0.8 9.0 0.139 FZD7; TGFBR1; PROM1; ABCG2; LRG5; FZD7 
143 2.2 5.6 0.028 0.06 5.6 0.945 GABARAPL1; HX2 
548g -1.6 7.3 0.010 -0.09 7.3 0.849 FHIT 
603 -2.6 8.0 0.007 -1.5 8.0 0.075 CTNNBIP1; WIF1; E2F1; CCND1; CCND2 
 
Table 5.23 Nodular SGC specific microRNA. Top 5 differentially expressed genes present in nodular 
SGC only when normalised to tarsal plate control and using a p-value <0.05 and Log2FC fold change >1.5. 
Pagetoid expression shown to demonstrate non-significant change within the subtype. LC, Log2FC; Exp, 






5.7.3 Pagetoid SGC microRNA 
 
Pagetoid expressed 53 significantly differentially expressed genes with a P value <0.05 
(Figure 5.15). Just under half (24) are down regulated and all genes Log2FC ranged from 
-2.3 to 2.7. Expression ranged from 2.1 to 11 with only 15 genes expressing more than 
5.0. The top 5 pagetoid specific genes are listed in Table 5.24. 
 
 
Fig 5.15 Pagetoid SGC specific microRNA. Fifty-three significant differentially expressed microRNAs 
unique to nodular SGC using a p <0.05 threshold. 
 
 Pagetoid vs. Control Nodular vs. Control  
miRNA LC Exp P-val LC Exp P-val Gene Target 
1308 2.7 5.9 0.014 0.4 5.9 0.695  
205 2.4 11.2 0.005 0.5 11.2 0.457 CDH1; ZEB1; ZEB2; EZR; 
LMNA; PTEN; PHLPP2; EZH2 
200a 2.1 7.7 0.024 0.7 7.7 0.385 MAPK14; APP 
1260 1.5 10.2 0.005 0.5 10.2 0.231 CCND1 
199a-3p/199b-3p -2.3 9.1 0.002 -0.7 9.1 0.217 CD44; AXL; NLK 
Table 5.24 Pagetoid SGC specific microRNA. Top 5 differentially expressed genes present in pagetoid 
SGC only when normalised to tarsal plate control and using a p-value <0.05 and Log2FC fold change >1.5. 
Nodular expression shown to demonstrate non-significant change within the subtype. LC, Log2FC; Exp, 







5.7.4 Comparison of nodular and pagetoid SGC microRNA 
 
Identification of shared genes revealed 39 that were differential expressed in both 
subtypes compared to tarsal plate control (Figure 5.16). The majority are upregulated with 
only 12 downregulated and Log2FC ranged from -1.9 to 4.8. The top 5 DE genes are 




Fig 5.16 Shared microRNA between nodular and pagetoid SGC. Thirty-nine significant differentially 
expressed microRNA shared between both subtypes using a p <0.05 threshold. 
 
 
 Nodular vs. Control Pagetoid vs. Control Gene Target 
miRNA LC Exp P-val LC Exp P-val  
16 4.7 9.1 0.038 4.8 9.1 0.035 Bcl-2 
9 4.1 6.2 <0.001 4.3 6.2 <0.001 CDH1 
34a 3.0 5.4 <0.001 2.8 5.4 <0.001 Bcl2; Survivin; CDK4; CDK6; CCND1; CCNE1; 
MYC; E2F3; MET; SIRT1; MTA2; WNT1; LEF1; 
CD44 
126 -1.1 10.9 0.021 -1.5 10.9 0.004  
619 -2.0 5.6 0.015 -1.5 5.6 0.047  
 
Table 5.25 Shared microRNA between nodular and pagetoid SGC. Top 5 differentially expressed genes 
present in both nodular and pagetoid SGC when normalised to tarsal plate control and using a p-value <0.05 




5.7.5 Validation of RNAseq differentially expressed genes 
 
Assessment of the driver mutations with SGC revealed no significant changes within the 
RNA array assessment. Only one gene came up in both techniques and that was SYCP2, 
which was 3.4/3.3 log2FC, 3.8/5.0 Exp, 8.1E-0.5/1.8E-0.5 P-value, for RNAseq/RNA 
array respectively. Two major families seemed affected though, the S100 and Histone 
proteins (Table 5.26). The latter, as mentioned, is in involved in chromosome structure 
and may reflect the chromosomal instability seen in the tumour. 
 
 
 RNAseq  RNA array  Subtype 
Gene LC Exp P-val LC Exp P-val  
SYCP2 3.4 3.8 8.1E-0.5 3.3 5.0 1.8E-0.5 Both 
S100A14    1.4 7.3 0.002 Nodular 
S100A8 3.2 9.3 0.03     
S100P 3.1 4.4 0.05     
HIST1H4B    2.0 4.3 0.008 Nodular 
HIST2H2BE 0.6 4.3 0.223 1.9 5.6 0.0001 Nodular 
HIST2H2AB    3.5 7.6 0.0002 Pagetoid 
HIST2H2AB    1.9 6.1 0.002 Nodular 
HIST1H2AC    1.0 4.9 0.06 Nodular 
HIST1H2AC    1.7 5.6 0.004 Pagetoid 
HIST1H2BI     1.7 4.6 0.0002 Pagetoid 
HIST1H2AI    2.2 5.2 0.0001 Pagetoid 
HIST1H3F    2.4 7.6 0.002 Pagetoid 
HIST1H3I    3.0 6.2 0.0002 Pagetoid 
HIST1H4L    1.8 3.8 0.0009 Pagetoid 
HIST1H4L    1.1 3.2 0.02 Nodular 
HIST2H4A    1.2 5.3 0.007 Nodular 
HIST2H4A    1.3 5.5 0.003 Pagetoid 
HIST1H4H 2.9 2.2 6.7E-0.3     
 
Table 5.26 Comparison RNAseq and Array expression. Expression seen in the histone and S100 family 
of genes demonstrating the burden across the 14 SGC samples, using a p-value <0.05 and Log2FC fold 








5.8 SGC MicroRNA validation using Taqman RT-qPCR 
 
5.8.1 Endogenous eyelid miRNA control selection 
 
For RNA RT-qPCR, there are well-documented housekeeping genes such as GAPDH or 
B-actin. The best method for deciding a housekeeping gene is to test the candidate in the 
tissues of interest to ensure similar expression is seen in all and that there is minimal fold 
change. For miRNA, there are no agreed universal housekeeping miRNA, so the 
expression levels of potential candidate housekeeping genes were assessed (Table 5.27) 
Hsa-miR-26a was highly expressed in both nodular and pagetoid SGC with minimal 
log2FC compared to normal eyelid tissue, so this was picked as the housekeeping gene. 
 
 Nodular vs. control Pagetoid vs. control 
MiRNA Log2FC Expression Log2FC Expression 
miR-361-5p -1.3 5.0 0.05 4.7 
miR-186-5p 1.9 4.0 1.2 4.0 
miR-26a-5p -0.33 11 -0.12 11 
miR-191-5p 1.3 6.3 2.3 6.3 
miR-451a -0.40 8.7 0.16 8.7 
miR-423-5p 0.84 5.4 0.3 5.4 
miR-320a -0.6 3.1 -0.4 3.1 
 
Table 5.27 Endogenous microRNA control selection. Listed are all possible endogenous controls for 
subsequent Taqman real time quantitative PCR with hsa-miR-26a-5p chosen as the control as it is highly 















5.8.2 Taqman miRNA qPCR 
 
Verification of five differentially expressed miRNA from the Nanostring microarray was 
performed using Taqman RT-qPCR and hsa-miR-26a as the housekeeping gene (Figure 
5.17). Hsa-miR-199a is significantly downregulated in both subtypes, but more so in 
pagetoid SGC which complements the array findings. Increased expression of hsa-miR-
205 was seen in the pagetoid subtype, again supporting the array data. Both hsa-miR-150 
and -34a are upregulated in nodular, but not pagetoid although there was a trend towards 
increased hsa-miR-34a expression. The former is a nodular specific miRNA on array 
scrutiny and this is validated on RT-qPCR. The later was supposed to be a shared miRNA. 





Fig 5.17 MicroRNA expression using Taqman RT-qPCR in SGC. Relative expression levels were 
determined for nodular and pagetoid SGC using Taqman RT-qPCR against normal eyelid tissue for miRNA 






5.9 Protein Expression in SGC  
 
5.9.1 Clinical features of SGC patients 
 
Fifteen patients with SGC were included for comparison against 15 nodBCC (Hh 
pathway driven tumour control) patients with a mean age of 68 and 64, years respectively. 
All of the SGC patients had non-metastatic disease, 10 nodular and 5 pagetoid, requiring 
wide excision or exenteration as treatment. 
 
5.9.2 Hedgehog expression in periocular SGC 
 
 
Hh pathway expression was detected in all 15 SGC and nodBCC tumours as demonstrated 
by the DAB immunostaining for PTCH1, SMO, Gli1 and Gli2 (Figure 5.18). Western 
blot of LNCaP-Gli1 cells a known hyper-expressed Hh pathway cancer cell line, 
demonstrated good specificity of each antibody with a clear band for the appropriate sized 
protein (Fig 4.17, section 4.4.4). PTCH1 expression was detected in the cytoplasm of both 
nodBCC and SGC (Fig 5.18 E & I respectively) however, PTCH1 expression was 
markedly more pronounced in SGC compared to nodBCC. Similar levels of SMO were 
observed in both nodBCC and SGC (Fig 5.18 F & J). Gli1 and Gli2 were detected in the 
cytoplasm and nuclei of both nodBCC and SGC (Fig 5.18 G, K, H & I respectively). Gli1 
expression was stronger in SGC compared to nodBCC whereas similar levels of Gli2 






Figure 5.18 Hedgehog pathway expression in SGC using DAB immunostaining. Representative 
pictures of Hedgehog pathway expression in positive control tissue (A-D), nodBCC (E-H) and SGC (I-L). 
A, breast tissue displays PTCH1 expression in the cytoplasm of the cells (black arrows). B, SMO expression 
in testicular tissue, within the Leydig cells and seminiferous tubules cells (black arrows). C, Gli1 nuclear 
and cytoplasmic expression in testicular tissue, particularly in the Leydig cells and seminiferous tubules 
(black arrows). D, Nuclear expression of Gli2 in intestinal tissue, specifically localized to epithelial cells 
of the intestinal glands.  E, PTCH1 expression in the cytoplasm (black arrows) of nodBCC, similar to 
control tissue. F, Similar SMO expression in nodBCC compared to control. G, Increased Gli1 nuclear 
expression in nodBCC compared to control tissue. H, Increased Gli2 nuclear expression compared to 
control tissue. I, Marked PTCH1 cytoplasmic expression in SGC compared to control and nodBCC. J, 
Slight increase in staining of SMO in the cytoplasm (black arrows) of SGC in contrast to nodBCC. K, 
Increased staining of nuclear (black arrows) and cytoplasmic Gli1 in SGC compared to nodBCC, and 
increased cytoplasmic expression compared to control. L, Nuclear staining of GLi2 (black arrows) in SGC 
that is similar to nodBCC, but more than control tissue. Scale bar represents 250 µm and all images are at 
200 X magnification. Antibody stains for PTCH1 (A,E,I), SMO (B,F,J), Gli1 (C,G,K) and Gli2 (D,H,L). 
PTCH1=Patched 1; SMO=smoothened; Gli1=Glioma-associated zinc transcription factor1; Gli2= Glioma-





DAB immunostaining is highly subjective as is the use of the immunoreactivity score and 
inter-observer variability has been shown in several studies. (Parker et al., 2002, von 
Wasielewski et al., 2002) Immunofluorescence was employed to semi-quantify the 
amount of protein expression in the SGC tumour in order to reduce this observer bias by 
computational counting along with the removal of background noise. Nevertheless, any 
immunohistochemistry method has many variables during processing so relative 
expression to another tumour processed in an identical fashion is a more robust way of 
analysing overall expression. In order to do this, a known aberrant Hh pathway tumour, 
nodBCC, was selected for comparison.(Saldanha et al., 2003) Hh signalling is normally 
switched off in the majority of adult tissues, however, some do transiently express Hh. 
These normal tissue samples represent physiologically expressed Hh and were also used 
for comparison to determine if expression was simply re-activation or aberrant 
overexpression. 
 
Immunofluorescence analysis was used to better quantify the amount of PTCH1, SMO, 
Gli1 and Gli2 expression in SGC and nodBCC (Fig 5.19). A comparison between SGC 
tumour and nodBCC tumour was made along with physiologically activated Hh 
signalling (Fig 5.20). PTCH1, SMO, Gli1 and Gli2 displayed higher levels of 
fluorescence in SGC compared to nodBCC (P<0.01) (Fig 5.20A). PTCH1, SMO and Gli-
2 were also expressed at higher levels in SGC than physiological Hh signalling (P<0.01). 
NodBCC had similar levels of PTCH1 and Gli2 to physiologically activated Hh, but 
markedly lower expression of SMO and Gli1 (P<0.01). Gli1 expression is lower in both 
tumours compared to normal expression; however, expression is still higher in SGC than 





Figure 5.19 Hedgehog pathway expression in SGC using immunofluorescence. Representative pictures 
of Hedgehog pathway expression proteins using immunofluorescence in positive control tissue (A-D), 
nodBCC (E-H) and SGC (I-L). Secondary antibody staining utilized AlexaFluor-568 and the colour 
converted into black and white using Image J for pictorial purposes. Scale bar represents 250 µm and all 
images are at 200 X magnification. Antibody stains for PTCH1 (A,E,I), SMO (B,F,J), Gli1 (C,G,K) and 
Gli2 (D,H,L). PTCH1=Patched 1; SMO=smoothened; Gli1=Glioma-associated zinc transcription factor1; 







Figure 5.20. Hedgehog pathway semi-quantified expression in SGC using immunofluorescence. Semi-
quantification of antibody expression (x-axis) within (A) SGC tumour, nodBCC tumour, control tissue and 
(B) stroma of SGC, nodBCC, control tissue using fluorescence intensity (y-axis) was determined in regions 
of interest as delineated by microscopy, ensuring a standardized area size whilst containing the same 
number of nuclei as determined by DAPI staining. Each tumour sample had an average of three readings. 
Each bar represents mean values ± SEM taken from 15 nodBCC, 15 SGC and control tissue samples for 
each Hh protein. *P<0.01, ** P<0.05. PTCH1=Patched 1; SMO=smoothened; Gli1=Glioma-associated 
zinc transcription factor1; Gli2= Glioma-associated zinc transcription factor2=Gli2. 
 
Comparison of stromal expression using immunofluorescence (Fig 5.20B) showed that 
PTCH1, Gli1 and Gli2 were more highly expressed in the stroma of SGC compared to 
nodBCC (P<0.01). PTCH1 and Gli2 were highly upregulated in SGC stroma compared 
to both normal expression and nodBCC (P<0.01). Gli1 is less expressed in SGC (P<0.05) 
and nodBCC (P<0.01) compared to physiological Hh expression. 
 
Levels of expression within SGC tumour were significantly higher than those observed 
in nodBCC. Furthermore, these levels were more than physiological re-activation except 
for Gli1 that was less than in normal Hh expressing tissue. It is estimated that up to 25% 
of tumours depend on Hh pathway activity for growth.(Lum and Beachy, 2004) Nodular 
BCC is a slow-growing cancer that metastasizes rarely.(Saldanha et al., 2003) In contrast, 
SGC is locally aggressive, metastasizes and has a risk of mortality of up to 29%.(Shields 
et al., 2004, Ni, 1982, Doxanas and Green, 1984) Thus, it is possible that the increased 
Hh expression seen in SGC accounts for its more aggressive nature compared to nodBCC. 
The exact role of Hh expression in SGC cannot be discerned from this study alone, as Hh 
signalling has been implicated in tumorigenesis, growth, progression, local invasion and 
metastasis.(Watkins et al., 2003, Thayer et al., 2003, Dahmane et al., 1997, Sanchez et 
al., 2005)  
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The stroma of SGC was found to express components of the Hh pathway and in particular, 
Gli2 was considerably more upregulated. Cancer can modify the surrounding non-
malignant tissue to facilitate local invasion.(Marsh et al., 2008) Gli2 is an activator of the 
Hh pathway and plays a critical role in medulloblastoma tumorigenesis, with loss of Gli2 
expression preventing the tumour formation.(Hui and Angers, 2011, Flora et al., 2009) 
Moreover, higher levels of Gli2 are associated with a loss of the cell adhesion molecule 
E-cadherin in melanoma cell lines with increased capacity for local invasion, higher 
levels correlated with the most aggressive tumours. (Alexaki et al., 2010) In contrast, 
knockdown models of Gli2 demonstrated reduced tumour growth in prostatic in vivo 
models.(Thiyagarajan et al., 2007) Hh expression as a lone stimulator is unlikely and 
crosstalk with multiple pathways can occur, for example, transforming growth factor-b 
(TGF-b) has been shown to promote Gli2 expression and is involved in tumour 
























5.9.3 HIST1H2 expression in periocular SGC 
 
Expression of HIST1H2BM within SGC was confirmed at a protein level with strong 
levels seen within all samples tested (Fig 5.21) 
 
 
Fig 5.21 HIST1H2BM expression in SGC using DAB immunostaining. Three SGC samples were 










5.10 Whole exome sequencing in SGC 
 
5.10.1 Shared driver mutations using MutSigCV and Intogen 
 
Retinoblastoma 1 (RB1) – chromosome 13q14.1 
RB1 is also an archetypal tumour suppressor gene that causes the hereditary childhood 
cancer, retinoblastoma (RB). The RB1 protein binds to the E2F family of transcription 
factors and represses the transcription of genes needed for the S phase of the cell cycle, 
thus, is a repressor of the cell cycle. (Nevins, 2001) Furthermore, RB is a paradigm for 
the Knudson’s two hit hypothesis whereby loss of both RB1 genes are required for the 
retinoblastoma to develop.(Cavenee et al., 1983) Nevertheless, loss of RB1 on both alleles 
although necessary, is likely not to be sufficient alone to initiate tumorigenesis. How loss 
of RB1 initiates cancer in retinoblastoma is probably dependent on the cell of origin 
assuming that cancer is a clonal expansion of a single cell in the first instance. Its role is 
more diverse that a tumour suppressor gene and may play a direct role in mitosis, genome 
stability via chromatin regulators, interact with ubiquitin ligases and more recently, 
cellular senescence.(Chinnam and Goodrich, 2011) The latter, results in permanent or 
long term prevention of cell proliferation in response to stress, provides a barricade to 
tumour initiation and both RB1 and TP53 are key TSGs required for enforcing this 
senescence barricade.(Courtois-Cox et al., 2008) Despite the variety of cancer inducing 
senescence mechanisms (such as DNA damage, oxidative stress, reactive oxygen species, 
heterochromatin formation) with the associated intermediate pathways involved, all 
routes pass through RB1 and TP53 control. Loss of both pathways in SGC may account 
for its highly aggressive nature. Small cell lung cancer is a highly aggressive cancer with 
a 5% 5 year survival and only contains few mutations, but TP53 plus RB1 are recurrently 
mutated.(Fiorentino et al., 2016) Moreover, functional inactivation of both RB1 and TP53 
can initiate small cell lung cancer in mice.(McFadden et al., 2014) 
 
Replication initiator 1 (REPIN1) – chromosome 7q36.1 
REPIN1 was first described as a DNA binding protein involved in DNA bending, but 
more recently shown to regulate adipocyte size and expression of glucose 
transporters.(Ruschke et al., 2010) High levels of REPIN1 (AP4) have been correlated 
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with a poor prognosis in colorectal cancer, breast and prostate cancer.(Jung et al., 2008b) 
Specifically, it upregulates the genes involved in EMT and cell proliferation.(Chen and 
Chiu, 2015) Moreover, it regulates MMP9, a metalloproteinase involved in stromal 
breakdown, thus promotes cell migration, which is an enhanced characteristic of 
SGC.(Ku et al., 2009) Interestingly, mutant TP53 and REPIN1 have shown to promote 
cell movement and invasion.(Chen and Chiu, 2015)  
 
Zinc finger protein 37A (ZNF37A) – chromosome 10p11.1 
Little is known about this zinc finger protein other that it is likely to be involved in DNA 
binding and transcription activity. However, the region that it sits in (the central region 
of chromosome 10) is also where genes for the inherited cancer syndrome reside: multiple 
endocrine neoplasia or MEN.(Tunnacliffe et al., 1993) 
 
Fragile Site, Folic Acid Type, Rare, Fra(10)(Q23.3) Or Fra(10)(Q24.2) Candidate 1 
(FRA10AC1) – chromosome 10q23.33 
Minimal data exists on this gene other that its association with amyloid in the 
cerebrospinal fluid with possible links to Alzheimer’s disease.(Yao et al., 2015)  
 
5.10.2 Drivers identified using MutSigCV algorithm 
 
Integrin Binding Sialoprotein (IBSP) – chromosome q22.1 
An elevated level has been seen in oesophageal squamous cell carcinoma and is thought 
to play a role in malignant progression with its presence related to a poorer 5-year survival 
compared to those not expressing IBSP.(Tang et al., 2014) Higher levels confer a poorer 
prognosis in renal cell carcinoma especially when co-expressed with osteopontin.(Righi 
et al., 2013) These comprise of a group entitled small integrin binding ligand N-linked 
glycoproteins (SIBLINGS) who mediate bone morphogenesis and may facilitate the 
metastasis of primary cancers to bone.(Kruger et al., 2014) SGC tends to metastasis to 
the lymph nodes first, but has been shown to go to the lung, liver and bone.(Husain et al., 
2008) 
 
Chromosome 16 Open Reading Frame 87 (C16orf87) – chromosome 16q11.2 




Interleukin 12 Receptor Subunit Beta 2  (IL12RB2) – chromosome 1p 31.3 
The IL-12 receptor consists of two subunits: IL12RB1 and 2. Cytokine IL-12 has been 
shown to regulate the inflammatory process and be part of the host immune defence. It 
has anti-tumour activity and can suppress UV radiation induced apoptosis.(Isomura et al., 
2008) Lack of signalling via IL12RB2 predisposes to autoimmunity and malignancy with 
loss of function found in B cell malignancies.(Airoldi et al., 2005) Polymorphisms within 
this gene confer risk of developing lung adenocarcinoma.(Prigione et al., 2016) 
 
Glutathione Peroxidase 3 (GPX3) – chromosome 5q33.1 
GPX3 plays an important role in the detoxification of hydrogen peroxide and is the only 
extracellular member of this family highlighting its importance in extracellular defence 
against the effects of reactive oxygen species. In vitro GPX3 was shown to reduce colitis-
induced carcinoma.(Barrett et al., 2013) Loss of function via hypermethylation has been 
demonstrated in several cancers including cervical, breast, gastric, oesophageal SCC and 
leukaemia.(Yao et al., 2015) Anti-invasiveness and growth effects of GPX3 have been 
shown to be mediated by deactivation of Erk-NFκB-SIP1 signalling in hepatocellular 
carcinoma confirming its role as a tumour suppressor gene.(Qi et al., 2014) 
 
Repetin (RPTN) – chromosome 1q21.3 
Epidermal differentiating genes have been clustered around chromosome 1q21.3 and 
RPTN is a member of the fused gene family that clusters around this region. Fused 
members including profilaggrin, trichohyalin and hornerin are associated with keratin 
intermediate filaments acting as a barrier in normal skin.(Huber et al., 2005) In addition, 
it is a member of the S100 family and can reversible bind calcium. Increased expression 
of repetin is a biomarker for susceptibility to inflammation.(Xu et al., 2014) Repetin is 
not just localised to the epidermis and expression has been shown in the brain with 
diminished levels associated with schizophrenia and bipolar disorder.(Wang et al., 2015c) 
  
Gap Junction Protein Delta 3 (GJD3) – chromosome 17q21.2 
This is a member of the connexin family involved in GAP junction formation. These 
intercellular communications are often lost in cancer and they act as tumour suppressor 
genes. Loss of function via hypermethylation of connexin including GJD3 has been 




Distal-Less Homeobox 6 (DLX6) – chromosome 7q21.3 
DLX6 has an important role during embryogenesis and works in unison with DLX5 in 
pharyngeal arch formation, especially establishing proximal-distal identity.(Depew et al., 
2002) They are also involved in endometrial maturation post-natally.(Bellessort et al., 
2016) Although DLX6 has not been reported in caners, the DLX family does play a role 
in promoting tumour growth and progression.(Li et al., 2015b) 
 
G Protein Subunit Gamma 2 (GNG2) – chromosome 14q22.1 
The heterotrimeric G protein comprises of a GNG2 dimer and G alpha subunit. This G 
protein is involved in a angiogenesis, differentiation, invasion and 
proliferation.(Schwindinger and Robishaw, 2001) Overexpression was shown to inhibit 
melanoma cell metastasis via a decrease in focal adhesion kinase activity.(Yajima et al., 
2014)   
 
G Protein-Coupled Receptor 31 (GPR31) – chromosome 6q27  
This G protein receptor has a high affinity for 12-(S)-hydroxy-5,8,10,14-eicosatetraenoic 
acid (12-S-HETE), an arachidonic acid metabolite secreted by platelet and tumour 
cells.(Guo et al., 2011) Increased expression of 12-S-HETE positively correlates with 
aggressive prostate cancer, as does GPR31 expression.(Honn et al., 2016) GPR31 
expression is an independent risk factor for poorer prognosis in colorectal cancer.(Zou et 
al., 2015)   
 
5.10.3 Drivers identified using Intogen algorithm 
 
Titin (TTN)– chromosome 2q31.2 
See section 3.2.3.iii. As mentioned, this is unlikely to be of biological significance.  
 
Pre-MRNA Processing Factor 31 (PRPF31) – chromosome 19q13.42 
PRPF31 is a splice site factor in pre-mRNA processing and required for tri-SNP 
formation along with its spliceosome activity.(Makarova et al., 2002) Mutations within 
this gene results in autosomal dominant retinitis pigmentosa (RP) and highlights that pre-
mRNA splicing is an important route to disease.(Liu and Zack, 2013) Polymorphisms 
within PRPF31 are associated with a higher risk of invasive breast cancer.(Peedicayil et 
al., 2010) Rescue of this gene has been shown using non-viral gene therapy 
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(nanoparticles) in the murine model and this has potential for SGC patients in the future 
if a loss of function is tumorigenic.(Pensado et al., 2016) 
 
Cubilin (CUBN) – chromosome 10p13 
This codes for a gene that is frequently located at absorptive epithelial layers and is a co-
transporter for vitamin, iron and lipoprotein.(Aminoff et al., 1999) Mutations in CUBN 
results in albuminuria.(O'Toole and Sedor, 2011) GWAS have shown genetic 
susceptibility in CUBN to gastric cancer and colorectal cancer.(Zhao et al., 2016, Al-
Tassan et al., 2015) 
 
SYNE1 – Chromosome 6q25.2 
See section 3.2.3.ii. SYNE1 is a nuclear membrane protein involved in structural cellular 
organisation in muscle and the central nervous system. It may not be biologically relevant; 
however, methylation has been shown in colorectal cancer and SNVs are associated with 
invasive ovarian cancer. 
 
 
5.11 RNA sequencing in periocular SGC 
 
5.11.1 Upregulated genes in SGC 
 
Small Proline Rich Protein 2A (SPRR2A) – Chromosome 1q21.3 
This was initially described as a keratinocyte protein involved in structural integrity but 
is also a stress and wound healing modulator by reducing reactive oxygen species and 
allowing transient EMT.(Mizuguchi et al., 2012) In liver disease, including cancer, it 
promotes EMT of biliary epithelium via ZEB-1 as part of normal and pathological wound 
healing response.(Mizuguchi et al., 2014) SPRR2A expression in cholangiocarcinoma 
induces permanent EMT, aids tumour growth and creates a permissive environment for 
local invasive behaviour – a key feature of pagetoid SGC.(Specht et al., 2013) In addition, 
SPRR2A is a repressor of P53 dependent transcriptional activity by interfering with 
TP53-EP300 activity and increasing HDAC1 expression.(Mizuguchi et al., 2012) This 





Small Proline Rich Protein 2D (SPRR2D) – chromosome 1q21.3 
Similar to the above-related family member, this protein is expressed in both neoplastic 
and inflammatory disease.(De Heller-Milev et al., 2000)  
 
Serpin Family B Member 4 (SERPINB4)– Chromosome 18q21.33 
Serine protease inhibitor family B inhibit granzymes released by NK cells and cytotoxic 
T lymphocytes that induce cell death as part of the innate immune system.(Smyth et al., 
2001) One such granzyme, GrM, is a potent inducer of tumour cell death that SERPINB4 
inhibits by forming a stable complex; expression of SERPINB4 by tumour cells shields 
them from GrM apoptosis along with NK cell death.(de Koning et al., 2011) 
Oropharyngeal squamous cell carcinoma and primitive neuroectodermal tumours of the 
brain both express SERPINB4.(van Kempen et al., 2016, Vermeulen et al., 2016) 
 
Serpin Family B Member 3 (SERPINB3) – Chromosome 18q21.33 
SERPINB3 is another member of the family B serpins. It was originally described as a 
squamous cell antigen in those who had cervical SCC, and subsequently it is associated 
with lung, liver plus head and neck cancer.(Turato and Pontisso, 2015) It augments liver 
carcinogenesis by increasing transcription of MYC through the YAP pathway.(Turato et 
al., 2015) It is associated with both the TGF-B and Wnt signalling to create a tumorigenic 
microenvironment that confers a poor prognosis in liver cancer.(Pontisso et al., 2014) 
 
Alanine And Arginine Rich Domain Containing Protein (AARD)– Chromosome 8q24.11 
Little is known about this gene other than it has a predilection for testicular 
tissue.(Svingen et al., 2007) 
 
Synaptonemal complex protein 2 (SYCP2) – chromosome 20q13.33 
Synaptonemal protein complexes are required for the joining of homologous 
chromosomes during the meiotic prophase stage. Specifically, during zygotene (the 
second stage of prophase), homologous chromosomes come together allowing inter-
homolog repair of the preceding stage’s programmed double stranded breaks (DSB). A 
feature of this repair mechanism is the tripartite protein structure formed by the 
synaptonemal complex (SC) that synapses homologous chromosomes along their length. 
SYCP2 works in concert with the lateral element protein SYCP3 and the cohesion protein 
RAD21. Furthermore, SYCP2 acts as the linker between SYCP3 and SYCP1, hence binds 
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the lateral elements and the transverse filaments; an essential step for proper chromosome 
synapses. (Winkel et al., 2009) Another possible role for SC complexes is centromere 
coupling. Overexpression occurs in HPV positive oropharyngeal squamous cell 
carcinoma.(Martinez et al., 2007) Interestingly, this was also detected in the separate SGC 
samples below using array analysis, thus validating this as an important differentially 
expressed gene in SGC. 
 
S100 Calcium Binding Protein A8 (S100A8) – chromosome 1q21.3 
S100A8 is a zinc and calcium binding protein involved in the regulation of inflammatory 
and immune response. It is part of the S100 protein family that regulated both intracellular 
and extracellular homeostasis mechanisms and when released into the extracellular 
matrix can promote sustained inflammatory damage.(Lim et al., 2016) Specifically, it 
promotes migration of colorectal cancer cells via the NF-KB pathway in 
macrophages.(Zha et al., 2016) Moreover, S100A8 is essential for cell migration and 
invasion but not necessary for proliferation.(Lim et al., 2016) 
 
S100 Calcium Binding Protein P (S100P) – chromosome 4p16.1 
S100P has a similar general function as mentioned above with the P standing for placenta 
as the original tissue of detection. S100P however, is more associated with metastatic 
disease and plasma levels are related to a higher chance of metastasis in breast cancer, 
but these levels come down with subsequent treatment making S100P a potential 
metastatic cancer marker.(Peng et al., 2016) Similar to S100A8, it also promotes cell 
proliferation via the NF-KB pathway with an extracellular interaction with receptor for 
activated glycation end products (RAGE).(Prica et al., 2016) It has a multitude of roles 
in carcinogenesis and therapeutic blocking agents have been used including cromolyn, an 
anti-allergic drug.(Prica et al., 2016, Arumugam et al., 2013) 
 
Histone Cluster 1, H4h (HIST1H4H) – chromosome 6p22.2 
Histones are part of the wrapping of DNA so it can be packed into a small space. An 
octamer of histones (two H2A-H2B dimers with a H3-H4 tetramer) has 146 bp of DNA 
wrapped around it (termed the nucleosome) and linked to other nucleosomes with linker 
DNA.(Grunstein, 1990) Linker histones sit at the base of the nucleosome and result in a 
larger increase in DNA supercoiling as well as chromatin condensation.(Khochbin, 2001) 
The nucleosomes look like beads on string (euchromatin) and this is further wrapped 
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using linker histones (such as histone H1) to form a supercoiled structure heterochromatin 
(during gene inactivity).(Smith and Santisteban, 1998) The exact structure of chromatin 
(ultimately a chromosome) depends on the exact phase of the cell cycle: the metaphase 
chromatin is known as the classic chromosome (duplicated chromosome) seen during 
mitosis when they became visible on microscopy (karyotyping). Histone modification is 
a potential therapeutic target and targeting of the methylation sites on histones occurs 
with Temozolomide, a DNA methylating chemotherapy agent and could potentially be 
used in SGC patients.(Wang et al., 2016a)  
 
Epithelial Cell Adhesion Molecule (EPCAM) – chromosome 2p21 
EPCAM is a transmembrane cell adhesion protein and expressed in the majority of 
epithelial tissue. Consequently, overexpression is seen in many epithelial caners 
including colorectal, breast, gastric, liver and prostate.(Andree et al., 2016) Higher levels 
of expression are correlated with a poorer prognosis in breast cancer.(Ohashi et al., 2016) 
Due to its widespread prevalence in epithelial cancers, antibodies have been developed 
to target EPCAM and phase 1 trials have occurred using Catumaxomab in peritoneal 
metastasis, however, significant side effects do occur including fatal hepatitis.(Borlak et 
al., 2016) 
   
Fatty Acid Binding Protein 5 (FABP5)– Chromosome 8q21.3 
FABP5, whose role is in fatty acid transport, is expressed in all tissues of the body despite 
first being detected in keratinocytes and overexpressed in psoriasis.(Ogawa et al., 2011) 
Overexpression is seen in cancers and confers a poorer prognosis in triple negative breast 
cancer.(Liu et al., 2011a) Expression of FABP5 in concert with specificity protein 1 (SP1) 
and MYC is important in prostate carcinogenesis.(Kawaguchi et al., 2016) Together 
FABP5 and peroxisome proliferator-activated receptor delta (PPAR∂) enhance 
proliferation, migration and invasion in breast cancer.(Levi et al., 2013) 
 
5.11.2 Downregulated genes in SGC 
 
Phosphorylase, Glycogen, Muscle (PYGM) – chromosome 11q13.1 
PYGM is an enzyme that resides in muscle to carry out glycogenolysis. Mutations in 
PYGM results in a glycogen storage disease, McArdle disease or myophosphorylase 
deficiency.(Nogales-Gadea et al., 2015) WES of rare aggressive breast cancer revealed 
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PYGM mutations in 30% of cases and is downregulated in several cancers suggesting a 
role for glycogen metabolism in cancer evolution.(Dieci et al., 2016)  
 
Chromogranin B (CHGB) chromosome 20p12.3 
The neuroendocrine system contains secretory granules which encompass chromogranin 
A and B. CHGA has been shown to be useful to monitor neuroendocrine tumours, 
whereas CHGB is less important.(Monaghan et al., 2016)  Low CHGB levels in 
pancreatic neuroendocrine tumours have been associated with malignant tumours and 
metastasis.(Weisbrod et al., 2013) The relevance to SGC is unclear. 
 
Immunoglobulin Heavy Constant Gamma 1 (G1m Marker) (IGHG1) – 
chromosome14q32.33 
Immunoglobulin is a Y shaped protein secreted by plasma cells (antibody) or found on 
the surface of cells. The two ends of Y contain an area that binds to a specific antigen (the 
paratope) and is hypervariable in order to bind to lots of different antigens. Four 
polypeptide chains make up the Y region, two heavy and two light chains. The heavy 
chain consists of a variable and constant domain, as does the light chain and IGHG1 codes 
for the constant heavy chain. IGHG1 is the most important isoforms of the 
immunoglobulins produced by the body and binds efficiently to effecter cells such as 
macrophages, NK cells, neutrophils and triggers the humeral immune response that kills 
cancer cells. Loss of expression would seem to confer a benefit for SGC to evade the 
body’s immune system. Nevertheless, several studies have shown an increase in IGHH1 
within pancreatic cells aids proliferation and silencing IGHH1 in prostate cancer cells 
promotes apoptosis, although the mechanisms for benefiting the cancer are unclear.(Li et 
al., 2011)  
 
CD74 Molecule (CD74) – chromosome 5q33.1 
CD74 plays an essential role in major histocompatibility class 2 antigen presentation 
complex. Expression has been detected in many cancers with higher expression levels in 
gastric cancer associated with a poorer prognosis.(Ishigami et al., 2001) Blocking of 
CD74 has been attempted in B-cell malignancies with the development of Milatuzumab 
which has passed phase 1 trials in 2010; however, nothing has been heard since these 
trials.(Berkova et al., 2010) It highlights that caution should be taken as to block 
something just because it is over-expressed without knowing its biological significance 
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could be risky. SGC is one of the most aggressive tumours, so that loss of CD74 with 
immune evasion may be an important factor. 
  
Gelsolin (GSN) – chromosome 9q33.2 
Gelsolin is required for cytoskeletal turnover and regulates protease secretion. 
Specifically, it acts to breakdown actin in concert with vimentin and together are normally 
up regulated to promote tumour growth and invasiveness.(Huang et al., 2016a) 
Nevertheless, GSN can be both an inhibitor and effector of apoptosis; GSN can enhance 
DNAse1 and apoptotic activity through the GSN-HIF1-a-DNase 1 pathway.(Li et al., 
2012a) Decreased expression has also been seen in a variety of cancers including breast, 
prostate, gastric, kidney and so it is thought that it may act as a tumour suppressor in 
certain situations.(Winston et al., 2001) Lower levels of GSN in bladder cancer conferred 
a poorer prognosis and predominantly lower levels were seen in the presence of TP53 
mutations.(Sanchez-Carbayo et al., 2007) 
 
Collagen Type I Alpha 2 (COL1A2) – chromosome 7q21.3 
Collagen Type I Alpha 1 (COL1A1)– chromosome 17q21.33 
Type I collagen contains two alpha 1 chains and one alpha 2 chain to form a triple helix, 
COL1A1 codes for alpha 1 and COL1A2 codes for alpha2. During cancer transformation 
in vitro, collagen production is decreased. The more indolent solid tumours tend to have 
a surrounding stroma comprising of type 1 collagen.(Smith et al., 1983) Loss of 
surrounding type I collagen may confer a benefit for locally invasive tumours and 
COL1A2 is frequently silenced by hypermethylation in cancer.(Sengupta et al., 2003) 
This loss of a collagen capsule may allow for faster SGC growth and induce the pagetoid 
behaviour that is seen clinically allowing the tumour to seed indiscriminately. A decrease 
in COL1A1 is seen in liver cancer with a return to expression after chemotherapy 
suggesting the potential for COL1A1 to be a biomarker with its presence indicating 
remission.(Hayashi et al., 2014)  
 
Collagen Type III Alpha 1 (COL3A1)– chromosome 2q32.2 
Type III collagen is frequently associated with type I collagen within connective tissue 
so it is not surprising that both are down regulated together. A study into nasopharyngeal 
carcinoma showed the enhancement of invasive behaviour with hsa-miR-29a/b, which in 
turn regulates COL3A1.(Qiu et al., 2015)  
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Apolipoprotein E (APOE)– chromosome 19q13.32 
APOE plays a role in lipid metabolism and protein synthesis, but is also involved in tissue 
repair, immune response and cell growth. Overexpression has been shown in gastric 
cancer.(Shi et al., 2015a) Genetic polymorphisms within the gene have demonstrated an 
increase risk in renal cell carcinoma, but not testicular cancer.(Liu et al., 2015a, Lv et al., 
2015) 
 
Decorin (DCN) – chromosome 12q21.33 
DCN is a proteoglycan who plays a role in stimulating autophagy, inflammation and 
inhibits tumorigenesis, so acts as tumour suppressor. It is often secreted by fibroblasts 
and modifies cellular behaviour. Loss of DCN allows renal cell carcinoma proliferation 
and metastasis via downregulation of P21 and E-cadherin.(Xu et al., 2016) Gain of 
function KRAS mutations have been shown to suppress DCN to aid colorectal cancer 
growth.(Mlakar et al., 2009) DCN mediates its anti-cancer effects by antagonising 
TGFB.(Qian et al., 2014) Loss of this TSG in SGC may confer a benefit.  
 
Muscle related genes of unknown significance 
Myosin, Heavy Chain 4, Skeletal Muscle (MYH4) 17p13.1 
This is a skeletal muscle coding protein and biologically is unlikely to be related cancer. 
It is however, located at the same chromosomal location as TP53 which is preferentially 
lost in SGC and hence is probably a passenger. 
 
Parvalbumin (PVALB) – chromosome 22q12.3 
PVALB is involved in muscle relaxation, however, may be a useful tumour marker to 
detect conversion from benign adenoma to carcinoma in thyroid cancer.(Cerutti et al., 
2011) 
 
ATPase Sarcoplasmic/Endoplasmic Reticulum Ca2+ Transporting 1 (ATP2A1) – 
chromosome 16p11.2 
This is an enzyme involved in muscle excitation and unlikely to be of significance. 
 
Myosin, Heavy Chain 1, Skeletal Muscle, Adult (MYH1) – chromosome 17p13.1 





Sarcalumenin (SRL) – chromosome 16p13.3 
SRL is a muscle related gene and unlikely to be related to cancer growth. 
 
Creatine Kinase, M-Type (CKM) – chromosome 19q13.32 
CKM muscle specific creatine kinase. 
 
Calsequestrin 1 (CASQ1)- chromosome 1q21 
This is a skeletal muscle protein. 
 
Tropomyosin 2 (Beta) (TPM2) - chromosome 9p13.3 
TPM2 is a gene involved in slow muscle fibre contraction and mutations can result in 
myopathy. 
 
Titin (TTN)– chromosome 2q31.2 
See section 3.2.3.iii 
 
 
5.12 SGC RNA subtype analysis  
 
5.12.1 Nodular SGC messenger RNA 
 
RNA, U7 small nuclear 141 pseudogene (RNU7-141P) - chromosome 20q13.33 
A pseudogene is a sequence that is related to a known gene but does not have the ability 
to be expressed or code for a polypeptide, hence falls under the family of a non-coding 
RNAs. Small non-coding RNAs include the well-known transfer RNA (tRNA) and uracil 
rich small nuclear RNAs such as small nuclear, small nucleolar, transfer RNA (tRNA) 
and Y RNAs (see below). The U symbol is used to denote their nuclear location.(Rogers, 
1985) In general, the formation of processed pseudogenes requires the expression of both 
L1 proteins.(Esnault et al., 2000) They are classed as a dysfunctional group, but can retain 
promoter or splice site activity, however, their biological activity is not clear. With over 
40% homology with functional genes, they are described as ancestral remnants of a gene 
suggesting they diverged as part of an evolutionary event.(Wei et al., 2001) In some cases, 
their non-functionality is derived from the fact they contain multiple mutations such as 
premature stop codons or frameshifts, thus may be an evolutionary by-product of 
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accumulated mutations. Although pseudogenes are inactive by definition, they can still 
be inserted into the genome and unwittingly contribute to exons of other genes through 
alternative splicing of a transcript. Rarely, they undergo gene resurrection by undergoing 
gene conversion, whereby there is a mismatch during homologous recombination. In the 
same manner, the pseudogene can act a template for a variant for a gene that could be 
advantageous as well as deleterious.  
 
Y RNA (Y_RNA.52-201) – chromosome 6q15 
This is a small non-coding 96 bp RNA sequence. Initially Y RNAs were described as 
being in the cytoplasm of the cell, hence given the Y prefix in contrast to the 
aforementioned U RNA which were discovered in the nucleUs when looking at the 
associated antigens Ro60 and La of systemic lupus erythematosus.(Lerner et al., 1981) 
The Y RNAs have binding sites for proteins and the function of this complex is implicated 
in RNA processing or quality control mechanisms. (Wolin et al., 2012) Although Y RNAs 
are part of the small non-coding RNA group too, they have a known essential biological 
role in the initiation of chromosomal DNA replication. (Krude et al., 2009) Blocking of 
Y RNAs in Xenopus laevis (African claw frog) and Danio rerio (zebrafish) embryos is 
lethal due to abrogation of DNA replication, arresting of the cell cycle followed by cell 
death.(Collart et al., 2011) 
 
Synaptonemal complex protein 2 (SYCP2) – chromosome 20q13.33 
See section above 5.4.2 Detection of SYCP2 using a second modality validates this as an 
important gene in SGC tumourigenesis. 
 
Small nucleolar RNA, C/D box 51 (SNORD51) – chromosome 2q33 
Small nucleolar RNA (snoRNA) are non-coding RNAs implicated in the modification of 
tRNA, ribosomal RNA and small nuclear RNAs. C/D box snoRNAs are involved in 
methylation, hence can control gene expression. SNORD50A and 50 B (both co-localised 
on Chromosome 16) are recurrently deleted in human cancer and their loss is associated 
with reduced survival. (Siprashvili et al., 2016) Specifically, SNORD50 suppresses the 
activity of RAS oncoproteins and loss of them in cancer enhances KRAS activity along 






Small Cajal body-specific RNA 8 (SCARNA8) – chromosome 9p22.1 
SCARNA8 is a type of snoRNA localised to sub-organelles (cajal bodies) within the 
nucleus of proliferative cells, thus may reflect the presence of excessive cell division.   
 
RNA, U7 small nuclear 57 pseudogene (RNU7-57P) – chromosome 1q21.3 
This is a pseudogene of unknown significance. 
 
Small Cajal body-specific RNA 1 (SCARNA1) – chromosome 1p35.3 
This is a snoRNA of unknown significance 
 
 
5.12.2 Pagetoid SGC messenger RNA 
 
Immunoglobulin kappa joining 3 (IGKJ3) - chromosome 2p11.2  
The light chain consists of a variable and constant domain (as do the heavy chain) and 
can be one of two types, either lambda or kappa chain, however, both cannot be present 
on the same antibody (i.e. two lambda or two kappa). In order to generate a unique 
immunoglobulin, the variable region is encoded by several subgenes that undergo somatic 
recombination. These subgenes include variable (V), diversity (D) and joining (J) 
segments (such as IGKJ3) that are tandemly arranged across the DNA. The B-lymphocyte 
will randomly select these subgenes to arrange a unique variable region to a specific 
antigen (known as V(D)J or somatic recombination).(Tonegawa, 1983) IGKJ3 sits in an 
IGK cluster of genes located on the short arm of chromosome 2 whereby a 1800 kb 
segment encodes 76 IGK genes, 34 functional, 32 pseudogenes, 7 open reading frames 
and 3 unknown.(Barbie and Lefranc, 1998) Activation may reflect the body’s immune 
reaction to SGC or aberrant activation.  
 
Chemokine (C-X-C motif) ligand 9 (CXCL9) – chromosome 4q21.1 
Chemokines are small signalling proteins (cytokines) released from cells and whose name 
originates from their ability to signal leucocyte traffic by inducing chemotaxis. In cancer 
they have competing roles and can have an anti-tumour effect by attracting immune cells 
or assist in tumour spread, invasion and proliferation.(Gorbachev and Fairchild, 2014) 
CXCL9 tends to act as an inflammatory chemoattractant rather than a homeostatic 
chemokine. It acts through CXCR3, a G Protein-coupled receptor (GPR); however, the 
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resultant effect is dependent on the receptor isoform. One effect is to activate the 
phosphatidylinositol 3-kinase (PI3K) and Protein Kinase B (Akt) pathway. Within 
tumours and its milieu, CXCL9 may have a dual role. The local tumour 
microenvironment harbours activated macrophages that release chemokines, especially 
CXCR3 receptor ligands, namely CXCL9/MIG and CXCL10/IP-10 that in turn attract 
CXCR3 expressing T-lymphocytes and natural killer cells. Nevertheless, tumour cells can 
also release chemokines and melanoma endothelial cells have been shown to secrete 
CXCL9, which subsequently assists in tumour migration across an endothelial 
monolayer.(Amatschek et al., 2011) CXCL10 was also overexpressed by log2FC 2.5 
(P<0.001) compared to nodular log2FC 0.4, P =0.397. 
 
Immunoglobulin kappa variable 1-5 (IGKV1-5) – chromosome 2p11.2 
As mentioned, the immunoglobulin undergoes somatic recombination (V(D)J 
recombination) involving the variable subgene. Overexpression of IGKV1-5 is seen in 
chronic lymphocytic leukaemia and demonstrates a bias towards the use of this subgene 
rather than random somatic recombination. (Stamatopoulos et al., 2005). Having light 
chain bias (IGKV1-5 and IGKJ3) prompts speculation that an over expressing functional 
kappa chain is important in SGC.  
 
 
Chemokine (C-X-C Motif) Receptor 4 (CXCR4) – chromosome 2q22.1 
In contrast to most chemokine receptors, CXCR4 is relatively monogamous to the 
chemokine CXCL12 (aka stromal derived factor 1, SDF-1). CXCL12 promotes blood 
vessel formation in the embryo and recruits endothelial progenitor cells in the adult. 
(Eman et al., 2014, Cavallero et al., 2015) In addition, CXCL12 is induced by 
proinflammatory stimuli. CXCR4 is overexpressed in many cancers, confers a poorer 
prognosis and linked to invasion and metastasis. (Ohtani et al., 2009, Chen and Zhong, 
2015, Rave-Frank et al., 2015, Lombardi et al., 2013) Contradictory to this is a study in 
breast cancer demonstrating that CXCR4 correlates with prolonged disease free, 
metastasis free and overall survival, however, the same study states that higher levels also 
correlate with oestrogen receptor negative breast cancer which in its self-confers a poorer 
prognosis.(Dalm et al., 2015) 
 
CXCR4 also binds ubiquitin, the small regulatory protein, and mediates an anti-
inflammatory action. (Majetschak, 2011) Interestingly, ubiquitin specific peptidase 1 
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(USP-1) is significantly (P=0.002) overexpressed (expression 5.0) by log 1.2 in the 
pagetoid subtype only. Ubiquination is required for DNA repair and USP-1 removes 
ubiquitin (deubiquinates) thereby acting as a modulator of DNA repair. Furthermore, 
USP-1 deubiquitinates Proliferating Cell Nuclear Antigen (PCNA), Fanconi Anaemia 
Complementation Group D2 (FANCD2) and Group I (FANCI); all are important 
components of the Fanconi anaemia DNA repair pathway. 
 
Another action of CXCR4 is to bind macrophage migration inhibitory factor (MIF). MIF 
suppresses the anti-inflammatory effects of glucocorticoids. In colorectal cancer, MIF 
production correlates with the metastatic potential and poorer prognosis. (He et al., 2009)  
 
DBF4 Zinc Finger Pseudogene 1 (DBF4P1) –chromosome 10q23.1 
Long non-coding (lnc) RNA have transcripts longer than 200 nucleotides and part of this 
family is DBF4P1 at 1892 nucleotides long. Lnc RNA lack conservation across species 
in contrast to small RNA such as microRNA or snoRNA, but this assertion occurs when 
applying conservation rules used for protein coding sequencing (such as the retention of 
an open reading frame); different rules may be required for lncRNAs. (Mercer et al., 
2009) Their functionality is still disputed; however, they have been shown to play a 
critical role in certain cancers. LncRNA Urothelial cancer associated-1 (UCA1), promotes 
cell cycle progression and proliferation in bladder cancer. (Xue et al., 2015) Higher 
expression of UCA1 has been shown in non-small cell lung cancer and related to 
histological grade and lymph node metastasis. (Wang et al., 2015b) Another example of 
functionality: the lncRNA HOXA cluster antisense RNA2 (HOXA-AS2), correlates with 
gastric cancer severity and potentially induces epigenetically silencing of P21 (a mediator 
of cell cycle G1 phase arrest) by binding to EZH2. (Xie et al., 2015, Huang and Yu, 2015) 
DBF4P1 has also been linked to the mitotic cell cycle super pathway. (Institute, 2015) 
 
(RP11-44K6.2) – chromosome 8 
This is a short (102 bp) non-coding RNA that contains two exons, but termed a sense 






Histone Gene Cluster 1, H2B Histone family, Member M (HIST1H2BM) – chromosome 
6p22.1 
See section 5.4.2. A similar gene was discovered using RNAseq on separate SGC 
samples, hence the detection of HIST1H2BM highlights that these histones may play a 
significant role in SGC, especially in light of the chromosomal instability depicted in 
Figure 5.10. Unopposed mitosis is the hallmark of cancer and HIST1H2BM has been 
validated as a breast cancer associated protein in vitro. (Choong et al., 2010) 
 
Cyclin-Dependent Kinases Regulatory Subunit 2 (CKS2) – chromosome 9q22.2 
CKS2 is involved in several stages of the cell cycle. It has been shown to downregulate 
TP53 and upregulate cell cycle regulators cyclin A, B1 and CDK.(Kang et al., 2009, Shen 
et al., 2013a) The latter two, cyclin B1-CDK protein kinase, are known as mitosis 
promoting factor and is an essential component to allow the cell to progress through the 
G2 phase of the cell cycle.(Vassilev et al., 2006) CSK2 has been shown to be linked with 
Y-box binding protein 1 (YB-1) whereby the silencing of YB-1 downregulated CKS2.(Yu 
et al., 2010) Interestingly, YB-1 was over expressed (9.1) by log 1.3 (P=0.008) in pagetoid 
only and may be due to this direct relationship with CSK2. Increased CSK2 expression 
has been seen in hepatocellular, oesophageal, gastric, colorectal and prostate 
cancer.(Shen et al., 2010a, Wang et al., 2013b, Tanaka et al., 2011, Notterman et al., 2001, 
Lan et al., 2008) Furthermore, higher expression correlated with increased tumour size, 
poorer histological grade, worse TNM status and reduced survival.(Shen et al., 2010a, 
Tanaka et al., 2011) Hsa-miR-26a directly alters the expression of CSK2.(Lv et al., 2013) 
 
Nucleolar and Spindle associated protein 1 (NUSAP1) – chr15q15.1 
Microtubules are long, hollow structures making up the cytoskeleton of the cytoplasm 
and also found in the nucleus where they are involved in the mitotic spindle that separates 
chromosomes during mitosis and the meiotic spindle during gamete production. 
Microtubule-associated proteins (MAP), such as NUSAP1, regulate the movement of 
microtubules and can have both a stabilising or destabilising effect. NUSAP1 is 
selectively expressed in proliferating cells at the transition of G2 to mitosis, localises to 
the central spindle microtubules, plus, in both excessive and depleted states, leads to 
defective chromosomal segregation.(Raemaekers et al., 2003) NUSAP1 is degraded by 
anaphase-promoting complex/cyclosome (APC/C)-Cdh1 E3 ubiquitin ligase.(Li et al., 
2007) Positive regulators of NUSAP1 transcription include v-myc avian 
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myelocytomatosis viral oncogene homolog (MYC), lin-9 DREAM MuvB core complex 
component (LIN9) and nuclear transcription factor Y, alpha (NF-YA).(Fujiwara et al., 
2006, Reichert et al., 2010, Hussain et al., 2009) MYC was significantly (P<0.001), 
expressed (7.3) by log2FC 1.5 in the pagetoid subtype only. In addition, it has shown to 
promote expression by the loss of RB1 via the RB1/E2F transcription factor 1 (E2F1) 
axis. (Gulzar et al., 2013, Gordon et al., 2015) Moreover, WES SGC data highlights the 
loss of RB1 function. As mentioned, RB1 is mutated in SGC and so augment its 
expression. Moreover, E2F1 is upregulated in both nodular (P=0.005, expression 4.9) and 
pagetoid (P=0.007, expression 4.9) by log2FC 1.3. A negative transcription regulator is 
forkhead box O1 (FOX01), a known tumour suppressor gene that is significantly 
(P=0.003) reduced in nodular by log2FC -1.1, but insignificantly (P=0.169) reduced 
(log2FC -0.4) in pagetoid.(Takano et al., 2007) CDK1 inhibits NUSAP1 interaction with 
microtubules by phosphorylation and was found to be significantly (P=0.005) 
overexpressed (3.7) by log2FC 1.2 in pagetoid only. NUSAP1 has a role in prostate 
cancer, breast cancer and in aggressive subtypes of melanoma. (Gordon et al., 2015, Lauss 
et al., 2008, Ryu et al., 2007)  
 
Chromosome 2 Open Reading Frame 47 (C2orf47) – chromosome 2q33.1 
Open reading frames are potentially translatable DNA sequence that has a both a start and 
stop codon with a string of in-frame sense codons between them.(Andrews and 
Rothnagel, 2014) If they are less than 250 codons long they are deemed short ORF 
(sORF) and C2orf47 is a 291 amino acids long mitochondrial protein.(Hayden and Bosco, 
2008) The function of C2orf47 is predicted to involve in RNA/nucleotide binding. 
(Delgado et al., 2014a) Hsa-miR-16 has been shown to reduce the expression of C2orf47 
and the miRNA study below showed this miRNA is significantly (P=0.03) over expressed 
(expression 9.1) by log2FC 4.8 in both the nodular and pagetoid subtype. Furthermore, 
C2orf47 has been implicated in cancer (gaining the term oncoORF) and is proportionally 
expressed in childhood acute lymphocytic leukaemia. (Yang et al., 2009) OncoORFs 
have also been associated with prostate, hepatic and brain cancer.(Delgado et al., 2014b)  
 
Cyclin-Dependent Kinase Inhibitor 3 (CDKN3) - chromosome 14q22 
CDKN3 has to dual role as a protein phosphatase inhibitor in the control of the cell cycle. 
Firstly, it combines with and dephosphorylates Cyclin-Dependent Kinase 2 (CDK2), 
hence prevents its activation, which in turn reduces the aforementioned RB1/E2F axis 
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repression of transcription of genes needed for the S phase of the cell cycle.(Yeh et al., 
2003, Niculescu et al., 2004) Secondly, it promotes the progression of the cell cycle by 
desensitising p21 action when combined with TP53 and E3 ubiquitin-protein ligase 
Mdm2 (MDM2) which in turn reduces TP53 gene target production.(Demetrick et al., 
1995) It acts as a survival biomarker and inactivation decreases cell proliferation in 
cervical and ovarian cancer.(Barron et al., 2015, Li et al., 2014b, Zhang et al., 2015b) It 
is also overexpressed in lung adenocarcinoma, breast and colorectal carcinoma. (Yang 
and Sun, 2015, Taylor et al., 2010, Xing et al., 2012, MacDermed et al., 2010) 
 
Structural Maintenance of chromosomes Flexible Hinge Domain Containing 1 
(SMCHD1) – Chromosome 18p11.32 
Structural maintenance of chromosome (SMC) family of proteins have a dual role in the 
mitotic segregation of chromosomes, namely chromosome condensation and sister 
chromatid cohesion.(Ball Jr and Yokomori, 2001) In addition, they play a role in DNA 
recombination and repair.(Hopfner et al., 2000) SMCDH1 is recruited to sites of DNA 
damage (along with Ku80 and RAD51) and its deficiency reduces cell survival in 
response to DNA damage.(Coker and Brockdorff, 2014) SMCHD1 also regulates X 
chromosome lyonisation (through maintenance of hypermethylation of CpG islands), 
carries out telomere silencing, and regulates a subset of monoallelic expressing gene 
clusters found on autosomes.(Mould et al., 2013, Grolimund et al., 2013) Mutations in 
SMCHD1 can lead to facioscapulohumeral muscular dystrophy type 2 (FSHD2) and in 
the physiological state, is implicated in silencing of Double Homeobox 4 (DUX4), whose 
encoded protein is overexpressed in FSHD2.(Daxinger et al., 2015) It has been suggested 
that it is a tumour suppressor gene in some leukaemia and lymphomas where it is often 
down regulated.(Leong et al., 2013) In addition, it may have a role to play in the 
perturbations of the inactive X chromosome seen in cancer.(Chaligne and Heard, 2014)  
 
Lacritin (LACRT) gene – chromosome 12q13.2 
The lacrimal gland, accessory lacrimal glands of Wolfring that are found throughout the 
conjunctiva, and meibomian glands express high levels of lacritin that is in the secretion 
of tears.(Ubels et al., 2012, Liu et al., 2011b) LACRT was significantly (P=0.009) 





5.12.3 Shared nodular and pagetoid mRNA 
 
Thymidylate Synthetase (TYMS) – chromosome 18p11.32 
Deoxyuridine 5’-monophosphate (deoxyuracilmonophosphate or dUMP) is converted to 
deoxythymidine monophosphate (dTMP) using thymidylate synthase which uses a 
methyl group from N5,N10-methylene tetrahydrofolate (THF). This is an essential step for 
DNA replication and repair. Chemotherapy agent 5-fluorouracil inhibits thymidylate 
synthase and gets misincorporated into nucleic acid (both DNA and RNA) causing failed 
replication.(Longley et al., 2003) TYMS overexpression is seen in aggressive forms of 
prostate cancer, lung, breast, gastric, colorectal and renal cell carcinoma.(Burdelski et al., 
2015, Kotoula et al., 2012, Pestalozzi et al., 1997, Formentini et al., 2004, Popat et al., 
2004) The exact role is not clear, but it has been shown to promote malignant phenotype 
in excess and lead to drug resistance. (Rahman et al., 2004, Ahn et al., 2015) Moreover, 
the may be a mechanistic link between TYMS overexpression and chromosomal 
abnormalities in prostate cancer and it is possible there is a link too with SGC which is 
chromosomally unstable.(Burdelski et al., 2015) 
 
Histone Cluster 1, H2bd (HIST1H2BD) – chromosome 6p22.2 
Histone Cluster 1, H2ae (HIST1H2AE) – chromosome 6p 22.2 
Histone Cluster 1, H2bm (HIST1H2BM) – chromosome 6p22.1 
All three are up regulated significantly in both subtypes reinforces the possibility they are 
important driver gene for both and may represent an early ‘trunk’ derangement in SGC.  
 
Small Nucleolar RNA Host Gene 1 (SNHG1) - chromosome11q12.3 
Activated TP53 can act to repress or activate target genes. More recent evidence has 
shown that it can regulate miRNA, lncRNA and snoRNA including the repression of 
SNHG1.(Yu et al., 2015a) The exact role of this gene is not clear, however, snoRNA can 
be processed into smaller miRNA sometimes termed sno-miRNA or sno-derived small 
RNAs (sdRNAs).(Taft et al., 2009) SNHG1 can be processed into SNORD25, SNORD28 
and sno-miR-28 and is negatively regulated by p53. (Yu et al., 2015a) However, SNHG1 
is induced in irradiated lymphoblastoid cell lines which were TP53 positive and negative, 
suggesting an alternate regulator after a genotoxic insult.(Chaudhry, 2013) Its role as an 
oncogene is suggested by its interaction with TP53 along with the overexpression 
expression of SNHG1 is seen in breast cancer, gastric cancer and lung cancer. (Cao et al., 
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2013, Yu et al., 2015a, You et al., 2014) Loss of TP53, as suggested by the WES data 
may allow for uncontrolled SNHG1 expression in SGC. 
 
Other important shared genes 
Notch 2 N-Terminal Like (NOTCH2NL)- chromosome 1q21.2  
This was the highest expressed (over 9) gene in both subtypes although the log2FC scores 
were only slightly more than control at log2FC 1.5 (P=0.001), log2FC 1.2 (p=0.007) for 
nodular and pagetoid respectively. The log2FC score was not particularly high and so it 
did not enter the top differential expressed shared genes, but its role may still be 
important. Notch signalling is important for physically adjacent cell communication and 
is involved in a raft of processes including cell fate decisions. These decisions include 
stem cell/progenitor cell pool and differentiating cell lineages. Notch interaction with 
other pathways has been shown to be important in cancer transformation; however, there 
are some instances where it can be adverse to tumour progression.(Grishina, 2015, Miele 
et al., 2006, van Es and Clevers, 2005) There are four Notch receptors and Notch2 has 
shown to confer aggressive behaviour in hepatocellular carcinoma cells.(Hayashi et al., 
2015) Mutations have been seen in NOTCH2NL mutations are seen in anaplastic 
astrocytoma (WHO grade III), a more aggressive form of brain tumour. (Killela et al., 
2014) 
 
Frizzled Class Receptor 6 (FZD6) – chromosome 8q22.3 
Frizzled receptors are part of the Wnt signalling pathway. FZD6 was overexpressed by 
log2FC 2.1 (expression 6.4, P<0.001), log2FC 1.9 (expression 6.2, P<0.001) in nodular 
and pagetoid respectively. Wnt4 binds to FZD6 to act as a negative regulator of canonical 
beta-catenin Wnt signalling via a non-canonical route: transforming growth factor-beta-
activated kinase (TAK1)-NEMO-like-kinase (NLK) pathway.(Golan et al., 2004, Lyons 
et al., 2004) The receptor also binds secreted-frizzled related protein 1 (SFRP1), a known 
tumour suppressor that acts as a negative feedback response to beta-cantenin/TCF 
activity.(Bafico et al., 1999) Furthermore, Hedgehog-Gli signalling induces SFRP1 to 
keep differentiating epithelial cells away from the effects of canonical Wnt 
signalling.(Katoh and Katoh, 2006) Despite the suppressive actions of the receptor, its 
overexpression is seen in neuroblastoma and squamous cell carcinoma cancer, but not in 
benign skin hyperplasia.(Haider et al., 2006, Cantilena et al., 2011) FZD6 was associated 
with aggressive neuroblastoma cells with stem cell features (expressing Twist1 and 
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Notch1) and chemoresistance. (Cantilena et al., 2011) Hsa-miR-199 negatively regulates 
FZD6 and this miRNA is significantly (p=0.002) reduced by log2FC -2.3 in pagetoid 
only. 
 
5.13 SGC microRNA subtype analysis 
 
5.13.1 Nodular SGC microRNA 
 
Hsa-miR-150 – chromosome19q13.33 
Hsa-miR-150 plays a role in haematopoiesis and differentiation of C and T lymphocytes, 
the later in conjunction with hsa-mir-155.(Kozomara and Griffiths-Jones, 2014) 
Increased expression is correlated with a poorer survival in patients with prostate 
cancer.(Dezhong et al., 2015) It promotes growth and malignant behaviour in breast 
cancer by suppressing the pro-apoptotic receptor, Purinergic Receptor P2X, Ligand Gated 
Ion Channel, 7 (P2X7) expression.(Huang et al., 2013)  In contrast, it has shown to 
suppress Mucin 4, Cell Surface Associated (MUC4) by binding to the 3’ UTR with an 
associated decrease in HER2 expression that suppresses growth and malignant behaviour 
in pancreatic cancer cells, providing evidence for a role as a tumour suppressor 
miRNA.(Srivastava et al., 2011) Tumour suppressor action of hsa-miR-150 has also been 
noted in epithelial ovarian cancer and shown to reduce invasion and metastasis by 
suppressing the transcriptional repressor, Zinc Finger E-Box Binding Homeobox 1 
(ZEB1). (Jin et al., 2014) Interestingly, ZEB1 is significantly (P=0.004) downregulated 
by log2FC -1.1 (expression 4.6) compared to control and pagetoid, which correlates with 
hsa-miR-150 expression in these tissues suggesting that it is playing a tumour suppressor 
role in nodular SGC through ZEB1 suppression. Further tumour suppressive roles have 
been noted in colorectal and hepatocellular cancer by targeting V-Myb Avian 
Myeloblastosis Viral Oncogene Homolog (MYB), Matrix Metallopeptidase 14 
(Membrane-Inserted) (MMP14).(Feng et al., 2014, Liang et al., 2007) Moreover, MYB, 
MMP14, HER2, P2X7 and MUC4 are not differentially expressed in SGC. The tumour 
suppressive action may help nodular SGC to behave in a less aggressive fashion 






Hsa-miR-142-3p – chromosome 17q22  
This is a dominantly expressed miRNA in the adult haemopoetic system including 
megakaryocyte maturation and maintaining normal actin cytoskeletal dynamics. 
(Chapnik et al., 2014) It acts as a tumour suppressor and represses Transforming Growth 
Factor, Beta Receptor 1 (TGFRB1) in non-small cell lung cancer; Prominin 1 (PROM1), 
ATP-Binding Cassette, Sub-Family G (WHITE), Member 2 (Junior Blood Group) 
(ABCG2), and Leucine-Rich Repeat Containing G Protein-Coupled Receptor 5 (LRG5) 
in colon cancer cells, and Frizzled Class Receptor 7 (FZD7) in cervical cancer.(Lei et al., 
2014, Shen et al., 2013b, Deng et al., 2015) 
 
Hsa-miR-143 – chromosome 5q13.3 
This miRNA is highly conserved and thought to be involved in cardiac morphogenesis. 
In cancer, it is suppressed in metastatic prostate cancer and when re-expressed, prevents 
cell proliferation.(Coarfa et al., 2015) It is also downregulated in gastric cancer and when 
over expressed, is potent at autophagy via GABA (A) Receptor-Associated Protein Like 
1 (GABARAPL1).(Du et al., 2015) Moreover, hsa-miR-143 is inversely correlated to 
Inhibin, Beta A (INHBA) in oral squamous cell carcinoma, whose high levels of protein 
activin A are correlated with lymph node metastasis, tumour differentiation and poor 
survival.(Bufalino et al., 2015) Further tumour suppressor actions are seen in prostatic 
cancer where it targets hexokinse 2 and it is down regulated in breast cancer.(Zhou et al., 
2015, Chang et al., 2015)  
 
Hsa-miR-548g – chromosome 4q31.23 
The family of miR-548 are found across all chromosomes, but poorly conserved 
evolutionary and primate specific.(Liang et al., 2012) The sequence of this miRNA is 
found within a tumour suppressor gene, Fragile Histidine Triad (FHIT) that may suggest 
that it has a related role to play.(Hu et al., 2014) Downregulation of miR-548-3p is seen 
in breast cancer cells, and when it was over expressed, a decrease in proliferation and 
concomitant rise in apoptosis noted. (Shi et al., 2015b) Loss of this potential TSG may 
confer an advantage to SGC. 
 
Hsa-miR-603 – chromosome 10p12.2 
Over expression is seen in glioma tissue and it directly targets WNT Inhibitory Factor 1 
(WIF1) and Catenin, Beta Interacting Protein 1 (CTNNBIP1); the former activates the 
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Wnt/b-catenin pathway.(Guo et al., 2015) Excess is also seen in pancreatic cancer.(Yu et 
al., 2012) It is found to be downregulated in laryngeal squamous cell carcinoma where it 
was shown to inhibit E2F1, a controller of tumour suppressor proteins.(Ayaz et al., 2013) 
It targets CCND1 and CCND2 expression by acting as a tumour suppressor gene in 
thyroid carcinoma.(Mussnich et al., 2013) Loss of this potential TSG may confer an 
advantage in nodular SGC. 
 
 
5.13.2 Pagetoid SGC microRNA 
 
Hsa-miR-1308 - chromosome 
Although, this apparent miRNA has been found to be raised in multiple myeloma, it’s 
actually a 5’ cleaved fragment of tRNA.(Jones et al., 2012) 
 
Hsa-miR-205 – chromosome 1 q32.2 
Increased levels of this miR-205 prevents TGFB1 induced epithelial to mesenchymal 
transition (EMT) in vitro and specifically inhibits the cadherin-1 (CDH1) transcriptional 
repressors ZEB1 and ZEB2.(Gregory et al., 2008) Its action on ZEB1 also radiosensitises 
cells by preventing DNA repair and is down regulated in radioresistant breast cancer 
cells.(Feng et al., 2014) SGC does seem to be radiosensitive with good survival rates at 5 
years in a small, 13 patient case series and radiotherapy remains an option in those who 
are too unwell or refuse surgical intervention.(Hata et al., 2012) Downregulation seems 
be an important step for metastatic tumours, however, raised levels of hsa-miR-205 
promoted vascular endothelial growth factor (VEGF) invasion of ovarian cancer cells by 
targeting Ezrin (EZR) and lamina A/C (LMNA).(Li et al., 2015a) Higher levels are 
associated with adverse clinical outcome in bladder cancer through its action on ZEB1 
(by maintaining an epithelial phenotype) and ultimately being controlled by tumour 
protein 63.(Tran et al., 2013) Although this goes against the logic that EMT is required 
for metastasis, EMT plasticity is likely to be required for cells in distant sites to proliferate 
in their new locations (i.e. undergo MET). ZEB1 is down regulated in nodular -1.1 
log2FC (P=0.004, expression 3.5) but there is non-significant change in the pagetoid at -
0.3 log2FC (p=0.387, expression 4.3). Upregulation of hsa-miR-205 occurs in NSCLC 
and directly represses PTEN and PHLPP2 expression, which in turn activates the 
AKT/FOXO3a and AKT/mTOR signalling pathways respectively.(Cai et al., 2013) An 
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interaction between EZH2, MALAT1 and hsa-mir-205 to control b-catenin through 
EZH2 occurs in renal cell carcinoma.(Hirata et al., 2015) EZH2 is over expressed in both 
subtypes, 1.4 log2FC (P=0.01, expression 5.4) nodular and pagetoid 1.6 log2FC 
(P=0.004, expression 5.7).  
 
Hsa-miR-200a – chromosome 1 p36.33 
The miR-200 family are involved in EMT as mentioned above. In addition, hsa-miR-200a 
has a physiological role in dendritic cell maturation and activation in unison with growth 
hormone via the Kelch-Like ECH-Associated Protein 1/ Nuclear factor erythroid 2-
related factor 2 (Keap1/Nrf2) pathway, a critical pathway that protects cells from 
oxidative and electrophilic stress.(Liu et al., 2015d) Activation of this pathway through 
hsa-miR-200a to protect cancer cells from oxidative stress also occurs in oesophageal 
squamous cell carcinoma.(Liu et al., 2015c) It works with hsa-miR-141 to target mitogen-
activated protein kinase 14 (MAPK14) to enhance the oxidative stress tumour growth 
response in ovarian cancer.(Mateescu et al., 2011, Zhu and Gao, 2014) Interestingly, hsa-
miR-141 is significantly (p=0.009) upregulated by log2FC 2.6 (expression 7.1) compared 
to control and nodular subtype. In breast cancer, hsa-miR-200a has been shown to 
suppress Gap junction alpha-1 protein (GJA1) that aids in metastatic spread. Other 
tumour suppressor actions include inhibiting tumour growth in neuroblastoma cells by 
targeting Amyloid Beta (A4) Precursor Protein (APP).(Gao et al., 2014) 
 
Hsa-miR-1260 – chromosome 14q24.3 
Hsa-miR-1260 probably has a role in the PI3K/Akt pathway in hepatocellular cancer cells 
by targeting G1/S-specific cyclin-D1 (CCND1).(Yan et al., 2013) Overexpression is seen 
in cutaneous malignant melanoma, oestrogen receptor positive breast cancer and 
downregulation is seen in gastric cancer.(Sand et al., 2013, Park et al., 2014, Ma et al., 
2013) The latter may have a reciprocal relationship with hsa-miR-29 in gastric cancer and 
this is significantly (P=0.0002) down-regulated (Log2FC -1.6, expression 9.8) in the 
pagetoid subtype, thus supporting a reciprocal relationship.  
 
Hsa-miR-199a-3p+miR-199b-3p – chromosome 19p13.2 + 9q34.11 respectively 
This miRNA acts as a tumour suppressor gene in several cancers including ovarian 
carcinoma, osteosarcoma, colorectal cancer and thyroid cancer .(Kozomara and Griffiths-
Jones, 2014, Tian et al., 2014, Han et al., 2014, Minna et al., 2014) Furthermore, it is 
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upregulated at a post-transcriptional level by TP53.(Wang et al., 2012a) Hsa-miR-
199a+3p has been shown to target CD44 glycoprotein (an oncoprotein) that aids in 
osteosarcoma cell adhesion and migration, with increased CD44 expression contributing 
to the aggressive nature of the tumour.(Gao et al., 2015) This inverse association has also 
been noted in hepatocellular carcinoma.(Henry et al., 2010) CD44 was found to be 
significantly (P=0.005, expression 7.8) overexpressed (log2FC 1.2) in pagetoid subtype 
only, which would support the reciprocal association with hsa-miR-199a+3p. It has also 
been shown to target AXL Receptor Tyrosine Kinase (AXL) which in turn regulates 
invasion and metastasis through the PI3K/AKT pathway.(Tian et al., 2014) 
 
5.13.3 Comparison of nodular and pagetoid SGC microRNA 
 
Hsa-miR-16 – chromosome 13q14.3 
In over half of chronic lymphocytic leukaemia cases there is a loss of chromosome 13q 
where this miRNA resides. Subsequent to this study, hsa-miR-16, along with an 
associated cluster of miRNA, are found to target cyclin D1, MCL1, and Bcl-2.(Pekarsky 
and Croce, 2015) The latter being over expressed in almost all CLL cases and is a direct 
target of hsa-miR-16 and -15. Bcl-2 is non-significantly (P=0.7) downregulated (log2FC 
-0.2, expression 4.0) in the nodular subtype, but still overexpressed (log2FC 1.5, 
expression 5.6, P=0.009) in pagetoid. Hsa-miR-16 has anti-angiogenic properties by 
targeting VEGF and fibroblastic Fibroblast Growth Factor Receptor 1 (FGFR1). 
(Caporali and Emanueli, 2011) 
 
Hsa- miR-9 – chromosome 1 q23.1 
Physiologically, this regulates neural differentiation in the central nervous system by 
targets FoxG1, Hes1 or Tlx and involved in apoptosis.(Coolen et al., 2013, Yuva-
Aydemir et al., 2011) In breast cancer, hsa-miR-9 excess leads to increased cell motility 
and invasiveness by targeting CDH1; its expression is activated by MYC and MYCN.(Ma 
et al., 2010) 
. 
Hsa- miR-34a – chromosome 1p36.22 
This miRNA forms part of the TP53 suppressor network by modulating TP53 targets and 
forms a positive feedback loop via sirtuin 1 (SIRT1).(Lai et al., 2012) It has many 
suppressive effects in several different cancers including E2F Transcription Factor 3 
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(E2F3) in neuroblastoma plus colorectal cancer, MET Proto-Oncogene, Receptor 
Tyrosine Kinase (MET) in hepatocellular carcinoma, CD44 in prostate cancer, AXL in 
ovarian cancer and G1/S-specific cyclin-E1 (CCNE) in lung cancer.(Cho, 2007, Tazawa 
et al., 2007, Li et al., 2009, Li and Lam, 2015, Li et al., 2015c, Han et al., 2015) 
Nevertheless, in the presence of over expressed MYC, hsa-miR-34a behaves differently 
and as mentioned earlier, MYC is over expressed in the pagetoid subtype. Specifically, 
in myc-driven tumours, hsa-miR-34a improves cell survival based on its ability to reduce 
TP53 levels, in a myc mediated and dependent fashion, hence is helping the cancer cells 
to survive.(Sotillo et al., 2011) 
 
Hsa-miR-126-chromosome 9q34.3 
Hsa-miR-126 is expressed in epithelial cells, particular vascular endothelial cells where 
it plays a role in pro-angiogenesis by inhibiting Sprouty-Related, EVH1 Domain 
Containing 1 (SPRED1).(Wang et al., 2008) It acts as a TSG by targeting V-Crk Avian 
Sarcoma Virus CT10 Oncogene Homolog (CRK) in gastric cancer, ADAM9 in breast 
cancer, PAK4 in ovarian cancer, RhoA/ROCK signalling in colorectal cancer and 
SLC7A5 in small cell lung cancer.(Feng et al., 2010, Wang et al., 2015a, Luo et al., 2015, 
Li et al., 2013) Loss of this TSG confers a benefit for SGC. In pancreatic carcinoma, loss 
of hsa-miR-126 is crucial for progression via ADAM9. Down regulation in oral squamous 
cell carcinoma induces angiogenesis and lymphangiogenesis, conferring a poorer 
prognosis.(Sasahira et al., 2012)   
 
Hsa- miR-619 – chromosome 12q24.11 
Little data has been published on this miRNA. It has been associated with coronary heart 
disease.(Hou et al., 2014) Predicted gene targets include MAPK9. 
  
Hsa-miR-21 – chromosome 17q23 
Oncomir 21 was present in both nodular (Log2FC 2.6; exp 9.7; P<0.01) and pagetoid 










5.14 Summary of results 
 
Overall mutational burden of SGC was low and more in keeping with a visceral tumour 
that only contains a few hundred variants. This was unexpected; as an eyelid lesion it was 
thought that it might also be a UV induced tumour like BCC. Furthermore, it was thought 
that its close proximity to the skin with penetration through the skin on occasion along 
with spread along the visible bulbar conjunctiva would allow for the collection of UV 
type mutations. The later may explain some of the more aggressive SGC samples 
accumulating more UV type mutations. There was a large proportion of G>T (C>A) 
changes which may reflect a tobacco type or a defective DNA mismatch repair signature.  
 
Analysis of specific mutations identified five shared mutations between the two 
algorithms including two, well known tumour suppressor genes TP53 and RB1.  Intogen 
analysis picked the dynein family that was ubiquitously affected in all samples. DNAH14 
has recently been describes as a driver mutation in ovarian cancer (Braun, 2013). They 
are thought to play a role in chromatid segregation and may be involved in the 
chromosomal instability.  
 
WES revealed four pathways significantly mutated in all five samples, namely the cell 
cycle, pancreatic cancer, Wnt signalling pathway and dopaminergic synapse. Pancreatic 
cancer is one of the most aggressive cancers with a poor 5-year survival rate and behaves 
in a similar fashion. Locally invasive behaviour may be explained by mutations found 
within the ubiquitin mediated proteolysis pathway, which is also differentially expressed. 
 
Chromosomal instability was highlighted with areas of amplification at chromosome 8 
where the MYC gene resides and loss of the short arm of chromosome 17 where TP53 
sits. SGC therefore, comprises genomic instability rather than mutational instability. 
Further pointers come from the RNA analysis with both modalities underlining the over-
expression of SYCP2, part of a protein complex required for the joining of homologous 
chromosomes during planned DSB. 
RNAseq Pathway showed upregulation of mismatch repair, nucleotide excision repair, 
and homologous recombination supporting the chromosomal level of change. SGC often 
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spreads in a pagetoid fashion with skip lesion and invades with ease. Downregulation of 
cell adhesion, extracellular matrix organisation and collagen formation would aid with 
this locally invasive behaviour. Correlation of WES and RNAseq data demonstrated 
upregulated ‘cell cycle’, ‘ubiquitin mediated proteolysis’ and ‘Wnt signalling’ pathways. 
These pathways together will aid tumour growth and assist in extracellular matrix 
breakdown for local spread.  
 
Subtype analysis of pagetoid and nodular SGC revealed the histone gene cluster family 
as important to both, again supporting chromosomal instability. Further chromosome 
genes included NUSAP1 and SMCHD1 in the pagetoid type along with important 
chemokines that may assist is pervasive spread.  
 
Oncomir hsa-miR-21 was found in both subtypes and targets tumour suppressor genes 
PTEN and PDCD4. Loss of hsa-miR-199a occurs in the pagetoid subtype and this was 
confirmed using RT-qPCR. This allows uncontrolled oncoprotein CD44 activity that in 
turn promotes invasion plus metastasis. Furthermore, it targets AXL, which promotes 
invasion and metastasis, thus confirming that hsa-miR-199a is a tumour suppressor. 
Another pagetoid specific miRNA was hsa-miR-205a whose over-expression is thought 
to promote local invasion, and although an inhibitor of EMT, may push distant metastasis 
into MET, thus allowing them to colonise their new location. Furthermore, it controls b-
catenin (Wnt signalling is upregulated) through an interaction with EZH2 and MALAT1. 
Nodular specific hsa-miR-150 can suppress pro-apoptotic factors, but has also been 
shown to behave in a tumour suppressive manner and is thought to act via ZEB1 
suppression, which is downregulated in nodular SGC only. 
 
Protein expression of HIST1H2BD showed increased staining in both subtypes 
supporting aforementioned data on chromosomal instability. Surprisingly, protein 
analysis also demonstrated the expression of the canonical Hh pathway, namely PTCH1, 
SMO, Gli1 and Gli2 in SGC. Moreover, the expression patterns are beyond normal 
reactivation levels, suggesting aberrant signalling. Hedgehog pathway activation occurs 
in periocular SGC, in both the tumour and surrounding stromal tissue at a higher level 
than nodBCC, a known Hh driven tumour. The timing for any treatment modification of 
the Hh pathway would be dependent on its specific role in the pathogenesis of SGC, and 
further studies are required to determine this.  
Results	in	sebaceous	gland	carcinoma	
	 274 
5.15 Potential treatment targets 
 
Activating tumour suppressor genes (TSG) 
Blocking an overexpressed kinase or an oncogene has been the mainstay of 
pharmacological treatment in cancer. Reactivating a tumour suppressor gene is an 
onerous task, but restoration of wildtype TP53 has improved the radio or chemosensitivity 
of a tumour. The concept of priming the body’s defences to a kill the tumour may be more 
beneficial route in the future rather than a pan-toxic drug that targets dividing cells. Both 
TP53 and RB1 are mutated in SGC and represent an attractive target. How to restore or 
produce wildtype TSGs requires a different approach and ultimately needs to be 
personalised to the tumour in question. Activation of TSG regulators is one route: MDM2 
is a negative regulator of TP53 and inhibiting their interaction results in an increase in 
TP53. Nutlin was the first MDM2 molecule and has undergone clinical trials.(Khoo et 
al., 2014) Second generation have already been developed that are less likely to succumb 
to tumour resistance and are undergoing clinical trials. (Morris and Chan, 2015) 
Presumably, some wildtype TP53 is required. 
 
Matrix Metalloproteinase 9 (MMP9) inhibitors 
Extracellular matrix can be modified by metalloproteinases, which also modify 
inflammation and growth. MMP9 is especially associated with pathological inflammation 
in vascular disease, inflammatory bowel disease and cancer.(Rodriguez et al., 2010) 
REPIN1 was picked up as a driver mutation using two algorithms and regulates MMP9 
production. Non-selective MMP inhibitors have been used in humans with mixed results 
and significant side effects. Being selective for MMP9 has been a focus since the initial 
results of the non-selective inhibitors and two have been developed, the antibodies 
REGA-3G12 and GS-5745, the latter being in phase 1 clinical trials for solid tumours 
(ClinicalTrials.gov identifiers NCT01831427, NCT02077465, and 
NCT01803282).(Marshall et al., 2015)  
 
Histone deacetylase 1 (HDAC1) inhibitor 






Pre-MRNA Processing Factor 31 (PRPF31) - non-viral gene therapy 
Small molecules or nanoparticles have been developed as a delivery system as a non-viral 
gene therapy to restore PRPF31 in autosomal dominant RP.(Pensado et al., 2016) 
Injection into the subretinal space in Prpf31A216P/+ mice restored visual acuity and 
highlights that restoration of this gene is possible. However, the expression of PRPF31 
was neither up nor down, so it is not clear if it is a loss or gain of function and restoration 
would only be beneficial if it was a TSG. 
 
S100 Calcium Binding Protein P (S100P)  
S100P has been identified in a vast number of cancers and normally overexpressed. 
S100P interacts with RAGE stimulate cell growth and this interaction is blocked using 
Cromolyn and a 5-methyl analogue which is more potent.(Arumugam et al., 2013) 
Antibodies to S100P have shown promise in combination with chemotherapy agents in 
pancreatic cancer.(Dakhel et al., 2014) A novel method of reducing S100p is by 
incorporating an antisense mRNA within a retrovirus to target cancer cells.(Prica et al., 
2016) 
 
Histone Cluster 1, H4h (HIST1H4H) – DNA methylating agent 
Many of the histone family of proteins are altered in SGC. Temozolomide is an alkylating 
agent used in the most aggressive forms of brain tumour and glioblastoma multiforme. It 
has also noted that it can methylate histone proteins and this is thought to be part of its 
anti-cancer action.(Wang et al., 2016a) 
 
Epithelial Cell Adhesion Molecule (EPCAM) inhibitor 
Epithelial cancers often express the epithelial cell adhesion molecule and represent an 
attractive target. It is not only an adhesion molecule, but also involved in signalling, 
migration, proliferation and differentiation.(Ohashi et al., 2016) Overexpression 
correlates with aggressive behaviour and thought to assist in invasiveness plus render the 
tumour chemo-resistant. Catumaxomab is an antibody initially given via the 
intraperitoneal route for malignant ascites was noted to benefit tumours outside of the 
treatment zone suggesting an overall anti-cancer benefit. A phase 1 trial of repeated 
intravenous (rather than intraperitoneal) administration of 7µg in solid epithelial tumours 
(mainly colorectal cancer) demonstrated with chills, pyrexia and hepatotoxicity.(Mau-
Sorensen et al., 2015) Although not part of the phase 1 study, none of the 16 patients 
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demonstrated an effective reduction in tumour burden. Rather than a treatment modality, 
it could be used as a monitoring of tumour burden or recurrence as newer technologies 
have been developed to detect very small amounts of EPCAM positive tumour cells 
within the blood.(Andree et al., 2016)  
 
Thymidylate Synthetase (TYMS) 
TYMS was one of four shared, overexpressed genes in both nodular and pagetoid SGC. 
It is an enzyme involved in DNA synthesis and has been a target for chemotherapy agent 
5-fluorouracil for some time. Pemetrexed is a newer anti-folate, which is active in a 
variety of solid tumours.(Adjei, 2001) Variants in TYMS have been associated with 
chemoresistance to 5FU, especially when in excess. Incidentally, platinum based agents 
seem to be more effective despite not traditionally known as an anti-folate agent.(Kotoula 
et al., 2012)  
 
Pathway inhibition  
Wnt signalling inhibition 
Both WES and RNAseq data support the overexpression of the Wnt signalling pathway 
in SGC. Both subtypes were shown to overexpress FZD6. Moreover, loss of hsa-miR-
199a, which targets FZD6 in pagetoid, compounds the situation.  See section 3.8 for 
treatment possibilities.  
 
Hedgehog pathway inhibition 
Activation of the Hh pathway in SGC raises the possibility of medical treatment for these 
tumours, and potentially avoiding exenteration. Attenuation of the Hh pathway has been 
shown to be successful by using SMO inhibitors, with Vismodegib presently being the 
most widely used compound in clinical trials and used for locally advanced or metastatic 
BCC.(LoRusso et al., 2011, Demirci et al., 2015) Furthermore, neoadjuvant treatment 
with Vismodegib to reduce tumour size in BCC has been successful in making tumours 
more amenable to surgery.(Ally et al., 2014) Vismodegib has been trialled in a variety of 
cancers, including pancreatic, ovarian cancer, breast and prostate cancers and other SMO 
inhibitors are emerging such as Sonidegib and BMS-833923.(Queiroz et al., 2012) It is 
possible these agents could be efficacious in advanced or metastatic SGC and if such a 
neoadjuvant response could be replicated it may allow the preservation of sight by 





6 GENERAL DISCUSSION AND CONCLUSION 
 
6.1 Overview of study 
 
Cancer is an increasing burden on humanity with NMSC being the most prevalent. BCC, 
the commonest NMSC, within the periocular region exhibits a high risk of recurrence, 
especially the morphoeic subtype. In contrast, SGC is a rare life-threatening cancer that 
has a predilection for the periocular region and often require mutilating surgery to save 
life. 
 
BCCs within the H zone, including periocular, have a higher risk of recurrence, behave 
more aggressively and those around the eye area are a risk to sight.(Mosterd et al., 2008) 
Compounding this is a histological diagnosis of morphoeic BCC (mBCC), which is a 
high risk factor for recurrence and often requires Mohs micrographic surgery to ensure 
complete histological resection.(Malhotra et al., 2004) SGC has two broad macroscopic 
presentations, namely nodular or pagetoid. Misdiagnosis is common, often labelled as a 
benign chalazion in its nodular form or conjunctivitis in the conjunctival, pagetoid type. 
Thus, it is described as a masquerading lesion with delays to diagnosis often greater than 
a year. Pagetoid expansion of the skin or conjunctiva carries a higher risk of orbital 
exenteration.(Chao et al., 2001) Despite aggressive treatment there is a high recurrence 
rate and metastasis often occurs via the lymphatics to the cervical lymph nodes.(Buitrago 
and Joseph, 2008) Mortality rates were once very high at 29%, but there is a significant 
range depending on which treatment modality is employed and can be as good as 6% in 
a centre of excellence.(Doxanas and Green, 1984, Shields et al., 2004, Ni, 1982). 
 
Whole exome sequencing (WES) of 10 periocular mBCC were compared to 10 nodBCC; 
5 periocular and 5 below the head to allow for histological and site specific evaluation. 
BCCs in the periocular region were hypothesised to have a greater tumour burden and 
higher UV signature than BCC elsewhere (elseBCC) with mBCC being the most 
deranged. Overall burden was less in mBCC than nodBCC, mutational signature was not 
different and locality had no effect. The confounding factor is that normal skin cells 
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contain thousands of mutations including those in damaging genes such as NOTCH1 and 
TP53 in up to 21% and 5% of the time respectively. (Martincorena et al., 2015)  
 
In contrast, WES of SGC revealed a visceral tumour like mutational burden suggesting 
that is not originating from any form of skin cell. Nevertheless, if mutational burden is 
not relevant to pathogenesis, then the specific types of mutations present within the 
tumour are what define the tumour’s aggressiveness. Two tumour suppressor genes were 
found to be associated with SGC, along with REPIN1 that regulates stromal 
metalloproteinase MMP9 and underline its locally invasive behaviour. By identifying 
those driver genes specific to the tumour such as HECTD4 and FLNB in mBCC, it may 
give the clinician the ability to predict outcome. For example, if there is a tumour that 
looks not too dysplastic on histology but harbours the mBCC mutations then perhaps 
these are the patients that need closer follow-up. The functional consequence of these 
genetic changes needs to be ascertained and the use of 3D BCC in vitro models or 
organotypics should allow this to be done (see future work, section 6.2.1). Adding these 
genes to a known list of cancer associated genes and testing them in patients could help 
to stratify risk and lead to a more personalised approach to cancer care (see future work, 
section 6.2.3). Moreover, the presence or absence of these genes may be able to help with 
the prognosis and determine who require regular follow up and who may be discharged 
(see section 6.2.3).  
 
Perhaps a more sensible approach is to look at a family of genes rather than a specific 
gene or variant, for example, the dynein or histone family in SGC. It is possible that they 
act in a similar fashion so that any one of the genes will result in chromosomal instability, 
nevertheless modelling these changes would help to elucidate their true function.  We 
know that genomic instability is not solely mutational and chromosomal instability may 
play a large role in cancer behaviour. Large number of genes can be lost or amplified in 
a single event and arguably more detrimental to the cell than a single base change. 
Karyotyping may have gone slightly out of fashion, but when NGS becomes better at 
looking at the chromosome, then a clearer picture on overall genomic instability will be 
discerned. Currently NGS is a weak at looking chromosomes especially with difficult to 
detect abnormalities such as inversions or large deletions. Karyotyping is still looked at 
in clinical practice in terms of prognosis such as the presence of trisomy 12 within the 
tumour being a poorer prognosis in retinoblastoma.(AbdelSalam et al., 2008)  
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Presence of the gene or mutation is only the first step and its subsequent expression (loss 
or gain of function), is important to determine. For example, loss of hsa-miR-199a 
expression may indicate pagetoid behaviour and poorer prognosis in SGC. Expression of 
a whole pathway rather than just one gene may be more relevant to cancer behaviour. 
Traditionally we look at the fold change of a gene such as 4.5x increase in hsa-miR-205-
5p in pagetoid SGC. However, a small increase or decrease all 140 genes of a pathway is 
likely to have more profound effect than just a 4.5 fold change in one gene. Detecting a 
loss of immune pathways such has ‘Natural killer cell mediated cytotoxicity’ and ‘Fc 
Epsilon RI signalling pathway’ may indicate a poor prognosis in BCC.  
 
6.2 Future work 
 
6.2.1 Organotypics and testing therapeutics 
 
An in-vitro cell model of BCC has been developed in our lab using a the Matrigel 3D 
organotypic system as a model for skin: The dermis is formed using Matrigel, human 
fibroblasts and collagen. Subsequently, human keratinocytes are seeding on top of the 
dermal model and cultured using an air-liquid interface to mimic human skin such that 
the fibroblasts grow in culture but the keratinocytes don’t. Immortalised human 
keratinocyte cell lines can be modified using retroviral shRNA (RNAi) to suppress 
PTCH1 and a BCC model is formed. By knocking out PTCH1 only, for example NEB1-
shPTCH1, localised colony formation is seen similar to a nodBCC phenotype, but no 
stromal invasion is seen. Thus, it would be good to knock out or over express the mBCC 
genes too, such as knockout of HECTD4 within the keratinocyte, to see if it transforms it 
into a locally invasive mBCC phenotype. If a mBCC phenotype is obtained, therapeutic 
agents such as those described in the potential treatment targets could be added to the 
model to see if it modifies behaviour. 
 
6.2.2 Deep sequencing driver gene analysis for SGC 
Candidate driver genes were ascertained in a small population of 5 SGC, however, further 
analysis using deep sequencing on a larger population would help to refute or support 
these group of genes. Nineteen candidate genes were picked based on the Intogen and 
MutSigCV significance and biological relevance (see Table 6.1). Fifteen FFPE sample 
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have been identified for DNA extraction and will be sent for targeted, deep sequencing 
at x1000 depth.  
 
Gene Chromosome Start position End position Length/bp 
IL12RB2 chr1 67773046 67862583 89538 
RPTN chr1 152126070 152131704 5635 
DNAH14 chr1 225117355 225586996 469642 
IBSP chr4 88720701 88733601 12901 
GPX3 chr5 150399998 150408554 8557 
SYNE1 chr6 152442818 152958534 515717 
GPR31 chr6 167570359 167571319 961 
REPIN1 chr7 150065878 150071133 5256 
DLX6 chr7 96635289 96640352 5064 
DNAH11 chr7 21582832 21941186 358355 
CUBN chr10 16865964 17171816 305853 
ZNF37A chr10 38383263 38412278 29016 
FRA10AC1 chr10 95427639 95462329 34691 
RB1 chr13 48877882 49056026 178145 
GNG2 chr14 52327021 52436518 109498 
C16orf87 chr16 46835958 46865074 29117 
GJD3 chr17 38516904 38520945 4042 
TP53 chr17 7571719 7590868 19150 
PRPF31 chr19 54618789 54635150 16362 
Table 6.1 Deep sequencing of 19 potential SGC driver genes. Selected driver genes for SGC deep 
sequencing on 15 samples. Probes are designed against the human reference genome 19 University of 
California Santa Cruz (UCSC) and National centre of biotechnology information (NCBI) 37.7. 
 
6.2.3 Cancel panel analysis and personalised medicine 
Driver genes from both our cohort and the Bonilla et al cohort could be further tested in 
a prospective study. At present, archival tissue is often used and it is still not clear what 
these changes mean to the patient in terms of prognosis or need for follow-up. By carrying 
out a cancer panel test encompassing the potential drivers on tissue samples in a 
prospective study, better data can be captured on its relevant to histology, recurrence risk 
and prognosis. Due to the low incidence of SGC, it would require an unfeasible length of 
time to collect enough patients. BCC is so frequent that it would be feasible to carry out 
a prospective study and depending on the power required, enough patients could be 
collected over the course of a 1 year.  
 
Gene panels are becoming more common place in the NHS, but are mainly used to detect 
germline mutations for specific conditions such as congenital cataract or hearing loss. 
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Currently on the NHS, as an example, a blood sample (1-3ml) can be taken from a child 
with bilateral cataract, sent to a lab in Leeds where accredited DNA extraction, library 
preparation and Illumina Hiseq sequencing is performed on 114 known cataract causative 
genes. Bioinformatics is carried out and potentially pathogenic variants confirmed using 
conventional Sanger sequencing. A medical report is made of the clinical interpretation 
of the known variants identified. A technical report is made of the coverage along with a 
list of non-validated variants of unknown clinical significance. The whole process costs 
the NHS £1100 and has a fairly long turnaround time of 80 working days. This turnaround 
time has implications in cancer where adjunctive treatments such as chemotherapy may 
need to be started immediately after excision or even as a neoadjuvant therapy.  
 
Cancer panels really started when the BRCA1 and BRCA2 were being offered to women 
who were at high risk developing breast or ovarian cancer. Since around 2013, there has 
been an expansion to test for other cancer related genes. Breast cancer is at the forefront 
of cancer panels and there are over 10 different companies providing a gene panel service, 
but the fact that we can test for them does not mean that the are clinically relevant for that 
individual, and in some cases could induce more unnecessary anxiety.(Easton et al., 2015) 
Cancer Research UK have recently approved the use of a custom panel containing 80 
genes where the clinician can choose 19 genes pertaining to the patient’s cancer for a 
fixed price of £860 and 16 week turnaround. This was developed after a large 
epidemiology project, the collaborative oncological gene-environment study (COGS) 
looked at 200,000 patients genome, half with cancer and the other half without and 
discovered 80 genes that conferred an increased risk of developing cancer.(Michailidou 
et al., 2013, Garcia-Closas et al., 2013, Bojesen et al., 2013, Pharoah et al., 2013, Eeles 
et al., 2013)  This is still on a blood sample, hence will be looking at germline DNA and 
the risk of developing certain cancers or having a relapse. However, there are caveats 
with these gene panel analyses. Just over 100 patients have been analysed using the 80-
gene panel and the rate of unknown variant detection currently stands at 25% (personal 
communication with Professor Eeles, Royal Marsden Hospital). Therefore, a quarter of 
the patients will be given an unnerving result at the end of the test and it is then not clear 
what to do next. Having such a high potentially false positive result may not lend itself 




The work carried out in this PhD focuses on the mutations found in the cancer rather than 
the germline, and as such a cancer panel relating to these genes would have to be tested 
on the biopsy sample using the surplus tissue not required for histological sampling. 
Fortunately, this technique has been perfected in our lab using laser capture 
microdissection and low input DNA extraction methods for WES. As mentioned earlier, 
the current lag time to detection of the variants from the biopsy and definitive excision / 
adjunctive treatment is an issue, however, it is hoped that with newer technology such as 
the minion, results can be obtained in less time. Personalised genetic medicine is already 
occurring in cancer, for example in melanoma, BRAF V600E or V600K positive patients, 
are eligible for MEK inhibitors (Trametinib [Mekinist]) or BRAF protein inhibitors 
(Vemurafenib [Zelboraf] and dabrafenib [Tafinlar]) under National Institute for Health 
and Care Excellence (NICE) guidelines. Having a personalised approach to cancer care 
and tailoring treatment according to the types of mutations or chromosomal instability 
will be the future of tumour therapy as more of the potential treatment targets mentioned 
in the previous chapters become more widely available.  
 
Then there are the general concerns with genetic testing as we start to use these tools 
more often and screen more of the genome: who has access to this data? Can insurance 
companies ask for the details? Can family members request the results, especially if a 
germline test, as it may pertain to them too? Is the DNA stored indefinitely for future 
testing as technologies improve? Can companies or government agencies request access 
to this DNA for testing, for example the police in a criminal enquiry? With the advent of 
CRISP-Cas9 with its ability to modify sections of DNA with incredible accuracy, it is 
only a matter of time before we have to face these huge moral dilemmas of gene editing. 
Perhaps with cancer it is an easier answer, especially removal of an inherited cancer gene, 
so that the subsequent progeny will never be affected. Lets hope we, the international 












Cancer Research UK is the world’s leading charity in beating cancer through research 
and advertises its Herculean task ‘of bringing forward the day when all cancers are cured’. 
And what a day that would be, to have Cancer crushed beneath the foot of Hercules! 
 
During my 18-month viva, I casually commented that cancer took over the cellular 
machinery for its own advantage and I was quickly shot down by the examiner who said 
that cancer cannot take over the body or its machinery. I reflected on this later on and I 
was still not happy with either viewpoint. It made me contemplate, what actually is 
cancer? As a scientist, I can talk about mutational advantage, survival of the fitness, 
consumption of the body’s resources, destruction of normal tissue so it cannot function 
etc. However, as a doctor who cannot ignore the art of medicine, the patient who is 
diagnosed with cancer (the patient with cancer rather than the cancer patient) will never 
be the same again. Benign, indolent, aggressive, remission or terminal; yes they are very 
different in terms of outcome, but once the label is given, it cannot be taken away and is 
forever set within the mind. Of course, watching my Dad with terminal prostate cancer it 
may seem obvious. So going back to my flippant comment: does cancer take over the 
body? Yes, permanently. Either within the subconscious, preconscious or conscious 
mind. A good friend told me that doctors are the gatekeepers between land and the great 




Individual gene level comparison of subtypes for selected pathways 
 
 MORPHOEIC NODULAR 
Gene Exp LC P-val Exp LC P-val 
PTCH1 5.7 1.2 0.009 5.7 1.8 0.002 
SMO 4.5 1.2 0.01 4.5 0.2 0.63 
Gli1 4.9 1.5 0.004 4.9 1.8 0.006 
Gli2 5.1 1.1 0.01 5.1 0.9 0.09 
STK36 4.5 -0.1 0.86 4.5 0.1 0.778 
LRP2 3.1 1.0 0.03 3.1 1.7 0.014 
CREBBP 7.1 0.3 0.33 7.1 0.2 0.52 
HHIP 3.6 2.3 0.001 3.7 1.4 0.021 
SIN3A 6.3 0.2 0.69 6.3 0.2 0.6 
BMP4 4.0 0.1 0.94 4.0 -0.4 0.64 
CSNK1A1 5.6 -0.1 0.88 5.6 -0.3 0.44 
CSNK1E 6.0 0.1 0.92 6.0 0.1 0.838 
PRKACB 4.9 -0.5 0.22 4.9 -0.1 0.93 
PRKX 6.8 0.9 0.03 6.8 0.5 0.13 
WNT2 0.4 0.6 0.60 0.35 1.8 0.145 
Table A1.1 Hedgehog pathway expression in mBCC and nodBCC. Mutational burden in 10 mBCC and 




















 MORPHOEIC NODULAR 
Name Exp LC P-val Exp LC P-val 
SLIT2 5.0 -0.6 0.22 5.0 0.5 0.34 
EPHA3 1.8 -0.5 0.65 1.8 -0.4 0.72 
EPHB1 0.9 0.3 0.80 0.9 -0.2 0.87 
DCC 0.3 3.8 <0.01 0.3 0.7 0.41 
LRRC4C  1.2 -2.1 0.15 1.2 0.1 0.96 
ROBO2 3.1 -0.4 0.70 3.1 -0.1 0.98 
SLIT3 6.4 0.5 0.15 6.4 0.4 0.36 
UNC5C -1.0 -0.3 0.85 -1.0 1.0 0.49 
EPHA7 -0.7 -1.8 0.23 -0.8 0.8 0.56 
FES 2.8 -1.0 0.25 2.8 -1.2 0.24 
NGEF -7.3 1.7 0.18 -0.7 -2.9 0.05 
NFAT5 5.8 -0.2 0.53 5.8 0.1 0.72 
NFATC2 5.5 -1.0 0.02 4.6 -0.1 0.89 
PAK6 3.3 0.5 0.46 3.3 -0.3 0.72 
PLXNC1 4.8 -1.3 0.03 4.8 -0.1 0.89 
SEMA3E 1.9 0.1 0.97 3.0 0.1 0.97 
SEMA4D 5.0 -0.6 0.21 5.0 -1.2 0.07 
SEMA6C 0.7 0.1 0.92 0.7 1.0 0.99 
ROCK1 7.3 -0.2 0.64 7.3 0.1 0.95 
Table A1.2 Axonal guidance pathway expression in mBCC and nodBCC. Mutational burden in 10 




















 MORPHOEIC NODULAR 
Name Exp LC P-v Exp LC P-v 
CREBBP 7.1 0.2 0.5 7.1 0.3 0.3 
NFATC2 4.6 -0.1 0.9 5.5 -1.0 0.02 
NFAT5 5.8 0.2 0.7 5.8 -0.2 0.5 
RHOA 9.3 -0.1 0.7 9.3 -0.1 0.9 
TBL1X 5.8 0.1 0.7 5.8 -0.8 0.1 
PPP3R1 4.1 -0.1 0.9 4.1 0.2 0.8 
MAPK9 5.0 0.4 0.4 4.9 0.1 0.8 
LRP6 5.9 0.9 0.04 5.9 0.6 0.2 
PRKACA 5.0 0.4 0.6 5.0 -0.1 0.8 
EP300 7.0 0.2 0.7 3.1 -0.1 0.9 
CHD8 7.1 -0.2 0.6 7.1 0.3 0.4 
NFATC4 3.8 0.8 0.2 4.7 -0.6 0.3 
CSNK2A1 6.9 -0.3 0.4 6.9 0.3 0.4 
PORCN 2.3 -2.2 0.02 2.3 -0.5 0.7 
AXIN1 3.0 -0.8 0.4 3.0 -0.1 0.9 
FZD3 5.0 0.04 0.9 5.0 0.7 0.2 
SFRP4 2.9 1.1 2.2 2.9 -1.2 0.3 
DVL1 1.5 -1.3 0.3 1.5 0.3 0.7 
MAPK8 4.6 0.1 0.8 1.5 0.3 0.7 
WNT5B 2.5 -1.5 0.2 2.5 -1.2 0.2 
FZD10 2.8 0.3 0.7 2.8 0.9 2.3 
PPP2R5D 4.5 0.9 0.2 4.5 0.3 0.6 
CSNK1A1 5.6 -0.3 0.5 5.6 -0.1 0.9 
ROCK2 7.0 0.3 0.4 7.0 0.1 0.9 
APC 6.4 0.5 0.2 6.4 -0.3 0.4 
WNT10A 1.4 -0.1 0.9 1.4 -1.4 0.3 
PPP2R1B 4.9 0.4 0.3 4.9 0.3 0.6 
PPP3CA 7.2 0.2 0.5 7.2 -0.7 0.06 
TP53 7.0 0.3 0.4 7.0 0.1 0.8 
SMAD4 6.4 -0.2 0.6 6.4 0.1 0.8 
TCF7L2 6.2 0.7 0.07 6.2 -0.1 0.9 
PLCB3 2.1 -0.6 0.6 2.1 0.1 0.9 
CTBP1 6.9 0.9 0.03 6.9 0.7 0.07 
DVL3 5.9 0.4 0.3 5.9 -0.1 0.9 
PRICKLE2 0.1 0.1 0.6 0.1 -0.9 0.4 
SOX17 0.2 -2.2 0.1 -0.2 -1.5 0.3 
PRKCB 2.6 -1.6 0.1 2.6 -1.6 0.1 
 
Table A1.3 Wnt signalling pathway expression in mBCC and nodBCC. Mutational burden in 10 mBCC 





 MORPHOEIC NODULAR 




INPP5D 3.8 -0.5 0.5 3.8 -1.4 0.03 
FYN 6.5 0.3 0.5 6.5 -0.4 0.4 
GAB2 4.0 -0.7 0.4 4.0 -0.7 0.4 
MAP2K3 4.7 -0.6 0.3 4.7 -0.2 0.7 
MAPK9 5.0 0.4 0.4 4.9 0.1 0.8 
SOS2 5.5 0.4 0.3 5.6 -0.1 0.9 
PIK3CG 0.7 -2.8 0.04 0.7 -2.4 0.05 
MAPK8 4.8 0.1 0.8 4.9 -0.3 0.6 
MAPK14 6.1 -0.4 0.3 6.1 -0.3 0.4 
AKT3 4.3 -0.8 0.1 4.3 -0.5 0.4 
VAV1 1.6 -2.5 0.09 1.6 -0.8 0.5 
PIK3R1 7.8 0.7 0.07 7.8 0.7 0.08 
MS4A2 0.9 1.7 0.3 0.9 -0.6 0.6 
FCER1G 4.6 -1.5 0.04 4.6 -0.5 0.3 
PRKCB 2.6 -1.6 0.1 2.6 -1.6 0.1 
RAC3 1.2 1.2 0.4 1.2 1.7 0.2 
PIK3CD 3.4 -1.0 0.3 3.4 -1.5 0.04 
HRAS 3.9 -0.7 0.3 3.9 -0.4 0.5 
PLA2G6 0.4 -0.3 0.8 0.4 1.1 0.4 
PLCG2 4.1 0.1 0.9 4.1 -1.3 0.04 
 
Table A1.4 Fc epsilon RI signalling expression in mBCC and nodBCC. Mutational burden in 10 mBCC 
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